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SUMMARY 
Novel approaches are required to address Alzheimer’s disease (AD) in our 
ageing population, with recent interest focused on inflammation and oxidative stress 
(OS). Disruption of NF-E2-related factor 2 (Nrf2) signalling increases OS and promotes 
AD. Amyloid precursor protein (APP) is intimately linked with AD, with the Swedish 
mutation (hAPPswe) used in numerous transgenic models. Furthermore, increasing 
importance has been placed on the suggested link between nutritional status and AD. To 
assess Nrf2 as a potential target in AD, we examined the effect of metabolic stress, by 
chronic high fat (HF) feeding or acute lipopolysaccharide (LPS) treatment on the brains 
of aged WT, Nrf2
-/-
, hAPPswe and Nrf2
-/-
/hAPPswe mice. 
Nrf2
-/-
 mice displayed impaired entorhinal cortex-dependent cognition, with 
raised basal hippocampal inflammation. The inflammatory state was attenuated by 
chronic HF feeding, whilst maintaining insulin sensitivity. In contrast, hAPPswe did not 
display an inflammatory response to HF feeding, but demonstrated impaired insulin 
signalling; in line with AD-associated insulin resistance. Additionally, Nrf2
-/-
 mice 
display increased glial cell activation and activation of mitogen activated protein 
kinases and mitochondrial impairment. These may be indicative of OS-induced cellular 
dysfunction and is supported by an aggravated response to LPS, which potentiates IL-1β 
production. Furthermore, despite an attenuated LPS response following the induction of 
tolerance, Nrf2
-/-
 mice maintain glial cell activation following treatment which may be 
suggestive of a primed immune environment within the brain. 
In conclusion, these data indicate altered glucose homeostasis in both Nrf2
-/-
 and 
hAPPswe mice, as previously reported. Further, we advocate that Nrf2 plays a key role in 
mitochondrial function and health and may be important for the ameliorative effects of 
HF feeding. Taken together, mitochondrial dysregulation and associated OS may help 
explain the development of cognitive impairment in Nrf2
-/-
 mice.  This may be relevant 
for AD given the age-dependent decline in Nrf2 expression in humans. 
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1 INTRODUCTION 
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1.1 DEMENTIA AND ALZHEIMER DISEASE 
Alzheimer Disease (AD) is the most prevalent cause of dementia in both 
developed and developing countries. Dementia itself is not a disease but a syndrome 
associated with deterioration of memory, thinking and behaviour; all of which impact 
on day to day living. Three further diseases are associated with the development of 
dementia; these are vascular dementia (VaD), dementia with lewy bodies and 
frontotemporal dementia (FTD). AD affects approximately 60-70% of the 850,000 
dementia sufferers in the U.K. (Alzheimer's Research U.K. (ARUK), 2015), and it is 
estimated that 47.5 million people suffer from a form of dementia worldwide (World 
Health Organisation (WHO), 2015a). A progressive and irreversible neurodegenerative 
disorder, AD is associated with widespread neuronal cell death resulting in gradual 
cognitive decline centred round memory loss. Strongly correlated with ageing, the risk 
of developing AD almost doubles every 5 years from the age of 65 (Qiu et al., 2009). It 
is currently believed that AD pathology is initiated at least 10 years prior to the 
development of symptoms and subsequent clinical diagnosis of dementia. 
Propagating from subregions of the 
medial temporal lobe (MTL), the 
entorhinal (ERC) and 
parahippocampal cortices, AD 
spreads into the hippocampus 
causing cell death related shrinkage 
(See Figure 1.1; Didic et al., 2011). 
This neuronal damage continues to 
unfold, moving into the cerebral 
cortex where progressive 
impairment is reflected by a mild to 
moderate AD diagnosis. Increasing 
overall brain shrinkage due to cell 
death eventually results in the 
diagnosis of severe AD that 
correlates with acute cognitive 
impairment. AD was first described 
by Dr. Aloysius ‘Alois’ Alzheimer 
in 1906 following his long-term clinical following of a 51 year old woman, Auguste D., 
Figure 1.1 Anatomical progression of AD 
related pathology in the human brain 
Pictorial representation of the pathological spread of 
Amyloid-β protein aggregates (A) and tau 
neurofibrillary inclusions (B) throughout the 
development of AD in the human brain. Adapted 
from Goedert (2015) 
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who presented with very particular 
symptoms including short-term memory 
loss and disorientation (Alzheimer et al., 
1995). Post-mortem analysis enabled the 
discovery of two major AD pathologies: 
extracellular fibrous plaques primarily 
made up of β-amyloid (Aβ) protein, and 
intracellular neurofibrillary tangles 
(NFTs) made up of hyperphosphorylated 
microtubule tau protein aggregates 
(Figure 1.2; Karran et al., 2011). Despite 
their requirement for a confirmed 
diagnosis, the exact role of these pathologies in AD progression remains unclear and 
hotly debated (Castellani & Smith, 2011). Recent research has indicated that the 
upregulation of Aβ may be a cellular coping mechanism to protect neurons from 
unmanageable levels of oxidative stress (OS; Bonda et al., 2010). 
The rate of incidence of AD is predicted to continue increasing, with incidences 
of dementia diagnoses expected to broach 70 million worldwide by 2030 (WHO, 
2015a). Much of the estimated increase in disease diagnosis will be largely attributable 
to rising numbers of patients being reported in low and middle income countries. 
However, the lack of curative treatment options severely hampers the successful 
management of the disease, resulting in long-term treatment and care costs currently 
estimated at over £20 billion per year to the National Health Service (NHS; ARUK, 
2015). Whilst the most common current treatments include the glutamate receptor 
antagonist memantine and acetylcholine esterase inhibitors, such as donepezil, these are 
largely symptomatological treatments with minimal impact on the underlying disease 
progression. Many clinical treatments are now being combined with non-invasive 
interventions such as cognitive stimulation therapy (CST). CST makes use of a range of 
stimulating social activities and group exercises and has been shown to provide 
improved maintenance of cognitive function when compared to standard treatment 
alone (Aguirre et al., 2013). Additional non-pharmacological approaches in use to aid in 
the management of AD include interventions such as music therapy and sensory 
stimulation, both of which have been suggested to aid with symptoms of dementia such 
as agitation. In addition, the co-medication of commonly associated conditions such as 
depression, anxiety and agitation may help improve patient’s quality of life. As yet, 
Figure 1.2 Histopathology image 
depicting the hallmark protein deposits 
of Aβ and neurofibrillary tangles used 
as the gold standard of disease diagnosis 
for AD (Van Leuven, 2013) 
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there are no diagnostic tests or screening tools available for diagnosis of AD at a pre-
symptomatic disease stage. Disease diagnosis of sporadic AD is still only provided upon 
presentation with cognitive or behavioural impairment, with definitive confirmation 
supplied by post-mortem pathology examinations to confirm the presence of plaques 
and tangles. In addition, given the nature of AD and its often slow progression rate, the 
cause of death for many patients is attributed to acute causes of mortality such as 
pneumonia and diseases of the circulatory system (Brunnström & Englund, 2009). This 
can act as a confounding factor when analysing clinical data; as well as highlighting the 
importance and complexities of long-term clinical care for patients suffering from 
dementia. 
Novel research has ascribed roles for alternative targeting mechanisms such as  
metal ion chelators to reduce the spread of reactive oxygen species (ROS) and Aβ 
vaccines or Aβ binding molecules to prevent the build-up of Aβ (Salomone et al., 
2011). However, in order to improve patient outcome, treatments targeted at earlier 
stages of disease progression are required. These are dependent on establishing a more 
in depth knowledge of the mechanisms of disease initiation and early progression. In 
addition, the development of relevant biomarkers for use in clinical diagnosis is of 
particular importance. These include reliable markers of early stage AD development, 
potentially preventing the onset of much of the irreversible cell loss associated with AD, 
and disease stage dependent markers to aid in assessing the most appropriate treatment 
interventions. From a therapeutic perspective, consistent biomarkers that allow 
confirmation of treatment efficacy would allow for the tailoring of any necessary 
pharmacological intervention. Biomarkers currently linked with early cognitive 
dysfunction, in both humans and animal models, include reductions in brain glucose 
utilisation as measured by fluorodeoxyglucose positron emission tomography resulting 
in altered energy homeostasis. In addition, both decreased insulin in the brain as well as 
insulin resistance, and an increased prevalence of OS which most closely tracks AD 
development are also used as biomarkers in AD (de la Monte, 2009; Mosconi et al., 
2009; Yao et al., 2009; Bonda et al., 2010). This alteration in insulin signalling and 
energy homeostasis may be a key factor in gaining further understanding of AD. 
Diabetes UK describes insulin resistance as the prolonged presence of elevated insulin 
in the body leading to insulin desensitisation resulting in an impaired response to the 
hormone’s signalling pathway (DiabetesUK, 2015). Moreover, whilst essential for the 
subsequent development of diabetes, it is also associated with increased inflammation 
which may long-term be important in further dysregulation of the energy balance as is 
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suspected to occur in AD. Finally, AD has more recently been linked with central 
insulin signalling impairment leading to insulin resistance, with Aβ thought to have a 
detrimental impact on insulin receptor activity and localisation (Xie et al., 2002; Zhao 
& Townsend, 2009; Moloney et al., 2010). This in turn may play a role in the 
subsequent development of cognitive impairment. 
In order to better understand the processes occurring during the progression of 
AD, much of the early research performed in the field concentrated on the 
characterisation and classification of the two key AD associated pathologies of Aβ and 
phosphorylated tau aggregation. These hallmark pathologies, first described by Alois 
Alzheimer at the turn of the twentieth century, remain essential for confirmation of AD 
diagnosis following posthumous tissue analysis. Over the years, a variety of disease-
linked mutations have been discovered in both of these dysregulated protein pathways. 
The mutations in Aβ are largely associated with the early onset familial form of AD 
(FAD), whilst those associated with tau protein have been linked with the spectrum of 
diseases covered by FTD. Work performed using these mutations have helped further 
our understanding of the potential function of the relevant proteins in health and 
disease.  
1.1.1 Tau Protein and Pathology 
Accumulation of tau protein has been cited as playing important roles in many 
neurodegenerative diseases including FTD and AD, but also neurodegenerative 
disorders such as Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). 
Tau protein belongs to the family of proteins known as microtubule-associated proteins 
(MAP). Discovered simultaneously by Nunez and colleagues in France and Kirschner 
and colleagues in the U.S.A. in 1977 (Cleveland et al., 1977a; Cleveland et al., 1977b; 
Fellous et al., 1977), its cellular role centres around regulating and managing 
microtubule formation (Avila et al., 2004). It is primarily found in neurons, although 
can on occasion be found in certain glial cells, and is heavily post-translationally 
modified. It is these post-translational modifications that regulate tau’s role in 
assembling and stabilising microtubules (Iqbal et al., 2005). The most studied of these 
secondary modifications is phosphorylation. Phosphorylation of tau has been reported to 
be assisted by a multitude of different kinases, including such ubiquitously expressed 
enzymes as glycogen synthase kinase 3 (GSK3), cyclin-dependent kinase 5 and 
members of the mitogen-activated protein kinase (MAPK) family (Mandelkow & 
Mandelkow, 2012).  
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AD NFTs are made up of a combination of paired helical filaments (PHF) and 
straight filaments. Research has shown that tau is the primary protein present in the 
PHFs. This has led to the coining of the term ‘tauopathies’ to define neurodegenerative 
diseases in which pathological aggregation of tau protein is observed. Other examples 
of tauopathies include PD, where aggregates are largely localised in the substantia nigra 
pars compacta region of the brain and associates with other PD protein aggregates such 
as Lewy bodies, and many others including ALS and those disorders encompassed by 
the umbrella term of FTD (Spires-Jones et al., 2009; Lei et al., 2010). It is aberrant 
processing of the post-translational modifications of tau, such as phosphorylation, 
glycosylation and the addition of β-N-acetyl-glucosamine (GlcNac) by O-
GlcNAcylation, which are largely to blame for its pathology associated toxicity. 
Specifically, hyperphosphorylation has been found to be a precursor to the formation of 
PHFs and NFTs in AD. However, formation of PHFs is not solely associated with the 
development of AD NFTs and an accumulation of PHF formations can also be found in 
other known tauopathies. More recently, as increasing research goes into better 
understanding other post-translational modifications, it has been suggested that a 
balance between the different modifications possible for tau is necessary for 
maintaining correct cell function. Aberrant glycosylation of tau in vitro has been shown 
to facilitate its subsequent phosphorylation whilst inhibiting its dephosphorylation by 
protein phosphatases, thereby promoting increasing the ratio of phosphorylated to non-
phosphorylated tau (Liu et al., 2002a; Liu et al., 2002b). Additionally modification of 
tau protein via O-GlcNAcylation has been shown to negatively regulate protein 
phosphorylation with in vitro and rodent in vivo evidence suggesting a role for 
decreased O-GlcNAcylation in AD pathology development (Liu et al., 2004; Yuzwa et 
al., 2012). This may reflect a link between the alterations seen in brain metabolism and 
the aberrant processing of tau seen in the brains of AD patients. 
1.1.2 The Amyloid Precursor Protein Processing Pathway and Aβ 
In 1987, eighty years after the original discovery of Aβ protein plaques by A. 
Alzheimer, several independent laboratories identified Aβ proteins as cleavage products 
of a large transmembrane precursor protein, subsequently named amyloid precursor 
protein (APP) (Thinakaran & Koo, 2008; Figure 1.3). APP is a ubiquitously expressed 
type 1 membrane glycoprotein and is the product of the APP gene found on 
chromosome 21, the same chromosome responsible for Down’s syndrome (DS). DS, 
which is caused by the presence of an extra copy of chromosome 21 and therefore an 
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additional copy of APP, is characterised by both physical and cognitive deficits. 
Individuals diagnosed with DS as a result of a full chromosomal replication go on to 
develop early onset AD and many of these show clinical signs of AD-type dementia 
(Millan Sanchez et al., 2012). In addition, a patient presenting with only segmental 
trisomy of chromosome 21 and lacking the region coding for APP showed no signs of 
dementia development (Prasher et al., 1998), further supporting an important role for 
APP in AD development.  
 
Figure 1.3 Domain structure and homology of the APP protein family 
In total, three major isoforms of APP are known to be formed as a result of 
alternative splicing of APP, namely APP695, APP751, APP770 (Figure 1.3). Named after 
their total amino acid content both APP751, the predominant peripheral isoform, and 
APP770 are widely expressed. They are similar in that they both contain a serine protease 
inhibitor domain called the Kunitz proteinase inhibitor (KPI) domain. In contrast, the 
principle neuronal isoform of APP is APP695 which lacks the exon 7 located KPI 
domain (Ling et al., 2003). Recent research has implicated the KPI domain in the 
control of protein dimerization, trafficking and processing; suggesting it in turn may be 
dysregulated in disease pathogenesis (Ben Khalifa et al., 2012). Additional mammalian 
members of the APP protein family include APP-like protein 1 and 2 (APLP1 and 
APLP2 respectively), with APLP1 more closely resembling the domain composition of 
APP770 whilst APLP2 is most similar to APP695. Whilst the Aβ domain is unique to 
APP, other conserved regions are present across all three proteins including the so 
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called E1 and E2 domains (Figure 1.3). Moreover, although both APP and APLP2 are 
ubiquitously expressed APLP1 is solely expressed within the brain, giving further 
indications that despite their structural similarity there may be functional differences 
between these protein homologs. 
Further investigation uncovered APP processing pathways dependent on the 
action of three protein secretases, namely α-, β- and γ- secretase, responsible for the 
processing of APP down two focal signalling cascades (Figure 1.4). Whilst cleavage of 
APLP1 appears independent of β-secretase activity, unlike APLP2, both APLP proteins 
have been shown to generate intracellular fragments (termed ALIDs) in a γ-secretase 
dependent manner (Eggert et al., 2004) indicating at least partial processing 
conservation between these proteins. With a variety of proposed physiological roles, 
members of the APP family are largely accepted to have dominant trophic roles in 
neurons and at the synapse. The essential role played by the APP family in neuronal 
development was confirmed by the development of knock-out (KO) models for each 
protein. Ablation of more than one family member such as APP/APLP2, APLP1/APLP2 
or APP/APLP1/APLP2 all prove lethal shortly after birth. This indicates a key 
physiological role for APLP2 in particular, with a certain degree of inbuilt redundancy 
amongst the remaining family members (for review of known physiological functions 
see Müller & Zheng, 2012).  
Despite their similarity in structure to APP, there has been less research 
performed investigating the roles of the APLP proteins. However, research into the 
mechanisms driving the lethality of the double KO model of APP/APLP2 implicated 
dysfunctional management of the insulin system, suggesting a potentially important 
functional role of the APP protein family in glucose and insulin homeostasis (Needham 
et al., 2008). Subsequent work utilising the information that both insulin and insulin-
like growth factor-1 (IGF-1) are capable of activating α-secretase cleavage has indicated 
that whilst α-cleavage of APP and APLP2 are both activated as a result of IGF-1 this 
occurs via two different enzymes, namely ‘a disintegrin and metalloproteinase’ 
(ADAM) 10 and ADAM17 (aka tumor necrosis factor-α converting enzyme (TACE); 
Jacobsen et al., 2010). This suggests that whilst these proteins are similar in structure 
they may yet have subtly different downstream effects following similar stimuli. 
Although APP, APLP1 and APLP2 can all be cleaved by similar enzymes (α-, β-, γ- 
secretases) the resulting products vary in length, further supporting a role for analogue 
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specific signalling abilities resulting from the same initial cleavage pathways (Shariati 
& De Strooper, 2013). 
 
Figure 1.4 Schematic representation of the pro-amyloidogenic and non-
amyloidogenic pathways of APP processing.  
Where α-secretase represents enzymes such as ADAM 10 and 17, β-secretase represents the β-
site APP cleaving enzyme 1 and 2 (BACE1 and 2) 
Despite these findings, to date there has been little indication that either APLP1 
or APLP2 produce toxic cleavage products that contribute to the development of AD. 
However, structural analysis has supported the physiological presence of not only 
homodimers within the APP family but also heterodimers combining multiple APP 
family members. Furthermore, this dimerization has been suggested to be influential not 
only for correct protein action at the synapse, but also for the channelling of APP down 
either amyloidogenic or non-amyloidogenic cleavage (Baumkötter et al., 2012). It has 
since been suggested that homodimerisation of APP may promote the amyloidogenic 
processing of APP, whilst heterodimerisation with APLP1 or APLP2 has been 
suggested to decrease the affinity of APP for cleavage by BACE1 thereby attenuating 
the production of Aβ (Kaden et al., 2012). Therefore, whilst not directly required for 
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production of Aβ, dysfunctional alterations in APLP levels or the ratio of homo- and 
hetero- dimerization of APP may be influential in the development and progression of 
AD. 
1.1.2.1 Amyloidogenic cascade 
The amyloidogenic pathway is responsible for the production of the toxic Aβ 
peptide found in aggregated plaques in AD. Initiated by β-secretase cleavage of APP 
within its luminal domain, the amyloidogenic pathway sees shedding of a large 
percentage of the soluble ectodomain of APP (sAPPβ). Release of the sAPP fragment 
leaves a membrane associated carboxy terminal fragment (β-CTF) behind. It is this 
membrane associated β-CTF fragment that is cleaved within its transmembrane domain 
by a second secretase enzyme, γ-secretase, to form the Aβ fragments now so commonly 
associated with AD (Figure 1.4). The main toxic species of Aβ, namely Aβ1-40 and Aβ1-
42, can both be produced by this cleavage and coincide with the release of an APP 
intracellular domain (AICD) fragment that varies in size according to the γ-secretase 
cleavage site. Aβ1-42 being a more hydrophobic molecule has an increased 
predisposition towards fibril formation and, therefore, is largely responsible for driving 
the production of the insoluble plaques seen in AD despite accounting for only a small 
percentage of total amyloid produced (Zhang et al., 2011). Aβ peptides are released into 
the extracellular environment and the AICD is released into the cytoplasm where it most 
often relocates to the nucleus following stabilisation by binding of members of the Fe65 
scaffolding/adaptor protein family (Turner et al., 2003). Once in the nucleus, it can act 
as a transcription factor reportedly upregulating genes such as GSK3β and the Aβ-
degrading enzyme neprilysin (Kim et al., 2003; Pardossi-Piquard et al., 2005). Highly 
labile in nature, AICD can be rapidly degraded by insulin degrading enzyme (IDE), 
especially when not stabilised by Fe65 (Müller et al., 2008).  
The enzymes that perform the initial cleavage of APP at the β-site, instigating 
the amyloidogenic pathway cascade, have since been identified as aspartic proteases, 
BACE1 and BACE2 respectively. Their discovery has prompted investigations into 
their potential use as therapeutic targets, with research predominantly targeted at 
BACE1. This may in part be due to the expression profiles of BACE1 and BACE2, with 
BACE1 being shown to have a higher expression in the central nervous system (CNS) 
and brain regions than BACE2, which is more widely expressed in the periphery (Cole 
& Vassar, 2007). In addition, subsequent work using BACE1
-/-
 mouse models has 
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highlighted it as the predominant β-secretase responsible for the production of Aβ (Luo 
et al., 2001). 
BACE1, which was first identified by Citron and colleagues in 1999, is known 
to be expressed both in neurons and astrocytes (Vassar et al., 1999; Roßner et al., 
2005). It is predominantly localised to the Golgi apparatus and cellular endosomes 
within the cell cytosol from which Aβ peptides are produced, and is described as the 
rate limiting step in Aβ production (Vassar, 2001). It is worth noting that APP is not the 
sole substrate processed by BACE1, with other substrates ranging from APLP2 to more 
recent reported hits such as various members of the neuroligin family and insulin-like 
growth factor-binding protein 2 (Kuhn et al., 2012). Induction of BACE1 activity is 
strongly influenced by a variety of both environmental and cellular stressors including 
OS, hypoxia, inflammation and metabolic challenges such as obesity and impaired 
insulin/leptin signalling (Cole & Vassar, 2007). BACE1
-/-
 mouse models fed a high fat 
diet are protected against diet-induced obesity (DIO) and have enhanced insulin 
sensitivity compared to BACE1
+/+
 controls (Meakin et al., 2012). In addition, BACE1 
activity positively correlates with ageing in both human and mouse brains (Fukumoto et 
al., 2004); and has been implicated in the management of energy homeostasis with 
BACE1 expression being increased following energy inhibition, a chronic state in AD 
development (Velliquette et al., 2005).  
Recent research has shown the BACE1 promoter region to harbour functional 
binding sites for a number of well-known stress activated transcription factors such as 
peroxisome proliferator-activated receptor γ (PPARγ) , nuclear factor κ-light-chain-
enhancer of activated B cells (NF-κB) and hypoxia inducible factor-1 (HIF-1) many of 
which are also associated with other AD risk factors such as obesity and stroke (Sastre 
et al., 2006; Bourne et al., 2007; Zhang et al., 2007; for comprehensive review see 
Chami & Checler, 2012). Further work has suggested that BACE1 cleavage products, 
such as Aβ, may act as danger-associated molecular pattern molecules (DAMP), 
capable of initiating and perpetuating immune responses in the absence of other 
infectious agents (Heneka et al., 2014). The action of DAMPs contrasts with those of 
pathogen-associated molecular pattern molecules (PAMPs) which partake in a similar 
role but require the presence of an initiating infectious factor such as lipopolysaccharide 
(LPS). However, both DAMPs and PAMPs are important in the management of the 
immune system and the resolution of cellular damage. 
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1.1.2.2 Non-Amyloidogenic Cascade 
The alternative, non-amyloidogenic, APP processing pathway (Figure 1.4) 
involves an initial cleavage by α-secretase within the Aβ sequence, which causes 
shedding of the ectodomain (sAPPα) leaving behind a membrane bound α-CTF. The 
placement of the α-secretase cleavage within the Aβ site prevents the production of Aβ 
by subsequent γ-secretase cleavage. Instead, transmembrane γ-cleavage produces a 
smaller p3 protein as well as the previously mentioned AICD. Although the molecular 
identity of α-secretase remains to be fully established, the most commonly quoted are 
zinc-metalloproteinases that show increased APP cleavage when overexpressed. Of 
these the three most frequently named are ADAM 9, 10 and 17, part of the disintegrin 
and metalloproteinase ADAM family (Boseman-Roberts et al., 1994; Turner et al., 
2003; Zhang et al., 2011). 
Members of the ADAM family have been linked with a variety of roles 
including cell growth and migration, cell-cell communication and both intra- and extra- 
cellular signalling. Divided into two groups, catalytically active and inactive, both 
ADAM 10 and 17 fall into the cluster of zinc containing catalytically active enzymes 
(Edwards et al., 2008). ADAM activity is known to be regulated by specific tissue 
inhibitors of metalloproteinases (TIMPs), with Amour and colleagues showing that 
ADAM10 interacts with both TIMP1 and TIMP3 (Amour et al., 2000). Contrasting with 
BACE1 cleavage which occurs largely in endosomes and the Golgi apparatus, α-
secretase cleavage of APP occurs at the plasma membrane (Thinakaran & Koo, 2008). 
In addition to APP, ADAMs have been shown to share many substrates in common with 
both BACE1 and γ-secretase including Notch related ligands as well as E-cadherin (Six 
et al., 2003; Maretzky et al., 2005). And whilst both ADAM 9 and 17 have been 
implicated in APP processing, it is ADAM10 that appears to be the constitutively active 
α-secretase enzyme with in vitro knockdown models suggesting neither ADAM9 nor 
ADAM17 are able to compensate fully for its loss (Kuhn et al., 2012). In addition, work 
done in ADAM10 overexpressing mouse models show increased sAPPα and decreased 
Aβ production which is reversed in models overexpressing a mutated inactive form of 
ADAM10 (Postina et al., 2004). Moreover, improvements were also seen in Morris 
water maze performance in ADAM10 overexpressing mice suggesting an improvement 
in cognitive function following increased α-secretase cleavage. These effects may in 
part be associated with the neuroprotective and neurotrophic roles suggested for the 
sAPPα cleavage product, which also includes inhibition of common stress related 
pathways such as the MAPK known as c-jun N-terminal kinase (JNK) (Copanaki et al., 
13 
2010; for review on ADAMs see Vingtdeux & Marambaud, 2012). Taken together, 
current research suggests targeting of both α- and β- secretase pathways may provide 
beneficial therapeutic avenues for pharmacological intervention. 
1.1.2.3 APP processing and disease 
Under healthy physiological conditions, the non-amyloidogenic α-secretase 
pathway cleaves 90% of APP. Little is known about the induction mechanisms involved 
in the overproduction of Aβ by BACE1 in the sporadic form of AD, which is the most 
common; although much research has centred on this area of research in recent years 
(see below). It is also worth noting that the detrimental effects associated with AD 
cannot be entirely attributed to an increase in production of Aβ. Other factors such as 
tau related toxicity and vascular damage, including an increase in microinfarcts in AD 
brains and alterations to the blood brain barrier (BBB), have been associated with 
damaging effects in conjunction with those attributed to Aβ (Kalaria, 2010). Indeed, Aβ 
deposition within the brain microvasculature has been recorded with a predominance of 
Aβ1-40 as opposed to the Aβ1-42 more strongly associated with plaque deposition. This 
has been further supported by data from the both the Dutch (APPE693Q) and Italian 
(APPE693K) FAD mutations that have an increased production of Aβ1-40 and consistently 
develop hereditary cerebral amyloid angiopathy and subsequently hereditary cerebral 
haemorrhage with amyloidosis, strongly linking the alterations occurring in AD with 
those of VaD (Agyare et al., 2013). In addition, hypoxia-induced damage as a result of 
vascular impairment has been suggested to increase the expression of APP, which may 
be of importance in the initiation of the amyloidogenic cascade and AD (Wang et al., 
2002).  
As previously mentioned, the different forms of Aβ are not produced equally. 
Similar to the ratio of amyloidogenic to non-amyloidogenic processing of APP, a 
change in the ratio of Aβ1-42/Aβ1-40 peptides produced has been described in forms of 
both FAD and sporadic AD, with increased production of Aβ1-42 to Aβ1-40 associated 
with enhanced amyloidogenic damage (Yoshiike et al., 2003; Hellström-Lindahl et al., 
2009; Kuperstein et al., 2010). Experimental models have also demonstrated altered 
APP metabolism can occur as a result of various cerebral insults including synaptic 
damage and altered energy metabolism. Acute mouse models of energy inhibition such 
as described by Velliquette and colleagues (2005), where impairment of brain energy 
metabolism resulted in increased BACE1, sAPPβ and Aβ, supports more recent work in 
a type I model of diabetes (TID). In the described model of TID, streptozotocin-induced 
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insulin-deficient diabetes further diminished cognitive performance in a mouse model 
of AD whilst increasing the severity of AD pathological markers and GSK3 activity 
(Jolivalt et al., 2010). In addition, rodent models of metabolic stress including feeding 
of high fat/cholesterol diets, which in turn leads to impaired insulin signalling, has been 
shown to increase BACE1 expression whilst BACE
-/-
 mice are protected from weight 
gain and maintain normal metabolic signalling (Meakin et al., 2012; Wang et al., 
2013b). In conjunction with rodent models, human studies have also reported links 
between AD and altered metabolic state with reports linking brain hypometabolism as 
well as obesity with the development of AD (Blass et al., 2000; Marchesi, 2011). 
Moreover, a growing body of evidence supports a central role of OS as an early event in 
AD and also as a major factor in the alteration of APP processing (Mohmmad Abdul et 
al., 2006; Karuppagounder et al., 2009; Choudhry et al., 2012).  
Although the mechanisms responsible for altering BACE1 activity are still 
uncertain, what is clear is that a variety of stressors are capable of inducing the altered 
activity including inflammation, OS, hypoxia and metabolic dysregulation. One 
suggested pathway linked with increased amyloidogenic processing of APP via BACE1 
is through the interaction of stress-induced MAPK proteins such as JNK. It has been 
shown that under pro-oxidant conditions, BACE1 expression is upregulated through 
activation of JNK in vitro (Tamagno et al., 2005; Tamagno et al., 2009). Further 
investigations have revealed that a similar stress-induced activation of γ-secretase by 
JNK is observed in neuroblastoma cell lines stably expressing human APP695 (Shen et 
al., 2008; Quiroz-Baez et al., 2009). This upregulation in β- and γ- secretase activity has 
been associated with contemporaneous impairment of endogenous antioxidant enzymes 
such as Cu/Zn-superoxide dismutase activity implying inhibitory or damaging effects to 
the endogenous neuroprotective system (Schuessel et al., 2005). Inhibition of JNK 
activity has been shown to negatively impact on Aβ production, attenuating the 
progression of AD in animal models by preventing the phosphorylation of APP by JNK 
(Mazzitelli et al., 2011). However, as with many facets of this disease it is unlikely to 
be the sole responsibility of one signalling cascade, and a combination of a multitude of 
factors taken together that are more likely at fault. 
1.1.3 Genetic Factors in AD 
Following on from its initial discovery, AD is now separated into two different 
forms. FAD, which is known to be primarily linked to genetic mutations in a subset of 
genes, occurs earlier in life (often before the age of 65) and accounts for a very small 
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number of cases each year. Whereas late onset or sporadic AD, whose aetiology 
remains unknown, is the predominant form of AD and is more common in those over 
the age of 65. Sequencing of full length APP followed on from that of Aβ, providing the 
genetic data necessary to identify a variety of mutations in families presenting with 
FAD across multiple generations (Weggen & Beher, 2012). This sequencing revealed 
multiple mutations in the APP gene (Chartier-Harlin et al., 1991; Goate et al., 1991; 
Figure 1.5), as well as subsequently highlighting the importance of mutations within the 
catalytic subunit of the γ-secretase enzyme through the identification of the presenilins 
(PSEN1 and PSEN2; Sherrington et al., 1995). A full list of the mutations associated 
with AD can be found at a variety of databases, such as the ‘AD & FTD mutation 
database’ (Cruts et al., 2012), and the number of known mutations has increased 
exponentially since those initial discoveries in the early 1990s.  
 
Figure 1.5 Sequence localisation of a selection of well-known APP mutations.  
Where red boxes depict detrimental mutations and green depict protective mutations. 
Despite the boom in number of newly described mutations, their localisation has 
remained restricted to a small subset of proteins, namely APP, PSEN1 and PSEN2 in 
the case of AD, all of which are involved in the amyloid pathway. Mutations found 
within the catalytic subunit of γ-secretase, either PSEN 1 or 2, increase the ratio of the 
more toxic Aβ1-42/Aβ1-40 produced (Figure 1.5). In a similar manner, mutations found 
within the γ-secretase cleavage region of APP, such as the Indiana (APPV717F) and 
London (APPV717I) mutations, also alter the ratio of amyloid produced in favour of the 
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1-42 isoform (Figure 1.5). And whilst a number of APP regions have been linked with 
FAD related mutations, all occur within or surrounding the Aβ region of APP, with 
mutations found within Aβ, such as the Dutch (APPE693Q) and Arctic (APPE693G), 
increasing the number of Aβ fibrils produced (Hall & Roberson, 2012). 
Worthy of particular note is the APP related mutation first highlighted in two 
Swedish families with histories of FAD in 1992; and subsequently prompting the 
coining of the term hAPPswe (Mullan et al., 1992). This mutation was found to occur at 
exon 16 of the APP gene within the Aβ coding region and caused by a double nucleic 
base transversion (G to T and A to C) at codons 670 and 671 (Figure 1.5). This prompts 
the substitution of two amino acids, namely lysine (K) to asparagine (N) and methionine 
(M) to leucine (L). In turn this alters the affinity of APP for cleavage by β-secretase, 
and the cellular localisation at which the cleavage occurs changes from the endosome to 
Golgi-derived vesicles, eliminating the need for reinternalization and recycling of APP 
prior to cleavage by BACE1 (Felsenstein et al., 1994; Haass et al., 1995). This change 
in APP processing pathway alters the ratio of non-amyloidogenic/amyloidogenic 
processing resulting in an increased production of Aβ compared to the wild type (WT) 
APP. Incorporation of the double Swedish mutation into rodents was one of the first 
successful transgenic models to replicate at least in part the pathologies seen in AD 
patients (Reaume et al., 1996). This sparked the development of a multitude of different 
transgenic animal models used in aiding ongoing research in the field; and many of 
these models today still incorporate the Swedish APPK670N/M671L alone or in combination 
with other AD related mutations. In stark contrast to the number of detrimental 
mutations now documented, a single mutation has thus far been linked with a protective 
phenotype towards AD. The so called ‘Icelandic mutation’ (APPA673T; Figure 1.5), only 
recently identified by Jonsson and colleagues (2012), occurs adjacent the BACE1 
cleavage site on APP resulting in ~ 40% reduction in amyloidogenic compounds in vitro 
and preventing the advent of cognitive decline in the elderly. The discovery of the 
Icelandic mutation therefore raises a crucial point suggesting a limited reduction in 
BACE1 regulated APP cleavage is sufficient to provide a protective environment. This 
then advocates a role for partial BACE1 inhibition as a pharmaceutical target for 
treatment of AD. 
Finally, whilst cases of mutation driven FAD remain rare in comparison to late 
onset AD, geneticists hypothesised the likely presence of genes which though not 
directly causative would predispose individuals to develop AD. This was proven to be 
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correct when, in 1993, a correlation between apolipoprotein E (ApoE) isoform and AD 
was demonstrated in both FAD and sporadic AD cohorts (Roses, 1996). Three isoforms 
of ApoE exist designated simply ε2, ε3 and ε4. Research has shown that presence of the 
ε4 isoform significantly increases an individual’s risk of developing AD, and also drops 
the age of diagnosis. Subsequent to this discovery and with the development of genome 
wide research platforms, further genes have been identified as contributing towards 
increased risk of developing AD. These include genes such as clusterin and bridging 
integrator 1, but none have demonstrated as potent an effect as that seen for ApoE 
(Roses, 1996; Kauwe et al., 2011). 
1.2 OXIDATIVE STRESS AND NEURODEGENERATION 
OS is caused by an imbalance between the pro-oxidant, ROS and reactive 
nitrogen species (RNS), and antioxidant systems. Long-term exposure to ROS and 
RNS, which are by-products of various metabolic pathways, is cytotoxic (Emerit et al., 
2004). This can occur by direct injury, such as deoxyribonucleic acid (DNA) damage, or 
indirectly by causing lipid peroxidation; and results in cell death by necrotic or 
apoptotic pathways. The brain is particularly sensitive to OS due to high oxygen 
throughput, high levels of unsaturated lipids and transition metals, including copper 
(Cu) and iron (Fe), as well as mitochondria. Although scientists have known about OS 
for a long time, it has more recently been implicated as an early event in AD (Castellani 
et al., 2001; de Vries et al., 2008; Bonda et al., 2010; Cruz-Sánchez et al., 2010) and 
other neurodegenerative disorders including PD and ALS.  
1.2.1 Mitochondrial Dysfunction 
The origins of ROS species associated with AD remain unclear, with both 
enzymatic (e.g. Cyclophilin D; Borger et al., 2011) and non-enzymatic pathways (e.g. 
impaired mitochondrial respiration) being implicated. However, it is likely to be largely 
due to the formation of highly reactive hydroxyl radicals from hydrogen peroxide 
(H2O2), produced in particular by the mitochondria. Overproduction of radical 
compounds occurs as a result of a breakdown of the endogenous detoxification system 
and damage to metabolic pathways and organelles. Mitochondria, due to their high level 
of adenosine triphosphate (ATP) production, are likely to be the largest producers of 
ROS in the brain. As a result of ageing, mitochondrial function is known to decline 
which causes an increased production of ROS due to premature electron leakage from 
the electron transport chain (ETC) and a deterioration in energy metabolism, both of 
which are exacerbated in AD (Figure 1.6; Swerdlow, 2011). It has been shown that, in 
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AD, neuronal and astrocytic energy metabolism is widely affected further implicating 
the mitochondria as primary ROS sources.  
Several of the enzyme complexes associated with mitochondrial oxidation of 
substrates to produce energy have been shown to be disrupted both in early stages of 
AD and in post-mortem brains. Further work, using primary cultures from a variety of 
rodent models, has corroborated these findings following administration of Aβ in vitro. 
Included in those enzymes altered are the pyruvate dehydrogenase (PDH) complex, the 
α-ketoglutarate dehydrogenase (KGDH) complex of the tricarboxylic acid cycle, and 
complex IV (COX IV) of the electron transport chain (Figure 1.6; Blass et al., 2000; 
Casley et al., 2002; Allaman et al., 2010). This is supplemented by recent research 
implicating earlier Aβ accumulation in the synaptic mitochondria when compared with 
their non-synaptic compatriots (Du et al., 2010). This is further supported by work 
performed in so called ‘cybrid models’ of AD that incorporate patient mitochondrial 
deoxyribonucleic acid (mtDNA) into cells devoid of mtDNA. Cells derived from AD 
patients were shown to induce ROS production, reduce ATP and cytochrome c oxidase 
or COX IV levels when compared to those cells derived from age-matched healthy 
controls. An increased sensitivity to Aβ toxicity and worsening bioenergetic function 
over time were also seen in cells derived from AD patients contrary to those from 
controls (Cardoso et al., 2004; Trimmer et al., 2004).  
1.2.2 Brain Hypometabolism 
A role for alterations in brain metabolism leading to a hypometabolic state as 
part of AD progression has been documented since the 40’s and 50’s (Blass et al., 
2000). As mitochondria are the energy powerhouses of the cell, it is not unreasonable to 
assume that mitochondrial dysfunction may go hand in hand with adaptations in the 
metabolic profile of the brain. Indeed, this appears to be the case in AD with the advent 
of a multitude of new imaging techniques, more accurate and versatile, revolutionising 
the field. Many recent publications have been able to highlight the importance of 
decreased central glucose metabolism in AD patients, in some cases prior to cognitive 
changes commonly associated with the disease stage seen at diagnosis (De Santi et al., 
2001; Mosconi et al., 2008a; Mosconi et al., 2008b; Mosconi et al., 2009; Chen et al., 
2011). Decreases of ~25% in the cerebral metabolic rate (CMR) of glucose (CMRg) are 
seen in AD, and are often accompanied by changes in the metabolic rate of oxygen 
(CMRO2) when compared to controls (Blass et al., 2000; Cunnane et al., 2011).  
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Although it is still not entirely clear on how far these changes affect other 
metabolic substrates, Bubber and colleagues demonstrated a strong correlation of 
decreased CMRg with key decarboxylase dehydrogenase enzymes, in particular PDH 
and KGDH, of the tricarboxylic acid cycle (TCA). These findings were supported by 
changes in both succinate dehydrogenase and malate dehydrogenase, increased activity 
of which is supportive of a change to an alternative energy metabolism pathway to 
bypass the blocks apparent in the TCA cycle (Bubber et al., 2005). Corroborating the 
importance of these enzymes in AD, work in vitro and in vivo using mouse models of 
AD and isolated cell samples from patients has shown a co-localisation of amyloid 
within the mitochondria. In addition, the accumulation of mitochondrial amyloid 
appears to parallel that of other AD-type pathologies. This deposition was subsequently 
shown to have detrimental effects on mitochondrial respiration with decreased activity 
of both complex III (succinate-cytochrome c reductase) and COX IV (Caspersen et al., 
2005). Supporting these findings, a cortical proteome analysis performed by Chou and 
colleagues (2011) using a triple transgenic mouse model of AD, highlighted the 
dysregulation of many of the above mentioned enzymes, alongside members of other 
key mitochondrial processes such as fatty acid oxidation and ketone body metabolism. 
In light of this, the alterations in glucose transport receptors within the CNS during the 
progression of AD may have an amplified effect. A decrease in the levels of glucose 
transporter (GLUT) 1 and GLUT3 have been shown in AD patients when compared to 
controls, with decreases in the regulatory factor HIF-1 also observed (Liu et al., 2008). 
Impairment of the glucose transport system and energy metabolism in AD has also 
raised the possibility of alteration of the insulin signalling pathway (See for full reviews 
Blass et al., 2000; Mamelak, 2012).  
1.2.3 Targeting the antioxidant system as treatment of OS 
Possibly due to a lack of BBB penetration, trials of excess antioxidant 
administration to AD patients have been unsuccessful. Modified antioxidants with 
improved BBB permeation have been put forward as novel forms of pharmacological 
intervention, such as the mitochondrial targeted antioxidant, MitoQ. MitoQ combines 
the endogenous antioxidant ubiquinone with a triphenylphosphonium cation, allowing it 
to cross the BBB and accumulate inside the mitochondria as a result of its altered ionic 
state. Compounds such as MitoQ are being trialled in animal models of AD with some 
success, although it is too early to predict effects in humans (McManus et al., 2011). 
Other therapeutic avenues include the upregulation of endogenous antioxidant systems 
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consisting of enzymes such as thioredoxin (Trx; Figure 1.7), glutathione peroxidase 
(GPX; Figure 1.7) and haem oxygenases (HMOX). The antioxidant response element 
(ARE) is an enhancer element that is responsible for the regulation of many constitutive 
and induced antioxidant enzymes and the control of cellular redox homeostasis. As 
such, it has strong therapeutic potential for oxidative stress related neurodegeneration 
and this has prompted further research into its regulation under stressed and non-
stressed conditions. The ARE is activated through binding of the transcription factor, 
nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) which itself is regulated by 
repressor proteins such as Kelch-like ECH-associated protein 1 (Keap1). 
 
Figure 1.7 Overview of the antioxidant mechanisms of key endogenous small 
antioxidant molecules.  
(A) Direct mechanism of action of the Trx redox system in detoxifying oxidized proteins after a 
stress event. Reduced Trx catalyses the reduction of disulfides (s-s) within damaged oxidized 
proteins. Trx is detoxified through reduction by thioredoxin reductase (TrxR), which relies on 
NADPH turnover for electron donation. (B.) Trx can also act indirectly by fuelling the turnover 
of peroxiredoxin (Prx), which acts to detoxify ROS such as H2O2 directly. (C) Glutathione 
(GSH) may also be oxidized by ROS and oxidized proteins, generating a s-s bridge between two 
glutathione molecules and catalyzed by glutathione peroxidase (GPX), forming GSSG. The 
GSSG can be reduced back to two GSH molecules by the action of glutathione reductase 1 
(GSR1), and utilizing NADPH as the electron donor. 
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1.3 NRF2 ANTIOXIDANT RESPONSE ELEMENT 
1.3.1 Nrf2-ARE Discovery and Structure 
Nrf2 belongs to the basic-region leucine zipper (bZip) protein family, and at least three 
Nrf members are currently known and have been sequenced, namely Nrf1, Nrf2 and 
Nrf3. Nrf2 was originally isolated and localised by Yuet Kan and collaborators in the 
mid-90s where they were subsequently able to show that unlike Nrf1 it did not appear to 
have a role in murine growth and development (Moi et al., 1994; Chan et al., 1995; 
Chan et al., 1996). The cytoprotective role of Nrf2 against oxidative or electrophilic 
stress was first described by Venugopal & Jaiswal in 1996, when they investigated the 
role of Nrf2 in ARE mediation of NAD(P)H quinone oxidoreductase 1 (NQO1) gene 
expression (Venugopal & Jaiswal, 1996). They were able to show that in the presence 
of xenobiotics Nrf1 and Nrf2 upregulated the expression and induction of NQO1. This 
was corroborated by the development of Nrf2
-/-
 mice that failed to induce the production 
of phase II detoxifying enzymes such as NQO1 (Itoh et al., 1997). It is now well 
accepted that Nrf2 controls an array of over 200 genes under both basal non-stressed 
homeostatic conditions as well as following induction by redox perturbation (McMahon 
et al., 2001; Chanas et al., 2002; Thimmulappa et al., 2002). Whilst many of these 
genes have actions directly related to cytoprotection, as had initially been suggested, 
others have more varied cellular actions. These hits include links with lipid and 
carbohydrate metabolism and regulation of chemokine receptor binding implicating a 
direct link with Nrf2 to the immune system response (Chartoumpekis et al., 2013).  
Nrf2 has since been shown to contain a number of distinct regions known as 
Nrf2-ECH homology (Neh) domains, and to date seven Neh domains have been 
described each with their own functional relevance (Figure 1.8 A). The C-terminal Neh3 
domain is involved in the transcriptional activation of Nrf2 and has been shown to 
interact directly with binding to CHD6 (a chromo-ATPase/helicase DNA binding 
protein) during Nrf2 transcription. This in turn suggests a role for the Neh3 domain in 
particular as a transactivation domain enabling increased gene transcription to occur 
(Nioi et al., 2005). The N-terminal domain Neh2, on the other hand, is crucial in the 
negative regulation of Nrf2’s activity. 
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Figure 1.8 Domain structures of human Nrf2 and Keap1 
(A) Nrf2 contains six well-conserved domains, from Neh1 to Neh7. Neh2 is essential for Keap1 
complex formation and Neh1 is notably involved in the dimerization of Nrf2 with small Mafs, 
whilst more recently Neh6 has been shown to be important in β-TrCP binding. (B) In Keap1, 
the bric-a-brac, tramtrack, broad-complex/Poxvirus Zinc finger (BTB/POZ) domain contributes 
to homodimerisation. IVR is essential for interaction with Cullin 3 (Cul3), whilst the Kelch 
repeat domain (β-propellor structure) is essential for interaction with Nrf2.  
 
Following on from the discovery of Keap1 in 1999, and its identification as an 
electrophile regulated suppressor of Nrf2 activity, the Neh2 domain was found to be 
vital in successful binding of Keap1 to Nrf2 (Itoh et al., 1999; Katoh et al., 2005). 
Electrophiles are described as molecules or ions that are electron deficient in some 
form, with these ranging from compounds with an overt positive charge (e.g. H
+
), 
through those with a partial positive charge (δ+; HCl), to those who fail to satisfy the 
octet rule (e.g. Borane). Further research showed it was possible for the Keap1 Kelch 
region to bind specifically to the Nrf2 amino terminal, which was antagonised by the 
presence of the electrophilic compounds diethylmaleate and catechol (Figure 1.8; Itoh et 
al., 1999). Research has since elucidated a clearer view of the most likely mechanism of 
action and regulation of the Nrf2-Keap1 complex as well as the importance of the 
remaining Neh domains (Kobayashi et al., 2002; McMahon et al., 2003; McMahon et 
al., 2004; Kobayashi & Yamamoto, 2006; McMahon et al., 2006; Wang et al., 2013a). 
1.3.2 Nrf2 Mechanisms of Repression and Activation 
Nrf2 is tightly regulated by Keap1 homodimers and the response initiated by the various 
stimuli is mainly down to destabilisation of the Nrf2-Keap1 complex. Although 
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originally believed to have a relatively passive cytosolic tethering action, further 
research indicates that Keap1 exerts a more dynamic role in Nrf2 repression and 
degradation. Keap1 is known to homodimerize and disruption of this dimerization 
greatly diminishes its ability to bind Nrf2 (Zipper & Timothy Mulcahy, 2002). Crystal 
structure analysis showed that the repeat sequence in the Kelch domain contains six 
structurally similar β-propeller blades. One of these blades binds to a conserved hairpin 
motif at the C-terminus end of the Neh2 Nrf2 domain prompting further binding of the 
Neh2 domain already described by also binding at the DLG motif thereby enhancing 
stabilisation of the complex (Kensler et al., 2007). Keap1 aids in the targeting of Nrf2 
for ubiquitylation by acting as a substrate adaptor protein for the cullin-3 (Cul3) RING-
box 1 (RBX1) E3 ubiquitin ligase complex (CRLKeap1; Figure 1.9; Kobayashi et al., 
2004; Zhang et al., 2004). In this way, Keap1 is able to quickly channel Nrf2 down a 
proteasomal degradation pathway, maintaining only low basal levels of antioxidant 
activity under normal physiological conditions.  
More recent work has highlighted an alternative Keap1-independent regulatory 
pathway of Nrf2. It is through this pathway that the Neh6 domain of Nrf2 exerts its role 
(McMahon et al., 2004). Two conserved peptide motif regions, DSGIS and DSAPGS, 
within the Neh6 domain are recognised by the β-transducin repeat-containing protein 
(β-TrCP). Phosphorylation of the DSGIS motif of β-TrCP by GSK3 increases its ability 
to repress Nrf2 activity allowing further control of Nrf2 regulation (Rada et al., 2011; 
Rada et al., 2012; Chowdhry et al., 2013). It is worth noting that the Neh6 domain, 
unlike the better-described Neh2 domain, is redox insensitive thereby separating the 
roles of the two repression pathways known to exist for Nrf2 management. This opens 
the door for other mechanisms of regulation which may include indirect modulation 
through the insulin signalling pathway by influencing GSK3 activity through Akt 
regulated inhibitory phosphorylation. Furthermore, this may provide another link 
between altered Nrf2 activity and the progression of AD given the reported elevation in 
GSK3 activity in AD, confirmed by attenuation of amyloid pathology following GSK3 
inhibition (Avrahami et al., 2013). 
Nrf2 activation occurs largely as a result of redox or inflammatory stress 
exposure. Upon cellular stress stimulation the ability of Keap1 to present bound Nrf2 
for degradation is inhibited by modulation of cysteine residues present on Keap1. This 
modulation results in failure to induce proteasomal degradation of the CNC-bZIP factor 
on Nrf2, in turn allowing for a build-up of unbound newly translated Nrf2 to occur. Free 
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Nrf2 is then able to bypass the Keap1 
complex and cross out of the cytoplasm 
into the nucleus, whereupon it can bind 
to so called small musculoaponeurotic 
fibrosarcoma (Maf) proteins forming 
dimers (Figure 1.9). Three Maf proteins 
have currently been characterised, 
namely MafF, MafG and MafK. This 
dimerization in turn prompts the binding 
of Nrf2 to ARE and thereby induces 
increased gene transcription by Nrf2 
(Kobayashi & Yamamoto, 2006). 
Of note is the ability of different 
electrophiles, including reactive metals, 
to induce the alteration of different 
stress sensors on the Keap1 motif; 
indicating the ability to specifically 
manipulate Keap1 inhibition targeting 
depending on the stress pathway 
present. This is in large part due to the 
relatively cysteine rich make up of 
Keap1. Targeting of diverse reactive 
cysteines within the Keap1 makeup by 
electrophiles usually results in the 
stabilisation of the Nrf2-Keap1 
complex, as mentioned above. In 
particular, Cys-273 and Cys-288 are 
essential in maintaining the normal 
cellular turnover of Nrf2 (Yamamoto et 
al., 2008); whilst Cys-434 also targeted 
by innate electrophiles such as NO-
induced 8-nitroguanosine-3ʹ,5ʹ-cyclic 
monophosphate causes Nrf2 induction 
by S-guanylation of Keap1 (Figure 1.10; 
Figure 1.9 Nrf2 regulation by Keap1 
under stressed and basal conditions. 
Basal: Newly synthesized Nrf2 is rapidly 
sequestered in the cytoplasm by Keap1. Once 
bound it is targeted for proteasomal degradation 
following the formation of the CRLKeap1 
complex. Rapid ubiquitylation and degradation 
of Nrf2 releases the Keap1 homodimer leaving 
it free to bind Nrf2 and repeat the process. A 
small percentage of Nrf2 evades Keap1 
binding, translocates to the nucleus, 
heterodimerizes with small Maf proteins and 
maintains low level transcription of ARE-
driven genes. Stressed: Keap1-Nrf2 complexes 
undergo a conformational modification that 
prevents the CRLKeap1 driven ubiquitylation 
of Nrf2. Unable to release Nrf2, Keap1 is 
prevented from curtailing further Nrf2 turnover, 
allowing newly synthesized Nrf2 to bypass 
Keap1 binding and translocate directly to the 
nucleus where it heterodimerizes with small 
Maf proteins and induces increased target gene 
transcription by binding to ARE sequences. 
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Fujii et al., 2010). More recently studies have investigated the potential therapeutic role 
of other electrophiles, such as tert-butylhydroquinone (tBHQ) and sulforaphane (SFN), 
in the treatment of neurodegenerative disorders including PD and AD. Both tBHQ and 
SFN have been shown to interact with Cys-151 within the BTB domain of Keap1 
alongside the stress-induced cell signal response NO (Figure 1.10; McMahon et al., 
2010). Studies have since suggested potentially beneficial roles for SFN/tBHQ 
activation of Nrf2 using transgenic mouse models of AD that demonstrated increased 
clearing of amyloid following administration of tBHQ and protective effect for SFN on 
dopaminergic neuron toxicity in a model of PD (Akhter et al., 2011; Morroni et al., 
2013). Nrf2 interacts with both exogenous and endogenous compounds, such as SFN 
and nitric oxide (NO) which is predominantly produced through the activity of nitric 
oxide synthases (NOS). In addition, the transcriptional activity of Nrf2 can also be 
induced by a number of reactive metal(loid)s including Zn
2+
, Cd
2+
 and Se
4+
. Reactive 
metals differ from many other Nrf2 activators in their simultaneous use of two reactive 
cysteine sites on the Keap1 residue, namely Cys226 and Cys613 (Figure 1.10). Zn2+, 
the most likely physiological reactive metal candidate, along with other metals non-
covalently interacts with these cysteins which form a transient disulphide bridge in the 
presence of H2O2 (Fourquet et al., 2010; McMahon et al., 2010). 
 
Figure 1.10 Summary of preferred cysteine binding sites for a selection of 
commonly referred to Nrf2 activators 
Recent research in single cells has elucidated that one of the mechanisms behind 
the Keap1 modulatory inhibition results from increased strength of binding via the 
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ETGE and DLG motifs. Using fluorescence imaging live microscopy, it has been 
possible to identify two distinct conformations of the Nrf2 complex combining either a 
single or dimerised form of Keap1. Inducers promote the accumulation of the ‘closed’ 
Keap1 dimerised Nrf2 complex preventing the proper cycling of Nrf2 and sequestering 
Keap1 molecules inhibiting them from binding further Nrf2 (Baird et al., 2013). 
Implications of this would place the emphasis on changes within the RBX1-Cul3-Keap1 
setup instead of on Keap1-Nrf2 binding to alter the susceptibility of the complex to 
ubiquitination. Indeed, alterations in conformation of the RBX1-Cul3-Keap1 towards 
prevention of ubiquitination are supported by a lack of evidence towards activators of 
Nrf2 being capable of inducing release of the bound Nrf2 (Eggler et al., 2005). 
As the discovery of the second known modulator for Nrf2, β-TrCP, occurred 
only recently; its mechanism of action is less well characterised. Two isoforms of β-
TrCP are known to exist, referred to simply as β-TrCP1 and β-TrCP2. As previously 
alluded to, degradation of Nrf2 by β-TrCP targeting is aided by GSK3 phosphorylation. 
β-TrCP has been shown, like Keap1, to bind to a Cul-RBX complex known as SCFβ-
TrCP
. In addition to the RBX1 protein, members of the SCF family of E3 ubiquitin 
ligases each consist of the adapter protein Skp1, the scaffold protein Cul1 and an F-box 
substrate receptor protein, the identity of which is dependent on the substrate to be 
ubiquitinated (Wu et al., 2003). GSK3, known to be constitutively active unlike the 
majority of other kinases, can be negatively regulated by the phosphoinositide 3-kinase 
(PI3-K)/Akt insulin-signalling pathway (see above). Research has suggested a link 
between alterations in insulin and changes in Nrf2 signalling (Loh et al., 2009; 
Chowdhry et al., 2010). Therefore, it is possible this alternative repression pathway is 
partly responsible for these changes. However, more work is needed to fully 
characterise β-TrCP and its role in Nrf2 regulation as well as potential roles outside of 
the Nrf2 pathway. For a comprehensive and exhaustive review, it is worth referring to 
work in press from our collaborators (Tebay et al., 2015). 
1.3.3 Nrf2-ARE and the CNS 
Nrf2 is ubiquitously expressed, with high levels expressed in many of the major 
organs such as the heart, lungs, liver and brain. In relation to the distribution of Nrf2 
within the CNS certain discrepancies exist, with studies reporting Nrf2 to be present in 
neurons, glial cells or neurons and glial cells (Hong et al., 2010; Tanaka et al., 2011). 
Some of these discrepancies may be linked with the manner of Nrf2 activation and the 
individual stressors administered. However, it is now well accepted that both glial cells 
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and neurons can express Nrf2 within the brain and this expression increases following 
trauma (Dang et al., 2012). In general it is thought that glial cells have increased 
activation of the Nrf2 pathway following trauma, in no small part due to their important 
roles regarding management and resolution of inflammation and other damaging events 
(de Vries et al., 2008; Johnson et al., 2008). Research using known inducers of the Nrf2 
pathway, such as sulforaphane, have been shown to improve resolution of trauma 
related damage and diminish detrimental toxic effects of ROS such as protein 
carbonylation (Hong et al., 2010). Activation of the Nrf2-ARE pathway in astrocytes 
has been shown to promote astrocyte cellular survival when exposed to stresses (Lee et 
al., 2003; Shih et al., 2003). And with the preponderance of research supporting a role 
for OS, inflammation and ROS it is maybe not surprising that Nrf2 has become, in 
recent years, a target for research within the neurodegeneration field.  
1.4 GLIAL CELLS AND NEUROPROTECTION 
Cells falling under the umbrella term of glia incorporate a variety of subtypes 
including oligodendrocytes, astrocytes, microglia and Schwann cells. Previously, many 
glial cells were believed to play only a limited role in maintaining healthy brain 
function. However, it is now understood that they are equally as important as their 
neuronal counterparts in many cases, and partake in a wide variety of intra and inter-
cellular processes. Of particular interest and of relevance to AD are the astrocyte family, 
which are known to be important in direct interactions with their surrounding neurons 
including such roles as energy homeostasis and maintaining healthy neuronal signalling 
profiles. Another of the key cell types believed to be of importance in AD and 
neurodegenerative disorders are the microglia, so called resident macrophages of the 
CNS. 
1.4.1 Astrocytes 
A star-shaped sub-type of glial cells, astrocytes are interspersed among neurons 
in the brain using their extensive processes to form organised domains with little 
overlap observed between adjacent cells. The specialisation of the processes put out by 
the astrocytes promotes their ability to affect a wide range of pathways within the brain 
(Verkhratsky et al., 2010). This ranges from close interaction with neurotransmitters 
released into neuronal gap junctions prompting the coinage of the term tripartite 
synapse (replacing the previously accepted solely neuronal bipartite synapse), to the 
endfeet processes that link with intraparenchymal blood vessels (Bélanger et al., 2011; 
Tremblay et al., 2011). This complex network of processes, along with their unique 
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architectural and phenotypic features, enables them to play a vital role in neuronal 
homeostasis as well as contributing to neuronal function and promoting neuronal 
survival through the release of intrinsic factors. Astrocytes have been shown to have a 
role in neuronal energy metabolism playing a part in glucose, insulin and glutamate 
pathways. The so-called astrocyte-neuron lactate shuttle model is initiated by glutamate-
induced astrocytic activation. Although initially contested, further research appears to 
support the theory that subsequent lactate production by astrocytes is released into the 
extracellular space allowing for its potential use as an energy source by neurons, either 
at a basal level or as a result of cellular activation (Loaiza et al., 2003; Kasischke et al., 
2004; Serres et al., 2004; Magistretti, 2006; Erlichman et al., 2008; Wyss et al., 2011). 
Other known astrocytic roles include ion and water homeostasis, tissue repair and 
defence against OS (Allaman et al., 2010; Bélanger et al., 2011). 
In order to maintain healthy cerebral function, it is important that the symbiotic 
relationship between astrocytes and neurons is correctly maintained. The dysregulation 
of this relationship has been shown to play an important role in many neurodegenerative 
disorders including Alexander disease, caused by a primary dysfunction of astrocytes 
and characterised by the presence of intracellular protein aggregates (Rosenthal fibres), 
PD, ALS and AD (Verkhratsky et al., 2010; Wang et al., 2011; Yoshida & Nakagawa). 
As mentioned previously, OS has been linked with early stage neuronal damage in 
numerous neurodegenerative disorders. Overwhelming the astrocytic OS defensive 
system and/or affecting its protection mechanisms leads to neuronal impairment, as a 
result of disruption to the symbiotic relationship mentioned above as well as the 
damaging production of ROS. However, OS has also been shown to cause a glial 
reaction that results in the production of activated microglia and astrogliosis which can 
prompt the subsequent release or activation of potentially detrimental mediators such as 
the NF-κB pathway, NO and glutamate (Hamby et al., 2006; Sofroniew, 2009). 
Astrogliosis is characterised by hypertrophy of the cell, changes in gene expression and 
alterations in the expression of the cytoskeleton intermediate filaments, glial fibrillary 
acidic protein (GFAP) and vimentin (Barreto et al., 2011). The presence of astrogliosis 
has been noted as part of the post mortem pathology associated with AD, with some 
located within the Aβ plaques. Further studies have shown that when Aβ is administered 
in culture, astrocytes are able to internalize and degrade the Aβ fragments. However, 
this causes metabolic changes to the astrocytes, which can be detrimental especially at 
higher doses of Aβ (Allaman et al., 2010). This posits an important role for astrocytes in 
the metabolism and removal of Aβ in both healthy and AD brains. Recent research 
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suggests that the upregulation in Aβ and resultant changes in astrocytes could be the 
result of a protective mechanism to allow neurons to survive under much higher levels 
of OS (Smith et al., 2002; Hayashi et al., 2007; Nakamura et al., 2007; Nunomura et al., 
2010). In view of the above, the investigation of astrocytes and endogenous antioxidant 
mechanisms as targets for AD becomes all the more essential. 
1.4.2 Microglia 
Microglia are a form of glial cell termed the resident macrophages of the CNS 
and as a result are one of the frontlines of immune defence within this system. The idea 
of resident macrophage cells within the brain and CNS was first suggested in the early 
parts of the 20
th
 century by Pio del Rio-Hortega and his key hypotheses still hold true 
today (Kettenmann et al., 2011). However, it wasn’t until the 1960s with work 
performed by Kreutzenberg using his novel facial nerve lesion model that microglial 
research really started to take off. The novel lesion model allowed the study of 
microglia injury responses without disrupting the BBB and with the added benefit of 
being able to separate out the role of microglia from invading monocytes (Kettenmann 
et al., 2011). Following on from Kreutzenberg’s work, the introduction of an efficient 
technique for isolating large numbers of microglia from rodent brains by Giulian and 
Baker (1986), allowed more detailed in vitro studies of microglia to be undertaken. 
Microglia have since been shown to exist in a distinct ‘resting’ state, associated with 
healthy tissue. However, they are armed with the ability to rapidly and profoundly alter 
their cell morphology, gene expression and functional behaviour in response to 
traumatic or detrimental alterations in tissue conditions. This alteration from the typical 
resting state has since been termed microglial activation, and enables microglia to return 
to a more mobile phenotype allowing them to migrate to sites of damage or infection by 
following a chemotactic gradient. Tissue damage can also induce an increase in 
microglial cell proliferation, with microglial cells playing a crucial role in the 
coordination of the CNS immune response but also in the subsequent re-establishment 
and maintenance of a healthy tissue environment and cellular population. 
More recent research has overturned the long-term belief that microglial cells 
present within a healthy brain environment were quiescent and functionally dormant. 
Scientists have now indicated that even under optimal environmental conditions 
microglial cells are constantly scanning their surroundings, with resting motility of 
cellular projections occurring in as little as a couple of minutes (Davalos et al., 2005; 
Nimmerjahn et al., 2005). It has also been demonstrated that microglia are capable of 
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communicating directly with neurons even whilst maintaining their so-called ‘resting 
state’ (Tremblay et al., 2010; Li et al., 2012). This may in turn suggest a role for the 
constant microglial adjustment in aiding microglia to respond rapidly to perceived 
threats.  
The activation of microglial cells can, in a similar manner to classical 
macrophages, be subdivided into two predominant phenotypes defined by their 
chemical profiles as either pro-inflammatory (M1) or anti-inflammatory (M2). Although 
not always mutually exclusive, as some cytokines such as interleukin (IL)-6 can have 
both pro- and anti- inflammatory roles, a subset of well-established inflammatory 
mediators are often used to ascribe either an M1 or M2 phenotype to macrophages and 
microglial cells. Characterisation of an M1 phenotype is often confirmed through the 
presence of cytokines including IL-1β , tumour necrosis factor-α (TNF-α) and high 
levels of IL-12, in combination with other cell markers, such as chemokines, and 
activation of stress-induced pathways including NF-κB (Martinez & Gordon, 2014). In 
contrast, an M2 phenotype is more often attributed in the presence of high levels of IL-
10 combined with low IL-12, increased expression of transforming growth factor-β 
(TGF-β) and, in mice, heightened expression of markers such as YM1 (aka chitinase-3-
like protein-3; Chi3l3) and arginase-1 (Arg1). However, what is becoming increasingly 
clear is the complex ability of the stimuli-response interaction to define the resulting 
macrophage response; preventing the absolute categorisation of many of the 
subsequently expressed signalling molecules. 
Recent work has suggested a potential priming ability of microglial cells, 
exemplified by a heightened response to any secondary stimuli. This usually results in 
an increased M1 like phenotype with an amplified release of known pro-inflammatory 
markers. Ageing has been suggested as one of the factors capable of inducing a priming 
effect in microglial cells (Dilger & Johnson, 2008), with studies using animal models 
suggesting an important role for ageing in altering the manner in which the immune 
system responds to challenges (Luo et al., 2010). Ageing being the biggest risk factor 
for many neurodegenerative conditions it is maybe not surprising that microglial 
priming and alterations in both microglial and astrocytic responses have been associated 
with not only AD but also PD, Prion’s disease and ALS amongst others (Li et al., 2004; 
Cunningham et al., 2005; Purisai et al., 2007; Schilling & Eder, 2011; Ramaglia et al., 
2012). It is also worth making note of the association of infection related immune 
insults in the aged and a propensity for increased development of neurodegenerative 
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diseases including direct effects on immune related cells such as microglia and 
astrocytes (Butovsky et al., 2005; Henry et al., 2009; Hughes et al., 2010; Sy et al., 
2011). For more information and a thorough and exhaustive review on microglial 
physiology and function, one should refer to the work published by Kettenmann and 
colleagues (2011). 
1.5 AD AND THE IMMUNE SYSTEM RESPONSE 
Along with OS, a role for alterations in the immune system has been suggested 
as being influential in the development of AD. In particular an increased presence of 
inflammation and associated markers has been reported in patients diagnosed with AD. 
However, the immune response is a highly intricate and diverse system with multiple 
potential points of activation and some of these responses will be affected by the 
relatively isolated status occupied by the brain. This is largely due to the bodies 
additional protective barriers placed around this potentially highly vulnerable organ 
which include such shielding measures as the BBB. 
1.5.1 Innate vs Adaptive Immune Response 
Two main forms of immune response exist in humans and are largely conserved 
throughout the mammalian kingdom. These are the innate and adaptive immune 
response and they each have key roles in the adaptation of the body to detrimental 
events such as infections and trauma (Parkin & Cohen, 2001). The innate immune 
system is responsible for any immediate reaction to a perceived threat. It does not 
differentiate between specific pathogens and instead relies on the recognition of 
conserved features of pathogens by its arsenal of cells to induce an activation cascade 
capable of destroying the threat. Activation of the innate immune pathway can lead to 
two main outcomes, which are inflammation and phagocytosis. Included in the cells that 
are involved in phagocytosis are the macrophages such as the microglia of the CNS 
described previously. As they can also be present in permanent resident form, they are 
some of the first immune cells to respond to an insult and therefore play and important 
role in the initiation of the immune response cascade both releasing and being targeted 
by many of the important signalling compounds involved in the orchestration of the 
immune response. 
On the other hand, as the name suggests the adaptive immune system relies on 
building up a library of previous pathogen exposures, allowing it to produce specific 
immune responses targeted to individual pathogens following any re-exposure. This 
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tends to be a slower process than the innate immune response and is reliant on 
information from prior exposure to function. However, it is worth noting that many 
immune cells will not exclusively be activated by either immune pathway and cells 
including the likes of macrophages can be activated by both the innate and acquired 
immune pathways through differing mechanisms (Davies & Taylor, 2015). By this 
stage, it is clear that the immune system comprises a highly complex network of 
reaction cascades as well as cell types, all of which are capable of catering to specific 
components of a toxic insult or injury. 
1.5.2 Neutrophils, natural killer cells, B Cells and T Cells; the 
contribution of the blood born immune cells 
Balancing factors from both the innate and adaptive immune system, blood born 
immune cells play a crucial role in the response to immune challenges. Participants in 
the innate immune response such as neutrophils and natural killer (NK) cells are able to 
rapidly respond to novel immune threats. Neutrophils, the most abundant type of white 
blood cell in the majority of mammals, are rapidly released from the bone marrow into 
the blood upon immune activation and react to cytokines and chemokines in order to 
orient themselves towards the target site (Parkin & Cohen, 2001). They are one of the 
hallmark cells in the acute phase response of the innate immune system and have just 
recently been suggested to play a more active role in the development of hallmark 
pathologies related to AD (Zenaro et al., 2015).  
Believed to be involved in obesity-related peripheral inflammation, B-cells, T-
cells and NK cells are all lymphocytes, with both B- and T- cells playing central roles in 
the adaptive immune response (Seijkens et al., 2014). B-cells are primarily responsible 
for the production of an immune antibody response and are activated and released from 
the spleen having migrated there from the bone marrow. Furthermore, memory B-cells 
circulate in the blood stream and enable the rapid response to previously detected 
antigens typical of the adaptive immune system. T-cells, which mature in the thymus 
instead of the spleen, are split into different sub-families according to their 
physiological role, and include T helper cells and natural killer T cells. Whilst T-helper 
cells aid other members of the immune response as the name suggests, natural killer T 
cells help bridge the gap between the innate and adaptive immune response by 
recognising glycolipid rather than major histocompatibility complex (MHC) molecules. 
Finally, NK cells are critical to the innate immune system instead of the adaptive 
immune response, providing backup to the neutrophil response they differ from other 
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lymphocytes as they do not require MHC markers and antibodies in order to detect 
stressed cells, thereby filling a niche role within the immune system (Parkin & Cohen, 
2001). The role of many of the key blood born immune cells in the inflammatory 
response in neurodegenerative disorders, such as AD, was for many years deemed 
minimal, with the majority of the immune response triggered in AD believed to be 
driven and regulated by resident immune cells such as microglia (Heneka et al., 2015). 
However, recent work has supported a role for peripherally derived immune cells in the 
promotion of AD pathology and may coincide with impairment of the BBB and amyloid 
deposition in the vasculature (Togo et al., 2002; Baik et al., 2014; Zenaro et al., 2015). 
1.5.3 The Role of Chemokines and Other Signalling Molecules in the 
Immune Pathway 
As was described previously, it is already understood that resident immune cells 
such as microglia can undergo differentiation or priming to promote either of two 
different cell profiles. These are described as either a pro-inflammatory M1 profile or a 
resolution state designated as M2. Key to distinguishing these two differentiation states 
is the individual signalling molecule profile associated with them. Signalling molecules 
such as cytokines and chemokines are essential in aiding the orchestration of the 
immune system’s response to a perceived threat. They also play a role in identifying 
potentially relevant downstream pathways for further investigation as the presence of 
specific molecules may predominantly favour the activation of particular downstream 
signalling. 
1.5.3.1 Pro-inflammatory Signalling 
Key members of the pro-inflammatory signalling pathway, which as the name 
indicates promotes the maintenance of an inflammatory state, are well characterised and 
include cytokines such as IL-1β, TNF-α, and interferon-γ (Mosser & Edwards, 2008). 
Other pro-inflammatory signals include the likes of inducible nitric oxide synthase 
(iNOS), which is primarily driven by the presence of an oxidative environment. 
Markers such as IL-6, as mentioned previously, are capable of acting in either a pro- or 
anti-inflammatory manner depending on the context of the exposure. Release of pro-
inflammatory signals, as well as instigating the activation of many pathways within the 
immune system such as the activation and/or recruitment of immune cells, can also 
initiate subsequent downstream signalling leading to changes in both gene and protein 
markers. An example can be made of IL-1β, which subsequent to cleavage by caspase 1 
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can impact on numerous cellular processes including cell differentiation and targeting of 
cells for apoptosis.  
IL-1 is a small family of cytokines comprising to date eleven members, with the 
two well most well-known and best-characterised isoforms known simply as IL-1α and 
IL-1β (Palomo et al., 2015). Products of two separate genes present on chromosome 2, 
both IL-1α and IL-1β are produced as precursor proteins requiring cleavage to present 
their mature form (Patel et al., 2003). And whilst pro-IL-1α is active prior to cleavage, 
although its activity is significantly enhanced following cleavage; pro-IL-1β requires 
activation by the converting enzyme, caspase 1. Cleavage of IL-1β by caspase 1 occurs 
upon activation of the inflammasome, which is integral to caspase-1 activation. 
Initiation of inflammasome production is an important part of the innate immune 
response when challenged with PAMPs (e.g. LPS) and DAMPs (e.g. Aβ) and its 
composition includes several pattern recognition receptor (PRR) families such as 
nucleotide-binding domain, leucine-rich repeat containing protein receptors (NLRs) and 
the absent in melanoma 2-like receptors, both of which are present in the human and 
mouse complex (Takeuchi & Akira, 2010).  
Upon stimulation, relevant members of these families can oligomerise and form 
a caspase-1-activating scaffold whereby inactive pro-caspase-1 is recruited and as a 
result of oligomerisation is autoproteolytically cleaved to its active form. Although 
some stimuli dependent variations are observed in inflammasome make-up and activity, 
in general their role remains very similar with the majority combining to form a 
variation on a caspase-1 scaffold. NLRP3 inflammasome, so called after the 
predominant protein used to construct it, responds to the widest array of stimuli and 
these can include those such as mitochondrial ROS production, release of cathepsin B 
from ruptured lysosomes and the translocation of NLRP3 to the mitochondria (Guo et 
al., 2015). In the majority of cell types, NLRP3 must be primed, an example of which is 
through lipopolysaccharide binding to the PRR toll-like receptor-4 (TLR4). In addition, 
breaking research has shown that inflammasomes may play a key role in the 
propagation of inflammation from cell to cell (Franklin et al., 2014). Furthermore, 
activation of IL-1β signalling as a result of inflammasome formation and activity has 
now been linked with the development of not only AD, but also some of the other 
known risk factors for AD, such as type II diabetes (TIID), as well as other forms of 
neurodegenerative disease including PD (Hook et al., 2008; Stienstra et al., 2011; 
Vandanmagsar et al., 2011; Yan et al., 2015).  
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1.5.3.2 Anti-Inflammatory Signalling 
As for the pro-inflammatory signalling molecules, interleukins can also play an 
important role in the so-called anti-inflammatory or resolution pathway. Molecules 
involved in the termination of an inflammatory or immune response are most commonly 
engaged in roles such as the down-regulation of pro-inflammatory signals (including 
those mentioned above), enhancing removal of cellular debris and dysfunctional cells, 
as well as promoting healthy cellular regrowth where necessary. In other words, 
following activation of the inflammatory pathway and recruitment of immune cells by 
inflammatory markers, under normal conditions the anti-inflammatory signalling 
promotes the resolution of the immune response and a return to a healthy tissue 
environment. One of the most characterised anti-inflammatory cytokines is another 
member of the interleukin family, IL-10. Although first described as a T helper 2 
(TH2)-type cytokine, expression of IL-10 has since been shown to be much more 
widespread than a single cell type within the adaptive immune system. Expression of 
IL-10 is now known to be associated with many immune cell types including a variety 
of different adaptive immune cells, such as T-cells and  B-cells, as well as cells forming 
part of the innate immune response, such as myeloid dendritic cells (DC), macrophages, 
NK cells and neutrophils (Saraiva & O'Garra, 2010). IL-10 has been shown to play an 
active role in the suppression of pro-inflammatory cytokines such as many of those 
listed above and has been shown to be decreased in chronic inflammatory diseases such 
as multiple sclerosis. However, interleukins are not the only signalling molecules 
capable of attenuating an inflammatory state. Molecules such as Arg1, YM1 and 
mannose receptor 1 (MRC1) are just some of the other commonly represented anti-
inflammatory markers in the literature (Mosser & Edwards, 2008). 
1.5.3.3 Chemokine Signalling 
Chemotactic cytokines, better known as chemokines, are a group of small 
signalling molecules secreted from cells that act as chemoattractants and activate both 
immune and non-immune cells in the periphery as well as the CNS. With the first 
chemokine identified in 1977 (platelet factor 4 aka CXCL4), the understanding of the 
importance and variety of roles performed by these small chemokines has greatly 
increased. Due to the size the chemokine family has reached in current times, it has 
been subdivided into four families based on the number and spacing of the conserved 
cysteine residues in the N-terminal position. These families are labelled CXC, CC, 
CXC3 and C, and are named according to the systematic nomenclature. However, as 
many compounds were only later identified as having chemokine activity; many 
37 
chemokines have two nomenclatures still in regular use. A list of some of the 
chemokines more frequently associated with neurodegenerative diseases can be found in 
Table 1.1; and whilst many are widely expressed due to their key role in recruitment of 
immune cells, a small subset has been suggested as being dysregulated in AD 
(McLarnon, 2012). 
Signalling through members of the G-protein coupled receptor family, 
chemokines are believed to largely induce downstream inductions through the Gαi 
pathway (Ransohoff, 2009). Alternative pathways, however, also include activation of 
MAPK enzymes, such as the insulin sensitive extracellular-signal-regulated kinases 
(ERK) 1/2 MAPK. Although many chemokines can be produced and released by 
circulating immune cells, they have also been shown to be expressed in resident 
regulatory cells such as the astrocytes and microglia of the CNS, and more recently in 
neuronal cell populations (Rostène et al., 2011). They are important modulators of the 
immune response throughout the body, however, they are particularly crucial within the 
CNS and the brain where there is often an altered immune response in comparison to 
that observed in the periphery (Ransohoff, 2009). Recent work has also indicated an 
endocrine role for some of the chemokines expressed natively in the brain. This may be 
of importance with regards to alterations in hormonal and immune response during 
disease (Callewaere et al., 2007). 
Chemokine Chemokine 
Receptor 
Cell recruitment and function 
MCP-1 
(aka CCL2) 
CCR2 Phagocyte infiltration and microglial accumulation 
MIP-1α 
(aka CCL3) 
CCR1, 
CCR5 
Accumulation of activated glial cells and T cells, 
migration of immune cells from blood to brain 
RANTES 
(aka CCL5) 
CCR1, 
CCR3, 
CCR5 
Migration of peripheral immune cells, potential 
induction of alternative microglial immune 
response 
IL-8 
(aka CXCL8) 
CXCR2, 
likely CXCR1 
Potent chemoattractant for activated microglia and 
neutrophils 
SDF-1 
(aka CXCL12) 
CXCR4 Attracts both brain and peripheral immune cells, 
anti-inflammatory 
Fractalkine 
(aka CX3CL1) 
CX3CR1 Suppression of microglia activation, 
neuroprotective 
Table 1.1 Summary of commonly quoted chemokines, their receptors and their 
main physiological functions in relation to AD.  
Where MCP-1 is monocyte chemotactic protein-1, MIP-1α is macrophage inflammatory 
protein-1α, RANTES is ‘regulated on activation, normal T cell expressed and secreted’ and 
SDF-1 is stromal cell-derived factor-1. See Azizi et al. (2014), Lee et al. (2012a) and Bose & 
Cho (2013), McLarnon (2012) for further information. 
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1.5.4 The Complement Immune System 
Members of the complement 
immune system stem largely from the 
liver, and can be found circulating 
within the blood stream and the 
extracellular fluid within tissues. 
They are a family of distinct plasma 
proteins, many of which are proteases 
that are themselves activated by 
proteolytic cleavage, and are 
responsible for the activation of the 
complement cascade which promotes 
the phagocytosis and/or lysis of 
pathogens. Although three activation 
pathways exist for the complement 
cascade, namely classical, lectin and 
the alternative pathway, they all 
combine to produce the same end 
function (Figure 1.11). The classical 
pathway is activated through 
exposure to activators, and these can 
include factors such as immune 
complexes, microbes and even 
certain specific protein motifs including fibrillar amyloid (Veerhuis et al., 2011). 
Activation of the pathway prompts the cleavage of C3 to form C3b which plays a key 
role in targeting molecules for phagocytosis. Working via an approach termed as 
opsonisation, C3b is deposited on the outer membrane of microbes with its presence 
targeting those molecules for phagocytosis and increasing the rate at which pathogens 
are neutralised.  
Induction of the alternative pathway dispenses with the need for activators, 
relying instead on spontaneous hydrolysis of the internal thioester bond of circulating 
C3 to form so called ‘C3b-like C3’ which in turn binds with a second factor, factor B. 
This is itself cleaved to form C3 convertase initiating the cascade. As no outside 
initiator is required, the alternative pathway provides a constant turnover and 
Figure 1.11 Simplified overview of 
complement system activation and its key 
physiological outputs 
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availability of the key opsonising C3b molecule of the complement system through tight 
balance of regulatory factors. Finally, the lectin pathway responds to PAMPs by 
recognition of mannose-binding lectin (MBL). MBL binds repeated carbohydrate 
patterns on the surface of pathogens and specific protease members of the complement 
cascade (MBL-associated serine protease; MASPs) recognise MBL initiating activation 
of the system (Bonifati & Kishore, 2007). Following activation, the individual strands 
of the complement system coalesce to activate cleavage of the focal C3 protein. It is this 
fragmentation of the C3 protein that drives the immune system response, allowing for 
cascading cleavage of subsequent complement proteins and induction of the 
inflammatory, phagocytic and lysis responses associated with the complement immune 
system. 
In recent years, research has indicated a role for the complement system in AD 
along with alterations in a multitude of other immune related proteins. Increased gene 
expression of complement related proteins have been shown in the brains of AD 
patients (Yasojima et al., 1999; Strohmeyer et al., 2000). Whilst later work has linked 
progression of AD, as measured by the well described Braak stage scale, with 
progressive alterations in the particular subset of complement proteins demonstrating 
the highest degree of expression (Veerhuis et al., 2011). Recent work using AD animal 
models has also supported a role for the complement system in AD (Chakrabarty et al., 
2010), although mouse models of AD may not prove to be the optimal system to 
investigate changes in complement induction (Reichwald et al., 2009). 
1.5.5 The Immune System and Its Response to Infection 
Infection, which is a common activator of our immune system from birth, has 
also been implicated in neurodegenerative conditions. Susceptibility to infectious agents 
is correlated with aging once past infancy. In addition, an increased presence of 
infection related markers such as LPS or endotoxins have been associated with 
disorders demonstrating chronic low-grade inflammation such as obesity, TIID, 
atherosclerosis, etc.. 
Of particular importance in many infection-related responses are the TLRs, 
members of the PRR family. Present on most residential immune cells, TLRs are a key 
part of the innate immune system recognising structurally conserved microbial 
molecules. In humans, there are ten known forms of TLRs with additional and 
alternative receptors identified in rodents. TLRs share common motifs with the 
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interleukin-1 receptors and many interleukin cytokines will target TLRs during an 
immune response. Through the use of genetically modified mouse strains, it has been 
established that each individual TLR is responsible for the response to a specific subset 
of molecules. In the case of LPS, found in the outer membrane of gram negative 
bacteria such as those responsible for meningitis and meningococcal disease, activation 
is through the TLR4 receptor and is one of the better documented TLR pathways. 
Known to be present to varying degrees in even so called healthy individuals, LPS is 
commonly used as an infection-inducing agent in research in areas including 
metabolism, immunology and drug development. Studies have previously demonstrated 
the presence of an increased endotoxin load under conditions of DIO (Cani et al., 2007). 
More recent studies have also indicated a potential role for LPS in the development of 
insulin resistance and resulting metabolic disruption, indicating it may have a more 
specific role to play in energy metabolism related disorders than simply aiding in the 
maintenance of a chronic inflammatory state (Lassenius et al., 2011; Pussinen et al., 
2011). Whilst interest of late has also lighted on a potential role for systemic infections 
in the development of certain neurodegenerative diseases including AD (Sly et al., 
2001; Sheng et al., 2003; Cunningham et al., 2009; Krstic et al., 2012), mutation of the 
TLR4 receptor has been shown to impact on Aβ pathology in a mouse model of AD, 
increasing pathology and negatively impacting on cognition (Song et al., 2011). Finally, 
the impact of LPS on the ageing system in AD may be of particular importance given 
the potentiating effect observed when PAMPs and DAMPs are present in the same 
environment (Heneka et al., 2014). 
1.5.6 The Immune System and Disease 
Designed to protect the body from perceived damaging exposures such as 
infection and trauma; the immune system as a whole, like other pathways, is still open 
to dysregulation. In fact, dysregulation of the immune system is the primary cause of 
diseases of the autoimmune variant such as ALS, and altered immune responses have 
been associated with long-term chronic inflammation such as occurs in obesity. It is 
now well established that increased inflammatory responses and activation of the 
immune system occur in many forms of neurodegenerative disease and AD is no 
exception. Links have been shown between increased inflammatory markers such as IL-
1β and TNF-α, alterations in chemokine profiles and increased activation of resident 
regulatory glial cells often inducing increased infiltration of immune cells such as 
peripherally derived macrophages and neutrophils. Increased expression of molecules 
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such as the chemokines MCP-1, fractalkine, MIP-1α, MIP-1β, RANTES and interferon-
γ induced protein-10 (IP-10/CXCL10) in reactive astrocytes have all been linked with 
AD pathology in vitro (Johnstone et al., 1999; Xia et al., 2000). And whilst many 
patient cohort studies have failed to consistently report changes in specific circulating 
cytokines as measures of disease progression, it is well accepted that there is a localised 
presence of inflammatory cytokines occurring during neurodegeneration.  
Another avenue down which dysfunctional activation of the immune system has 
been linked with neurodegenerative diseases, such as AD, is through the presence of 
increased markers of peripheral microbial infection such as LPS. In vitro studies have 
indicated that LPS is capable of interacting with amyloid production and its metabolism, 
with ICV LPS accelerating the rate of amyloid pathology in mice modelling the human 
APP Indiana (APPV717F) mutation (Qiao et al., 2001). Furthermore, IP LPS has been 
suggested to increase amyloid deposition and the ratio of Aβ1-42:Aβ1-40 in WT ICR mice, 
with cognitive impairment also associated with LPS treatment of these mice (Lee et al., 
2008). Moreover, phagocytosis and LPS-driven inflammation have been reported to 
increase the expression of both APP and Aβ from mononuclear phagocytes, providing a 
direct connection between LPS driven inflammation, activation of immune cells and 
increased amyloidogenic processing of APP (Spitzer et al., 2010). And there are 
indications of heightened levels of LPS in the plasma of patients presenting with either 
mild cognitive impairment (MCI) or AD despite being termed free of active infection 
when bloods were taken (Zhang et al., 2009). Finally in the elderly, these detrimental 
impacts from the immune system response occur in an environment also impaired by 
decreased levels of Nrf2 as a result of its natural age related decline. 
1.6 LIFESTYLE RELATED RISK FACTORS FOR AD 
As has been previously described there are no causative genetic mutations 
associated with sporadic AD, unlike the early onset FAD. The strongest risk factor is, in 
fact, simply age. Accordingly, research has been on-going to identify further risk factors 
with strong correlations to AD in order to aid in the targeting of new treatments and in 
the identification of potential early disease mechanisms. As might be expected, a 
selection of known health risks have now also been correlated with increased risk of 
developing AD including factors such as smoking, hypertension, obesity and TIID. 
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1.6.1 Hypertension and Vascular Dysfunction 
Hypertension is itself a risk factor for cardiovascular events as well as being one 
of the triad contributing to metabolic syndrome, the other two being TIID and obesity. 
However, long-term hypertension is not limited to a detrimental effect on the periphery 
and is also a risk factor for cerebral events such as stroke. As a result, it is more 
commonly associated with VaD. As the name suggests, VaD results from impaired 
blood supply to the brain such as may occur following a series of small strokes, or may 
result from small vessel disease impairing blood flow in the microvasculature of the 
brain. The cerebral microvasculature encompasses the network of capillaries within the 
brain, but also the small arterioles and venules that support the capillary bed. It is 
damage to this vital supply network along with parts of the microvasculature that have 
been used to describe the vascular damage seen in both AD and VaD. More specifically, 
Aβ deposition has been shown to impact on vessel health through a reduction in vessel 
density, increases in the number of fragmented vessels present and changes in vessel 
diameter amongst others that have been used to describe the vascular changes observed 
in both AD and VaD (Zlokovic, 2005). Although VaD is classified as a separate form of 
dementia, a proportion of all dementia sufferers are diagnosed with so called mixed 
dementia, which is most often described as a combination of both AD and VaD 
pathologies. However, in more recent years this distinction has been questioned and the 
lines between AD and cerebrovascular disease, of which VaD is a form, have blurred 
with hallmark pathologies crossing the divide from both sides (Smith & Greenberg, 
2009; Kalaria, 2010).  
Changes in hypertension, as well as cholesterol and obesity, are known to be 
relatively complex in persons who go on to develop dementia. Patients presenting with 
AD have been shown to have lower blood pressure, cholesterol and body mass index 
(BMI) despite high levels of all of these factors in mid-life being associated with AD 
development. Recent research suggests AD driven impairment of the hypothalamus, 
mediated by increased inflammation and endoplasmic reticulum (ER) stress, may be the 
driving factor behind this switch in presenting phenotype (Ishii et al., 2014; Clarke et 
al., 2015). Aβ deposits have been shown to occur in the vasculature, and some groups 
suggest that lesions within the microvasculature may be some of the early symptoms of 
AD (Marchesi, 2011). It is now thought that the majority of Aβ vessel damage starts in 
the leptomeningeal and cortical cerebral vessels, before spreading to the subcortical 
layers and beyond (Viswanathan & Greenberg, 2011). Aβ is deposited on the outer 
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walls of vessels, where impaired clearance results in protein aggregation which works to 
undermine the vessels outer wall through the destruction of smooth muscle cells, 
leading to vessel weakening (Thal et al., 2008). Furthermore, vascular deposition of 
amyloid is associated with increased inflammation, increased risk of cerebral 
angiopathy and impaired blood flow leading to increased risk of hypoxic damage 
(Agyare et al., 2013). Aβ-related vascular damage continues spread inwards through the 
lamina following the disruption of the smooth muscle cells within the damaged vessels 
(Grinberg et al., 2012). Although it is worth noting that limited structural damage to the 
subsequent endothelial layer has been reported, suggestions of functional impairment 
have been made, with administration of Aβ inducing endothelial constriction (Park et 
al., 2011).  It is thought that increased deposition of damaging proteins and damage to 
the vasculature resulting from conditions such as hypertension, promote a detrimental 
environment towards the maintenance of healthy vascular function and contribute to 
both AD and VaD (Smith & Greenberg, 2009; Sosa-Ortiz et al., 2012). In addition it has 
also been suggested that key proteins believed to be involved in the transport of Aβ into 
the circulation, such as low-density lipoprotein receptor-related protein 1 (LRP1) in 
smooth muscle cells and CD36 in the endothelium, may be downregulated and/or 
impaired in AD (Park et al., 2011; Kanekiyo et al., 2012). These may prove to be useful 
alternative targets for future treatment initiatives. 
1.6.2 Obesity and Inflammation 
It is well established that there is an obesity epidemic spreading across both 
developed and developing countries; driven at least in part by our more sedentary 
lifestyle and increased consumption of refined food products marked by increased 
dietary consumption of fats and sugars. Incidences of obesity have more than doubled 
since 1980 according to the WHO, with almost 40% of the world’s adults overweight in 
2014 and 13% obese (WHO, 2015b). Obesity is defined as abnormal or excessive fat 
accumulation that may impair health and is directly caused by a positive energy 
imbalance resulting from increased energy consumption versus energy expenditure in an 
individual. Alteration of this energy balance results in a plethora of effects on both 
hormonal and metabolic pathways such as reduced respiratory quotient, 
hyperinsulinaemia, glucose intolerance and low grade inflammation (Lee, 2011). This 
imbalance is what leads to the subsequent hypertrophy and hyperplasia of white adipose 
tissue (WAT; de Ferranti & Mozaffarian, 2008). However, it is worth noting that WAT 
is not solely made up of adipocytes with other components including fibroblasts, 
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resident macrophages and monocytes playing just as important a role (Vázquez-Vela et 
al., 2008). 
The obesity driven storage of excessive lipids and subsequent adipocyte 
dysfunction combine to enable excess circulation of free fatty acids. The release of pro-
inflammatory mediators from dysfunctional WAT, combine with changes in other 
important tissues including the liver and the CNS, to induce the establishment of a pro-
inflammatory state following a high fat (HF) diet. Adipose derived factors, such as 
TNF-α, IL-6, IGF-1, are known to be increased in the circulation of people diagnosed 
with obesity, along with crucial hormones responsible for managing energy 
homeostasis, such as leptin and resistin (Vázquez-Vela et al., 2008). These factors 
combine to bring about a state of both central and peripheral leptin and insulin 
resistance and lead to glucose intolerance (Arnold et al., 2014; Davis et al., 2014). A 
secondary consequence of the change in cytokine output is an alteration of the resident 
WAT macrophages from the traditional M2 profile associated with healthy WAT, to the 
classically activated M1 profile. This in turn promotes the recruitment and M1 
differentiation of further macrophages, propagating and maintaining the inflammatory 
state whilst obesity persists (Balistreri et al., 2010). More recently data has indicated a 
role for central insulin and leptin signalling impairment in AD leading to insulin and 
leptin resistance in the brain. Central insulin resistance in AD has been suggested to be 
linked to insulin receptor relocation with a diminished presence of downstream insulin 
signalling products (Zhao & Townsend, 2009; Moloney et al., 2010). In addition, mouse 
models of AD have been shown to present with attenuated levels of leptin in the brain 
which may be linked to impaired hypothalamic signalling and an inhibition of leptin 
signalling following accumulation of leptin receptor within NFT (Pérez-González et al., 
2011; Bonda et al., 2014; Ishii et al., 2014; Perez-Gonzalez et al., 2014). 
As mentioned previously, obesity in midlife has been associated with increased 
risk of AD despite AD itself being associated with a consistent decrease in bodyweight 
over time (Marchesi, 2011). Of particular relevance to AD, are the chronic 
inflammatory state induced by obesity along with the alterations in insulin and leptin 
signalling. Studies performed in rodents have shown associations between HF diet-
induced obesity and memory impairment in a variety of tasks, strengthening the 
potential link between obesity and AD (Granholm et al., 2008; White et al., 2009; 
Morrison et al., 2010; Pistell et al., 2010; Freeman et al., 2011). Many of the other 
disorders that commonly accompany obesity have also been intimated as risk factors in 
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their own right for AD, and these include hypertension (see 1.6.1), TIID (see 1.6.3), 
chronic activation of immune cells and elevated presence of infectious agents such as 
LPS (see 1.5.6; Cani et al., 2007; de La Serre et al., 2010; Lee, 2011; Oliveira et al., 
2011; Nakarai et al., 2012). 
1.6.3 Diabetes Mellitus and Insulin Resistance 
Diabetes mellitus of the type II variant, otherwise known simply as TIID, results 
from a dysfunction of the body’s use of the insulin it produces along with chronic 
elevation of circulating glucose. It is far more common than the earlier onset type I 
variant, accounting for approximately 80% of cases, and is strongly associated with 
previously described risk factors for AD such as hypertension and obesity. The 
pathophysiological factors behind TIID are limited to dysfunction of the insulin 
pathway. Twofold, they are described as deteriorating function of the insulin secreting 
β-cells of the pancreas, and the diminished effect of insulin on its various target tissues 
which has since been termed insulin resistance (Correia et al., 2012).  
Insulin resistance is linked with increased levels of OS and mitochondrial 
dysfunction, promoting cell death; all of which are also markers associated with late-
onset AD. Furthermore, patients under treatment for TIID that are given insulin have the 
highest chance of going on to develop dementia (van der Heide et al., 2006). However, 
this should be balanced by the increased severity of the disease, which is usually 
associated with insulin prescription. Insulin itself has been shown to accelerate APP 
metabolism to Aβ by increasing the rate at which Aβ is trafficked from the Golgi and 
trans-Golgi network to the plasma membrane. Insulin also promotes secretion of Aβ and 
prevents degradation once released, by inhibiting the insulin-degrading enzyme. It 
would also appear that once present at a high enough concentration, Aβ can further 
deregulate insulin signalling by acting as a competitive inhibitor to insulin binding (van 
der Heide et al., 2006; de la Monte, 2009; Cholerton et al., 2011). This is supported by 
research from our lab showing that inhibition of BACE1 in animal models increases 
insulin sensitivity and decreases circulating glucose levels (Meakin et al., 2012). 
BACE1 inhibition in particular, as well as insulin sensitisation, could have beneficial 
effects on preventing AD development. 
In addition to the functional changes mentioned above, insulin has also been 
linked with alterations in learning and memory. Studies of acute insulin administration 
consistently show improvements in spatial memory formation through hippocampal site 
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activation (Park et al., 2000; Zhao et al., 2004; Haj-ali et al., 2009). Furthermore, 
mouse models of AD presenting with induced impaired insulin sensitivity have shown 
aggravated disease pathology (Ho et al., 2004; Devi et al., 2012). Clinical trials using 
acute insulin treatment have also been performed, most commonly with intranasal 
insulin administration. These appear to replicate other acute trials performed in rodents, 
with many showing improved cognition following treatment (Craft et al., 2012). It is 
clear therefore from the complex and sometimes contradictory effects of chronic vs 
acute insulin administration and its relationship with ageing and AD that insulin is 
intimately linked with many aspects of AD pathology. What is still unclear is whether 
these alterations are part of the causative process aiding in initiation of the disease or 
whether they occur as a result dysfunction within alternative pathways. 
1.7 NRF2 IN DISEASE PATHOLOGY 
The ubiquitous expression profile of Nrf2, in combination with the large number 
of genes under its control, has lent it to be a subject of interest in a variety of disease 
pathologies. Links have been established between Nrf2 and degenerative diseases as 
diverse as various forms of cancer, obesity and associated non-alcoholic steatohepatitis 
(NASH), kidney disease and more recently neurodegenerative disorders such as PD and 
AD. 
1.7.1 Cancer 
Despite being the most heavily researched function of Nrf2 to date, the role of 
Nrf2 in cancer remains unclear, appearing to play a role at both ends of the spectrum. 
As previously explained, too little Nrf2 heightens ROS production and impacts cellular 
health and protection. Concurrently, heightened Nrf2 expression is present in many 
forms of cancer, often as a result of somatic mutation-induced constitutive activation 
attenuating cellular apoptosis and promoting tumour propagation (Wang et al., 2008; 
Hayes & McMahon, 2009). As a result, although Nrf2 is clearly important both in its 
ability to prime an environment for pre-cancerous changes it is also capable of aiding 
established tumour growth and progression. Taken together, current research warrants 
further work in this field to establish the intricacies of the role Nrf2 is clearly able to 
play. Further research is also necessary to establish any potential for Nrf2 as a 
therapeutic target for cancer, and whether its usefulness will be overly limited by its 
opposing roles. Furthermore, this knowledge can serve as a cautionary tale regarding the 
duplicitous and complex role played by Nrf2 in disease development.  
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1.7.2 Metabolic Syndrome and NASH 
Whilst the relationship between metabolic syndrome and AD has been portrayed 
earlier, the role of Nrf2 has yet to be described. In order to better understand the varied 
and vital roles that Nrf2 appears to play within diverse disease progressions, it is 
important to demonstrate the intricate and varied effects such a ubiquitously expressed 
protein is capable of exerting. This is well exemplified by the complexities of Nrf2 
involvement within the different symptoms of the metabolic syndrome. 
1.7.2.1 TIID and obesity  
As discussed previously, there have been numerous publications linking obesity 
and TIID with development of AD. In turn there have been roles suggested for Nrf2 in 
the progression of obesity and in TIID development; although this is a relatively new 
area of research with regards to Nrf2. Nrf2 has been implicated in the development of 
insulin resistance, lipogenesis and adipogenesis (Seo & Lee, 2013). However, the 
described relationship of Nrf2 with obesity is not clear-cut as has been demonstrated by 
some of the studies published in recent years. In order to further dissect the potential 
role of Nrf2 in metabolic disease, researchers have proceeded down one of two routes: 
through increased Nrf2 activity by pharmacological activation or through the use of 
Keap1 knock down (KD) and/or Nrf2 knockout (Nrf2
-/-
) animal models of Nrf2 
dysregulation. 
Gene expression studies have confirmed the multitude of genes regulated in an 
Nrf2 dependent manner, and have enabled scientists to classify them broadly into two 
different groups (Abdullah et al., 2012; Chartoumpekis et al., 2013). Those are: 1) 
Shared antioxidant genes present across different tissues analysed and largely involved 
in the tissues defence against damaging factors such as oxidants and electrophiles; and 
2) tissue specific families of genes that are relevant to particular correct management of 
functions essential to the tissues in question. Of particular relevance to the impact of 
Nrf2 on metabolic syndrome, is the subset of genes found to be specifically regulated by 
Nrf2 within the liver. These genes are largely linked with the management of lipid 
homeostasis and more specifically the metabolism of fatty acids and other lipids. The 
fact that these genes are primarily repressed by Nrf2 has been confirmed recently in an 
expression study using Nrf2
-/-
 mice (Chartoumpekis et al., 2013). These discoveries 
suggest a potentially important link between Nrf2 activity and the development of 
aspects associated with metabolic syndrome such as TIID and obesity, both of which 
are associated with energy imbalances and alterations in the management and roles of 
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lipids, triglycerides and their metabolism. Linking in with the suggested role of Nrf2 in 
lipid processing, altered lipid management is also seen in AD with isoforms of ApoE, 
important in the management of triglyceride-rich lipoprotein constituents, known to 
alter a person’s risk of developing AD.  
Consequently, studies using genetic or pharmacological activation of Nrf2 have 
demonstrated reductions in lipid levels within the liver, as well as in other tissues such 
as the white adipose tissue (Tanaka et al., 2008; Shin et al., 2009). This suggests that 
Nrf2 is intimately involved in lipogenesis and therefore obesity. However, it has been 
noted that ablation of Nrf2 does not, as might have been expected, induce an increase in 
adiposity although there are noted alterations in key lipid metabolism components 
including those related to the production of triglycerides (Shin et al., 2009; Pi et al., 
2010). Instead, it is likely that dual activity is exerted by Nrf2, whereby increased 
activation of Nrf2 beyond a basal level provides some beneficial effects on obesity but 
ablation of Nrf2 inhibits alternative adipogenic pathways. Indeed, further investigation 
of Nrf2 showed it to play a role in the regulation of PPAR-γ; a known adipogenic 
transcription factor (Tanaka et al., 2008; Pi et al., 2010). It is also of note that the 
particulars of the diet in use can affect the alteration in Nrf2 related activity with recent 
work by Milder and Patel (2012) demonstrating an alternative induction of Nrf2 in 
response to administration of a ketogenic as opposed to HF diet. 
1.7.2.2 NAFLD and NASH 
Fatty liver disease is characterised by abnormal retention of triglycerides within 
liver cells, otherwise known as steatosis of the liver. Non-alcoholic fatty liver disease 
(NAFLD) describes the variant of fatty liver disease resulting from mediators other than 
excessive chronic alcohol abuse, which falls under the alternative categorisation simply 
named alcoholic liver disease. Non-alcoholic steatohepatitis, or NASH, is a more severe 
progression of fatty liver disease where patients have progressed beyond the reversible 
NAFLD disease state. The condition is associated with disorders that influence the 
body’s fat metabolism pathways, and as a result, can be a consequence of metabolic 
syndrome. It is of interest with regards to Nrf2, given the evidence just portrayed 
promoting the importance of Nrf2 in the healthy regulation of fat metabolism and the 
potential for dysregulation of this control when subjected to challenges such as HF 
feeding. In support of its role in lipogenesis mentioned earlier, Nrf2
-/-
 mice have an 
increased predisposition towards the development of NAFLD and NASH when 
challenged with a diet high in fat, which is overturned by Nrf2 activation (Tanaka et al., 
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2008; Chowdhry et al., 2010; Sugimoto et al., 2010; Zhang et al., 2010). This promotes 
Nrf2 as a potential target in the management of these aspects of the metabolic 
syndrome, whilst advocating a certain degree of caution due to the obvious multi-
faceted role Nrf2 plays within the body as advocated by the long list of known regulated 
genes. 
1.7.3 Role of Nrf2 in Cardiovascular Disease and Ischaemia 
Cardiovascular disease (CVD) is already cited as a risk factor for AD, as 
previously mentioned, with initial epidemiology studies reporting an increased presence 
of CVD within a population diagnosed with dementia in comparison to those not 
presenting with dementia (Newman et al., 2005). Upon further investigation, and 
similar to its role in cancer, Nrf2 has been shown to have a complex relationship with 
cardiovascular associated pathologies. Loss of functional Nrf2 has been implicated in 
the accelerated and aggravated response of murine hearts to models of haemodynamic 
stress such as occurs through the implementation of transverse aortic constriction (Li et 
al., 2009). Furthermore, disruption of Nrf2 increases the susceptibility of the heart to 
succumb to the ROS produced following periods of acute exercise (Muthusamy et al., 
2012). In addition, Nrf2 has also been implicated in diabetes related cardiomyopathies 
with the TIID db/db mouse model displaying depleted arteriole levels of Nrf2 in 
comparison to their non-diabetic controls along with impaired vessel constriction and 
elevated ROS (Velmurugan et al., 2013). This phenotype was rescued following 
administration of the Nrf2 activator SFN.  
Nrf2 has further been implicated in ischaemia/reperfusion injury, important not 
only in cardiovascular diseases but also other disorders such as chronic kidney disease, 
TIID and cerebrovascular diseases. Similar to the beneficial arteriole effects described 
by Velmurugan and colleagues, preconditioning of db/db hearts through the use of 
hydrogen sulphide activates Nrf2 and downstream ERK, protecting the tissue from 
subsequent ischaemia/reperfusion injury (Peake et al., 2013). In addition, treatment of 
mice with dimethyl fumarate induced the activation of Nrf2, providing a protective 
environment against periods of cardiac ischaemia which was abolished in mice lacking 
Nrf2 (Ashrafian et al., 2012). This may be of particular interest given dimethyl 
fumarates recent clinical approval by the FDA for the treatment of recurrent MS, 
making it a potential candidate for repurposing. Furthermore, loss of Nrf2 in an STZ-
induced diabetic nephropathy mouse model results in a significant worsening of 
pathology when compared to mice expressing Nrf2 (Jiang et al., 2010), whilst activation 
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of Nrf2 has been suggested to be protective against cerebral ischaemia/reperfusion 
injury following post-treatment with an Nrf2 inducer (Peng et al., 2013). This would 
indicate that the beneficial effects of Nrf2 activation with regards to 
ischaemia/reperfusion injury are not tissue specific, and may be of therapeutic interest. 
1.7.4 Role of Nrf2 in Neurodegeneration and Alzheimer’s Disease 
Due to the widespread presence of high levels of OS in many metabolic and 
neurodegenerative diseases, Nrf2 has been implicated as a therapeutic target for 
multiple disorders including neurodegenerative conditions such as AD. Nrf2 has only 
recently been investigated as a possible therapeutic target in AD and more specifically 
in glial cells. As mentioned previously, Nrf2 is expressed in astrocytes and the presence 
of functioning Nrf2 provides a neuroprotective effect to astrocytes in situations of 
cellular stress. In neuron-astrocyte co-cultures, this neuroprotective effect spreads to 
include the neurons and improves cell survival over neurons cultured alone (Johnson et 
al., 2008). It should also be noted that insulin/IGF1 regulated neuroprotection is in part 
dependent on the PI-3k pathway (van der Heide et al., 2006). When inhibited, this 
pathway also disrupts Nrf2 regulated neuroprotection implying possible links between 
changes in energy homeostasis and insulin, dysregulation of Nrf2, increases in oxidative 
stress and the role of astrocytes and the immune system in AD (Nakaso et al., 2003; 
Beyer et al., 2008). Astrocytes are able to internalise Aβ and, when subsequently co-
cultured with neurons, the astrocytic metabolic changes associated with Aβ 
internalisation appear detrimental to neuronal survival with increased neuronal death 
compared with controls (Allaman et al., 2010). Use of tBHQ, a known Nrf2-ARE 
activator, in Ntera2/D1 neuron-like cells (NT2N) neuronal cells inhibited the formation 
of Aβ after exposure to H2O2. Co-culturing the NT2N neurons with astrocytes increased 
the neuroprotective effect of tBHQ, with higher levels of Nrf2 in both neurons and 
astrocytes, as well as lower levels of Aβ formation (Eftekharzadeh et al., 2010). Finally, 
significant improvement in spatial learning of aged APP/PSEN1 mice was observed 
after the administration of a lentiviral vector encoding human Nrf2. This was linked 
with an increase in insoluble Aβ vs. soluble Aβ with no increase in overall Aβ burden, 
and a drop in the amount of inflammatory astrogliosis present (Kanninen et al., 2009). 
Furthermore, the only clinical application of an Nrf2 activator (dimethyl fumarate) to 
date is for the treatment of relapsing-remitting forms of MS and occasionally for the 
treatment of psoriasis). It is believed that activation of the Nrf2 system aids in targeting 
the associated inflammation and OS that occurs during MS, aiding in protecting and 
51 
potentially slowing the nerve damage that occurs as the disease progresses (Linker et 
al., 2011; Venci & Gandhi, 2013). Given that a similar issue is being targeted in AD, 
this may support a role for treatments such as dimethyl fumarate in AD in the future.  
However, despite more being known about potential mechanisms behind 
alterations in key AD proteins than ever before; scientists are little closer to 
understanding the intricacies of its development than they were fifty years ago. The 
heightened inflammatory response previously reported in Nrf2
-/-
 mice suggest it may be 
of benefit in the further study of AD given the increasing body of knowledge 
implicating dysregulation of the immune system response and age related decreases in 
cellular response strategies. In particular, the links already suggested between Nrf2 and 
changes in neurodegenerative conditions support the Nrf2
-/-
 model as a potentially 
useful model for research into modelling of an early disease stage paradigm. 
1.8 PROJECT AIMS 
Taken together these data suggest an important role for the loss of antioxidant 
regulating Nrf2 in the development of a pro-AD environment. In particular, it implicates 
Nrf2 in the dysregulation of inflammation and cellular damage associated with the 
occurrence of obesity, a risk factor for developing AD. 
With this in mind, the main aim of this project was to assess the effect of Nrf2 
loss in the brains of animals targeted with DIO or systemic infection, both believed to 
impact on the development of the metabolic syndrome. This was assessed by examining 
brain tissue following either long-term feeding of a HF diet, or short term repeated IP 
administration of LPS. Moreover, to further assess the potential involvement of Nrf2 
loss in the development of a pro-amyloidogenic environment, a novel double transgenic 
model was developed. To make the assessment more physiologically relevant, all 
studies were performed in aged adult mice, allowing for the incorporation of an ageing 
interaction not normally seen in studies of metabolic disease. 
In order to assess the effects of genotype along with those of the different 
stressors administered (HF diet or peripheral LPS), a range of gene and protein 
expressions were assessed along with in vivo measurements and cognitive evaluations. 
We concentrated our efforts on those genes and proteins associated with markers of 
inflammation (e.g. IL-1β, YM1), resident glial cell activation and migration (e.g. GFAP, 
Iba1, MCP-1) and pathways commonly associated activation as a result of elevated 
stress (e.g. NF-κB, MAPK). Further to this, we also investigated the effect the 
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interventions mentioned above had on proteins associated with known AD pathology 
(e.g. APP, BACE1), in addition to markers of mitochondrial dysfunction (e.g. Mitofusin 
2) given the growing evidence of links between mitochondrial dysfunction and AD. In 
this way we could chronical the alterations caused by impaired antioxidant defence, and 
therefore increased ROS and RNS, on AD promoting factors following a metabolic 
syndrome intervention. 
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2 MATERIALS AND 
METHODS
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2.1 MATERIALS 
2.1.1 Chemicals 
Ammonium persulphate (APS), benzamidine HCl, bovine serum albumin 
(BSA), Bradford reagent, citric acid, ethylene diamine tetraacetic acid (EDTA), 
ethylene glycol tetraacetic acid (EGTA), ethidium bromide, glycerol, β-
mercaptoethanol, paraformaldehyde (PFA), Phenylmethylsulphonyl fluoride (PMSF), 
Ponceau S, sodium dodecyl sulphate (SDS), sodium orthovanadate, 
tetramethylenediamine (TEMED), TrisAcetate, Triton X-100 and Tween
®
-20 were 
purchased from Sigma Aldrich. Ethanol, glycine, hydrochloric acid, methanol, sodium 
chloride, sodium hydroxide, sodium pyrophosphate (NaPPi) and sucrose came from 
VWR International. Bromophenol blue and tris(hydroxymethyl)aminomethane (TRIS) 
base were from Fisher Scientific. Agarose was purchased from Bioline. Nuclease free 
H2O was from Life Technologies.  
2.1.2 Machines 
7500 and 7900HT real-time PCR system (96 well plate) and relevant software (Applied 
Biosystems/Life Technologies), OTF 5040 microtome cryostat (Bright Instrument 
Company Ltd.), GeneFlash (Syngene bioimaging) acrylamide gene visualiser with 
Pulnix lens and Mitsubishi p93 thermal printer, TCS SP5 Confocal microscope with 
LAS AF software (Leica), NanoDrop ND-8000 with Nanodrop 8000 v. 2.3.2 software 
(Thermo Scientific), Odyssey infrared (IR) Western blot imager (Li-Cor Biosystems) 
with Odyssey (v. 3.0) and Image Studio (v. 4.0) Software, EnVision 2104 multilabel 
reader spectrophotometer (PerkinElmer), Veriti thermal PCR cycler (96 well) and an 
SRX-101A X-ray film developer (Konica-Minolta). 
2.2 ANIMALS 
2.2.1 Animal maintenance and housing conditions 
All animal procedures performed were approved by the British Home Office 
Animal Scientific procedures act (1986) under the project licence number 60/4280 held 
by Professor Michael L.J. Ashford and with approval of the University of Dundee 
Animal Ethics Committee. Mice were maintained on a 12 h light/dark cycle with an 
environmental temperature of 20-23°C, ad libitum access to food and water, and 
bedding material to allow nests to be built. Mice were maintained on the RM1 standard 
diet (RC; 7.5 % fat, 75.75 % carbohydrate and 17.5 % protein by energy (801151, 
55 
Special Diet Services)) unless part of the high fat (HF) feeding study. HF fed mice were 
maintained on a diet containing 45% fat (45% fat, 35% carbohydrate, 20% protein 
(824053, Special Diet Services)). 
All mice were maintained in standard size cages in groups of between two and 
five animals of the same sex. Exceptions were made for one mouse each in the Nrf2
-/-
/hAPPswe Saline and LPS groups, which had been housed singly, due to the very limited 
number overall of animals available from this genotype. All cages were given a shelter 
which was either a red tube or u-shaped roof. All mice undergoing behaviour tasks were 
given the same type of shelter in their cages to maintain uniform environmental factors 
across the different cages. Mice from a cage where only some animals were assigned to 
behaviour tasks were maintained in their full social group throughout until the animals 
were taken for tissue to minimise any impacts on social environment during the study. 
No additional environmental enrichment was provided for the duration of the studies. 
2.2.2 Generation of Nrf2 KO mice 
Whole body Nrf2 KO (Nrf2
-/-
) mice were gifted by Professor J.D. Hayes 
(University of Dundee). This model of Nrf2
-/-
 mice was first introduced by Itoh et al. 
(1997). The authors made use of the targeting vector SV40 nuclear localisation signal-β-
galactosidase (lacZ) recombinant gene to replace the b-Zip region of the Nrf2 gene; 
resulting in a model displaying non-functional, disrupted Nrf2 expression. These mice 
were previously backcrossed onto the C57Bl/6 background for 8 generations by 
Professor J.D. Hayes lab and mice were maintained by homozygotic breeding on the 
same background strain. It is generally accepted that 6 generations of backcrossing is an 
acceptable number in order to develop a majority genetic consistency. 
2.2.3 Generation of hAPPswe mice 
hAPPswe transgenic (Tg) mice were obtained from Jackson Laboratories (Strain: 
B6.129-Tg(APPswe)40Btla/Mmjax). This mouse line, also known as the R1.40 mouse 
owing to the R1 embryonic stem (ES) cells used when producing the line, was 
originally generated and further characterised by Lamb et al. (1997; 1999). They 
express the full length human APP gene sequence containing the well documented 
Swedish mutation (APPK670N/M671L) under the control of the murine APP promoter. The 
murine APP promoter is expressed ubiquitously with different APP isoforms 
demonstrating some isoform specific tissue localisation. hAPPswe animals were 
backcrossed for more than 20 generations on a C57Bl/6 background strain and were 
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subsequently maintained on this genetic background, with Tg carriers bred to WT mice 
due to reported increased mortality in young homozygous animals 
(JacksonLaboratories, 2015). Hemizygous Tg carrier mice were used for the relevant 
studies undertaken and are still reported to produce 7-8x the level of brain Aβ1-42 protein 
at 3-4 months of age although no plaque deposition is reported until much older (24-26 
months; Lamb et al., 1999). 
2.2.4 Generation of a novel AD mouse line 
A novel double transgenic mouse line was developed using the two existing 
mouse lines mentioned above. Mice from the Nrf2
-/-
 line were bred with hemizygous 
hAPPswe expressing mice. This cross produced a mouse line delineated by the 
combination of ubiquitous Nrf2
-/-
 and hemizygotic hAPPswe expression driven through 
the murine APP promoter. This line has subsequently been referred to as Nrf2
-/-
/hAPPswe 
for simplicity. This novel mouse line, with a C57Bl/6 background strain, was 
subsequently maintained by crossing Nrf2
-/-
/hAPPswe mice with transgenic mice from 
the Nrf2
-/-
 colony. 
2.2.5 Genotyping of mouse lines 
Following weaning, mice were ear notched for identification, using a well-
established notch number and localisation protocol, and the collected ear punch biopsy 
was used for genotyping analysis. DNA was extracted using the Extract-N-AMP Tissue 
polymerase chain reaction (PCR) kit. In short, 100 μl of extraction solution (E7526, 
Sigma-Aldrich) was mixed with 25 μl of tissue preparation solution (T3073, Sigma-
Aldrich) and added to the tissue. Samples were briefly centrifuged, ensuring the tissue 
notches were submerged in the solution, prior to being incubated at room temperature 
for 10 min. The samples were vortexed and incubated for a further 3 min at 95°C. 
Lastly, 100 μl of neutralisation buffer (N3910, Sigma-Aldrich) was added to each 
sample, and these were stored at 4°C. The PCR was performed using the Novagen
®
 
KOD Hot Start polymerase kit (71086, Merck Millipore) and optimised for each 
primer/genotype combination. Relevant controls were run on a regular basis including 
known positive and negative samples, as well as samples lacking DNA. Individualised 
PCR primer and cycling information is detailed below, with all primers being 
synthesised by Sigma-Aldrich. Nrf2
-/-
 mice were genotyped by Dr. Paul Meakin, with 
remaining mice being genotyped by Dr. P. J. Meakin, postdoctoral PhD student S. M. 
Jalicy or myself. All notching was performed by licensed practitioners. 
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2.2.5.1 Nrf2-/- 
Due to the design of the Nrf2
-/-
 model, a combination of three primers was used. 
A generic Nrf2 forward coding primer, a reverse primer coded to recognise the original 
WT mouse Nrf2 sequence and a second reverse primer designed to recognise the LacZ 
disruption thereby signifying a knockout genotype (Table 2.1). 
Primer Sequence 5’  3’ Primer Type 
Primer Sequence 
Origin 
1516 
ACA AGC AGC TGG CTG 
ATA CTA CC 
Generic Nrf2 
forward 
Dr. C. J. Henderson, 
University of Dundee 
1517 
CAC TAT CTA GCT CCT 
CCA TTT CCG AG 
WT Nrf2 reverse 
1518 
TGG GAT AGG TTA CGT 
TGG TGT AGA TGG 
β-gal Nrf2 reverse 
Table 2.1 List of PCR primers and their sequences used for Nrf2
-/-
 mouse line 
Individual PCR reaction mixtures included 5 μl of genomic DNA and final 
concentrations of 0.6 μM forward primer and 0.3 μM each of the reverse primers, and 
were combined with the elements of the Novagen
®
 KOD Hot Start polymerase kit. This 
resulted in absolute concentrations of 1x KOD hot start buffer, 1.5 mM MgSO4, 0.2 mM 
dNTPs, and 1 U KOD hot start DNA polymerase made up to a final volume of 50 μl 
with nuclease free PCR grade H2O. Samples were placed in the thermal PCR cycler and 
run under the conditions detailed in Table 2.2. 
Step N° Step Temperature (˚C) Duration (s) 
1 Polymerase Activation 94 120 
2 Denaturation 94 20 
3 Annealing 62 15 
4 Elongation 70 7 
5 Repeat steps 2-4 35x 
6 Hold 4 ∞ 
Table 2.2 Heat cycling PCR programme for genotyping of Nrf2
-/-
 earnotches 
The manufactured PCR products were mixed with 6x loading dye (G2101, 
Promega) to ease sample loading and visualise sample gel migration. Samples were run 
alongside a 100 base pair (bp) PCR reference marker (G1881, Promega) on a 1% 
agarose gel containing ethidium bromide (Appendix I; see chapter 7.1, Table 7.4) at 120 
V in Tris-acetate-EDTA (TAE) buffer (Appendix I; see chapter 7.1, Table 7.4) for 40 
min at room temperature. The gel was viewed by exciting the ethidium bromide stained 
DNA with ultraviolet (UV) light in a GeneFlash imaging machine and an image 
captured for record purposes using a p93 Mitsubishi high resolution thermal printer. 
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Primer design countenances the visualisation of WT and Nrf2
-/-
 band in a single 
reaction. The LacZ motif insertion increases the size of the recognised PCR product 
from 537 bp (WT) to 684 bp for the LacZ disrupted Nrf2 gene (Figure 2.1). Presence of 
solely the larger product confirms the homozygotic genotyping of Nrf2
-/-
 mice. 
 
Figure 2.1 Example image of PCR products produced by genotyping of Nrf2
-/-
 mice 
2.2.5.2 hAPPswe 
Owing to the similarity in weight of the PCR end products, two separate 
reactions were run in order to genotype the hAPPswe mouse line. One reaction with 
forward and reverse primers designed to recognise the murine APP sequence 
(oIMR8744 and oIMR8745), and a second reaction containing the primers coding for 
the human transgene (oIMR6938 and oIMR6939; Table 2.3). 
Primer Sequence 5’  3’ Primer Type 
Primer Sequence 
Origin 
oIMR6938 
CTT CAC TCG TTC 
TCA TTC TCT TCC A 
Transgene forward 
Jackson Laboratory 
oIMR6939 
GCG TTT TTA TCC 
GCA TTT CGT TTT T 
Transgene reverse 
oIMR8744 
CAA ATG TTG CTT 
GTC TGG TG 
Internal +ve 
control forward 
oIMR8745 
GTC AGT CGA GTG 
CAC AGT TT 
Internal +ve 
control reverse 
Table 2.3 List of PCR primers and their sequences used for hAPPswe mouse line 
Individual PCR reaction mixtures included 1 μl of genomic DNA and final 
concentrations of 0.8 μM forward and reverse primers for each reaction once combined 
with the elements of the Novagen
®
 KOD Hot Start polymerase kit. This resulted in 
absolute concentrations of 1x KOD hot start buffer, 1.5 mM MgSO4, 0.2 mM dNTPs, 
and 1 U KOD hot start DNA polymerase made up to a final volume of 25 μl with 
nuclease free PCR grade H2O. Samples were placed in the thermal PCR cycler and run 
under the conditions detailed in Table 2.4. 
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Step N° Step Temperature (˚C) Duration (s) 
1 Polymerase Activation 95 180 
2 Denaturation 95 30 
3 Annealing 67 30 
4 Elongation 72 30 
5 Repeat steps 2-4 35 x 
6 Terminal elongation 72 300 
7 Hold 4 ∞ 
Table 2.4 Heat cycling PCR programme for genotyping of hAPPswe earnotches 
As for the Nrf2
-/-
 genotyping described above, the manufactured PCR products 
were mixed with 6x loading dye and samples were run alongside a 100 bp PCR marker 
ladder on an 2% agarose ethidium bromide gel (Appendix I; chapter 7.1, Table 7.4) at 
120 V in TAE buffer for 40 min at room temperature. The gel was viewed by exciting 
the ethidium bromide stained DNA with UV light and an image captured. PCR products 
were examined from the two individual reactions. The internal positive control reaction 
produces a band at a molecular weight of ≈ 200 bp in all samples and can therefore also 
serve as a sample quality control confirming the extraction of DNA from the earnotch. 
The second PCR reaction, isolating a product at a molecular weight of 84 bp, enabled 
the identification of the transgenic animals (Figure 2.2). However, presence of non-
specific band close to that demarking the Tg APP band (see Figure 2.2 WT column) 
caused genotyping issues that resulted in mice being falsely allocated the Tg genotype. 
Subsequent to this being found, PCR gels were run for longer to ensure full separation, 
PCR products were run separately in case of cross-PCR primer contamination and 
positive and negative controls were run on every gel. However, this resulted in much 
reduced group sizes in our double transgenic line, resulting from re-allocation of false 
positive animals and a decrease in the number of available correctly genotyped animals. 
 
Figure 2.2 Example image of PCR products produced by genotyping of hAPPswe 
mice 
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2.3 IN VIVO STUDIES 
2.3.1 High Fat Metabolic Study 
Adult mice from three transgenic genotypes, namely Nrf2
-/-
, hAPPswe and Nrf2
-/-
/hAPPswe, were used alongside appropriate WT controls. Mice were placed on the study 
for a period of 14 months, with some additional mice being used for the purposes of the 
behaviour work carried out. Total numbers of mice used in each group, including those 
for the behaviour task were as follows: WT RC = 47, WT HF = 20, Nrf2
-/-
 RC = 29, 
Nrf2
-/-
 HF = 37, hAPPswe RC = 11, hAPPswe HF = 12, Nrf2
-/-
/hAPPswe RC = 10, Nrf2
-/-
/hAPPswe HF = 12. Animals harvested for this study were then split into two groups, one 
for biochemistry (tissue was flash frozen) and the other for immunohistochemistry 
(tissue was perfuse fixed). 
2.3.1.1 Feeding 
All mice were weaned onto a standard rodent diet (RM1). At 8-10 weeks of age, 
mice were allocated to either the RC control arm of the study or the HF treatment arm 
of the study. This gave rise to 8 separate experimental groupings. Mice in the HF study 
arm were placed on a 45% fat diet (see chapter 2.2.1) with 1 week dietary crossover 
period. Mice were weighed weekly once the diet change had commenced. Both male 
and female mice were used for the purposes of this study. 
2.3.1.2 Intraperitoneal Glucose Tolerance Test 
Peripheral glucose tolerance was assessed by intraperitoneal (IP) glucose 
tolerance test (IPGTT) at 15 months of age following 55-57 weeks of dietary 
intervention. Although not as deemed to be as accurate as the gold standard 
measurement associated with clamp studies, IPGTTs were deemed to be more 
appropriate given the long-term nature of the study and remain more accurate 
measurements than the more basic HOMA (homeostatic model assessment) or FIRI 
(fasting insulin resistance index).  
All IPGTTs were performed by Dr. A.D. McNeilly, postgraduate PhD student 
S.M. Jalicy and Dr. P.J. Meakin in accordance with the standard protocol. In brief, 
following overnight starvation fasted blood glucose measurements were taken using ~1 
µl of tail vein blood placed on a glucose strip and the glucose concentration quantified 
using a glucometer (Gluco Rx Nexus TD-4277 glucose meter and compatible strips). 
Following basal measurements, glucose was injected IP at a concentration of 1 g/Kg 
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(25% solution in PBS) and whole blood glucose levels were measured at 15, 30, 60, 90 
and 120 min post injection, using the same method as described above.  
2.3.1.3 IP Insulin tolerance test 
Peripheral insulin tolerance was assessed by IP insulin tolerance test (ITT) at 16 
months of age following 59-61 weeks of dietary intervention. After a 4 h starvation 
period fasted blood glucose measurements were recorded as described above. Following 
basal measurements, insulin was injected IP with a solution of insulin consisting of 0.75 
U/Kg of recombinant human insulin (Actrapid
®
, Novo Nordisk). Blood glucose levels 
were again measured at 15, 30, 60, and 90 post IP injection as previously described. All 
ITT experiments were performed by Dr. A.D. McNeilly, postgraduate PhD student S.M. 
Jalicy and Dr. P.J. Meakin. 
2.3.1.4 Spontaneous alternation behavioural task 
Spontaneous alternation (SA) utilises rodents’ natural tendency to investigate 
novelty. It has previously been suggested to test spatial working memory, although 
other forms of memory have since been suggested for it instead such as dead reckoning, 
self-movement cues and/or response strategies (McNay et al., 2000; Lennartz, 2008; 
Vorhees & Williams, 2014). It can be performed in a variety of maze shapes, such as T, 
Y, +. This behavioural paradigm is considered to be largely hippocampal independent 
when performed without spatial localisation cues (egocentrically). However, some 
researchers maintain there is still a role for hippocampal centred learning even under 
egocentric conditions with the deposition of olfactory cues or the acquisition of spatial 
cues not noticeable by the tester (Lennartz, 2008). 
The successful completion of the task revolves around entry into as many 
alternative arms as possible based on the animal’s previous arm entry. The outcome 
measurement is described as a percentage alternation indicating the degree to which the 
animal has successfully completed arm alternations out of the total possible number of 
alternations based on the number of arm entries performed by any single animal. 
Measures of memory performance in the plus maze format used in this study are 
standardly reported as percentage 4/5 alternation (McNay et al., 2000). In brief, this 
means that within any consecutive five arm entries the animal must have entered every 
possible arm for it to count as a positive alternation (N, S, E and W). Therefore the total 
number of alternations possible equals the total number of arm entries performed minus 
four, allowing a percentage alternation value to be obtained (see chapter 3.6 for the 
formula). 
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An elevated plus maze was used to measure changes in SA in WT, Nrf2
-/-
, and 
Nrf2
-/-
/hAPPswe mice (see Figure 2.3). In order to measure SA instead of anxiety, the 
closed arm model of the maze was used. The same experimental room was used for all 
testing and within that room, the base of the maze was placed in the same position for 
each behaviour session as was the video camera tripod to ensure no localisation related 
interference. All sessions were videoed (HDR-XR260VE, Sony) and a second screen 
used during testing to allow real-
time monitoring of the task. 
All elements of the maze 
(4x removable black Plexiglas 
arms, 1x elevated base with 
adjustable feet (Figure 2.3)) were 
cleaned prior to the start of any 
assessment sessions with 
disinfectant surface wipes 
(Citroxx Bio
®
) to remove any 
potential olfactory cues. Mice 
were placed in the centre of the 
maze intersections and arm entries 
were recorded for a total of 10 
min. Between mice, the whole 
apparatus was again cleaned and 
dried before the next mouse was 
recorded. Mice were measured 
following consumption of either 
RC or HF diets and a selection of 
ages were assessed. Age intervals 
investigated were: 2.5 to 4.5 
months, 5.5 to 7.5 months, 9.5 to 
11.5 months, and 13 to 15 months. 
For ease of reference, these groups 
will now be referred to as 3 
months, 6 months, 10 months and 
14 months respectively. 
Figure 2.3 Pictorial representation of the 
elevated plus maze behavioural apparatus 
Where (A) depicts a side on view of the apparatus and 
(B) an aerial view. (C) describes the dimensions of the 
apparatus used for the cohorts in question. 
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Additional assistance for the behavioural work on this project was provided by Dr. A.D. 
McNeilly with contributions from undergraduate students S. Garner, R. Convery and D. 
Cavellini, who were awarded summer studentship project grants and aided in the 
recording of SA assessments and bodyweight measurements. 
2.3.2 Peripheral Infection Study 
Adult male (M) and female (F) mice from the transgenic Nrf2
-/-
 and Nrf2
-/-
/hAPPswe lines were used alongside appropriate WT controls. Mice were randomly 
subdivided into groups of between 11 and 14 for the WT and Nrf2
-/-
 genotypes 
according to availability (WT saline = 14, WT LPS = 11, Nrf2
-/-
 saline = 13, Nrf2
-/-
 LPS 
= 12), and in addition only 4 saline-treated and 3 LPS-treated Nrf2
-/-
/hAPPswe due to the 
aforementioned genotyping issues (see Chapter 2.2.5.2). Genders were split evenly 
across genotypes and treatments as much as possible. Mice were placed on the study for 
a period of seven days and followed the study plan outlined in Figure 2.4. 
 
Figure 2.4 Time-line for the peripheral infection study, depicting the order in 
which behavioural tasks and relevant habituation were performed 
Where NOR = novel object recognition and OL = object location. 
2.3.2.1 In vivo LPS treatment 
Adult mice were randomly allocated to either the saline or LPS study arm 
ensuring a comparable gender and genotype allocation across groups where possible. 
Mice were administered LPS via IP daily for a period of seven days. After reviewing 
relevant literature and taking into account the age of the animals in question a set dose 
of 2.5 μg of LPS in saline solution per mouse was used with a final dosage volume of 
100 μl or an equivalent volume of saline for the controls. Prior to initiating the 
programme, mice were placed in fresh cages and no further cage changes were 
performed throughout the duration of the study in order to minimise disruption to the 
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animals as this might have impacted on bodyweight and recovery. Injections were 
undertaken at the same time every day between the hours of 9.00 and 10.00 at which 
time daily weights were also recorded. Subsequent to initial injections, all mice were 
maintained in a quiet room on heat pads, and fresh softened RM1 diet was made 
available on a daily basis post IP injection. All IP injections in this study were 
performed by either Dr. A.D. McNeilly, postgraduate PhD student S.M. Jalicy or Dr. 
P.J. Meakin. 
2.3.2.2 Animal Behaviour 
Mice were handled daily for a minimum of two weeks prior to the 
commencement of the study, following which they were allocated to a treatment group. 
Behaviour tasks used included two object based tasks, namely the novel object 
recognition task (NOR) and the object location task (OL), as well as the previously 
described SA assessment (see 2.3.1.4). Both the NOR and the OL tasks rely on the 
innate rodent response to novelty resulting in investigative behaviour. Therefore, these 
tasks make a basic assumption tailored around the ability of rodents to recognise 
previously observed objects as familiar. Once this theory is established the tasks can be 
used to evaluate the animal’s ability to respond to (i) a simple introduction of novelty to 
an experimental paradigm (NOR) dependent on the perirhinal cortex, or (ii) alterations 
in the localisation of the familiar by incorporating the use of spatial queues (OL). Both 
of these tasks have been previously used in the behavioural evaluation of animal models 
of AD as they are considered to reflect, at least in part, other assessment paradigms used 
in both human and non-human primate models (Leger et al., 2013; Webster et al., 
2014). 
At the beginning of the study in each individual cohort mice were randomly 
assigned a running order, alternating treated and control animals in addition to object 
pairings and locations. For all tasks performed, mice were left for a minimum of 2 h 
post IP injection prior to any task participation. All mice were maintained on a heat pad 
when not undergoing behavioural testing and had access to both fresh softened chow 
and standard RC as well as water throughout. Furthermore, at the beginning and end of 
testing, as well as between each mouse or mouse group, any apparatus or objects in use 
were cleaned and dried in order to minimise any transfer of olfactory cues. All testing 
was filmed using either a fixed overhead video-camera (OL and NOR) or a video-
camera attached to a tripod (SA) but placed far enough away to not adversely affect the 
task being carried out. 
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2.3.2.2.1 Habituation 
Mice were habituated to the experimental room on a minimum of two occasions 
during the initial handling period prior to any task habituation occurring. A polystyrene 
box coated in wood effect sticky back plastic with two object grips was used for all 
behaviour tasks (Figure 2.5 A) and mice were first habituated to the experimental box 
on day 3 with their cage-mates for a total of 10 min per cage. The empty experimental 
box was placed in a designated location on a bench surface with spatial location queues 
in the top right and top left corners. Following group habituation, a further period of 
habituation was performed on the same day. The mice were place in the experimental 
box in the same order as for the group habituation, but this time they were habituated 
individually for a total of 8 min per mouse. This allowed all animals to have a break 
period between habituation sessions. 
 A further individual habituation session was performed on day 4 for a total of 
10 min per mouse. For any single cohort of mice both the NOR and OL tasks were 
performed using the same experimental box, dispensing with any requirements for 
separate habituation for the secondary object task. In addition, object pairings were used 
that had been previously established to engender the same degree of interest to aid in 
minimising object-based bias in either of these tests. All sessions were videoed and a 
second screen used during testing to allow real-time monitoring of the task. The 
assessment of SA, as described in 2.3.1.4, does not require any prior habituation to the 
apparatus, therefore no additional habituation was performed for this task. 
2.3.2.2.2 OL Task  
Mice were randomly assigned a running order, alternating treated and control 
animals, and object pairings and locations. On day 5 of the study, each mouse was 
placed individually in the test box previously used for habituation in the presence of two 
never-seen-before different objects (sample phase) for a duration of 10 min. Mice were 
placed in the behavioural box facing the south wall on every presentation in order to 
prevent inadvertent bias resulting from direct presentation of the mice to the objects in 
use. During the sample phase, the time spent investigating each object was measured 
and total time spent exploring was recorded following 10 min from placement in the test 
box. Mice were then removed from the test box and placed in an opaque holding box for 
10 min, bedded down with standard shavings which were renewed at the beginning of 
each day of testing.  
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Figure 2.5 Pictorial representation of the object-based behavioural apparatus and 
related tasks.  
Where (A) depicts the specifications of the apparatus, (B) demonstrates the task undertaken in 
the OL assessment where the novel object is identified by a circle in the test phase, and (C) 
demonstrates a basic replica of the NOR task where the novel object is again depicted by a 
circle in the test phase analogy. 
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Whilst the mouse was in the holding box, the test box and objects were cleaned 
and a new pairing of objects was placed in the test box. For OL, two replicas of one of 
the objects seen in the sample phase were used with a novelty of location associated 
with one of the objects (see Figure 2.5 B). At the end of the holding phase, mice were 
placed again in the test box, facing the south wall of the box and now in the presence of 
the new object pairing. Individual object investigation was measured and noted 
following 10 min within the test box (test phase). Additional descriptions of objects 
utilised can be found in Appendix II (chapter 7.2). 
2.3.2.2.3 NOR Task 
On day 6 of the study, each mouse was placed individually in the test box 
previously used for habituation and facing the south wall (sample phase). In the 
presence of two copies of a novel object the time spent investigating each object and 
total time spent exploring for each mouse were recorded following a period of 10 min. 
Mice were then removed from the test box and placed in an opaque holding box for 10 
min, bedded down with standard shavings which were renewed at the beginning of each 
day of testing. During the holding time, the test box and objects were cleaned and a new 
pairing of objects was placed in the test box. For NOR, one object is a replica of an 
object seen in the sample phase and one object is entirely novel (Figure 2.5 C). At the 
end of the holding phase, mice were placed in the test box again in the presence of the 
new object pairing and individual object and total investigation were measured and 
noted at the end of 10 min (test phase). Additional descriptions of objects utilised can be 
found in Appendix II (see chapter 7.2). 
2.3.2.2.4 SA task 
Refer to chapter 2.3.1.4 for task setup. For the purposes of this study WT, Nrf2
-/-
, and Nrf2
-/-
/hAPPswe mice were assessed following either repeated IP of saline or LPS 
(see Figure 2.3 for apparatus description). All testing occurred the morning after the 
final IP procedure on the 7
th
 and final day of the study. Subsequent to this task, mice 
were sacrificed and tissue harvested as described below. 
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2.4 BIOCHEMISTRY 
2.4.1 Tissue Collection  
2.4.1.1 Frozen Tissue 
Mice were killed by cervical dislocation and the head was removed to allow 
blood to be captured. Brains were excised from the skull by performing a sagittal 
incision in the skin exposing the skull. Excess spinal cord and brain stem were cut away 
and small snips made at the base of the skull. The skull was then cut sagittally and 
peeled away to either side to allow access to the brain. Taking care to ensure no pieces 
of meninges were still lying across the brain, a rounded small spatula was used to 
remove the brain from the skull in one piece. Once out the brain was placed in ice-cold 
PBS to remove excess blood, facilitate dissection, and slow down tissue degradation by 
cooling the tissue. Dissection was performed on ice with the brain being divided 
sagittally and one half being used for protein analysis whilst the other half was set aside 
for RNA processing. Relevant brain regions excised were the hypothalamus, 
cerebellum, cortex and hippocampus. It is worth noting that in the case of the cortical 
tissue an effort was made to excise the same region each time. 
2.4.1.2 Perfuse Fixed Tissue 
Mice were placed in a CO2 box individually and deep narcosis induced using a 
gradual increase in CO2 levels, which precedes euthanasia following an overdose of 
CO2. An incision was made down their front to expose the rib cage. The sternum and 
front of the rib cage were cut away to expose the still-beating heart. A 10 ml syringe 
with a 1.1 mm gauge needle filled with ice-cold PBS was inserted in the posterior end 
of the left ventricle of the heart. A cut was made on the opposite side, permitting the 
PBS to be flushed through the vascular system and clear the blood from the animal. The 
empty syringe was replaced with a 10 ml syringe filled with ice-cold 4%-
paraformaldehyde (PFA) taking care to leave the needle in place. 4%-PFA was flushed 
through the cardiovascular system in order to achieve whole body fixation. The 
appearance of fixation tremors indicated both the true time of fixation and confirmed 
successful fixation had occurred. Desired organs were then dissected out whole, and 
placed in 4%-PFA for a further 24 h post-fixation to ensure full tissue fixation had 
occurred. After 24 h tissue was dehydrated by placing it in a sucrose solution (30% 
sucrose in PBS) at 4°C to minimise the chance of ice crystal formation upon subsequent 
freezing of the tissue. 
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2.4.2 Tissue lysis 
2.4.2.1 Protein 
Snap frozen tissue was placed in a 1 ml dounce glass homogeniser mortar and 
standard Triton X-100 cell lysis buffer (Appendix I; see chapter 7.1, Table 7.1), with 
freshly added inhibitors, was added to the mortar using tissue specific volumes as 
detailed in Table 2.5. A tight 1 ml glass pestle was used to homogenise the tissue, with 
the combination of the vacuum seal and abrasion of glass against glass enabling tissue 
and cell shearing. Once homogenised and no further tissue being observed, the sample 
was placed in an eppendorf tube at -20°C correctly labelled with genotype, diet, mouse 
ID and tissue type. For long-term storage samples were migrated to a -80°C freezer. 
Tissue Type Tissue amount Species Lysis buffer (μl) 
Cerebellum ½ Mouse 500 
Cortex ½ Mouse 500 
Hippocampus ½ Mouse 500 
Hypothalamus ½ Mouse 100 
Table 2.5 Details of tissue lysis volumes used for protein analysis 
2.4.2.2 RNA 
Snap frozen tissue stored at -80°C was placed in a 1 ml dounce glass 
homogeniser mortar. For all brain tissue types, 1 ml of TRI reagent was used to isolate 
RNA and a tight 1 ml pestle used to homogenise the tissue. Once fully homogenised, 
the sample was placed in eppendorf tubes designated solely for RNA use and stored in -
20°C freezer until required. Assistance in tissue extraction of samples from the 
metabolic study was provided by D. Cavellini as part of a summer studentship. 
2.4.3 Gene Expression using Real-Time qPCR 
2.4.3.1 RNA extraction 
Tissue homogenised in TRI reagent as per manufacturer’s instructions. Briefly, 
tissue was defrosted and left at room temperature for 5 min to ensure complete lysis. 
The extraction was initiated by the addition of 0.2 ml chloroform to each sample. 
Samples were shaken vigorously for 15 s each before being left to stand at room 
temperature for 15 min, followed by a 15 min centrifugation in a refrigerated (4ºC) 
centrifuge at 12000g. The centrifugation enabled the separation of the samples into 
layers largely divided into protein, DNA and RNA. The top layer of supernatant from 
each sample was removed and placed in fresh eppendorf tubes. The solution was mixed 
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using gentle inversion following the addition of 0.5 ml of isopropanol. Samples were 
again left to stand at room temperature for 10 min prior to centrifugation at 12000 g for 
10 min at 4ºC, resulting in the accumulation of an RNA pellet at the base of the tube. 
The supernatant was removed with particular care taken to not disturb the pellet and a 
final wash was performed through the addition of 1 ml of 75% ethanol to the pellet. 
Samples were vortexed in order to dislodge and disrupt the pellet, followed immediately 
by centrifugation at 4ºC for 5 min at 12000 g. Taking care to not disturb the pellet, as 
much of the supernatant was removed as possible prior to air-drying inside an extractor 
hood for 7.5 min. Samples were solubilised in 30 μl of RNase-free water before being 
heated at 58ºC for 15 min prior to being stored on ice for immediate use or at -80°C 
until required. 
2.4.3.2 Nanodrop 
RNA purity and concentration were evaluated using a NanoDrop ND-8000 
machine and software (Nanodrop 8000 v. 2.3.2). This Nanodrop spectrophotometer is 
equipped as a high throughput machine capable of analysing 8-samples at any one time. 
The pedestals were cleaned with 5 μl water a minimum of twice, prior to loading a 
water control. They were wiped down and cleaned again before loading the relevant 
vehicle control, in this case purified RNase-free water. 1.5μl per sample was loaded and 
the RNA concentration (ng/µl) was measured at 260 nm and used to calculate the 
volumes of sample required to form 1 μg complementary DNA (cDNA). 
2.4.3.3 cDNA synthesis 
First strand cDNA synthesis was performed using the SuperScript
TM
 II reverse 
transcriptase setup from Invitrogen as per manufacturer’s instructions. Briefly, a blend 
of 1 µl random primers (48190-011; Invitrogen), 1 µl 10 mM dNTP (18427-013; 
Invitrogen) and 1 μg extracted RNA were combined in nuclease free Eppendorf tubes 
and made up to a volume of 13 μl with RNase-free water. The mixture was heated at 
65°C in a heat block for 5 min and then briefly chilled on ice prior to being pulse 
centrifuged to collect the solution at the bottom of the tube. A combination of 4 µl 5x 
first strand buffer and 2 µl 0.1 M DTT (18064-014; Invitrogen) were added and the 
solution was gently mixed before being incubated at 25°C for 2 min. Following this, 1 
μl of SuperScriptTM II (18064-014; Invitrogen) was added, bringing the final volume of 
solution to 20 μl, and the samples were gently mixed. Reactions were incubated at 25°C 
for a further 10 min prior to being heated at 42°C for 50 min, allowing the reaction to 
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take place. Termination was achieved by heating the samples at 70°C for 15 min and the 
resulting synthesised cDNA was stored at -20°C until required. 
2.4.3.4 Real-Time qPCR  
TaqMan® assays are one of the most commonly used methodologies for real-
time quantitative PCR (qPCR) detection. TaqMan® gene expression arrays specifically 
target desired genes using a fluorogenic probe. In brief, the reaction contains a 
combination of forward and reverse DNA polymerase with a sequence specific primer. 
The primer incorporates a fluorescent reporter dye (in this case 5’-fluorescein) and a 
non-fluorescent quencher (in this case 3’-minor groove binder). When the probe is 
intact, close proximity of it to the quencher prevents emissions from the reporter dye by 
utilising fluorescence resonance energy transfer. During the extension cycle of the PCR 
if the probe has bound the target sequence, the 5’ activity of the Taq DNA polymerase 
cleaves the reporter dye from the primer sequence. This releases the dye into the 
solution allowing it to emit its characteristic fluorescence as it is no longer in repressed 
by the quencher, with this fluorescence recorded by the detection instrument of the RT-
qPCR system. 
For the purposes of our experiments a PCR reaction mix was prepared for each 
sample with final concentrations equating to 1x TaqMan® Universal PCR Mastermix, 
no AmpErase® (4324020; Applied Biosystems/Life Technologies), 1x primer/probe 
assay mix (Life Technologies; Appendix III chapter 7.3 for list of individual probes 
used) and 12.5 ng cDNA diluted in RNAse-free water. The final volume for each 
reaction of 20 μl was loaded into a 96-well optical reaction plate in duplicate (or 
triplicate for the work done in collaboration with Prof. S.M. Keyse) and briefly 
centrifuged to spin the solution down in each of the wells. The plate was placed in the 
RT-qPCR system (Applied Biosystems/Life Technologies) and the PCR reaction run as 
per Table 2.6. The cycle threshold values (Ct) were analysed via the ΔCt methodology 
with actin as the endogenous housekeeping control gene. 
Step N° Step Temperature (°C) Duration (s) 
1 Polymerase activation 50 120 
2 Initiation 95 600 
3 Denaturation 95 15 
4 Annealing 60 60 
5 Repeat steps 3 and 4 40 x 
Table 2.6 Heat cycling PCR programme for TaqMan RT-qPCR analysis 
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2.4.4 Protein Expression by Western Blotting 
2.4.4.1 Protein Content Determination 
Protein content from cell lysates was determined using a Bradford protein assay 
(Bradford, 1976), which utilises the change in absorbance of Coomassie Blue G-250 
from 465 nm to 595 nm upon protein binding to quantify protein content in unknown 
samples. Sterile 96-well plates were utilised and samples run in triplicate to minimise 
effects of potential pipetting error. 1 µl of sample lysate was diluted in 9 µl of dH2O, 
after which 250 µl of room temperature Bradford reagent (B6916, Sigma) was added to 
every well and the plate left for 15 min at room temperature. A standard curve was 
produced using increasing known concentrations of BSA (0, 0.25, 0.5, 1, 2, 5 mg/ml; 
Pierce Albumin Standard 23209, Thermo Scientific) diluted in dH2O, whilst lysis buffer 
was used as a blank for the samples. If required, samples were appropriately further 
diluted prior to addition to the plate to ensure all values fell within the parameters of the 
standard curve. Following a brief plate shake, the plate was read using a 
spectrophotometer set to 595 nm, replicates averaged and protein concentrations 
extrapolated from the standard curve for each sample. 
2.4.4.2 Western Blotting 
2.4.4.2.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The anionic detergent SDS is capable of dissolving hydrophobic molecules 
resulting in the production of protein complexes with a constant charge-to-mass ratio. 
Disrupting the proteins hydrophobic region breaks down secondary and tertiary 
structures linearising molecules coated in a uniform negative charge. This therefore 
allows the separation of proteins based solely on their molecular weight (MW) with no 
structural or charge dependent interference. The use of polyacrylamide gel acts to 
hinder the progression of proteins as they are driven by the electric current in a size 
dependent manner, with smaller molecules travelling faster down the gel towards the 
anode than those with larger MW. Standardised markers with known MWs are utilised 
to enable identification of the MW of the proteins being targeted. 
2.4.4.2.2 Bio-Rad self-poured SDS-PAGE setup 
Samples were made up to equivalent protein concentrations and SDS-containing 
sample buffer (Appendix I; see chapter 7.1, Table 7.1) was added. Samples were boiled 
for 5 min at 95°C and then cooled ready for running on Western blots. Proteins were 
resolved on self-poured SDS-PAGE tris-glycine gels using the Mini-Protean Tetra 
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electrophoresis system (Bio-Rad). Gels were cast in Bio-Rad casting stands and frames 
using 1.0 mm Bio-Rad glass spacer plates. 10% or 15% resolution gel solutions were 
poured depending on the proteins being probed for and gels left to polymerise. A 4% 
stacking gel was then poured and left to polymerise with a comb to produce the 
requisite number of wells (Appendix I; see chapter 7.1, Table 7.2 for gel constituents). 
Ultrapure Tris/Glycine/SDS running buffer (National Diagnostics; Appendix I; see 
chapter 7.1 Table 7.1) was used for electrophoresis at a constant voltage of 150 V for 
approximately 1h15.  
2.4.4.2.3 Nitrocellulose membrane protein transfer 
Following electrophoresis, proteins were transferred onto Amersham
TM
 
Protran
TM
 0.45 µM nitrocellulose membranes (GE Healthcare Life Sciences) using the 
aforementioned Bio-Rad Mini-Protean Tetra electrophoresis system, or Immobilon-FL 
membranes (Millipore) for the work done in collaboration with Prof. S.M. Keyse lab. 
The application of an electric current drives the negatively charged proteins out of the 
gel and onto the membrane ready for probing with the desired antibody.  
For transfer purposes the stacking gel was removed and transfer sandwiches 
were prepared from the cathode side as follows: a fibre blotting-pad, a sheet of filter 
paper, the polyacrylamide gel, a nitrocellulose membrane, a sheet of filter paper and a 
final fibre blotting-pad. Filter papers, pads and membranes were pre-soaked in transfer 
buffer (Appendix I; see chapter 7.1, Table 7.1). Proteins were transferred via 
electrophoresis in transfer buffer for 1 h at 100 V. Subsequent to transfer, the 
membranes were briefly placed in Ponceau S stain to ensure even transfer had occurred. 
Membranes were then rinsed using distilled water and cut where necessary prior to 
being rinsed with Tris-buffered-saline-Tween
®
 20 (TBS-T; Appendix I, see chapter 7.1 
Table 7.1). 
2.4.4.2.4 Immunoblotting 
To minimise non-specific binding membranes were blocked for 1 h in 10% w/v 
dried skimmed milk (Marvel
TM
) in TBS-T on a gentle rocker at room temperature. 
Membranes were incubated overnight on a gentle rocker at 4°C with the relevant 
primary antibody (Appendix IV; see chapter 7.4 for the list of antibodies used) 
following a brief TBS-T wash to remove excess blocking agent. Subject to the protein 
being probed for, blots were either processed for visualisation via infrared (IR) 
fluorescent secondary antibodies for acquisition on the Odyssey machine (Li-Cor); or 
74 
via horseradish peroxidase (HRP)-linked secondary antibodies for acquisition on X-ray 
film. 
2.4.4.2.4.1 Licor Odyssey  
Following removal of the primary antibody, membranes were washed in TBS-T 
for 3x 10 min, then blocked for 20 min in 5% BSA or milk. Membranes then underwent 
a quick wash and were probed with specific IR secondary antibodies (Table 2.7) in 
TBS-T for 1 h at room temperature with gentle rocking. After a further 3x 10 min 
washes in TBS-T, membranes placed in fresh TBS-T were imaged and densitometry 
quantified using the Odyssey system as per manufacturer’s instructions with relevant 
software. 
Antibody 
Supplier 
Product ID 
Dilution in TBS-T Host Conjugate 
Anti-Rabbit 
Rockland Inc. 
611-132-122 
1:10000 Goat 
Alexa Fluor 790 
(IR dye 800) 
Anti-Mouse 
Life Technologies 
A21057 
1:10000 Goat 
Alexa Fluor 680 
(IR dye 700) 
Table 2.7 List of IR dye linked secondary antibodies for use with the Odyssey 
scanner 
2.4.4.2.4.2 Film development 
Following removal of the primary antibody, membranes were washed in TBS-T 
for 3x 10 min and blocked for 20 min in 5% BSA/milk. Membranes then underwent a 
quick wash and were probed with specific HRP-linked secondary antibodies (Table 2.8) 
for 1 h at room temperature with gentle rocking. Membranes then underwent a further 
3x 10 min washes in TBS-T. Whilst the blots were being washed, an enhanced 
chemoluminescence (ECL) wash (Pierce
®
 ECL Western Blotting Substrate, Thermo 
Scientific) was prepared as per manufacturer’s instructions to allow visualisation of the 
protein-primary antibody-secondary antibody complex. Once washes were complete 
TBS-T was removed and ECL wash was placed on the blots and left for a minimum of 1 
min, ensuring the whole blot was coated. Blots were then placed in X-ray film cassettes 
inside plastic pockets. Under dark room conditions X-ray film (CL-XPosure
TM
, Thermo 
Scientific) was placed into the cassette for a range of times, depending on the protein 
being probed for. Films were then developed using a SRX-101A developer (Konica-
Minolta), and subsequently scanned onto a computer where they were quantified using 
Aida Image Analyser densitometry software (v.3.28). 
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Antibody 
Supplier 
Product ID 
Dilution Host Conjugate Blocking Agent 
Anti-Rabbit 
Thermo Scientific 
31460 
1:5000 Goat HRP N/A 
Anti-Sheep 
Thermo Scientific 
31480 
1:5000 Rabbit HRP N/A 
Anti-Chicken 
Promega 
G1351 
1:1000 - HRP 5% Milk 
Table 2.8 List of secondary antibodies for final processing by HRP-ECL reaction 
2.4.5 Quantification of Protein Carbonylation 
Protein carbonylation describes a form of protein oxidation promoted by the 
presence of ROS resulting in a modification of protein side chains containing 
methionine, histidine and tyrosine. Protein carbonylation most often refers to the 
formation of reactive ketone or aldehyde groups on a protein, these can then be used to 
measure ROS related protein damage. Addition of 2,4-dinitrophenylhydrazine (DNPH) 
causes the formation of DNP-hydrazones at the location of the aforementioned reactive 
groups. These hydrazones can then be quantified through the use of a DNP-specific 
antibody. Protein carbonylation was analysed using the Oxyblot
TM
 protein oxidation 
detection kit from Merck Millipore (S7150) as per manufacturer’s instructions. Briefly, 
protein lysates were prepared as previously described (chapter 2.4.2.1) and 2x 15 μg of 
mouse hippocampal or cortical protein lysate were prepared in eppendorfs, allowing for 
positive (DNPH) and control reactions for each sample. Each aliquot was then 
denatured with SDS diluted to a final concentration of 6% at room temperature. 
Samples were derivatised with either 10 μl of 1x DNPH solution or 10 μl of 
derivatisation-control solution for the control reactions. All tubes were incubated for 15 
min at room temperature following gentle mixing, after which the reactions were 
terminated using 7.5 μl of the provided neutralisation solution. Where necessary, 
volumes of reagents were adjusted to cater for the more dilute stock protein 
concentrations of the brain lysates whilst maintaining the same ratio of components 
within the reaction mix. 
Samples were run on 10% SDS-PAGE tris glycine gels. Briefly gels were made 
up as previously described (chapter 2.4.4.2.2) and 15 μl of sample was loaded per well 
making sure to alternate control and positive sample preparations, alongside 3 µl of 
protein standard. Gels were run for 15min at a constant 75V to allow stacking of initial 
load, and the remainder of the sample solutions were then added and the gels run for a 
further 15 min at a constant 75V to allow all the solution to enter the stacking gel. Gels 
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were then run at 100V until the bromophenol blue front from the standard had run off 
the bottom of the gel. Gels were transferred as previously described onto nitrocellulose 
paper (Chapter2.4.4.2.3) and membranes incubated in Oxyblot blocking/dilution buffer 
(OxyBlock; Appendix I; see chapter 7.1 Table 7.1) for 1 h at room temperature on 
gentle rocker. Anti-DNP primary antibody stock was diluted into OxyBlock prior to use 
at a dilution of 1:150, and membranes were incubated for 1 h at room temperature with 
gentle rocking. After incubation, membranes were briefly rinsed twice in 0.05% PBS-T 
(Appendix I; see chapter 7.1, Table 7.1), and washed for 1x 15 min in PBS-T followed 
by 2x 5 min in PBS-T with gentle rocking. Membranes were incubated in rabbit IR 
secondary antibody in TBS-T (see Table 2.7) for 1 h at room temperature with gentle 
rocking. Finally, membranes were washed as before and developed as previously 
described using the Odyssey scanner (chapter 2.4.4.2.4.1). 
Proteins differ in their transfer efficiency as well as their degree of carbonylation 
both of which can affect the immunodetection of the attached DNP moieties. It is also 
possible that different treatments and the effect of transgenic alterations could affect the 
ratio of individual protein carbonylation. As we were only interested in changes in 
overall protein carbonylation and to mitigate any transfer efficiency induced changes, 
four pre-selected regions were analysed and totalled in order to provide a measurement 
for protein carbonylation in our samples. 
2.4.6 Amyloid protein expression 
Triton-X 100 soluble mouse Aβ1-42 was measured in cortical lysates from RC 
and HF fed WT and Nrf2
-/-
 mice using an enzyme-linked immunosorbent assay (ELISA) 
kit (KMB3441, Invitrogen). Lysates were prepared as described in chapter 2.4.2.1 and 
the protein concentration quantified as described in chapter 2.4.4.1. Samples were 
diluted 1:10 into the provided Standard Diluent Buffer and the Aβ1-42 standard provided 
was made following manufacturer’s instructions. 100 µl of Aβ standard or sample were 
loaded in duplicate to wells pre-coated with a monoclonal antibody that recognises the -
NH2 terminus of mouse Aβ, the plate was gently mixed by tapping the side, covered 
with the provided plate cover and incubated for 2 h at room temperature with gentle 
rocking. The solution was then decanted and wells washed 4x with the provided wash 
buffer diluted to a 1x concentration. 100 µl of prepared mouse Aβ1-42 specific antibody 
was added to the wells and the plate gently mixed, covered and incubated for a further 1 
h at room temperature with gentle rocking. Wells were again washed 4x and incubated 
with HRP-tagged secondary antibody for 30 min at room temperature with gentle 
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rocking. Wells underwent a final wash (4x) before the addition of the stabilized 
chromogen (100 µl) which allows visualisation of the bound Aβ1-42 antibody in the 
wells. The plate was incubated in the dark at room temperature with gentle rocking for 
30 min before terminating the reaction through the addition of 100 µl of the provided 
Stop solution. The plate absorbance was read at 450 nm using a spectrophotometer and 
protein concentrations calculated using the absorbencies of the mouse Aβ standard 
curve based on known concentrations of Aβ protein. 
2.4.7 Immunohistochemistry 
2.4.7.1 Tissue preparation 
Tissue was used from perfuse fixed animals described in chapter 2.4.1.2. Upon 
initial transfer from fixative, tissue floats in 30% sucrose solution. Therefore, tissue was 
left for a minimum of 24 h, or the length of time taken for tissue to sink, prior to being 
used for experimental purposes. Plastic tissue block trays were labelled and a small 
amount of Shandom M1-Embedding matrix (Thermo Scientific) was placed in the tissue 
tray. Brains were removed from sucrose solution carefully dried on paper towel and, 
using a clean scalpel, cut sagittally down the midbrain. Any leftover sucrose solution 
was dried and hemispheres placed flat-side down in tissue trays and topped up with 
more M1-Embedding matrix solution until entirely covered. Tissue was quickly frozen 
using a cooling bath of dry ice/propan-2-ol that averages a temperature of -77°C. Once 
the embedding matrix was frozen and had turned opaque, trays were temporarily placed 
in dry ice if more tissue was being processed or stored immediately at -80°C for a 
minimum of 1 h to ensure tissue was fully frozen. 
2.4.7.2 Cryostat sectioning  
Tissue was removed from -80°C at least 30 min prior to sectioning and placed in 
cryostat to equilibrate. The tissue block was then mounted on a ball chuck with the flat 
side facing the blade using Cryo-M-Bed tissue freezing media (Bright Instrument 
Company Ltd.). Once set, the chuck was placed in the cryostat holder and the angle of 
slicing was altered until a whole section was being removed from the tissue block at 
every pass of the blade, promoting consistent sectioning across tissue blocks. Sections 
of 30 μm were taken with on average 4-5 sequential sections being taken followed by an 
equivalent number being skipped to allow captioning of brain sections across the 
different regions. Sections were carefully placed in cold PBS until brain was fully 
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sliced, upon which they were transferred to cryoprotectant solution (Appendix I; see 
chapter 7.1, Table 7.3) and stored at -20°C if not immediately required. 
2.4.7.3 Microscopy Slide Subbing 
In order to improve the adhesion of the microscope slides, these were subbed 
with a chrome-gelatin solution prior to use. A solution of pork gelatin was made up in 
dH2O and gently warmed on a magnetic stirrer to aid dissolution. A separate 1% stock 
solution of chromium (III) potassium sulphate (chrome alum; CrK(SO4)2·12H2O) was 
prepared in dH2O and allowed to solubilise at room temperature. Once dissolved 
chrome alum was added to the pork gelatin solution at a dilution of 1:10. This left a 
concentrated working subbing solution of 1% pork gelatin and 0.1% chrome alum. 
Frosted microscope slides (631-0907; VWR) were laid out on white roll and a 
small dot placed in the top left corner of the frosted section of each slide to enable 
differentiation of the subbed from non-subbed face of the slides. A soft paintbrush was 
used to paint the subbing solution onto the non-frosted upwards facing facet of the new 
slides. Slides were allowed to dry overnight in a dust free environment before being 
placed back in their original box ready for use. Subbing solution was made up fresh on 
the day of use each time as this can easily become infected with micro-organisms. All 
subsequent immunofluorescence (IF) was performed on subbed slides. 
2.4.7.4 Immunofluorescence brain section staining  
Free-floating sagittal sections approximating 0.6 mm from the midline were 
used for the purpose of the IF investigations. Sections were placed in a 24 well plate and 
rinsed in PBS on orbital shaker prior to commencing staining protocol to ensure 
removal of any remaining cryo-m-bed or cryoprotectant solution.  
2.4.7.4.1 Antigen retrieval 
Antigen retrieval is utilised to enable epitope retrieval of proteins when the 
cross-linking caused by fixation masks protein epitopes, preventing the primary 
antibody from successfully binding the protein of interest. Several variations of antigen 
retrieval are currently available with the one described below being one of the mildest. 
Other antigen retrieval solutions include the likes of formic acid, commonly used when 
staining for Aβ plaques. Briefly, sections being stained for the microglial/macrophage 
marker Iba1 were immersed in 10 mM citric acid (pH 6.0; Appendix I; see chapter 7.1, 
Table 7.3) after rinsing in PBS to remove any cryoprotectant solution. Brain sections 
were then placed in a pre-heated oven at 80°C for 30 min. The plate was then rapidly 
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cooled on ice prior to removal of the citric acid solution and proceeding with standard 
staining protocol detailed below. 
2.4.7.4.2 Immunofluorescence staining protocol  
All sections were placed in permeabilisation solution (Appendix I; see chapter 
7.1 Table 7.3) for 1 h at room temperature with gentle agitation on an orbital shaker. 
The solution was carefully pipetted off and replaced with blocking solution (Appendix 
I; see chapter 7.1, Table 7.3) for 1 h on an orbital shaker at room temperature to 
diminish non-specific antibody binding. Sections were then incubated in primary 
antibody (see Table 2.9) overnight at 4°C with gentle orbital shaking. 
Antibody 
Supplier 
Product ID 
Host Dilution Conjugate 
GFAP 
Millipore 
AB5541 
Chicken 1:500 - 
Iba1 
Millipore 
MABN92 
Mouse 1:250 - 
Anti-Mouse 
Jackson ImmunoResearch 
315-495-044 
Rabbit 1:500 DyLight 649 
Anti-Chicken 
Life Technologies 
A21449 
Goat 1:250 Alexa Fluor 647 
Table 2.9 List of antibodies used for immunohistochemistry of brain sections 
Sections were then washed for 3x 10 min in permeabilisation solution and 
incubated in the appropriate fluorophore tagged secondary antibody, as detailed in Table 
2.9 for 1 h at room temperature in the dark with gentle orbital shaking. Finally, sections 
were again washed for 3x 10 min in permeabilisation solution on a gentle orbital shaker 
at room temperature in the dark and given a final quick wash in PBS. Sections were 
stored short-term in fresh PBS at 4°C until ready for mounting onto subbed slides. Upon 
slide mounting excess PBS was removed and slides briefly dried before adding DAPI 
containing Vectashield mounting medium (Vector Laboratories Inc.) and affixing 
coverslips and sealing with nail varnish to prevent the slides drying out. Slides were 
stored in purpose-designed slide boxes at 4°C and later imaged using a TCS SP5 
confocal microscope (Leica). 
2.4.7.4.3 Confocal imaging setup 
Slides were imaged on a TCS SP5 Confocal microscope with associated LAS 
AF software (Leica). The microscope in question having access to light lasers of 
multiple wavelengths a list of the lasers used and relevant wavelength parameters for 
80 
each laser are detailed in Table 2.10. Slides were imaged using the microscope’s oil 
immersion 40x lens and in order to more accurately compare staining between 
genotypes and diets, settings were adjusted for the control group (RC fed WT) and 
maintained consistent throughout the remainder of the slide imaging for each protein of 
interest. In addition, controls were stained with every staining setup and negative 
controls were performed by omitting the primary antibody to ensure the fluorescence 
captured was not the result of auto-fluorescence signalling from the section. 
Laser Colour (spectrum) Antibody /fluorophore 
Fluorophore excitation / 
emission wavelength peaks (nm) 
405 Violet (UV) - /DAPI 358/461 
633 Far-red (visible) 
GFAP/AlexaFluor 
647 
650/668 
633 Far-red (visible) Iba 1/Dylight 649 652/670 
Table 2.10 Specifications of confocal lasers used  
2.5 STATISTICAL ANALYSIS 
Statistical analyses were performed using a variety of tests including t-tests and 
analysis of variance (ANOVA). Tests were predominantly performed in GraphPad 
Prism 5/6 software (GraphPad Software). Where analysis were not able to be performed 
using the aforementioned software, SPSS Statistics 21 software (IBM Corp. ©) was 
utilised instead enabling multivariate ANOVA to be performed, with where necessary 
follow up analysis of simple main effects in order to correctly assess terms of 
interaction. Results from ANOVAs are displayed as described below: 
F(dfBetween Groups, dfWithin Groups)= x, p = y 
Where F is the F value and stands for the ratio of two mean square values and is 
represented by a value x. The greater the value of x (above 1), the greater the 
significance of the result observed. Df stands for degrees of freedom which measure 
either the within or between group variability of the data being analysed. P stands for 
the significance of the result (or probability value) with y representing the output of the 
p-value. 
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3 THE ROLE OF NRF2 IN 
HIGH FAT FEEDING 
INDUCED 
INFLAMMATION 
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3.1 INTRODUCTION 
The pathological description of AD was first described at the turn of the 20
th
 
century by Alois Alzheimer, highlighting the role of misfolded proteins as defining 
markers of AD. Over a century later there are still a great many questions left 
unanswered in relation both to the role played by the hallmark proteins amyloid and tau, 
but also in reference to the mechanisms driving the development and progression of the 
disease. Studies involving amyloid and tau processing, as well as the discovery of 
genetic mutations within these protein pathways, have highlighted the importance of 
other important proteins such as ApoE and PSEN1/2. Many of these associated proteins 
have themselves subsequently been linked with detrimental mutations most of which 
have been associated with the development of FAD; or, as is the case with ApoE, are 
known risk factors contributing towards the likely development of AD. However, with 
the advent of genome wide association studies and the increasing collection of 
epidemiological data from elderly cohorts, other lifestyle risk factors have now been 
associated with AD. These include disorders such as metabolic syndrome, which 
incorporates obesity, diabetes, and hypertension, stroke and many risk factors associated 
with cardiovascular disease such as high blood pressure and high cholesterol. The rise 
of the worldwide obesity epidemic combined with the concomitant increase in life 
expectancy across many countries lays the groundwork for an exponential increase in 
the number of dementia cases diagnosed in the coming decades. However, this has also 
prompted an increased research interest in the links between these disorders.  
As described previously, a fundamental energy imbalance lies at the heart of the 
development of obesity. The increase in energy intake without a concomitant increase in 
energy expenditure results in a surfeit of hormonal and metabolic alterations, including 
many which are linked with alterations to insulin related pathways. Many of these 
modifications are strongly linked peripherally with changes in adipose tissue (white and 
brown) and centrally with the hypothalamic region of the brain, known to be important 
both in connecting the CNS to the endocrine system via the pituitary gland but also in 
the management of hunger and satiety signals. Accordingly, the hypothalamic region 
has been the primary region of the brain studied with regards to obesity. Subsequent 
research of this region has prompted the discovery of neuronal populations now known 
to play important roles in feeding (orexigenic) and satiety (anorexigenic), such as those 
expressing proteins including agouti-related peptide and cocaine- and amphetamine-
regulated transcript, both of which express receptors for leptin and insulin. However, 
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the key brain regions most often associated with AD are the hippocampus and cortex 
and it has only been more recently with the links suggested between mid-life obesity 
and AD that research has begun to emerge on the interaction of these regions with 
obesity related factors. 
Studies using AD related transgenic mouse models, as well as in vitro cell work, 
have implicated obesity as being factorial in alterations of known AD related pathways. 
HF feeding of WT mice has been shown to prompt increased levels of APP with an 
aggravated inflammatory response, whilst activation of APP in macrophages in vitro 
prompted the release of pro-inflammatory markers (Puig et al., 2012). In addition, 
studies performed on middle-aged and aged WT rats using a selection of diets high in 
factors such as cholesterol and hydrogenated fats demonstrated a clear alteration in 
immune-reactivity of key glial cells in the hippocampus (Granholm et al., 2008; 
Freeman et al., 2011). This suggests in turn that, in addition to numerous peripheral 
alterations, detrimental dietary changes are able to directly impact on brain 
biochemistry. Furthermore, these changes are not limited to the energy sensitive 
hypothalamic region of the brain, although alterations in hypothalamic signalling have 
also been reported (Kohjima et al., 2010). Numerous studies using transgenic mouse 
models have also suggested an important role for AD related proteins in the 
dysregulation of insulin signalling (Ho et al., 2004; Jung et al., 2011; Mody et al., 2011; 
Freeman et al., 2012; Hiltunen et al., 2012). This has led to some researchers coining 
the term ‘Type III diabetes’ in reference to AD (de la Monte & Wands, 2008), although 
this is by no means unanimously accepted. Furthermore, studies using models depleting 
AD related factors such as work produced from our own lab using BACE1
-/-
 mice 
support many of these alterations. BACE1
-/-
 mice fed a HF diet have a leaner phenotype 
in comparison to their WT counterparts, with improved insulin sensitivity and glucose 
homeostasis (Meakin et al., 2012). Moreover, caloric restriction (CR) in a mouse model 
of AD has been shown to improve amyloid pathology (Wang et al., 2005), whilst 
morbidly obese TIID patients have decreased expression of amyloid related markers in 
their blood following gastric bypass surgery and the subsequent associated CR (Ghanim 
et al., 2012). When put together, these studies all advocate for altered energy 
homeostasis playing a pivotal role in the regulation of factors known to be involved in 
the development and progression of AD. 
Although many studies have now demonstrated a role for chronic insulin 
resistance in the alteration of amyloid pathology, it is worth noting the opposing effect 
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observed in trials using acute insulin administration. Under these criteria where insulin 
is administered for a much shorter duration, an argument for favourable neuroprotective 
effects can be made. Low dose short-term infusion of insulin in TIID patients 
suppresses APP and PSEN proteins in the blood whilst ameliorating the patient’s anti-
inflammatory profile (Dandona et al., 2011). As mentioned previously, studies using 
intranasal insulin administration have been associated with improved cognition in 
healthy individuals and patients diagnosed with MCI and mild to moderate AD 
(Benedict et al., 2007; Craft et al., 2012). In addition, rodent studies have also 
demonstrated enhanced performance in a variety of experimental cognition tasks 
following central administration of insulin (Park et al., 2000; Zhao et al., 2004; Haj-ali 
et al., 2009; McNay et al., 2010). However, induction of a TIID model using HF 
feeding attenuates the beneficial effects of acute insulin administration on cognition 
whilst promoting an insulin resistant environment (McNay et al., 2010). 
In addition to impacting on pathophysiological and metabolic changes in both 
rodent models and patient cohorts, diets high in fat and other TIID related factors such 
as cholesterol and sucrose have been shown to negatively impact on cognition. WT 
mice fed a HF/high cholesterol diet and hypercholesterolemic transgenic mice 
demonstrated diet and transgene dependent memory impairment with simultaneous 
activation of the central inflammatory response, whilst hypercholesterolemia in an AD 
mouse model accelerated amyloid pathology (Refolo et al., 2000; Thirumangalakudi et 
al., 2008). Intake of high levels of sucrose is of particular relevance to TIID and a study 
performed using a transgenic mouse model of AD demonstrated that intake of high 
levels of sucrose was able to induce insulin resistance much like a HF diet. In addition, 
high sucrose intake exacerbated the amyloid pathology present and impaired memory in 
cognitive tests indicating that increased intake of fats is not a prerequisite for alterations 
in cognition (Cao et al., 2007). Moreover, whilst pharmacological treatment of 
conditions such as TIID and obesity will undoubtedly diminish the risk of subsequently 
developing dementia, these are by no means the only methods of contributing to an 
improved physical outcome. Studies in rodent models have suggested the importance of 
other lifestyle factors in improving cognition and metabolic related health factors. 
Maesako and colleagues have suggested an important role for exercise in the prevention 
of HF diet induced Aβ deposition and cognitive impairment over and above that 
produced by improved dietary control (Maesako et al., 2012b). Maesako and colleagues 
have previously demonstrated that addition of environmental enrichment factors for 10 
weeks, such as stands and toys, along with a running wheel improved both cognition 
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and amyloid pathology in HF fed APPSwe/Ind mice (Maesako et al., 2012a). This 
implicated a role both for environmental enrichment through the added access to objects 
and toys, and for exercise, through the free access to the exercise wheel and greater cage 
size, in positively impacting on AD-related pathology and symptoms. Subsequent to 
this, Maesako and colleagues went back and looked at the effects of dietary 
improvement on the paradigm developed, adding in a return to a RC diet either alone or 
in combination with the addition of environmental enrichment factors including the 
running wheel. From this second study they were able to show the beneficial effects 
associated with the addition of the running wheel and other objects superceded those 
associated with dietary improvement alone. Mice maintained on a HF diet throughout 
but given access to the exercise wheels and objects had significantly improved cognitive 
and pathological profiles when compared with the control group on a HF diet and with 
those who were switched to a RC diet without objects. Furthermore, there was no 
additional cognitive or pathological benefit over and above that seen with the objects 
alone when these were combined with a return to a RC diet (Maesako et al., 2012b). 
As has been previously mentioned, the majority of published literature is agreed 
on there being a role for increased ROS production during development of AD. This has 
resulted in an increased interest in the role of Nrf2 in neurodegeneration subsequent to 
its importance in the management and resolution of OS induced damage. In addition, 
Nrf2 has also been of increasing interest in relation to the study of the metabolic 
syndrome. Furthermore, expression of Nrf2 is known to negatively correlate with 
ageing with a concomitant increase in oxidising agents. Despite these revelations, 
relatively little work has been pursued to further characterise the role of depleted Nrf2 
expression in models of neurodegeneration and ageing, with work reported centring 
instead on the potential for a protective effect following induction of Nrf2 signalling. 
The majority of Nrf2
-/-
 research has concentrated on its potential role in the promotion 
of NASH and other diet dependent physiological alterations with a flurry of 
publications to that effect in recent years (Tanaka et al., 2008; Chowdhry et al., 2010; 
Sugimoto et al., 2010; Zhang et al., 2010). 
Due to the complexity of most brain related disorders, it is widely accepted that 
input from multiple factors come together to provide the environment required to enable 
diseases initiating changes. As a result, and bearing in mind the lack of overt pathology 
in the unchallenged Nrf2
-/-
 mouse model, a decision was made to incorporate an 
additional challenge above that of knocking out Nrf2. The majority of obesity research 
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studies using rodent models use a medium-term dietary intervention of typically up to 
five months. This is usually devised in such a way as to ensure animals reach the 
required weight category to be qualified as obese, and may be considerably shorter 
depending on the fat percentage of the diet in use. However, this has meant that few 
studies look at the long-term effects of HF feeding and the accompanying chronic low 
grade inflammation in the ageing brain. Therefore, in order to investigate changes in 
relation to their potential impact on early development of AD, dietary challenges on our 
mice were pursued for over a year and comparisons made between Nrf2
-/-
 mice and 
those expressing the hAPPswe FAD mutation. In addition, a double transgenic mouse 
model was produced by crossing the aforementioned mouse lines allowing for the 
elucidation of any synergistic effects. Furthermore, this provided a novel mouse model 
which incorporates factors thought to be important in the early stages of AD 
development. 
More specifically the aim of this study was to assess the effects of a long-term 
HF feeding systemic metabolic challenge on the brains of mice with an inflammatory 
and OS primed brain environment in the presence or absence of a pro-amyloidogenic 
human mutation. The main hypotheses based on the information available at the 
commencement of this project were as follows: 
1) Long-term HF feeding of mice lacking functional Nrf2 will result in an 
aggravated inflammatory state within the central tissue, similar to that 
previously described in the liver and proportional to the levels of Nrf2 
present in the brains of control animals. 
2) Loss of Nrf2 when targeted with an environmental stressor leading to 
systemic inflammation will negatively impact on cognition. 
3) Loss of Nrf2 when combined with a pro-amyloidogenic APP mutation 
(hAPPswe) and under the increased inflammatory conditions induced by HF 
feeding will accelerate the development of amyloid related pathology and 
may further impact on cognition. 
In order to try and confirm or disprove these hypotheses, mice from the above 
described genotypes (WT, Nrf2
-/-
, hAPPswe, Nrf2
-/-
/hAPPswe) were used. The main output 
measures for this study were an assessment of cognitive competence through the use of 
an elevated plus maze model of SA, an evaluation of AD related pathology 
advancement through protein and RNA assessment of specific AD-related proteins, and 
an evaluation of the central inflammatory and OS levels through the measurement of 
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commonly associated cytokines, proteins and support cells at either an RNA or protein 
level. 
In order to achieve this, mice were placed on a HF diet at 8-10 weeks of age and 
maintained on this diet until termination (see Chapter 2.3.1 for a group number and diet 
composition breakdown). Cognitive assessments were performed on mice aged 3, 6, 10 
and 14 months of age (see Chapter 2.3.1.4), with metabolic related measurements taken 
at 15 (IPGTT; see Chapter 2.3.1.2) and 16 (IPITT; see Chapter 2.3.1.3) months of age. 
At 16 months of age tissue was harvested from mice and either processed for 
biochemical analysis (see Chapters 2.4.1.1, 2.4.2-2.4.6) or immunohistochemistry (see 
Chapters 2.4.1.2 and 2.4.7). It is important to note that as a result of the genotyping 
problems that occurred (see Chapter 2.2.5.2) fewer mice than were originally allocated 
remained in the hAPPswe and Nrf2
-/-
/hAPPswe groups. As a result, any power calculations 
originally evaluated prior to setting up the study,  are no longer accurate for these 
groups. The resultant lower numbers will impact on our ability to confidently confirm 
significance on smaller biochemical changes recorded within these groups and therefore 
may prove to be a limiting factor for the interpretation of some of our results. 
3.2 NRF2 AND APP ARE EXPRESSED THROUGHOUT THE MURINE BRAIN 
In order to verify the expression of Nrf2, both in the brain as a whole and in the 
regions of specific interest for AD, snap frozen samples from WT mice were processed 
for gene expression analysis. Tissue was used from 4 distinct dissected brain regions: 
cerebellum, cortex, hippocampus and hypothalamus (Figure 3.1 A), with particular 
attention focused on the hippocampus and cortex as these are strongly implicated in 
AD. The hypothalamus is important in energy homeostasis, with altered brain energy 
metabolism now being cited as an additional marker of neurodegeneration (Wurtman, 
2015). The cerebellum is often used as a control brain tissue in the study of AD cases as 
it is less frequently affected by disease related changes in comparison to other 
commonly analysed regions. 
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Figure 3.1 Nrf2 is expressed throughout the mouse brain.  
(A) Pictorial representation of a sagittal mouse brain section denoting the four regions 
dissected for measurement of brain expression levels of relevant genes (adapted from 
the Allen Brain Atlas). RNA was extracted from aged WT mice and the four brain 
regions specified in (A) were investigated for expression levels of Nrf2 (B; n = 6). 
Relative expression of Nrf2 measured with commercial primers between WT and Nrf2
-/-
 
mice is portrayed for the hippocampus (C; n = 6) and the cortex (D; n = 6). Results are 
displayed as means ± s.e.m with all arbitrary units x1000 for simplicity, and analysed 
using one-way ANOVA with post hoc Bonferroni or unpaired Student’s t-test as 
appropriate, with ***, p < 0.001.  
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Analysis indicated a significant difference in Nrf2 expression between brain 
regions (F3, 20 = 45.46, p < 0.0001; Figure 3.1 B), with the cortex and hippocampus 
showing similar levels of expression. The hypothalamus has comparable expression 
levels to those seen in the cerebellum. However, there is a two fold increase in 
expression between those seen in the hippocampus/cortex and those seen in the 
cerebellum/hypothalamus (hippo.: 4.90 A.U. ± 0.57; cereb.: 10.7 A.U. ± 0.22; hypo.: 
10.5 A.U. ± 0.73; cortex: 4.89 A.U. ± 0.21; hippo. vs cereb. p < 0.001; hippo. vs hypo. p 
< 0.001; cortex vs cereb. p < 0.001; cortex vs hypo. p < 0.001; n = 6). This confirms the 
expression of Nrf2 in the brain regions tested, albeit with region specific degrees of 
expression. Due to the design of the Nrf2
-/-
 model at our disposal, verification of the 
model was not possible using commercially designed TaqMan primers. Primers would 
have to specifically recognise the b-Zip region of Nrf2 as this contains the disruption 
replacement lacZ motif of the model in question, whilst the remainder of the gene 
remains intact and therefore recognisable by the majority of commercial primers. This 
can be seen in Figure 3.1 for both the hippocampus (C; p > 0.05) and cortex (D; p > 
0.05). 
Articles delineating the expression of APP in the brain are more prolific than 
those found for Nrf2, in no small part due to its association with AD. Gene expression 
of murine APP (mAPP) across the four brain regions described above confirmed its 
presence in the mouse brain (Figure 3.2 A). The expression of mAPP reported is ~100 
fold higher than that shown for Nrf2, confirming its abundance in the central nervous 
system. The profile across the four brain regions is very similar to that seen for Nrf2, 
albeit with no significant differences between regions (p > 0.05). The hAPPswe model 
chosen for these studies uses the murine APP promoter as previously described in the 
methods section (see chapter 2.2.3). As a result, the expression pattern would be 
expected to correlate with that shown for mAPP. In order to confirm the presence of the 
human APP variant in the model, human specific gene expression was assessed in the 
hAPPswe and Nrf2
-/-
/hAPPswe models with WT mice used as negative controls. 
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Figure 3.2 APP expression is found throughout the mouse brain.  
RNA was extracted from aged WT mice and the four brain regions specified previously were 
investigated for expression levels of mAPP (A; n = 6). Expression of human APP was used to 
confirm the presence of the human APPswe gene in the single (hAPPswe) and double (Nrf2
-/-
/hAPPswe) transgenic mice in the two key brain areas related to AD, the hippocampus (B) and 
the cortex (C; n = 4-7). Following on from this, protein lysates were assessed across the four 
brain regions of WT mice for total APP expression (D) with exemplar blots in (E; n = 6). 
Results are displayed as means ± s.e.m, and units for the expression of hAPP have been x1000 
for simplicity and analysed using one-way ANOVA  with post hoc Bonferroni, where ***, p < 
0.001.  
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There is clear expression of hAPP observed compared to WT mice in the 
hippocampus (F2, 13 = 56.86, p < 0.0001), with both hAPPswe and Nrf2
-/-
/hAPPswe 
displaying significantly increased levels (WT: 0.380
 
A.U. ± 0.28; hAPPswe: 31.1
 
A.U. ± 
2.8; Nrf2
-/-
/hAPPswe: 30.3 A.U. ± 3.6; WT vs hAPPswe p < 0.0001, WT vs Nrf2
-/-
/hAPPswe p < 0.0001, n = 4-6; Figure 3.2 B), which corresponds to the heterozygotic 
breeding background with no significant differences between hAPPswe and Nrf2
-/-
/hAPPswe mice. Cortical expression of hAPP in the hAPPswe mice is significant at a little 
over half that of the equivalent levels of mAPP (F2, 13 = 179.9, p < 0.0001) and with 
both transgenic lines exhibiting significantly increased expression than the WT controls 
(WT: 1.01
 
A.U. ± 0.46; hAPPswe: 45.7
 
A.U. ± 2.9; Nrf2
-/-
/hAPPswe: 74.7 A.U. ± 5.5; WT 
vs hAPPswe p < 0.0001, WT vs Nrf2
-/-
/hAPPswe p < 0.0001, n = 4-7; Figure 3.2 C). 
However, the Nrf2
-/-
/hAPPswe mice have a further significant induction of expression 
over the hAPPswe mice bringing them to similar levels to that seen for mAPP (hAPPswe 
vs Nrf2
-/-
/hAPPswe p < 0.001, n = 4-6). In addition to gene expression, total APP protein 
levels were assessed in the brains of WT mice. A significant alteration was seen in 
protein across the brain regions tested (F3, 20 = 11.50, p < 0.0001; Figure 3.2 D), 
demonstrated by exemplar blots in Figure 3.2 E. The levels of APP protein in the cortex 
were significantly higher than in the hypothalamus and hippocampus (hypo.: 4.21 A.U. 
± 0.37; hippo.: 1.85 A.U. ± 0.38; cortex: 8.35 A.U. ± 1.3; hypo. vs cortex. p < 0.001; 
hippo. vs cortex p < 0.05; n = 6), whilst hippocampal levels were also significantly 
lower than the cerebellum (cereb.: 6.44 A.U. ± 0.84; hippo. vs cereb. p < 0.01, n = 6). 
3.3 OVEREXPRESSION OF HAPPSWE AND LOSS OF FUNCTIONAL NRF2 
HAVE OPPOSING EFFECTS ON ADIPOSITY FOLLOWING PROLONGED 
HIGH FAT FEEDING 
Having confirmed that Nrf2 and APP are both present across multiple mouse 
brain regions, we went on to assess the impact of a known AD risk factor, obesity, on 
our different mouse models. Due to the nature of AD as a disease strongly associated 
with ageing, mice were placed on a HF diet for longer than would be commonly 
performed whilst pursuing studies solely investigating the effects of excess nutrient 
intake on metabolic disease. Age matched mice were placed on a 45% HF diet at 8-10 
weeks of age and body weight measured at three different ages, three (Figure 3.3 A), six 
(Figure 3.3 B) and 14 months (Figure 3.3 C); to assess both the short and long term 
impact of consumption of a diet high in fats on weight gain across genotypes.  
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Figure 3.3 Long-term HF feeding causes a time and genotype dependent divergent 
change in weight gain in Nrf2
-/-
 and hAPP
swe
 transgenic mice. 
Age-matched Nrf2
-/-
, hAPP
swe
 and Nrf2
-/-
/hAPP
swe
 mice were placed on a RC or HF (45%) diet 
at 8-10 weeks of age. Mice were handled regularly and body weights recorded at 3 months of 
age (A), 6 months of age (B) and 14 months of age (C). All data presented as means ± s.e.m. 
Changes in body weight were compared between groups at each time interval by two-way 
ANOVA with factors of genotype and diet, post-hoc Bonferroni used as required. When 
positive interaction effects were reported, these replaced main effects on graphical 
representations of data, and were followed up through analysis of simple main effects with post-
hoc Bonferroni. * Indicates significantly different main effect (***, p < 0.001) and # indicates 
significant interaction effect (#, p < 0.05; ##, p < 0.01; ###, p < 0.001). 3 months: WT n = 9-14, 
Nrf2
-/-
 n = 12-22, hAPPswe n = 8, Nrf2
-/-
/hAPPswe n = 7-10; 6 months: WT n = 19-20, Nrf2
-/-
 n = 
20-22, hAPPswe n = 8, Nrf2
-/-
/hAPPswe n = 10-12; 14 months: WT n = 17-18, Nrf2
-/-
 n = 21-22, 
hAPPswe n = 5-11, Nrf2
-/-
/hAPPswe n = 5.  
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Mice were compared at each individual time point in order to assess the role of 
the two main factors, namely genotype and diet on total body weight as it is assumed 
that there will be a significant effect of time on all groups. At three months there is a 
significant main effect of genotype (F3,96 = 9.11, p < 0.0001) and diet (F1,96 = 131.2, p < 
0.0001). However, a significant diet*genotype interaction (F3,96 = 9.78, p < 0.0001) was 
also observed at three months. Analysis of the diet*genotype interaction using simple 
main effects described a significantly lower body weight of hAPPswe mice compared to 
both WT and Nrf2
-/-
 mice on the RC diet (WT: 31.13 g ± 0.75; Nrf2
-/-
: 29.70 g ± 0.50; 
hAPPswe: 23.46 g ± 1.29; WT vs hAPPswe p < 0.01, Nrf2
-/-
 vs hAPPswe p < 0.05). By 6 
months of age, there is no longer a significant diet*genotype interaction (p > 0.05). As 
would be predicted there is a main effect of diet (F1, 109 = 60.28, p < 0.0001) at 6 months 
of age with HF fed mice having increased body weights compared to their RC fed 
compatriots. There is no significant effect of genotype on body weight at 6 months (p > 
0.05). 
A final time point was measured at 14 months of age, at which point mice had 
been on a HF diet for about a year. Upon analysis highly significant main effects of 
genotype (F3,96 = 9.11, p < 0.0001) and diet (F1,96 = 131.2, p < 0.0001) were seen. 
However, similar to that previously observed at 3 months, there is a highly significant 
diet*genotype interaction (F3,96 = 9.78, p < 0.0001) at 14 months of age with genotype-
dependent differences in response to long term HF feeding. Further investigation of 
simple main effects pinpointed a significantly lower weight of HF-fed Nrf2
-/-
 mice in 
comparison to WT control HF-fed mice (WT: 48.32 g ± 2.28; Nrf2
-/-
: 38.84 g  ± 1.39; 
WT vs Nrf2
-/-
 p < 0.0001). hAPPswe mice were significantly heavier than both Nrf2
-/-
 
mice and Nrf2
-/-
/hAPPswe mice with a trend towards but non-significant increase in 
comparison to WT mice (hAPPswe: 56.50 g ± 1.17; Nrf2
-/-
: 38.84 g ± 1.39; Nrf2
-/-
/hAPPswe: 42.94 g ± 4.55; hAPPswe vs Nrf2
-/-
 p < 0.0001; hAPPswe vs Nrf2
-/-
/hAPPswe p < 
0.01). 
3.4 NRF2-/- MICE MAINTAIN INSULIN SENSITIVITY EVEN AFTER LONG-
TERM HIGH FAT FEEDING. 
As significant differences in total body weight of long term HF fed mice were 
observed in a genotype-dependent manner, measures for other markers associated with 
DIO were pursued. Aged mice from WT, Nrf2
-/-
 and hAPPswe lines that had been fed 
either a RC of 45% HF diet from 8-10 weeks of age were put through IPGTT (15 
months) and ITT (16 months). This allowed assessment of peripheral glucose clearance 
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and insulin sensitivity. As has been previously reported, HF fed WT mice on a C57Bl/6 
background demonstrate impaired glucose clearance and impaired insulin sensitivity 
(Fellmann et al., 2013). IPGTT induced changes in blood glucose levels are delineated 
below for the RC (Figure 3.4 A) and HF (Figure 3.4 D) cohorts. 
Analysis of the IPGTT AUC in RC mice showed a significant effect of genotype 
on glucose disposal (F2,32 = 9.176, p < 0.001; Figure 3.4 B). Nrf2
-/-
 mice demonstrate 
increased sensitivity to a glucose bolus, with significantly better glucose disposal 
compared with WT mice (WT RC: 1148 ± 40; Nrf2
-/-
 RC: 889.5 ± 54; WT RC vs Nrf2
-/-
 
RC p < 0.001, n = 12-15). No significant change was seen in glucose clearance between 
WT mice and those carrying the hAPPswe mutation (hAPPswe HF: 1017 ± 35.4; WT vs 
hAPPswe p > 0.05, n = 7-18), with no significant difference in weight seen under RC 
feeding (p > 0.05; Figure 3.4 C).  
When fed a HF diet long-term a significant difference in glucose management is 
seen between genotypes (F2,22 = 6.565, p < 0.01), where both Nrf2
-/-
 and hAPPswe mice 
have significantly altered glucose disposal. hAPPswe show an impaired ability to dispose 
of glucose following a bolus injection when compared to WT controls, whilst Nrf2
-/-
 
mice fed a HF diet maintain an improved clearance profile which is significantly better 
than that seen in hAPPswe mice (WT HF: 1556 ± 117; Nrf2
-/-
 HF: 1192 ± 152; hAPPswe 
HF: 2144 ± 58; WT HF vs Nrf2
-/-
 HF p > 0.05, WT HF vs hAPPswe p < 0.05, Nrf2
-/-
 HF 
vs hAPPswe HF p < 0.01, n = 4-16; Figure 3.4 E). This occurs despite no longer seeing a 
significant difference between WT and Nrf2
-/-
 mice fed a HF diet (F2,22 = 6.565, p < 
0.01; WT HF vs Nrf2
-/-
 HF p > 0.05, n = 4-16; Figure 3.4 F), although this may also be 
due to low numbers in the Nrf2
-/-
 group. However, HF-fed hAPPswe mice were found to 
be heavier than HF-fed WT mice on the day of testing (WT HF: 49.4 ± 2.1; hAPPswe 
HF: 55.7 ± 1.3; WT HF vs hAPPswe HF p < 0.05, n = 5-16) and therefore received a 
higher glucose dose as this is administered in a weight-dependent manner. This may 
prove to be influential in the development of glucose clearance changes displayed here. 
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Figure 3.4 Knocking out Nrf2 and overexpressing hAPPswe have opposing effects on 
glucose tolerance in aged high fat fed mice. 
Aged WT, Nrf2
-/-
 and hAPPswe mice fed a RC or HF diet from 8-10 weeks of age underwent IP 
glucose and insulin tolerance tests. At 15 months tail vein blood glucose was measured for 
IPGTT over a period of 120 min in RC (A) and HF (D) fed animals. The area under the curve 
(AUC) was calculated for each animal and are represented in B and E, whilst body weights on 
day of testing are presented in C and F respectively (WT n = 15-16; Nrf2
-/- 
n = 4-12; hAPPswe n 
= 5-8). ITTs (16 months) were performed using an insulin bolus. Tail vein blood glucose was 
measured over a period of 90 min for RC and HF fed animals. Body weights on day of testing 
(G and J) as well as basal fasted blood glucose levels (H and K) are reported for RC and HF fed 
animals respectively. Changes in blood glucose over time are represented as percentage of 
baseline values for RC (I) and HF (L) fed respectively (WT n = 13-14; Nrf2
-/- 
n = 4-12; hAPPswe 
n = 5-8). All data are represented as means ± s.e.m. AUC and basal glucose concentrations 
analysed by one-way ANOVA with post hoc Bonferroni, ITT were analysed by dietary group 
using repeated measures 2-way ANOVA with post-hoc Bonferroni (*, p < 0.05; **, p < 0.01). 
All experiments were performed and data collected by Dr. A.D. McNeilly, postgraduate PhD 
student S.M. Jalicy and Dr. P.M. Meakin  
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ITT were performed to assess insulin sensitivity across genotypes and diet 
groupings. There were no significant changes in RC fed animals at the time of ITT 
testing (p > 0.05; Figure 3.4 G). Further to this, fasted blood glucose levels showed no 
significant difference between genotypes on a RC diet with all groups reporting 
concentrations of ~6mM glucose (p > 0.05, n = 8-14; Figure 3.4 H). In contrast, Nrf2
-/-
 
mice fed a HF diet maintain a similar level of glucose to their RC counterparts whilst 
both WT and hAPPswe mice have higher circulating glucose levels after HF feeding 
(F2,19 = 3.656, p < 0.05; WT HF: 7.36 ± 0.31; Nrf2
-/-
 HF: 5.63 ± 0.70; hAPPswe HF: 6.64 
± 0.44; WT HF vs Nrf2
-/-
 HF p < 0.05, hAPPswe HF vs WT and Nrf2
-/-
 HF p > 0.05, n = 
4-13; Figure 3.4 K), despite no longer seeing a significant difference in weight (p > 
0.05; Figure 3.4 J). ITT percentage glucose response curves are reported for RC (Figure 
3.4 I) and HF (Figure 3.4 L) groups. From these graphs it is possible to see that, along 
with maintained glucose clearance, aged Nrf2
-/-
 mice remain more sensitive to an insulin 
bolus on a RC diet (F2,31 = 3.327, p < 0.05; WT RC vs  Nrf2
-/-
 RC p < 0.05). However, 
this effect is lost following long-term HF feeding (p > 0.05). 
3.5 PERIPHERAL EFFECTS OF LONG-TERM HIGH FAT FEEDING 
As well as affecting overall weight gain, consuming a diet high in fat is also 
linked with detrimental effects on specific peripheral organs. Organs such as the liver, 
that is responsible for a large percentage of the detoxification and metabolism of 
external factors, and the spleen, responsible for the production of some of the 
inflammatory related markers, are both prime targets for obesity driven impairment. 
Finally, there have been numerous publications linking obesity with cardiac remodelling 
and hypertrophy. As the animals in this study were placed on a HF diet for upward of a 
year, longer than many studies looking at obesity, a combination of ageing, diet and 
incorporation of transgenic mutations could all potentially play a role in altering organ 
physiology, including heart. 
All tissues examined were measured as both raw tissue weight and as a 
percentage of total body weight in order to tease out the effects of the main genotype 
and diet factors. There was shown to be a main effect of genotype (F3,72 = 5.69, p < 
0.01; n = 4-20) but not diet (p > 0.05) on total heart weight (Figure 3.5 A), exemplified 
by significant increases in the heart weights of the Nrf2
-/-
/hAPPswe mice compared to 
WT controls (WT: 0.179 g ± 7*10
-3
; Nrf2
-/-
/hAPPswe: 0.242 g ± 0.02; WT vs Nrf2
-/-
/hAPPswe p < 0.05) and both Nrf2
-/-
 and Nrf2
-/-
/hAPPswe having bigger hearts than the 
hAPPswe mice (Nrf2
-/-
: 0.209 g ± 0.01; hAPPswe: 0.159 g ± 9*10
-3
; Nrf2
-/-
/hAPPswe: 0.242 
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g ± 0.02; hAPPswe vs Nrf2
-/-
 p < 0.05, hAPPswe vs Nrf2
-/-
/hAPPswe p < 0.01). When body 
weight is accounted for and heart weight is measured as a percentage of bodyweight, a 
main effect of both genotype (F3,72 = 14.16, p < 0.0001) and diet (F1,72 = 41.86, p < 
0.0001) is seen (Figure 3.5 B), with HF feeding leading to a smaller percentage heart 
weight, which is to be expected. The main effect of genotype is caused by the increased 
percentage heart weight of both Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice over WT and hAPPswe 
mice (WT: 0.494 % ± 0.03; Nrf2
-/-
: 0.679 % ± 0.04; hAPPswe: 0.492 % ± 0.03; Nrf2
-/-
/hAPPswe: 0.762 % ± 0.09; WT vs Nrf2
-/-
 p < 0.0001; WT vs Nrf2
-/-
/hAPPswe p < 0.001, 
hAPPswe vs Nrf2
-/-
 p < 0.001, hAPPswe vs Nrf2
-/-
/hAPPswe p < 0.001). No diet*genotype 
interaction was observed (p > 0.05). It is worth noting that all tissue measurements were 
performed on whole organ weights. As a result, the alterations in cardiac weight 
observed could be further clarified by dissection of the cardiac tissue to ascertain the 
occurrence of any region specific alterations in tissue mass that might be indicative of 
pathological heart remodelling. 
Both a main effect of genotype (F3,72 = 8.582, p < 0.0001; n = 4-18) and a small 
but significant main effect of diet (F1,72 = 4.355, p < 0.05) were shown to impact on 
total liver weight. This is exemplified by a small HF feeding dependent increase in liver 
weight and significantly lower liver weights in the Nrf2
-/-
 mice compared to WT 
controls and hAPPswe mice (WT: 1.55 g ± 0.08; Nrf2
-/-
: 1.107 g ± 0.05; hAPPswe: 1.493 g 
± 0.09; WT vs Nrf2
-/-
 p < 0.001, hAPPswe vs Nrf2
-/-
 p < 0.05). When looking at liver as 
percentage of total bodyweight, a main effect of both genotype (F3,71 = 3.343, p < 0.05) 
and diet (F1,71 = 21.25, p < 0.0001) is seen. However, in this case there is also a 
significant diet*genotype induced interaction (F3,71 = 3.992, p < 0.05) with Nrf2
-/-
 and 
Nrf2
-/-
/hAPPswe mice having smaller livers as percentage of total body weight compared 
to WT and hAPPswe mice fed a RC but not HF diet (WT: 5.22 % ± 0.39;Nrf2
-/-
: 4.10 % ± 
0.15; hAPPswe: 5.17 % ± 0.26; Nrf2
-/-
/hAPPswe: 3.25 % ± 0.22; WT vs Nrf2
-/-
 p < 0.05, 
WT vs Nrf2
-/-
/hAPPswe p < 0.01, hAPPswe vs Nrf2
-/-
/hAPPswe p < 0.05).  
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Figure 3.5 HF feeding further impacts on changes in key physiological organs 
driven by the loss of Nrf2
-/-
. 
Tissue was harvested from aged (± 16 months) RC and HF fed WT, Nrf2
-/-
, hAPPswe and Nrf2
-/-
/hAPPswe mice. Organ weights were obtained for hearts (A) after clearing of any remaining 
blood, livers (B) and spleens (C) to investigate genotype related effects on peripheral tissue 
health. Organ weights were assessed in relation to total body weight on day of harvest in order 
to clarify any dietary related changes. These are reported as percentage body weight for the 
heart (D), liver (E) and spleen (F; WT n = 9-14, Nrf2
-/-
 n = 15-20, hAPPswe n = 5-9, Nrf2
-/-
/hAPPswe n = 4). Data is presented as means ± s.e.m. and analysed using two-way ANOVA with 
genotype and diet as designated factors, post-hoc Bonferroni performed as necessary. If positive 
factor interaction occurred, analysis was followed up by investigation of simple main effects 
with post-hoc Bonferroni. When positive interaction effects were reported, these replaced main 
effects on graphical representations of data. * indicates significant main effect of individual 
factor (*, p < 0.05; **, p < 0.01; ***, p < 0.001), # indicates significant interaction effect (#, p < 
0.05; ##, p < 0.01).  
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Only a main effect of genotype (F3,73 = 3.397, p < 0.05; n = 4-20) was seen for 
total spleen weight. This was illustrated by significantly larger spleens in both the Nrf2
-/-
 
and Nrf2
-/-
/hAPPswe mice compared to hAPPswe mice (Nrf2
-/-
: 0.121 g ± 7*10
-3
; hAPPswe: 
0.092 g ± 6*10
-3
; Nrf2
-/-
/hAPPswe: 0.132 g ± 0.01; hAPPswe vs Nrf2
-/-
 p < 0.05, hAPPswe 
vs Nrf2
-/-
/hAPPswe p < 0.05). Measuring percentage body weight of the spleens showed 
a main effect of both diet (F1,72 = 16.50, p < 0.001) and genotype (F3,72 = 7.074, p < 
0.001) but no significant interaction term (p > 0.05). Similar to percentage heart weight, 
HF feeding decreases the spleens percentage of total body weight. The genotype 
dependent effect is maintained, however, with Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice having 
larger spleens when compared to WT and hAPPswe mice (WT: 0.273 % ± 0.02; Nrf2
-/-
: 
0.392 % ± 0.03; hAPPswe: 0.281 % ± 0.02; Nrf2
-/-
/hAPPswe: 0.426 % ± 0.06; WT vs 
Nrf2
-/-
 p < 0.01,  WT vs Nrf2
-/-
/hAPPswe p < 0.05,  hAPPswe vs Nrf2
-/-
 p < 0.05, hAPPswe 
vs Nrf2
-/-
/hAPPswe p < 0.05). 
3.6 EFFECT OF NRF2-/- AND A HIGH FAT DIET ON AGEING COGNITION  
Cognitive impairment is often one of the first outward signs of dementia 
displayed by a patient. Moreover, obesity and TIID have both been associated with 
impaired cognition in a variety of mouse models (Valladolid-Acebes et al., 2011; 
Niedowicz et al., 2014; Tucsek et al., 2014) and clinical studies (Smith et al., 2011). 
Assessment of the effect of genotype along with high fat feeding over time on cognition 
was done using a model of continuous SA performed in a closed-arm elevated plus 
maze. In addition to a measure of SA, locomotor activity was assessed by comparing 
the number of arm entries performed over a set period of time (10 min). Mice fed a RC 
diet from WT, Nrf2
-/-
 and Nrf2
-/-
/hAPPswe backgrounds were assessed for alternation in 
SA at four individual time points, namely 3, 6, 10 and 14 months of age.  
There was no main effect of genotype on number of arm entries, indicating no 
impact on locomotor activity was produced by the loss of Nrf2
-/-
 or addition of hAPPswe 
at these time points. A main effect of time was observed (F3,133 = 7.055, p < 0.001), with 
all groups performing significantly fewer arm entries at 14 months than at 6 and 10 
months (6 months: 35.4 ± 1.6; 14 months: 27.9 ± 1.6; 6 months vs 14 months p < 0.01, 
10 months vs 14 months p < 0.01, n = 34-48; Figure 3.6 A). Moreover, a similar change 
is seen in the number of alternations performed. A main effect of time is again seen 
(F3,133 = 10.818, p < 0.001) with no effect of genotype, exemplified by significantly 
fewer alternations performed at 14 months than at previous time points for all groups 
concerned (3 months: 18 ± 1.3; 6 months: 17.9 ± 0.81; 10 months: 16.2 ± 0.98; 14 
100 
months: 11.6 ± 0.85; 3 months vs 14 months p < 0.01, 6 months vs 14 months p < 
0.001, 10 months vs 14 months p < 0.01, n = 20-48; Figure 3.6 B). 
From the measures determined above, percentage SA (%SA) was calculated 
with the equation described in Figure 3.6 C and previously described by McNay and 
colleagues (2000). When analysed, there were both main effects of genotype and time 
with no interaction seen between these factors on the ability of mice to perform 
egocentric SA (Genotype: F2,133 = 5.551, p = 0.005; Time: F3,133 = 4.630, p = 0.004). A 
significant decrease in %SA was seen over time with mice performing fewer successful 
alternations at 10 and 14 months than at 3 months (3 months: 65.5 ± 2.7; 10 months: 
52.1 ± 1.8; 14 months: 50.7 ± 3.2; 3 months vs 10 months p < 0.01, 3 months vs 14 
months p < 0.01, n = 20-48; Figure 3.6 D). Furthermore, mice harbouring the novel 
double mutation (Nrf2
-/-
/hAPPswe) were significantly impaired when compared to both 
WT and Nrf2
-/-
 mice with no significant difference seen between these two (WT: 58.4 ± 
2.0; Nrf2
-/-
: 55.8 ± 1.8; Nrf2
-/-
/hAPPswe: 45.8 ± 3.6; WT vs Nrf2
-/-
/hAPPswe p < 0.01, 
Nrf2
-/-
 vs Nrf2
-/-
/hAPPswe p < 0.05, n = 21-74). 
Further to analysing the effect of these mutations on cognition over time, we 
also compared the effect of HF feeding on cognition and locomotor activity over time in 
WT and Nrf2
-/-
 mice. When HF feeding is incorporated into the task performance, we 
see very different profiles for WT and Nrf2
-/-
 mice. Although no significant change is 
observed in cognition as measured by %SA and no diet*time*genotype interaction was 
observed, we do see both genotype*diet and time*diet interactions in the number of arm 
entries (Figure 3.7 A and E) and alternations (Figure 3.7 B and F) performed with HF 
fed Nrf2
-/-
 mice performing more arm entries and alternations than WT counterparts 
(genotype*diet: arm entries: F1,139 = 6.531, p = 0.012; alternations: F1,139 = 5.544, p = 
0.020. time*diet: arm entries: F1,139 = 6.531, p = 0.012; alternations: F1,139 = 5.544, p = 
0.020.). Furthermore, although no significant effect of is seen for diet alone, a main 
effect of genotype is reported for the number of arm entries and alternations performed 
(arm entries: F1,139 = 9.778, p = 0.002; alternations: F1,139 = 6.393, p = 0.013), whilst 
there is still a significant effect of time on the number of alternations performed as well 
as the ability to perform SA (Alternations: F1,139 = 7.145, p = 0.001; SA: F1,139 = 10.090, 
p < 0.001, Figure 3.7 C and G). This is matched by attenuated weight gain in mice 
lacking Nrf2
-/-
 fed a HF diet when compared to controls as has been described above 
(Figure 3.7 D and H, and refer back to Figure 3.4). 
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Figure 3.6 A time-dependent impairment in spontaneous alternation is seen in all 
groups whilst Nrf2
-/-
/hAPPswe decline more rapidly than WT and Nrf2
-/-
 mice. 
Mice from WT, Nrf2
-/-
 and Nrf2
-/-
/hAPPswe backgrounds were put through the closed arm 
elevated plus maze at four different ages, namely 3, 6, 10 and 14 months. Measures were taken 
for total number of arm entries performed (A) and total number of alternations performed (B). 
These were used to calculate %SA using the equation depicted in C, with results reported in D. 
All data are presented as means ± s.e.m. and analysed by ANOVA or MANOVA as appropriate. 
(3 months: WT: n = 9, Nrf2
-/-
: n = 11; 6 months: WT: n = 14, Nrf2
-/-
: n = 18, Nrf2
-/-
/hAPPswe: n = 
10; 10 months: WT: n = 19, Nrf2
-/-
: n = 22, Nrf2
-/-
/hAPPswe: n = 7; 14 months: WT: n = 7, Nrf2
-/-
: 
n = 23, Nrf2
-/-
/hAPPswe: n = 4).   
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Figure 3.7 HF feeding significantly increases activity in young and middle-aged 
mice lacking Nrf2 without impairing their ability to SA. 
RC and HF mice from WT and Nrf2
-/-
 were put through the closed arm elevated plus maze at 
three different ages, namely 3, 6, and 10 months. Measures were taken for total number of arm 
entries performed (A and E) and total number of alternations performed (B and F). These were 
used to calculate SA (C and G), whilst body weight was also measured on day of testing (D and 
H). All data are presented as means ± s.e.m. and analysed by ANOVA or MANOVA as 
appropriate. (3 months: WT: n = 6-9, Nrf2
-/-
: n = 10-11; 6 months: WT: n = 4-14, Nrf2
-/-
: n = 18-
26; 10 months: WT: n = 19, Nrf2
-/-
: n = 11-22).  
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Analysis revealed a significant diet dependent difference in the number of 
alternations and arm entries performed at individual time points by HF animals, with 
HF fed mice performing more arm entries and alternations at 3 months of age but 
significantly fewer by 10 months of age (3 months: arm entries: RC: 31.5 ± 2.3; HF: 
39.0 ± 2.7; RC vs HF p < 0.05; alternations: RC: 17.9 ± 1.4; HF: 22.7 ± 1.6; RC vs HF 
p < 0.05, n = 16-20. 10 months: arm entries: RC: 35.3 ± 1.6; HF: 12.3 ± 1.9; RC vs HF 
p < 0.05; alternations: RC: 16.7 ± 0.96; HF: 12.3 ± 1.9; RC vs HF p < 0.05, n = 11-41). 
This decrease in locomoter activity, as measured by arm entries, coincides in HF fed 
Nrf2
-/-
 mice with a slower body weight gain. In addition, a significant effect of diet on 
genotype is observed, with analysis using simple main effects showing that Nrf2
-/-
 mice 
perform more arm entries and alternations when on a HF diet compared to those on RC, 
an effect not replicated in WT mice (WT RC vs HF p > 0.05. Nrf2
-/-
: arm entries: RC: 
34.1 ± 1.5; HF: 39.6 ± 1.6; Nrf2
-/-
 RC vs HF p < 0.05; alternations: RC: 17.5 ± 0.9; HF: 
19.9 ± 0.98; Nrf2
-/-
 RC vs HF p = 0.078, n = 47-51). Finally the main effects of time are 
the same as described above and therefore shall not be reiterated here. 
3.7 THE EFFECT OF HIGH FAT FEEDING AND NRF2-/- ON INFLAMMATION 
AND PROTEIN CARBONYLATION MARKERS IN THE MOUSE BRAIN 
AD had been linked with an increased presence of brain inflammation, 
particularly in the regions surrounding abnormal protein depositions such as Aβ 
plaques. It is, as previously mentioned, also associated with obesity and the metabolic 
syndrome as well as strokes and cardiovascular events; all of which are linked to an 
increased presence of inflammation. We have already shown changes in size of some of 
the key peripheral organs involved in inflammation and metabolite detoxification. In 
order to assess the potential effect of our models with regards to a role in AD related 
inflammatory and other associated processes; age-matched aged brain tissue was 
processed for gene expression analysis by RT-qPCR from mice fed either a RC or 45% 
HF diet. 
A selection of standard pro-inflammatory genes (Mosser & Edwards, 2008) was 
profiled in the two key AD-associated brain areas, the hippocampus (Figure 3.8 A-D) 
and cortex (Figure 3.8 E-H). Predominantly, changes in pro-inflammatory markers 
occur in the hippocampus of Nrf2
-/-
 mice fed a RC diet. There is a non-significant trend 
for an increase in IL-1β in the hippocampus of Nrf2-/- mice compared to controls (WT 
RC: 1.00; Nrf2
-/-
 RC: 2.94 ± 0.99; WT RC vs Nrf2
-/-
 RC p = 0.08, n = 9-10; Figure 3.8 
A) with HF feeding of Nrf2
-/-
 causing a mild attenuation of the phenotype (Nrf2
-/-
 HF: 
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1.80 ± 0.36, WT RC vs Nrf2
-/-
 HF p = 0.07, n = 7-9). This profile is repeated for the pro-
inflammatory TNF-α with significant increases seen in RC-fed Nrf2-/- (WT RC: 1.00; 
Nrf2
-/-
 RC: 3.02 ± 0.84; WT RC vs Nrf2
-/-
 RC p < 0.05, n = 9-10; Figure 3.8 B), and 
non-significant changes in IL-6 and iNOS (Figure 3.8 C and D respectively). In all three 
cases, HF feeding of Nrf2
-/-
 appears to have an overall attenuating effect on pro-
inflammatory markers in the aged mouse hippocampus (Nrf2
-/-
 HF TNF-α: 0.880 ± 0.18; 
Nrf2
-/-
 RC vs Nrf2
-/-
 HF p = 0.06, n = 7-10).When looking at the effect of the presence 
of hAPPswe on pro-inflammatory markers it would appear to have an opposing effect to 
that seen in the Nrf2
-/-
, with either significant decreases such as that seen with IL-1β 
(hAPPswe: 0.773 ± 0.08, WT vs hAPPswe p < 0.05, n = 5) or no significant change as 
seen in the remaining markers IL-6, iNOS and TNF-α. HF-feeding has no significant 
impact on either hAPPswe or WT pro-inflammatory markers in the hippocampus. And 
although the low number of Nrf2
-/-
/hAPPswe hampers analysis they appear to show a 
profile similar to that seen in the Nrf2
-/-
 mice.  
In contrast to the hippocampus, the cortex showed very little change in pro-
inflammatory gene expression in any group excepting the hAPPswe mice. These again 
show a decreased pro-inflammatory profile across both RC and HF fed groups. This 
was demonstrated by significantly decreased IL-1β (WT RC: 1.00; hAPPswe HF: 0.5166 
± 0.0472; WT RC vs hAPPswe RC p < 0.001, n = 5-10; Figure 3.8 E), iNOS (WT RC: 
1.00; hAPPswe RC: 0.6370 ± 0.0768; WT RC vs hAPPswe RC p < 0.01, n = 6-10; Figure 
3.8 G), and TNF-α (WT RC: 1.00; hAPPswe HF: 0.5822 ± 0.134; WT RC vs hAPPswe RC 
p < 0.05, n = 5-10; Figure 3.8 H), with no change seen in IL-6 (Figure 3.8 F). 
Increases in pro-inflammatory cytokines are not the only marker associated with 
inflammatory and oxidative damage. In order to assess the role of changes in genotype 
and diet on protein carbonylation, a marker for protein damage, oxyblot protein assays 
were performed. Oxyblots utilise the site specific introduction of carbonyl groups 
following oxidative damage induced molecular modification to measure changes in total 
protein carbonylation that have occurred in the tissue of interest. Addition of DNP-
hydrazone to the protein carbonyl groups, opens them up to visualisation using a DNP-
specific HRP tagged secondary antibody. In order to assess the changes in total protein 
carbonylation, four areas on each positive sample lane were chosen at random and 
densitometry calculated for each box region. Exemplar blots are depicted with the 
regions analysed depicted on the control lane for both the hippocampus (Figure 3.9 A) 
and the cortex (Figure 3.9 B) of RC and HF treated WT and Nrf2
-/-
 mice.  
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Figure 3.8 Loss of Nrf2 drives a hippocampal dominant increase in pro-
inflammatory markers in the brain that is rescued by HF feeding. 
Brains harvested from aged RC and HF fed WT, Nrf2
-/-
, hAPPswe and Nrf2
-/-
/hAPPswe mice were 
dissected and the hippocampus and cortex were processed for gene expression analysis. A panel 
of commonly associated pro-inflammatory markers were investigated in all groups in both 
tissues; namely IL-1β (A + E), IL-6 (B + F), iNOS (C + G) and TNF-α (D + H) (WT n = 9-10, 
Nrf2
-/-
 n = 7-10, hAPPswe n = 4-6, Nrf2
-/-
/hAPPswe n = 4). Results are reported as means ± s.e.m., 
and analysed by one-sample and unpaired t-test where *, p < 0.05; **, p < 0.01; ***, p < 0.001.  
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Figure 3.9 Pictorial representations of oxyblot assays performed in the 
hippocampus and cortex of adult RC or HF fed animals.  
Aged adult mice fed either a RC or HF diet were harvested for tissue. Brains were excised and 
dissected from WT and Nrf2
-/-
 and half each of the hippocampus and cortex were lysed for 
protein. Equal amounts of protein were calculated and samples were run through the oxyblot 
assay per manufacturer’s instructions to assess changes in protein carbonylation. Exemplar blots 
depicting the hippocampus (A) and cortex (B) are labelled with regions used for later analysis 
on the left of the blot.  
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A total change in carbonylation was assessed using cumulative scores from all 
of the boxed regions analysed. Tables depicting the means and s.e.m. values for the 
individual box regions for each mouse group are depicted in Figure 3.10 A for the 
hippocampus and Figure 3.10 B for the cortex. Values obtained for total carbonylation 
were assessed for significant effects of genotype from the loss of Nrf2
-/-
, or a diet 
induced effect following long-term HF-feeding. No significant difference in brain 
protein carbonylation was seen in the hippocampus of any of the groups analysed (p > 
0.05; Figure 3.10 C). Significantly less protein carbonylation was seen in the cortex of 
HF-fed Nrf2
-/-
 mice, which was not replicated in HF-fed WT mice (WT RC: 1.00; Nrf2
-/-
 
HF: 0.595 ± 0.10; WT RC vs Nrf2
-/-
 HF p < 0.05, n = 4-6; Figure 3.10 D). 
Given the opposing effects observed in the Nrf2
-/-
 and hAPPswe mice with 
regards to pro-inflammatory marker profiles, a panel of anti-inflammatory, antioxidant 
and alternative immune markers was assessed. This allowed an evaluation of markers 
traditionally associated with inflammatory resolution (Mosser & Edwards, 2008). In 
contrast to the pro-inflammatory markers investigated the anti-inflammatory markers 
indicated changes predominantly in the cortical tissue (Figure 3.11 E-H) over 
hippocampal tissue (Figure 3.11 A-D). No significant changes were seen in anti-
inflammatory markers in the hippocampus, although a trend for an effect of HF feeding 
in WT and Nrf2
-/-
 mice can be observed for Arg 1 (Figure 3.11 A) and trend towards an 
increase in YM1 in Nrf2
-/-
 mice (Figure 3.11 B). However, in the cortex a trend towards 
an increase was seen in RC and HF fed Nrf2
-/-
 mice for Arg 1 (WT RC: 1.00; Nrf2
-/-
 RC: 
2.94 ± 1.3; Nrf2
-/-
 HF: 1.45 ± 0.13; WT RC vs Nrf2
-/-
 RC p > 0.05, WT RC vs Nrf2
-/-
 HF 
p < 0.05, n = 7; Figure 3.11 E) and YM1 (WT RC: 1.00; Nrf2
-/-
 RC: 3.49 ± 2.5; Nrf2
-/-
 
HF: 3.81 ± 1.2; WT RC vs Nrf2
-/-
 RC p > 0.05, WT RC vs Nrf2
-/-
 HF p = 0.05, n = 6-7; 
Figure 3.11 F). HF feeding induced a significant decrease in Arg 1 expression in HF fed 
hAPPswe mice (hAPPswe HF: 0.733 ± 0.0869; WT RC vs hAPPswe HF p < 0.05) with no 
change in YM1 from WT control and no significant changes in Nrf2
-/-
/hAPPswe mice in 
either Arg1 or YM1. 
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Figure 3.10 HF feeding prompts an amelioration in cortical protein carbonylation 
state in aged mice lacking Nrf2. 
Aged adult mice from WT and Nrf2
-/-
 backgrounds fed either a RC or HF diet were harvested 
for tissue. Brains were dissected and hippocampal and cortical tissue were lysed for protein and 
processed for an oxyblot assay as per manufacturer’s instructions. Blots were analysed at pre-
selected points and means ± s.e.m. displayed for the individual regions and the averaged total 
for both the hippocampus (A) and the cortex (B). Analysis of averaged total values is indicated 
in (C) and (D) respectively for the hippocampus and cortex. All data is displayed as means ± 
s.e.m., and analyses were performed using one-sample and unpaired t-test where * = p < 0.05. 
(WT: n = 4-6; Nrf2
-/-
: n = 4-5)  
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Figure 3.11 Loss of Nrf2 drives predominantly cortical increases in anti-
inflammatory and complement system markers. 
Brains harvested from aged RC and HF fed WT, Nrf2
-/-
, hAPPswe and Nrf2
-/-
/hAPPswe mice were 
dissected and the hippocampus and cortex were processed for gene expression analysis. 
Commonly referenced anti-inflammatory markers Arg1 (A + E) and YM1 (B + F) were 
measured alongside a marker for the complement system, C3 (C + G) part of the alternative 
immune activation pathway, and Nrf2
-/-
 (D + H) that drives transcription of many antioxidant 
genes (WT n = 6-9, Nrf2
-/-
 n = 5-8, hAPPswe n = 4-5, Nrf2
-/-
/hAPPswe n = 3-4; Nrf2 only: WT n = 
4-6, hAPPswe n = 5-6). Results are reported as means ± s.e.m., and analysed by one-sample and 
unpaired t-test where *, p < 0.05; **, p < 0.01.  
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C3, a member of the complement immune system cleaved into active forms and 
essential for complement cascade activation (Noris & Remuzzi, 2013), was assessed to 
investigate the potential role of alternative immune pathways in the protective effect of 
HF feeding on Nrf2
-/-
. Similar to the changes observed for the anti-inflammatory 
markers used, there is no change in C3 expression in the hippocampus of Nrf2
-/-
 mice 
although a trend towards an increase can be observed in the RC fed Nrf2
-/-
/hAPPswe 
mice (Figure 3.11 C). In the cortex there is a trend towards an increase in C3 in both RC 
fed Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice (WT RC: 1.00; Nrf2
-/-
 RC: 4.61 ± 1.9; Nrf2
-/-
/hAPPswe RC; 2.72 ± 0.59; WT RC vs Nrf2
-/-
 RC p > 0.05, WT RC vs Nrf2
-/-
/hAPPswe 
RC p = 0.06, n = 4-7; Figure 3.11 G). No changes are seen in any of the remaining 
groups. 
Nrf2, which as previously described drives the transcription of a large 
proportion of the antioxidant related genes, was assessed in the WT and hAPPswe RC 
and HF groups in order to investigate the effect of HF-feeding and/or the presence of 
hAPPswe on the basal expression of Nrf2. HF-feeding drives a significant decrease in 
hippocampal Nrf2 in WT but not hAPPswe mice (WT RC: 1.00; WT HF: 0.705 ± 0.06; 
WT RC vs WT HF p < 0.01, n = 6; Figure 3.11 D). No significant change in Nrf2 
expression was seen in the cortex of WT of hAPPswe mice (Figure 3.11 H). In addition, 
whilst IL-10 is also a commonly assessed anti-inflammatory cytokine, when a test plate 
was run the levels of IL-10 were found to be too low to be consistently measured in 
these samples and as a result it was not pursued further. 
3.8 DIET AND GENOTYPE AFFECT GLIAL CELL ACTIVATION IN AGED 
MOUSE BRAINS 
Combining the changes observed in macrophage infiltration in the WAT and the 
altered inflammatory profiles described above. A more in depth investigation of two of 
the dominant support cells present in the brain was performed, namely of the astrocyte 
glial cells and the brain resident macrophages known as microglia. Cortical and 
hippocampal brain homogenates from age-matched RC and HF fed mice were 
processed for both RT-qPCR and protein expression. Gene expression levels of F4/80, a 
macrophage marker, was assessed in WT, Nrf2
-/-
, hAPPswe and Nrf2
-/-
/hAPPswe mice. 
F4/80 was significantly increased in the hippocampi of Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice 
fed a RC diet but not their HF fed compatriots (WT RC: 1.00; Nrf2
-/-
 RC: 1.45 ± 0.13; 
Nrf2
-/-
/hAPPswe: 1.70 ± 0.19; WT RC vs Nrf2
-/-
 RC p < 0.01, WT RC vs Nrf2
-/-
/hAPPswe 
RC p < 0.05, n = 4-10; Figure 3.12 A). Only the HF fed hAPPswe mice showed an 
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increase in hippocampal F4/80 with no change seen following RC feeding (hAPPswe 
HF: 1.32 ± 0.09; WT RC vs hAPPswe HF p < 0.05, n =5-7).  
Only Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice have increased F4/80 expression in 
cortical tissue with no changes seen in WT or hAPPswe mice (WT RC: 1.00; Nrf2
-/-
 RC: 
1.33 ± 0.10; Nrf2
-/-
 HF: 1.30 ± 0.06; Nrf2
-/-
/hAPPswe RC: 1.37 ± 0.14; Nrf2
-/-
/hAPPswe 
HF: 1.25 ± 0.06; WT RC vs Nrf2
-/-
 RC p < 0.01, WT RC vs Nrf2
-/-
 HF p < 0.01, WT RC 
vs Nrf2
-/-
/hAPPswe RC p = 0.07, WT RC vs Nrf2
-/-
/hAPPswe HF p < 0.05, n = 4-10; 
Figure 3.12 C). Furthermore, no changes are observed in the protein levels of the 
astrocytic marker, GFAP, in the hippocampal tissue of HF fed animals (p > 0.05; Figure 
3.12 B). In the cortex, long term HF feeding drives a reduction in GFAP across 
genotypes with hAPPswe expressing mice having reduced basal levels of expression (WT 
RC: 1.00; WT HF: 0.4450 ± 0.0865; Nrf2
-/-
 HF: 0.4762 ± 0.0856; hAPPswe HF: 0.3208 ± 
0.103; Nrf2
-/-
/hAPPswe RC: 0.3769 ± 0.0736; Nrf2
-/-
/hAPPswe HF: 0.2852 ± 0.0426; WT 
RC vs WT HF p < 0.001, WT RC vs Nrf2
-/-
 HF p < 0.001, WT RC vs hAPPswe HF p < 
0.01, WT RC vs Nrf2
-/-
/hAPPswe RC p < 0.01, WT RC vs Nrf2
-/-
/hAPPswe HF p < 0.001, 
n = 4-10; Figure 3.12 D). HF-fed Nrf2
-/-
 mice also exhibit a significant reduction in 
GFAP expression when compared to RC-fed Nrf2
-/-
 mice (Nrf2
-/-
 RC: 1.770 ± 0.423; 
Nrf2
-/-
 RC vs HF p < 0.01, n = 8). Figure 3.12 E shows representative blots of GFAP 
protein expression in the hippocampus and the cortex of all eight groups. 
Microglia, like peripheral macrophages, are highly motile; much more so than 
some of the other glial cell population such as astrocytes. As an increased expression of 
the macrophage/microglial marker F4/80 was seen in both the hippocampus and cortex 
of the transgenic mouse models, a decision was made to investigate any changes 
registering in a sub-selection of chemokines. Chemokines released from resident 
immune cells, such as microglia and astrocytes, following inflammatory insult are most 
often chemoattractants that attract further immune cells to the area of damage. MCP-1 
and RANTES are both chemokines known to attract monocytes/macrophages. Given the 
presence of pro-inflammatory markers predominantly in the hippocampus, this is where 
the majority of markers were pursued.  
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Figure 3.12 Loss of Nrf2 drives increases in macrophage expression that is 
partially mimicked by astrocyte activation. 
Brains from aged adult mice were harvested, dissected and processed for gene and protein 
expression. Markers for macrophage activation (F4/80; A + C) and astrocyte activation (GFAP; 
B + D) were analysed by RT-qPCR or Western blot respectively for changes in expression in 
the hippocampus (A + B) and cortex (C + D). Exemplar blots are portrayed for both the cortex 
and hippocampus where β-actin was used as the protein loading control (E). All data portrayed 
as means ± s.e.m. and analysed by one-sample and unpaired t-test where * indicates 
significantly different from WT control and † indicates significantly different from HF fed WT. 
*, p < 0.05; **, p < 0.01; ***, p < 0.001; †, p < 0.05. WT n = 6-10, Nrf2-/- n = 6-10, hAPPswe n = 
5-6, Nrf2
-/-
/hAPPswe = 4.  
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There is no significant change in MCP-1 expression in the cortex, although a 
trend towards increased expression is seen in the RC-fed Nrf2
-/-
 mice (WT: 1.00; Nrf2
-/-
 
RC: 3.63 ± 1.9; WT RC vs Nrf2
-/-
 RC p > 0.05, n = 8-9; Figure 3.13 A). Hippocampal 
expression of both MCP-1 (Figure 3.13 B) and RANTES (Figure 3.13 D) show a trend 
towards increased expression in RC fed Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice in addition to a 
significant increase in expression of MCP-1 in HF-fed hAPPswe mice (MCP-1: WT RC: 
1.00; Nrf2
-/-
 RC: 2.49 ± 1.1; Nrf2
-/-
/hAPPswe RC: 6.21 ± 3.0; hAPPswe HF: 2.51 ± 0.45; 
WT RC vs Nrf2
-/-
 RC and Nrf2
-/-
/hAPPswe RC p > 0.05, WT RC vs hAPPswe HF p < 
0.05, n = 4-7. RANTES: WT RC: 1.00; Nrf2
-/-
 RC: 4.32 ± 2.5; Nrf2
-/-
/hAPPswe RC: 4.94 
± 2.3; hAPPswe HF: 1.93 ± 0.49; WT RC vs Nrf2
-/-
 RC and Nrf2
-/-
/hAPPswe RC p > 0.05, 
n = 4-10.). 
CCR2, the G-protein coupled receptor for MCP-1, appears to present a similar 
profile to that seen for hippocampal MCP-1, with increases in Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice (WT RC: 1.00; Nrf2
-/-
 RC: 2.90 ± 1.9; Nrf2
-/-
 HF: 2.52 ± 0.40; Nrf2
-/-
/hAPPswe RC: 1.83 ± 0.33; hAPPswe HF: 2.00 ± 0.34; WT RC vs Nrf2
-/-
 RC , Nrf2
-/-
 HF 
and Nrf2
-/-
/hAPPswe RC p > 0.05, WT RC vs Nrf2
-/-
/hAPPswe HF p = 0.06, n = 4-10; 
Figure 3.13 C). No significant changes are seen in the RANTES associated chemokine 
receptor (CCR5; Figure 3.13 E), with only a trend towards decreased expression 
following HF feeding of hAPPswe when compared to RC fed controls (hAPPswe RC: 1.31 
± 0.23; hAPPswe HF: 1.93 ± 0.49; hAPPswe RC vs hAPPswe HF p = 0.06, n = 5-6). This is 
a similar trend to that seen for the expression of CCR2 in hAPPswe mice. 
The majority of the changes associated with markers of chemokine and glial 
expression occur in the transgenic mouse lines lacking Nrf2. For this reason, these 
genotypes were taken forward, along with controls, for investigation of morphological 
changes by immunofluorescence of perfuse-fixed sagittal brain sections. Images were 
processed for two regions of the hippocampal structure: the adjoining dentate gyrus and 
hippocampal CA3 area and the upper arc of the hippocampal structure in the CA1 
region (Figure 3.14). As previously described, the hippocampal structure is important in 
correctly integrating and performing a multitude of learning and memory associated 
tasks. 30 μm sections, situated at ~0.6 mm from the midline, were stained for the well-
known astrocytic marker GFAP. 
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Figure 3.13 Nrf2
-/-
 mice show a trend for increased chemokine gene expression in 
the brains of aged adults. 
Brains from aged adult mice were harvested from RC and HF fed WT, Nrf2
-/-
, hAPPswe and 
Nrf2
-/-
/hAPPswe mice and hemispheres were dissected. The hippocampus and cortex were 
processed for gene expression analysis. The chemokine MCP-1 was investigated in the cortex 
(A) and hippocampus (B; WT n = 5-8, Nrf2
-/-
 n = 5-9, hAPPswe n = 5, Nrf2
-/-
/hAPPswe n = 4). 
Expression of further chemokine related genes (CCR2 (C), RANTES (D) and CCR5 (E)) were 
concentrated in the hippocampus which showed higher levels of inflammation (WT n = 6-10, 
Nrf2
-/-
 n = 6, hAPPswe n = 5, Nrf2
-/-
/hAPPswe n = 4). Results are reported as means ± s.e.m., and 
analysed by one-sample and unpaired t-test where *, p < 0.05.  
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Overall no change was 
observed in the morphology of 
astrocytes in HF fed WT mice, whilst 
RC fed Nrf2
-/-
 mice displayed 
increased presence of branching 
(Figure 3.15 A and B respectively). 
Furthermore, HF feeding of Nrf2
-/-
 
mice increases astrocytic branching, 
most obvious in the CA1 region of the 
hippocampus. Finally and most 
strikingly, Nrf2
-/-
/hAPPswe mice 
display clear branching under RC 
conditions, which is increased 
dramatically following HF feeding. It 
is also possible to observe astrocytic 
relocation in the CA1 hippocampal 
region (Figure 3.15 C; for preliminary 
cell count data see Appendix V, chapter 7.5). 
Unlike, F4/80 which is found on different types of immune cells, Iba1 is found 
specifically on macrophages and microglia. Therefore, although we cannot rule out the 
presence of infiltrated peripheral macrophages, the majority of cells picked up by this 
marker in the brain are likely to be the resident microglial cells. No apparent increase in 
Iba1 staining was seen following HF feeding of WT mice (Figure 3.16 A), which is in 
line with the lack of F4/80 induction. In addition, whilst it is possible to distinguish a 
small number of distinct Iba1 positive cells in RC fed Nrf2
-/-
 mice minimal induction is 
seen under basal conditions (Figure 3.16 B), indicating the change in F4/80 expression 
is likely reflecting an additional increase in alternative cell types. HF feeding of Nrf2
-/-
 
mice causes a noticeable increase in staining, whilst both RC and HF fed Nrf2
-/-
/hAPPswe mice present with increased Iba1 staining in the hippocampus (Figure 3.16 C). 
In conclusion, whilst the microglial staining is not as dramatic as the morphological 
changes seen in the astrocytes within the hippocampus both markers indicate alterations 
in glial cell state in Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice, particularly following HF feeding.  
Figure 3.14 Pictorial representation of 
hippocampal sub-regions of the mouse brain 
Where Sub = subiculum, DG Sg = granule cell layer 
of dentate gyrus, Po DG = polymorph layer of 
dentate gyrus, So = stratum oriens, Sp = pyramidal 
layer, Sr = stratum radiatum, slm = stratum 
lacunosum moleculare, mo = molecular layer of the 
dentate gyrus, and CA1-3 refer to the different 
subregions of the hippocampus 
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Figure 3.15 Removal of Nrf2 in the brains of mice increases astrocyte branching, 
which is further amplified by addition of hAPPswe in the hippocampus. 
Aged WT, Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice fed a RC or 45% HF diet from 8-10 weeks of age 
were perfuse fixed in 4%-PFA. Brains were removed whole and post-fixed for 24 h in 4%-PFA 
before being placed in 30% sucrose solution. Brains were cut down the midline and frozen in 
embedding matrix in a propanol/dry ice bath. Hemibrains were sectioned sagittally on a cryostat 
and 30 μm sections were captured and placed in PBS. Free floating sections were stained for the 
astrocytic marker GFAP, mounted on gelatin coated slides and imaged on a Leica confocal 
microscope using a fluorescent secondary antibody. Images of the CA3/Dentate gyrus and the 
CA1 region of the hippocampus were acquired. Sections were imaged using consistent confocal 
settings and appropriate software for WT (A), Nrf2
-/-
 (B) and Nrf2
-/-
/hAPPswe (C) mice (n = 2-3). 
Where DG Sg = granule cell layer of dentate gyrus, Po DG = polymorph layer of dentate gyrus, 
CA3 = pyramidal layer of CA3 region of hippocampus, CA1 = pyramidal layer of CA1 region 
of hippocampus, So = stratum oriens, Sp = pyramidal layer, Sr = stratum radiatum, and scale 
bars are 50 µm in length.  
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Figure 3.16 Nrf2
-/-
 mice show increased microglial staining following HF feeding 
with little change in the added presence of hAPPswe in the hippocampus. 
Aged WT, Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice fed a RC or 45% HF diet from 8-10 weeks of age 
were perfuse fixed in 4%-PFA. Brains were removed whole and post-fixed for 24 h in 4%-PFA 
before being placed in 30% sucrose solution. Brains were processed as for previously described 
and sectioned on a cryostat at 30 μm. Free floating sections underwent antigen retrieval with 10 
mM citric acid at 80°C for 30 min prior to being stained for the microglial and macrophage 
marker Iba1. Sections were mounted on gelatin coated slides and imaged on a Leica confocal 
microscope using a fluorescent secondary antibody. Sections were imaged using consistent 
confocal settings and appropriate software for WT (A), Nrf2
-/-
 (B) and Nrf2
-/-
/hAPPswe (C) mice 
(n = 2-3). Where DG Sg = granule cell layer of dentate gyrus, Po DG = polymorph layer of 
dentate gyrus, CA3 = pyramidal layer of CA3 region of hippocampus, CA1 = pyramidal layer of 
CA1 region of hippocampus, So = stratum oriens, Sp = pyramidal layer, Sr = stratum radiatum, 
and scale bars are 50 µm in length.  
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Finally, in order to assess the effect the changes seen in the astrocyte and 
microglial populations have on neuronal health, protein expression of synaptophysin 
(SYP) was assessed. SYP, a commonly used synaptic marker that correlates with 
synaptic health, was measured in the hippocampal and cortical homogenates of aged RC 
and HF fed mice. RC fed Nrf2
-/-
 mice have a significant loss of SYP in the hippocampus 
(WT RC: 1.00; Nrf2
-/-
 RC: 0.659 ± 0.13; WT RC vs Nrf2
-/-
 RC p < 0.05, n = 8-10; 
Figure 3.17 A with blot exemplars depicted in C) when compared to RC-fed WT 
controls. This hippocampal phenotype is not only rescued by HF-feeding but also 
further increased above the level of the WT RC control group (Nrf2
-/-
 HF: 1.89 ± 0.27; 
WT RC vs Nrf2
-/-
 HF p < 0.05, Nrf2
-/-
 RC vs Nrf2
-/-
 HF p < 0.001, n = 8-10). Moreover, 
HF-feeding also increases the level of SYP in the hippocampus of WT mice (WT HF: 
1.58 ± 0.22; WT RC vs WT HF p < 0.05, n = 8). 
In juxtaposition to both WT and Nrf2
-/-
 mice, both hAPPswe and Nrf2
-/-
/hAPPswe 
RC-fed mice have elevated levels of SYP in the hippocampus when compared to 
controls which is unaffected by HF-feeding (hAPPswe RC: 1.66 ± 0.26; Nrf2
-/-
/hAPPswe 
RC: 1.73 ± 0.29; hAPPswe HF: 1.81 ± 0.27; Nrf2
-/-
/hAPPswe HF: 1.68 ± 0.25; WT RC vs 
hAPPswe p = 0.07, WT RC vs hAPPswe HF p < 0.05, WT RC vs Nrf2
-/-
/hAPPswe RC p = 
0.08, WT RC vs Nrf2
-/-
/hAPPswe RC p = 0.07, n = 4-8). This suggests the addition of 
hAPPswe may impact on synaptic plasticity. 
In contrast to the hippocampus, cortical expression of SYP appears unaffected 
by loss of Nrf2
-/-
 or HF-feeding (p > 0.05; Figure 3.17 B with blot exemplars depicted in 
C). RC fed Nrf2
-/-
/hAPPswe mice show a drop in SYP staining when compared to WT 
RC in the cortex (WT RC: 1.00; Nrf2
-/-
/hAPPswe RC: 0.8031 ± 0.0259; WT RC vs Nrf2
-/-
/hAPPswe RC p < 0.01, n = 4-8; Figure 3.17 B). No overt induction in synaptic number is 
induced by HF feeding, as determined by SYP expression, in fact it induces a further 
significant depletion in synaptophysin expression in the Nrf2
-/-
/hAPPswe mice when 
compared to RC fed WT or Nrf2
-/-
/hAPPswe (Nrf2
-/-
/hAPPswe HF: 0.6010 ± 0.0592; WT 
RC vs Nrf2
-/-
/hAPPswe HF p < 0.01, Nrf2
-/-
/hAPPswe RC vs Nrf2
-/-
/hAPPswe HF p < 0.05, 
n = 4-8). 
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Figure 3.17 A greater impact on synaptic SYP expression is seen in the 
hippocampus than the cortex following loss of Nrf2
 
and HF feeding. 
Dissected brain tissue from aged RC and HF fed mice was processed for protein expression and 
probed for the synapse marker SYP in the hippocampus (A) and cortex (B). (C) Images of 
exemplar blots for both the hippocampus and cortex, where β-actin was used as the protein 
loading control. All data portrayed as means ± s.e.m. and analysed by one-sample and unpaired 
t-test where * indicates significantly different from RC fed WT control. *, p < 0.05; **, p < 
0.01; ***, p < 0.001. WT n = 7-8, Nrf2
-/-
 n = 7-10, hAPPswe n = 5-6, Nrf2
-/-
/hAPPswe n = 4. 
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3.9 THE EFFECT OF HIGH FAT FEEDING ON EXPRESSION OF PROTEINS 
COMMONLY ASSOCIATED WITH AD. 
In order to assess the effect of HF feeding on AD related markers such as APP 
and BACE1, tissue from aged, age-matched mice were processed for gene and protein 
expression analysis. There were no significant changes in the hippocampus of WT, 
Nrf2
-/-
 or hAPPswe for either mAPP (Figure 3.18 A) or BACE1 (Figure 3.18 B). HF 
feeding induces a small but significant increase in mAPP in Nrf2
-/-
/hAPPswe compared to 
HF fed WT mice (WT HF: 0.945 ± 0.05; Nrf2
-/-
/hAPPswe HF: 1.22 ± 0.07; WT HF vs 
Nrf2
-/-
/hAPPswe HF p < 0.05, n = 4-9). There was also a significant change in BACE1 
expression in the hippocampus of Nrf2
-/-
/hAPPswe mice with a significant decrease in 
RC animals compared to control that was recovered to control levels by HF feeding 
(WT RC: 1.00; Nrf2
-/-
/hAPPswe RC: 0.603 ± 0.09; Nrf2
-/-
/hAPPswe HF: 0.904 ± 0.05; WT 
RC vs Nrf2
-/-
/hAPPswe RC p < 0.05, Nrf2
-/-
/hAPPswe RC vs Nrf2
-/-
/hAPPswe HF p < 0.05, 
n = 4-9). 
In the cortex, Nrf2
-/-
 mice on a HF diet and Nrf2
-/-
/hAPPswe mice are the only 
groups showing significant changes in mAPP (WT RC: 1.00; WT HF: 1.03 ± 0.02; Nrf2
-
/-
 HF: 1.13 ± 0.04; Nrf2
-/-
/hAPPswe RC: 1.14 ± 0.02; Nrf2
-/-
/hAPPswe HF: 1.19 ± 0.07; 
WT RC vs Nrf2
-/-
 HF p < 0.05, WT RC vs Nrf2
-/-
/hAPPswe RC p < 0.01, WT HF vs Nrf2
-
/-
/hAPPswe HF p < 0.05, n = 4-10; Figure 3.18 F). Similar to the hippocampus, the only 
changes in BACE1 expression are seen in the Nrf2
-/-
/hAPPswe mice with decreased levels 
in the RC fed animals that are increased by HF-feeding (WT HF: 0.912 ± 0.07; Nrf2
-/-
/hAPPswe RC: 0.860 ± 0.08; Nrf2
-/-
/hAPPswe HF: 1.16 ± 0.07; Nrf2
-/-
/hAPPswe RC vs 
Nrf2
-/-
/hAPPswe HF p < 0.05, WT HF vs Nrf2
-/-
/hAPPswe HF p = 0.05, n = 4-10; Figure 
3.18 G). 
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Figure 3.18 HF feeding increases AD related APP and BACE1 in a brain region 
specific manner in WT and Nrf2
-/-
 mice. 
Brain tissue collected from aged adult mice was processed for gene and protein expression. 
Measures were taken for murine APP (A + F) and BACE1 (B + G) gene expression as well as 
total APP (human and mouse; D + I) and BACE1 (E + J) protein expression, with C and H 
showing exemplar blots for the hippocampus and cortex respectively, where β-actin was used as 
the protein loading control. All data portrayed as means ± s.e.m. and analysed by one-sample 
and unpaired t-test where * indicates significantly different from RC fed WT control and † 
indicates significantly different from HF fed WT. *, p < 0.05; **, p < 0.01; ***, p < 0.001; †, p 
< 0.05; ††, p < 0.01. WT n = 9-10, Nrf2-/- n = 7-10, hAPPswe n = 5-6, Nrf2
-/-
/hAPPswe n = 4.  
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Protein expression was run for total APP and BACE1 in the hippocampus and 
cortex with representative blots for each being shown in Figure 3.18 C and H 
respectively. There is a trend towards increased levels of APP in Nrf2
-/-
 mice which is 
concomitant with a decrease in expression in the cortex with no further significant 
dietary induced change (hippocampus: WT RC: 1.00; Nrf2
-/-
 RC: 1.16 ± 0.07; WT RC 
vs Nrf2
-/-
 RC p = 0.05, n = 10; Figure 3.18 D. Cortex: WT RC: 1.00; Nrf2
-/-
 RC: 0.745 ± 
0.09; Nrf2
-/-
 HF: 0.614 ± 0.08; WT RC vs Nrf2
-/-
 RC p < 0.05, WT RC vs Nrf2
-/-
 HF p < 
0.01, n = 10; Figure 3.18 I). In hAPPswe mice, increased levels of APP protein are seen 
in both hippocampal and cortical tissue, which is to be expected as the antibody should 
pick up both the mouse an human forms of APP (Hippocampus: WT HF: 1.11 ± 0.10; 
hAPPswe RC: 1.68 ± 0.08; hAPPswe HF: 1.66 ± 0.16; WT RC vs hAPPswe RC p < 0.01, 
WT RC vs hAPPswe RC p < 0.05, WT HF vs hAPPswe HF p < 0.01, n = 5-10. Cortex: 
WT HF: 0.865 ± 0.10; hAPPswe RC: 1.36 ± 0.11; hAPPswe HF: 1.32 ± 0.17; WT RC vs 
hAPPswe RC p < 0.05, WT HF vs hAPPswe HF p < 0.05, n = 5-10). Nrf2
-/-
/hAPPswe mice 
show a mixed profile for APP expression that appears to be controlled by the loss of 
Nrf2 with hippocampal levels elevated similar to the hAPPswe but cortical expression 
diminished mirroring the more marked decrease in expression demonstrated by the 
Nrf2
-/-
 mice (hippocampus: Nrf2
-/-
/hAPPswe HF: 1.71 ± 0.25; WT HF vs Nrf2
-/-
/hAPPswe 
HF p < 0.05, n = 4-10). 
HF feeding induces higher protein expression of BACE1 in both WT and Nrf2
-/-
 
mice but is not significant in the hippocampus of mice expressing hAPPswe (WT RC: 
1.00; WT HF: 1.55 ± 0.09; Nrf2
-/-
 RC: 0.862 ± 0.09; Nrf2
-/-
 HF: 1.70 ± 0.20; WT RC vs 
WT HF p < 0.001, WT RC vs Nrf2
-/-
 RC p < 0.01, Nrf2
-/-
 RC vs Nrf2
-/-
 HF p < 0.01, n = 
9-10; Figure 3.18 E). As seen with total APP expression, cortical expression of BACE1 
is inversed with HF feeding decreasing the expression in Nrf2
-/-
 mice but no change 
seen in WT mice fed a HF diet (WT RC: 1.00; Nrf2
-/-
 HF: 0.750 ± 0.11; WT RC vs 
Nrf2
-/-
 HF p < 0.05, n = 9-10; Figure 3.18 J). Similar to cortical APP expression, Nrf2
-/-
/hAPPswe mice fed a HF diet mimic the pattern seen in the HF fed Nrf2
-/-
 animals with 
decreases in BACE1 protein (Nrf2
-/-
/hAPPswe HF: 0.532 ± 0.04; WT RC vs Nrf2
-/-
/hAPPswe HF p < 0.01, n = 4-10). 
As the AD model used in these studies reflects a much milder pathology than 
many of the models currently available; no overt plaque deposition was observed in 
animals irrespective of genotype or diet. In order to assess any changes in soluble 
amyloid-β (sAβ) induced by the loss of Nrf2-/-, a commercially available murine 
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amyloid-β ELISA kit was run on cortical protein lysates (Figure 3.19). No significant 
changes in sAβ1-42 were seen in WT or Nrf2
-/-
 mice irrespective of which diet they were 
fed when normalised to total protein content (p > 0.05, n = 4-5; Figure 3.19). 
The amyloidogenic pathway is only one of the two main protein misfolding 
pathways associated with AD. Although the model chosen incorporates a mutation in 
the amyloidogenic pathway, protein was also run to assess potential changes in the 
second pathway, namely that of tau. Lysates were run on tissue as previously described 
and blotted for Ser396 p-tau and total tau protein in both the hippocampus (Figure 3.20 
A and B) and the cortex (Figure 3.20 C and D) and exemplar blots portrayed (Figure 
3.20 E). No significant increase in tau phosphorylation at the Ser396 site is seen in the 
hippocampus of these mice, despite a trend for increased phosphorylation in hAPPswe 
mice following HF feeding (p > 0.05; Figure 3.20 A). In the cortex, a diet dependent 
trend towards increased phosphorylation is seen in both the WT and Nrf2
-/-
 mice fed a 
HF diet (p > 0.05; Figure 3.20 C). Furthermore, both hAPPswe and Nrf2
-/-
/hAPPswe mice 
show a trend towards increased phosphorylation of tau under basal conditions in the 
cortex (p > 0.05) and it is likely low group numbers prevent these becoming statistically 
significant. 
No significant changes are observed in the expression of total tau in 
hippocampal tissue, with only hAPPswe HF animals showing a close to significant trend 
towards increased tau (WT RC: 1.00; hAPPswe HF: 1.37 ± 0.13; WT RC vs hAPPswe HF 
p = 0.06, n = 4-9). The increase in tau expression seen in cortex of the HF fed hAPPswe 
mice, however, does reach significance (WT RC: 1.00; hAPPswe HF: 1.23 ± 0.06; WT 
RC vs hAPPswe HF p < 0.05, n = 5-10). The only other change of interest in tau 
expression occurs in the Nrf2
-/-
/hAPPswe HF fed animals that demonstrate a drastic drop 
in total protein expression when compared to controls (Nrf2
-/-
/hAPPswe HF: 0.533 ± 
0.02; WT RC vs Nrf2
-/-
/hAPPswe HF p < 0.0001, n = 4-10). 
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Figure 3.19 HF feeding has no effect on the production of soluble murine Aβ1-42 in 
cortical tissue of aged WT and Nrf2
-/-
 mice. 
Aged mice fed either a RC or HF diet were sacrificed and brains were dissected and lysed for 
protein analysis. Soluble mouse Aβ1-42 was analysed by ELISA following manufacturer’s 
instructions using prepared protein lysates and values were normalised to total protein 
concentration obtained from Bradford protein assay. All values are expressed as means ± s.e.m., 
and analysed by two-way ANOVA. WT n = 5, Nrf2
-/-
 n = 4-5 
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Figure 3.20 HF feeding of hAPPswe mice increases protein expression of total tau 
with diet and Nrf2
-/-
 also impacting on tau phosphorylation. 
Brain tissue collected from aged adult mice was processed for protein expression. Measures 
were taken for p-tau (Ser396) and total tau expression in both the hippocampus (A + B) and 
cortex (C + D) respectively. (E) displays exemplar blots for both tissues, where β-actin was 
used as the protein loading control. All data portrayed as means ± s.e.m. and analysed by one-
sample and unpaired t-test where * indicates significantly different from RC fed WT control and 
† indicates significantly different from HF fed WT. *, p < 0.05; ***, p < 0.001; †, p < 0.05. WT 
n = 8-10, Nrf2
-/-
 n = 8-10, hAPPswe n = 4-6, Nrf2
-/-
/hAPPswe n = 3-4.  
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3.10 THE EFFECT OF NRF2 LOSS ON AKT SIGNALLING AND DOWNSTREAM 
NF-ΚB SIGNALLING  
We previously described changes seen in peripheral glucose disposal and insulin 
sensitivity both as a result of genotype, with Nrf2
-/-
 having improved glucose clearance 
and diet*genotype responses, where Nrf2
-/-
 mice maintained their insulin glucose 
clearance when HF fed and hAPPswe
 
had worsened glucose clearance. Combining this 
information with the potential protective role reported for insulin signalling, we looked 
at the role of Akt in the hippocampus and cortex of aged mice fed RC or HF diets long 
term. No changes were seen in total Akt or Akt phosphorylation at Ser473 in the 
hippocampus of aged mice (Figure 3.21 A). There is a trend towards increased Akt 
phosphorylation (Ser473) in the RC fed Nrf2
-/-
 mice with no notable changes in any of 
the other groups examined and no changes in total Akt (WT RC: 1.00; Nrf2
-/-
 RC: 1.14 
± 0.07; WT RC vs Nrf2
-/-
 RC p = 0.08, n = 10; Figure 3.21 B). This is supported by the 
exemplar blots depicted for both phosphorylated and total Akt (Figure 3.21 E).  
Akt signalling is just one of the pathways upstream of NF-κB capable of 
affecting its activation. NF-κB, normally bound to a repressor protein called IκBα, is 
released upon activation in order to enter the cell nucleus. As a result, proteasomal 
degradation of IκBα can be used as a marker of NF-κB activation with a decreasing 
presence of IκBα indicating increased activity of NF-κB. IκBα protein expression was 
evaluated in the hippocampus and cortex of age-matched, aged mice from RC and HF 
fed cohorts. A small but significant decrease in IκBα is seen in the hippocampus of 
Nrf2
-/-
 mice fed a RC diet with no other significant changes seen in this tissue (WT RC: 
1.00; Nrf2
-/-
 RC: 0.849 ± 0.06; WT RC vs Nrf2
-/-
 RC p < 0.05, n = 10; Figure 3.21 B). 
Whilst the cortex shows no change in RC fed animals, a significant drop in IκBα is seen 
in both transgenic lines lacking Nrf2
-/-
 when compared to RC fed controls (WT RC: 
1.00; Nrf2
-/-
 HF; 0.845 ± 0.07; Nrf2
-/-
/hAPPswe HF; 0.597 ± 0.10; WT RC vs Nrf2
-/-
 and 
Nrf2
-/-
/hAPPswe HF p < 0.05, n = 4-10; Figure 3.21 D). Again, representative blots are 
depicted in Figure 3.21 E alongside those for Akt.  
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Figure 3.21 PI-3k driven changes in Akt are not responsible for the protective 
effects of HF feeding in Nrf2
-/-
 mice, and only small changes in the related NF-kB 
stress response pathway are induced. 
Brain tissue collected from aged adult mice was processed for gene and protein expression. 
Measures were taken for relative expression of Akt phosphorylation (Ser473; A + C) and IκBα 
(B + D) protein expression, with E showing exemplar blots for the hippocampus and cortex 
respectively, where β-actin was used as the protein loading control. All data portrayed as means 
± s.e.m. and analysed by one-sample and unpaired t-test where * indicates significantly different 
from RC fed WT control and *, p < 0.05. WT n = 9-10, Nrf2
-/-
 n = 9-10, hAPPswe n = 5-6, Nrf2
-/-
/hAPPswe n = 4.  
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3.11 NO CHANGE IN IN A MARKER OF THE GLUTATHIONE DETOXIFYING 
PATHWAY FOLLOWING LONG-TERM HIGH FAT FEEDING 
It is well established that Nrf2
-/-
 drives the transcription of a multitude of 
primarily antioxidant genes once activated. Glutathione (GSH) is one of the most well-
known of these, acting as a reducing agent in the presence of unstable molecules such as 
ROS. Following production of GSH via a rate limiting enzyme step, it cycles through 
active (reduced) and inactive (oxidised) forms following binding of ROS. Here we have 
looked at the expression of glutamate cysteine ligase catalytic subunit (GCLC), which 
forms part of the rate-limiting enzyme step in GSH synthesis. No significant changes in 
GCLC expression were seen in the hippocampus of the RC and HF fed mice. However, 
a trend towards a HF induced increase in GCLC is seen in WT mice but it fails to reach 
significance on this occasion (WT RC: 1.00; WT HF: 1.27 ± 0.13; WT RC vs WT HF p 
= 0.07, n = 10; Figure 3.22 A).  
Similar to the hippocampus, there is no significant change in the cortical levels 
of GCLC in either of the single transgenic mouse models, nor does HF feeding induce a 
change in the WT mice. The only change in GCLC levels seen is a reduction in the HF 
fed Nrf2
-/-
/hAPPswe double transgenic model with a trend towards a decrease compared 
to RC fed controls and a significant decrease in comparison to the HF fed WT mice 
(WT RC: 1.00; WT HF: 1.10 ± 0.10; Nrf2
-/-
/hAPPswe HF: 0.643 ± 0.12; WT RC vs Nrf2
-
/-
/hAPPswe HF p = 0.06, WT HF vs Nrf2
-/-
/hAPPswe HF p < 0.05, n = 4-10; Figure 3.22 
B). Representative blots have been appended to visualise the changes in expression 
observed (Figure 3.22 C). 
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Figure 3.22 No change is seen in the rate limiting glutathione pathway GCLC 
enzyme in brain tissue as a result of HF feeding. 
Brain tissue collected from aged adult mice was processed for protein expression and Western 
blots were probed for the glutathione pathway enzyme GCLC (A + B). C portrays exemplar 
blots for the hippocampus and cortex respectively, where β-actin was used as the protein 
loading control. All data portrayed as means ± s.e.m. and analysed by one-sample and unpaired 
t-test where † indicates significantly different from HF fed WT mice and †, p < 0.05. WT n = 
10, Nrf2
-/-
 n = 7-11, hAPPswe n = 5-6, Nrf2
-/-
/hAPPswe n = 4. 
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3.12 A ROLE FOR STRESS-ACTIVATED MAPK ENZYMES IN HIGH FAT 
INDUCED RESCUE OF THE NRF2
-/-
 PHENOTYPE IN BRAIN TISSUE 
MAPKs are responsible for processing a diverse array of incoming stimuli 
including, but not limited to, pro-inflammatory, osmotic stress and insulin. The most 
commonly investigated MAPK are the JNK MAPK pathway, the p38 MAPK pathway 
and the pathway associated with ERK 1/2 and its phosphorylation. As these are 
pathways that can be activated by factors shown to be elevated in some of the models 
being investigated, JNK and ERK MAPKs were followed up in the hippocampal and 
cortical brain homogenates of our mice.  
Significant increases were seen in phosphorylation of both JNK isoforms in 
Nrf2
-/-
 and Nrf2
-/-
/hAPPswe in the hippocampus, with JNK 54 phosphorylation increased 
significantly both basally and under HF conditions in Nrf2
-/-
 and HF fed Nrf2
-/-
/hAPPswe  
when compared to WT mice (WT RC: 1.00; WT HF: 0.867 ± 0.08; Nrf2
-/-
 RC: 1.29 ± 
0.08; Nrf2
-/-
 HF: 1.54 ± 0.12; Nrf2
-/-
/hAPPswe HF: 1.67 ± 0.33; WT RC vs Nrf2
-/-
 RC and 
HF p < 0.01, WT HF vs Nrf2
-/-
 HF p < 0.001, WT HF vs Nrf2
-/-
/hAPPswe HF p < 0.01, n 
= 4-11; Figure 3.23 A). Furthermore, there is a trend for increased phosphorylation of 
the JNK 54 isoform basally in Nrf2
-/-
/hAPPswe mice (Nrf2
-/-
/hAPPswe: 1.59 ± 0.27; WT 
RC vs Nrf2
-/-
/hAPPswe RC p = 0.09, n = 4-10). Similar changes are seen in the 
phosphorylation of JNK 46 isoform with significantly increased phosphorylation seen in 
the HF fed Nrf2
-/-
 mice as well as the RC and HF fed Nrf2
-/-
/hAPPswe mice (WT RC: 
1.00; WT HF: 0.871 ± 0.09; Nrf2
-/-
 HF: 1.39 ± 0.15; Nrf2
-/-
/hAPPswe RC: 1.47 ± 0.14; 
Nrf2
-/-
/hAPPswe HF: 1.59 ± 0.34; WT RC vs Nrf2
-/-
 HF p < 0.05, WT HF vs Nrf2
-/-
 HF p 
< 0.01, WT RC vs Nrf2
-/-
/hAPPswe RC p < 0.05, WT HF vs Nrf2
-/-
/hAPPswe HF p < 0.05, 
n = 4-10; Figure 3.23 B). Further to this, there is a trend towards increased 
phosphorylation of the JNK 46 isoform in the RC fed Nrf2
-/-
 mice (Nrf2
-/-
 RC: 1.15 ± 
0.07; WT RC vs Nrf2
-/-
 RC p = 0.07, n = 10-11). 
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Figure 3.23 HF feeding of Nrf2
-/-
 mice activates the JNK pathway increasing 
phosphorylation of JNK in brain homogenates. 
Brain tissue collected from aged adult mice was processed for protein expression and run on 
Western blots. Membranes were probed for phosphorylated (Thr183/Tyr185) and total JNK. A 
ratio of phosphorylated to total protein was calculated for JNK 54 (A + D), JNK 46 (B + E) and 
total JNK (C + F) in hippocampal and cortical homogenates respectively. G portrays exemplar 
blots for the hippocampus and cortex respectively, where β-actin was used as the protein 
loading control. All data portrayed as means ± s.e.m. and analysed by one-sample and unpaired 
t-test where * indicates significantly different from RC fed WT control and † indicates 
significantly different from HF fed WT mice. *, p < 0.05; **, p < 0.01; †, p < 0.05; ††, p < 0.01; 
†††, p < 0.001. WT n = 9-10, Nrf2-/- n = 9-11, hAPPswe n = 5-6, Nrf2
-/-
/hAPPswe n = 4.  
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Total JNK showed an almost 1.5-fold significant induction in phosphorylation in 
the hippocampus of Nrf2
-/-
 mice following HF feeding with increased phosphorylation 
also seen in the RC fed counterparts (WT RC: 1.00; WT HF: 0.877 ± 0.08; Nrf2
-/-
 RC: 
1.24 ± 0.07; Nrf2
-/-
 HF: 1.41 ± 0.13; WT RC vs Nrf2
-/-
 RC p < 0.01, WT RC vs Nrf2
-/-
 
HF p < 0.05, WT HF vs Nrf2
-/-
 HF p < 0.01, n = 9-11; Figure 3.23 C). A trend towards 
increased induction in total JNK phosphorylation is seen in the RC fed hAPPswe mice 
when compared to WT controls, whilst Nrf2
-/-
/hAPPswe mice fed a HF diet have 
significantly increased JNK phosphorylation when compared to HF fed WT controls 
(Nrf2
-/-
/hAPPswe RC: 1.39 ± 0.15; Nrf2
-/-
/hAPPswe HF: 1.61 ± 0.32; WT RC vs Nrf2
-/-
/hAPPswe RC p = 0.06, WT HF vs Nrf2
-/-
/hAPPswe HF p < 0.01, n = 4-11). Furthermore, 
no significant changes were seen in the phosphorylation of JNK or either of its isoforms 
in the hippocampus of hAPPswe mice under RC or HF fed conditions (p > 0.05). 
A similar profile of JNK phosphorylation induction was seen in the cortical 
homogenates, with Nrf2
-/-
 mice displaying significant increases in JNK 54 
phosphorylation when compared to WT mice fed either a RC or HF diet (WT RC: 1.00; 
WT HF: 1.11 ± 0.06; Nrf2
-/-
 RC: 1.35 ± 0.15; Nrf2
-/-
 HF: 1.49 ± 0.15; WT RC vs Nrf2
-/-
 
RC p = 0.05, WT RC vs Nrf2
-/-
 HF p < 0.05, WT HF vs Nrf2
-/-
 HF p < 0.05, n = 9-10; 
Figure 3.23 D). A significant induction in JNK 54 phosphorylation is also seen in the 
cortex of Nrf2
-/-
/hAPPswe RC fed mice whilst Nrf2
-/-
/hAPPswe mice fed a HF diet have 
significantly increased JNK 54 phosphorylation when compared to HF fed WT mice 
(Nrf2
-/-
/hAPPswe RC: 1.75 ± 0.13; Nrf2
-/-
/hAPPswe HF: 1.69 ± 0.32; WT RC vs Nrf2
-/-
/hAPPswe RC p < 0.01, WT HF vs Nrf2
-/-
/hAPPswe HF p < 0.05, n = 4-10). No changes in 
cortical JNK phosphorylation were induced by HF feeding of the control WT mice (p > 
0.05), as can be seen in Western blot exemplars (Figure 3.23 G), nor were there any 
significant alterations in JNK 54 phosphorylation in hAPPswe mice (p > 0.05). 
Again phosphorylation of the JNK 46 isoform in the cortex presents a very 
similar profile to that seen for the JNK 54 isoform described above. Nrf2
-/-
 HF fed mice 
describe a significant increase in JNK 46 phosphorylation when compared to RC fed 
WT controls whilst a trend towards increased phosphorylation is also reported basally in 
Nrf2
-/-
 mice (WT RC: 1.00; Nrf2
-/-
 RC: 1.43 ± 0.21; Nrf2
-/-
 HF: 1.55 ± 0.21; WT RC vs 
Nrf2
-/-
 RC p = 0.08, WT RC vs Nrf2
-/-
 HF p < 0.05, n = 9-10; Figure 3.23 E). 
Furthermore, a trend towards increased phosphorylation of the JNK 46 isoform is seen 
in HF fed controls which is not apparent in the JNK 54 analysis (WT HF: 1.18 ± 0.09; 
WT RC v WT HF p = 0.06, n = 10). A significant induction in JNK 46 phosphorylation 
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is also seen in the cortex of Nrf2
-/-
/hAPPswe RC fed mice whilst Nrf2
-/-
/hAPPswe mice fed 
a HF diet have significantly increased JNK 46 phosphorylation when compared to HF 
fed WT mice (Nrf2
-/-
/hAPPswe RC: 1.78 ± 0.14; Nrf2
-/-
/hAPPswe HF: 1.73 ± 0.31; WT 
RC vs Nrf2
-/-
/hAPPswe RC p < 0.05, WT HF vs Nrf2
-/-
/hAPPswe HF p < 0.05, n = 4-10). 
In contrast, there were no significant alterations in JNK 46 phosphorylation in hAPPswe 
mice under either diet (p > 0.05). 
Finally, and given the matching profiles of both JNK isoforms, total JNK 
phosphorylation in the cortex was found to be increased in both Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice irrespective of diet fed (WT RC: 1.00; Nrf2
-/-
 RC: 1.43 ± 0.20; Nrf2
-/-
 
HF: 1.55 ± 0.19; Nrf2
-/-
/hAPPswe RC: 1.81 ± 0.15; Nrf2
-/-
/hAPPswe HF: 1.76 ± 0.30; WT 
RC vs Nrf2
-/-
 RC p = 0.06, WT RC vs Nrf2
-/-
 HF p < 0.05, WT HF vs Nrf2
-/-
 HF p > 
0.07, WT RC vs Nrf2
-/-
/hAPPswe RC p < 0.05, WT RC vs Nrf2
-/-
/hAPPswe HF p = 0.08, 
WT HF vs Nrf2
-/-
/hAPPswe HF p < 0.05, n = 4-10; Figure 3.23 F). Furthermore, a small 
increase in total JNK phosphorylation was seen in HF fed WT mice, whilst there was no 
significant change in JNK phosphorylation overall in hAPPswe mice (WT HF: 1.17 ± 
0.07; WT RC v WT HF p < 0.05, n = 10). This indicates an alteration in JNK 
phosphorylation driven by loss of Nrf2, with little further potentiation by HF feeding. 
When ERK MAPKs were analysed they were split into ERK 1 and ERK 2 as 
well as measuring the combined change observed. This is because the changes in an 
individual ERK are not always entirely comparative, with ERK 1 commonly less 
strongly expressed than ERK 2. Therefore this helped ensure the most accurate 
measurement of any changes that may occur. There is an almost three-fold induction in 
phosphorylation of hippocampal ERK 1 following HF feeding of Nrf2
-/-
 mice that is also 
seen in HF fed Nrf2
-/-
/hAPPswe mice when compared to both WT RC and HF fed mice 
(WT RC: 1.00; WT HF: 0.919 ± 0.07; Nrf2
-/-
 HF: 2.84 ± 0.75; Nrf2
-/-
/hAPPswe  HF: 3.37 
± 0.28; WT RC and WT HF vs Nrf2
-/-
 HF p < 0.05, WT RC vs Nrf2
-/-
/ hAPPswe HF p < 
0.01, WT HF vs Nrf2
-/-
/hAPPswe HF p < 0.001, n = 4-11; Figure 3.24 A). The HF 
induced increase in ERK 1 phosphorylation just fails to meet significance in the Nrf2
-/-
 
mice when compared to the RC fed controls, likely due to a mild non-significant 
increase in the RC fed mice (Nrf2
-/-
 RC: 1.42 ± 0.07; Nrf2
-/-
 RC vs Nrf2
-/-
 HF p = 0.06, n 
= 8-11).   
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Figure 3.24 Aged transgenic mouse models lacking Nrf2 have increased ERK 1 and 
2 MAPK phosphorylation, which is further enhanced by HF feeding. 
Brain tissue was harvested from mice and processed for protein expression by Western blot. 
Measures were taken for relative expression of phosphorylated (Thr202/Tyr204) and total ERK 
1 (A + D), ERK 2 (B + E)and combined ERK 1/2 MAPK expression (C + F) in the 
hippocampus and cortex of mice, with G showing exemplar blots for the hippocampus and 
cortex respectively, where β-actin was used as the protein loading control. All data portrayed as 
means ± s.e.m. and analysed by one-sample and unpaired t-test where * indicates significantly 
different from RC fed WT control and † indicates significantly different from HF fed WT. *, p 
< 0.05; **, p < 0.01; †, p < 0.05; ††, p < 0.01; †††, p < 0.001. WT n = 9-10, Nrf2-/- n = 9-10, 
hAPPswe n = 5-6, Nrf2
-/-
/hAPPswe n = 4.  
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Hippocampal phosphorylation of ERK 2 show a similar profile to that described 
for ERK 1, with non-significant increases in RC fed Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice and 
significant increases in ERK 2 phosphorylation in HF fed Nrf2
-/-
 and Nrf2
-/-
/hAPPswe 
mice (WT RC: 1.00; WT HF: 0.725 ± 0.08; Nrf2
-/-
 RC: 2.14 ± 0.63; Nrf2
-/-
 HF: 6.98 ± 
2.4; Nrf2
-/-
/hAPPswe  HF: 6.95 ± 0.81; WT RC and WT HF vs Nrf2
-/-
 HF p < 0.05, WT 
RC vs Nrf2
-/-
/hAPPswe HF p < 0.01, WT HF vs Nrf2
-/-
/hAPPswe HF p < 0.001, Nrf2
-/-
 RC 
vs Nrf2
-/-
 HF p < 0.05, n = 4-11; Figure 3.24 B). The only difference between 
hippocampal ERK 1 and 2 phosphorylation is the significant decrease in ERK 2 
phosphorylation following HF feeding in WT mice (WT RC vs WT HF p < 0.01, n = 
10).  
When total ERK 1/2 phosphorylation is assessed in the hippocampus it is clear 
that the dominant changes described previously remain. In addition to these the 
significant loss of phosphorylation in HF fed WT is present as well as an increase in 
phosphorylation in the RC fed double transgenic mice that now nears significance (WT 
RC: 1.00; WT HF: 0.857 ± 0.05; Nrf2
-/-
 RC: 1.56 ± 0.31; Nrf2
-/-
 HF: 3.87 ± 1.1; Nrf2
-/-
/hAPPswe RC: 2.70 ± 0.59; Nrf2
-/-
/hAPPswe  HF: 4.17 ± 0.38; WT RC vs WT HF p < 
0.05, WT RC and WT HF vs Nrf2
-/-
 HF p < 0.05, WT RC vs Nrf2
-/-
/hAPPswe RC p = 
0.06, WT RC vs Nrf2
-/-
/hAPPswe HF p < 0.01, WT HF vs Nrf2
-/-
/hAPPswe HF p < 0.001, 
Nrf2
-/-
 RC vs Nrf2
-/-
 HF p < 0.05, n = 4-11; Figure 3.24 C). Incorporation of the hAPPswe 
mutation does not affect hippocampal ERK phosphorylation even after HF feeding as 
can be seen from the protein blots (Figure 3.24 G). 
Cortical expression of ERK phosphorylation follows a similar pattern to that 
seen in the hippocampus of aged mice, with no changes seen in either the RC of HF fed 
WT and hAPPswe mice. Loss of Nrf2 induces phosphorylation of ERK 1 (WT RC: 1.00; 
Nrf2
-/-
 RC: 1.32 ± 0.14; WT RC vs Nrf2
-/-
 RC p < 0.05, n = 10; Figure 3.24 D) and 2 
(WT RC: 1.00; Nrf2
-/-
 RC: 1.93 ± 0.38; WT RC vs Nrf2
-/-
 RC p < 0.05, n = 10; Figure 
3.24 E), which is further increased by HF feeding and the addition of hAPPswe (ERK 1: 
WT HF: 0.909 ± 0.12; Nrf2
-/-
 HF: 1.78 ± 0.41; Nrf2
-/-
/hAPPswe HF: 2.55 ± 0.22; WT HF 
vs Nrf2
-/-
 HF p = 0.05, WT RC vs Nrf2
-/-
/hAPPswe HF p < 0.01, WT HF vs Nrf2
-/-
/hAPPswe HF p < 0.001, n = 4-10. ERK 2: WT HF: 0.9087 ± 0.119; Nrf2
-/-
/hAPPswe HF: 
2.550 ± 0.218; WT HF vs Nrf2
-/-
/hAPPswe HF p < 0.01, n = 4-10.). When analysed 
together there is a trend towards increased ERK phosphorylation in the Nrf2
-/-
 mice that 
no longer reaches significance, with a significant increase in protein phosphorylation 
expression seen in the Nrf2
-/-
/hAPPswe mice (WT RC: 1.00; WT HF: 0.949 ± 0.11; Nrf2
-
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/-
 RC: 1.35 ± 0.17; Nrf2
-/-
/hAPPswe RC: 2.76 ± 0.50; Nrf2
-/-
/hAPPswe HF: 2.82 ± 0.19; 
WT RC vs Nrf2
-/-
 RC and HF p > 0.05, WT RC vs Nrf2
-/-
/hAPPswe RC p < 0.05, WT RC 
vs Nrf2
-/-
/hAPPswe HF p < 0.01, WT HF vs Nrf2
-/-
/hAPPswe HF p < 0.001, n = 4-10; 
Figure 3.24 F). 
In order to better understand where in the pathway Nrf2 loss was impacting on 
the MAPK activation described above, work was undertaken in collaboration with the 
lab of Prof. S.M. Keyse, who specialise in the dual-specificity MAPK dephosphatases 
(DUSPs or MKPs) that act to clear phosphorylated MAPKs. It has been shown that 
whilst dephosphorylation of MAPKs can be performed by different groups of 
phosphatases, by far the largest family of MAPK-specific phosphatases are the DUSPs 
(Caunt & Keyse, 2013). DUSPs 6, 7 and 9 are believed to be ERK selective and located 
in the cellular cytoplasm, whilst 2, 4 and 5 are inducible nuclear variants, specifically 
regulating the nuclear dephosphorylation and accumulation of ERK. DUSP1, which is 
also a nuclear inducible DUSP, was analysed although it is known to interact not only 
with ERK but also with JNK and p38 isoforms. To that effect, hippocampal lysates 
were assessed for gene expression of some of the key DUSPs associated in particular 
with regulation of ERK activity. 
No effect of long-term HF feeding was seen on gene expression of the 
promiscuous DUSP1 in the hippocampus of WT mice (p > 0.05; Figure 3.25 A). Loss of 
Nrf2 appears to prompt a decrease in gene expression of DUSP1, which is rescued by 
HF-feeding (WT RC: 1.00; Nrf2
-/-
 RC: 0.774 ± 0.05; WT RC vs Nrf2
-/-
 RC p < 0.01, n = 
6). In contrast, DUSP2 expression, which is also located in the nucleus, was 
significantly depleted by long-term HF feeding (WT RC: 1.00; WT HF: 0.348 ± 0.08; 
Nrf2
-/-
 HF: 0.458 ± 0.09; WT RC vs WT HF p < 0.001, WT RC vs Nrf2
-/-
 HF p < 0.01, n 
= 6; Figure 3.25 B). In addition, a trend towards decreased expression of DUSP2 was 
also seen in RC fed Nrf2
-/-
 mice although this failed to reach significance with the 
numbers analysed (Nrf2
-/-
 RC: 0.662 ± 0.18; WT RC vs WT HF p > 0.05, n = 6). 
Differing from DUSP1 and 2, DUSP4 was not affected by either dietary or genotype 
changes in the hippocampus of aged mice (p > 0.05; Figure 3.25 C). DUSP5, the last 
nuclear DUSP assessed, was decreased significantly by both HF feeding of WT mice 
and loss of Nrf2 with no further effect of diet in these mice (WT RC: 1.00; WT HF: 
0.252 ± 0.05; Nrf2
-/-
 RC: 0.280 ± 0.06; Nrf2
-/-
 HF: 0.390 ± 0.10; WT RC vs WT HF p < 
0.0001, WT RC vs Nrf2
-/-
 RC p < 0.0001, WT RC vs Nrf2
-/-
 HF p < 0.01, n = 6; Figure 
3.25 D).   
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Figure 3.25 Loss of Nrf2 and HF feeding impact significantly on the gene 
expression of important MAPK DUSP proteins. 
Brain tissue was harvested from mice and processed for gene expression analysis by TaqMan 
RT-qPCR. Measures were taken for relative expression of DUSP1 (A), DUSP2 (B), DUSP4 
(C), DUSP5 (D), DUSP6 (E) and DUSP7 (F) in the hippocampus of aged mice. All data 
portrayed as means ± s.e.m. and analysed by one-sample and unpaired t-test where * indicates 
significantly different from RC fed WT control unless otherwise indicated. *, p < 0.05; **, p < 
0.01; ***, p < 0.001. WT n = 6, Nrf2
-/-
 n = 6. Gene expression data captured by PhD student 
Andrew M. Kidger as part of a collaboration with Prof. Stephen M. Keyse, Division of Cancer 
Research, University of Dundee.  
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Of the known ERK-specific cytosolic DUSPs, 6 and 7 were assessed as the 
expression level of 9 was too variable to be consistently picked up by RT-qPCR 
machine. The profile of DUSP6 expression was the same as that seen for the nuclear 
DUSP5 with both HF-feeding and Nrf2 loss impeding expression in the aged 
hippocampus (WT RC: 1.00; WT HF: 0.625 ± 0.03; Nrf2
-/-
 RC: 0.593 ± 0.05; Nrf2
-/-
 
HF: 0.672 ± 0.05; WT RC vs WT HF p < 0.0001, WT RC vs Nrf2
-/-
 RC p < 0.001, WT 
RC vs Nrf2
-/-
 HF p < 0.001, n = 6; Figure 3.25 E). Finally, DUSP7 was the only DUSP 
measured to be positively affected by HF feeding with WT mice showing a significant 
increase in expression (WT RC: 1.00; WT HF: 1.24 ± 0.07; WT RC vs WT HF p < 
0.05, n = 6; Figure 3.25 F). Furthermore, a trend towards increased expression was also 
seen in both Nrf2
-/-
 RC and HF fed mice, although this failed to reach significance 
(Nrf2
-/-
 RC: 1.19 ± 0.11; Nrf2
-/-
 HF: 1.18 ± 0.10; WT RC vs Nrf2
-/-
 RC and HF p > 0.05, 
n = 6). 
To see if the changes in DUSP gene expression just described were carried 
through to alterations in protein levels, those DUSPs with functioning Western blotting 
antibodies were assessed in hippocampal tissue lysates from WT and Nrf2
-/-
 RC and HF 
fed mice. In addition, to assess whether the upregulation in ERK phosphorylation was 
due to an increase throughout the pathway in combination with alterations of DUSP 
activity, we looked at protein levels of MEK 1/2 phosphorylation. MAPK kinases, or 
MEKs, activate the MAPK enzymes by means of phosphorylation. Phosphorylation by 
MAPK kinase kinase enzymes specifically activates MEK 1/2 to in turn dual 
phosphorylate and activate ERK 1/2. Despite no significant changes in gene expression, 
protein levels of DUSP4 were significantly decreased by HF feeding in WT mice (WT 
RC: 1.00; WT HF: 0.445 ± 0.04; WT RC vs WT HF p < 0.0001, n = 6; Figure 3.26 A). 
In addition, HF-feeding also impaired DUSP4 protein production in Nrf2
-/-
 mice; 
however, this was significantly attenuated when compared to HF fed WT mice (Nrf2
-/-
 
HF: 0.722 ± 0.10; WT RC vs Nrf2
-/-
 HF p < 0.05, WT HF vs Nrf2
-/-
 HF p < 0.05, n = 6). 
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Figure 3.26 Loss of Nrf2 and HF feeding impact significantly on both MEK1/2 and 
important ERK-related DUSP proteins in the hippocampus of aged mice. 
Brain tissue harvested from WT and Nrf2
-/- 
mice was processed for protein expression by 
Western blotting. Protein levels of DUSP4 (A), DUSP5 (B), DUSP6 (C), DUSP9 (D) and the 
ERK MAPKK MEK1/2 (E) were calculated by densitometry in the hippocampus of aged mice, 
where tubulin was used as the protein loading control. All data are portrayed as means ± s.e.m. 
and analysed by one-sample and unpaired t-test where * indicates significantly different from 
RC fed WT control unless otherwise indicated. *, p < 0.05; **, p < 0.01; ***, p < 0.001. WT n 
= 6, Nrf2
-/-
 n = 6. Protein data captured by PhD student Andrew M. Kidger as part of a 
collaboration with Prof. Stephen M. Keyse, Division of Cancer Research, University of Dundee.  
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Repeating a similar profile, DUSP5 protein was significantly affected by HF-
feeding with both WT and Nrf2
-/-
 mice presenting decreased protein levels following HF 
feeding (WT RC: 1.00; WT HF: 0.532 ± 0.07; Nrf2
-/-
 HF: 0.737 ± 0.06; WT RC vs WT 
HF p < 0.01, WT RC vs Nrf2
-/-
 HF p < 0.01, n = 6; Figure 3.26 B). Moreover, like 
DUSP4, DUSP5 shows an attenuated response in Nrf2
-/-
 HF fed mice although this falls 
just short of significance (WT HF vs Nrf2
-/-
 HF p = 0.06, n = 6). In contrast, despite 
significantly less gene expression, RC fed Nrf2
-/-
 mice reported too much variability in 
DUSP5 protein levels to report any significant change in comparison to controls. 
Furthermore, no change in protein level is reported in DUSP6 irrespective of genotype 
or diet in use (p > 0.05; Figure 3.26 C), but DUSP9 shows a diet dependent decrease in 
protein level recorded in both WT and Nrf2
-/-
 mice (WT RC: 1.00; WT HF: 0.547 ± 
0.05; Nrf2
-/-
 HF: 0.603 ± 0.05; WT RC vs WT HF p < 0.001, WT RC vs Nrf2
-/-
 HF p < 
0.001, n = 6; Figure 3.26 D). 
Finally, MEK1/2 phosphorylation was assessed in the hippocampus of aged WT 
and Nrf2
-/-
 mice. HF feeding induced a concomitant decrease in MEK phosphorylation 
alongside those seen in DUSP expression in WT mice (WT RC: 1.00; WT HF: 0.712 ± 
0.08; WT RC vs WT HF p < 0.05, n = 6; Figure 3.26 E). However, RC fed Nrf2
-/-
 mice 
report significantly increased levels of MEK phosphorylation in the hippocampus when 
compared to controls (Nrf2
-/-
 RC: 1.64 ± 0.24; WT RC vs Nrf2
-/-
 RC p < 0.05, n = 6). 
Moreover this increase in phosphorylation is maintained following HF feeding in Nrf2
-/-
 
mice in contrast to WT HF fed mice (Nrf2
-/-
 HF: 1.87 ± 0.40; WT RC vs Nrf2
-/-
 HF p = 
0.08, WT HF vs Nrf2
-/-
 HF p < 0.05, n = 6). To summarise the increase in ERK 
phosphorylation seen in Nrf2
-/-
 mice appears to be driven by alterations in both MEK 
1/2 and ERK-specific DUSPs. It would appear that under RC-fed conditions the 
increased ERK phosphorylation is driven primarily by increased activation of the ERK 
MAPK pathway with increased phosphorylation of MEK. However, on a HF diet this 
increased MEK phosphorylation is maintained and ERK phosphorylation is potentiated 
by a decrease in several ERK-specific DUSPs. 
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3.13 NRF2 DEPLETION DRIVES ALTERATIONS IN MOUSE BRAIN 
MITOCHONDRIA 
VDAC1 and COX IV are both markers of the outer mitochondrial membrane; 
with VDAC1 (aka porin), a voltage dependent anion channel protein playing a role in 
cell metabolism and mitochondrial apoptosis, and COX IV one of the subunits of the 
final complex in the electron transport chain. RC and HF fed aged mice were analysed 
for VDAC1 and COX IV expression in whole lysates as shown in the exemplar blots 
(Figure 3.27 A). HF feeding decreased expression of COX IV in both the hippocampus 
(WT RC: 1.00; WT HF: 0.340 ± 0.05; WT RC vs WT HF p < 0.0001, n = 8; Figure 3.27 
B) and cortex (WT RC: 1.00; WT HF: 0.333 ± 0.71; WT RC vs WT HF p < 0.0001, n = 
8; Figure 3.27 D) of WT mice by over 60% relative to RC fed WT mice. HF feeding of 
Nrf2
-/-
 mice also decreases COX IV expression in both the hippocampus (Nrf2
-/-
 HF: 
0.603 ± 0.11; WT RC vs Nrf2
-/-
 HF p < 0.0001, n = 8) and cortex (Nrf2
-/-
 RC: 0.974 ± 
0.14; Nrf2
-/-
 HF: 0.250 ± 0.04; WT RC vs Nrf2
-/-
 HF p < 0.0001, Nrf2
-/-
 RC vs Nrf2
-/-
 HF 
p < 0.001, n = 8). However, in the hippocampus COX IV expression remains 
significantly higher than that seen in HF fed WT mice (WT HF vs Nrf2
-/-
 HF p < 0.05, n 
= 8). 
Similar to levels of COX IV, HF feeding decreased VDAC1 protein in both the 
hippocampus (WT RC: 1.00; WT HF: 0.466 ± 0.05; WT RC vs WT HF p < 0.0001, n = 
8; Figure 3.27 C) and cortex (WT RC: 1.00; WT HF: 0.652 ± 0.03; WT RC vs WT HF p 
< 0.0001, n = 8; Figure 3.27 E) of WT mice relative those on a RC diet. HF feeding of 
Nrf2
-/-
 mice also decreased VDAC1 in the cortex with a trend towards a significant 
decrease seen in the hippocampus when compared to RC fed animals (hippocampus: 
Nrf2
-/-
 RC: 1.31 ± 0.16; Nrf2
-/-
 HF: 0.757 ± 0.21; Nrf2
-/-
 RC vs Nrf2
-/-
 HF p = 0.05, n = 
8. Cortex: Nrf2
-/-
 RC: 1.31 ± 0.15; Nrf2
-/-
 HF: 0.425 ± 0.03; WT RC and Nrf2
-/-
 RC vs 
Nrf2
-/-
 HF p < 0.0001, n = 7-8). However, in the cortex VDAC1 expression drops 
significantly compared to HF fed WT mice in Nrf2
-/-
 mice fed a HF diet (WT HF vs 
Nrf2
-/-
 HF p < 0.0001, n = 7-8). A trend towards increased VDAC1 is seen in the 
hippocampus and cortex of RC fed mice (Hippocampus: WT RC vs Nrf2
-/-
 RC p = 0.07, 
n = 8. Cortex: WT RC vs Nrf2
-/-
 RC p = 0.07, n = 7-8).  
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Figure 3.27 Loss of Nrf2 and HF feeding both impact on mitochondrial health and 
mitophagy markers. 
Brain tissue was harvested from mice and processed for protein expression by Western blot as 
previously described using whole lysates, with exemplars shown in A where β-actin was used as 
the protein loading control. Measures were taken for relative expression of COX IV (B + C), 
VDAC 1 (D + E), mitofusin 1(F + G) and mitofusin 2 (H + I) in the hippocampus and cortex of 
RC and HF fed WT and Nrf2
-/-
 mice, where β-actin was used as the protein loading control. All 
data portrayed as means ± s.e.m. and analysed by unpaired t-test where * indicates significance 
between groups. *, p < 0.05; **, p < 0.01, ***, p < 0.001. WT n = 7-8, Nrf2
-/-
 n = 6-8.  
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Changes in mitochondrial proteins can often be associated with a change in 
mitochondrial number or mitochondrial autophagy, otherwise known as mitophagy. In 
order to assess this possibility, two key fusion proteins were also analysed (mitofusin 1 
and 2). No genotype dependent changes were observed in mitofusin 1 in either the 
hippocampus (Figure 3.27 F) or cortex (Figure 3.27 H), though there was a significant 
dietary related induction following HF feeding in the hippocampus (WT RC: 1.00; WT 
HF: 1.90 ± 0.21; Nrf2
-/-
 RC: 0.858 ± 0.24; Nrf2
-/-
 HF: 2.21 ± 0.29; WT RC vs WT HF p 
< 0.01; WT RC vs Nrf2
-/-
 HF p < 0.01, Nrf2
-/-
 RC vs Nrf2
-/-
 HF p < 0.01, n = 8). 
Mitofusin 2, on the other hand, has opposing expression in the hippocampus and 
the cortex following HF feeding in Nrf2
-/-
 mice. In the hippocampus, expression of 
mitofusin 2 mimics that seen for mitofusin 1 with HF feeding stimulating expression in 
both genotypes (WT RC: 1.00; WT HF: 1.96 ± 0.23; Nrf2
-/-
 RC: 0.956 ± 0.30; Nrf2
-/-
 
HF: 2.53 ± 0.28; WT RC vs WT HF p < 0.01, WT RC vs Nrf2
-/-
 HF p < 0.001, Nrf2
-/-
 
RC vs Nrf2
-:-
 HF p < 0.01, n = 8; Figure 3.27 G). Cortical expression of mitofusin 2 
does not change as a result of HF feeding in WT or Nrf2
-/-
 mice when compared to WT 
RC animals. Expression of mitofusin 2 in Nrf2
-/-
 RC fed animals, however, is halved 
compared to WT controls which is recovered to control levels by HF feeding (WT RC: 
1.00; Nrf2
-/-
 RC: 0.500 ± 0.09; Nrf2
-/-
 HF: 0.948 ± 0.12; WT RC vs Nrf2
-/-
 p < 0.01, 
Nrf2
-/-
 RC vs Nrf2
-/-
 HF p < 0.05, n = 6-8; Figure 3.27 I). 
3.14 DISCUSSION 
3.14.1 Long-Term HF Feeding Has Contrasting Effects on Glucose 
Management and Body Weight in Nrf2
-/-
 and hAPPswe Mice  
Despite its ubiquitous expression, relatively little work has been done on Nrf2 in 
the brain in comparison to its study in other areas such as liver and cancer research. 
Confirmation of the presence of Nrf2 in the mouse brain was done via gene expression, 
where it was shown to be present in all four of the brain regions analysed. This was 
repeated for the APP mouse gene, establishing both of these key proteins as being 
present in the brain regions of interest. In addition, use of human specific probes 
permitted us to confirm the presence of the hAPP gene in our transgenic carriers, giving 
confirmation of the model in use. And whilst a small discrepancy was seen in the 
expression of hAPP in the cortex of Nrf2
-/-
/hAPPswe mice this did not appear to translate 
to any significant induction in total APP protein expressed in these mice.  
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Thereafter, our first aim was to assess the effect long-term HF feeding had on 
our models. There are a multitude of studies showing HF feeding causes weight gain, 
insulin resistance and impaired glucose disposal in WT mice on the C57/Bl6 
background (Winzell & Ahrén, 2004). The majority of these studies are pursued with a 
focus on obesity, and in some cases diabetes research. Indeed, transgenic models have 
been produced that develop a more pronounced disease phenotype such as the leptin 
deficient ob/ob mice and the db/db mouse that carries a functional defect in the long 
form leptin receptor. However, with most studies being centred round obesogenic and 
diabetic outcomes, very few studies have pursued the effects of HF feeding over a 
longer period of time. Along with a few other labs (Chartoumpekis et al., 2011; Meher 
et al., 2012), we have already shown that Nrf2
-/-
 mice maintain their insulin sensitivity 
and glucose disposal when placed on a HF diet for a standard period of 20 weeks 
(Meakin et al., 2014). Furthermore, a small number of studies have been pursued using 
AD mouse models which indicate that FAD related mutations may impact on peripheral 
energy homeostasis, especially when challenged by HF feeding (Kohjima et al., 2010; 
Mody et al., 2011). This is of particular interest given the reported risks conferred by 
obesity and TIID on development of dementia. We were able to show that long-term, 
Nrf2
-/-
 mice maintain their resistance to DIO, remaining significantly lighter than their 
HF fed WT counterparts at 14 months of age following a year of HF feeding. In 
addition, loss of Nrf2
-/- 
in Nrf2
-/-
/hAPPswe appears to counteract the trend for increased 
body weight seen in mice carrying the hAPPswe transgene alone.  
We have previously shown that Nrf2
-/-
 mice at 28 weeks have the same glucose 
clearance as WT mice when on a RC diet. However, when these were placed on a HF 
diet for 20 weeks, Nrf2
-/-
 mice demonstrated an improved glucose clearance compared 
to controls (Meakin et al., 2014). When IPGTTs were performed at 15 months on our 
aged cohort, we found that mice lacking Nrf2 had improved glucose clearance, even 
under RC conditions. In addition, both WT and hAPPswe mice had a similar clearance 
profile. The glucose sensitivity seen in the Nrf2
-/-
 correlates with lower total body 
weight at time of testing, and this may play an important role in the maintenance of 
glucose sensitivity seen in the HF fed Nrf2
-/-
 cohort. Furthermore, Nrf2
-/- 
mice fed a RC 
diet are more insulin sensitive than either WT or hAPPswe compatriots as demonstrated 
by ITT. And despite demonstrating an acute sensitivity to insulin at a younger age 
following only twenty weeks of HF feeding (Meakin et al., 2014), by 16 months of age 
Nrf2
-/-
 mice on a HF diet report a loss of insulin sensitivity similar to that seen in WT 
and hAPPswe mice. This may suggest a dysregulation of insulin signalling in Nrf2
-/-
 mice 
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fed a HF diet long term and may be linked with damage in the periphery such as is 
known to occur in the livers of these mice. In order to pursue this further, investigation 
of circulating insulin levels and analysis of the pancreas may elucidate whether these 
changes are down to depletion or dysfunction of endogenous insulin, whilst in vivo 
clamp studies may also be important in clarifying the alterations seen in Nrf2
-/-
 mice. 
Furthermore, assessment of hypothalamic tissue for alterations in key metabolic 
regulators would be important to illuminate the role of central vs peripheral regulation 
in these changes. 
In contrast, whilst Nrf2
-/-
 mice maintain their increased glucose sensitivity even 
after a year of HF feeding, hAPPswe mice portray an exacerbated clearance profile 
following long-term HF feeding even when compared to WT mice on the same diet. 
This exacerbation appears to occur despite similar body weights to those seen for HF 
fed WT mice and may indicate an important role for alterations in APP processing on 
obesity in aging. This is in line with the recent study by Vandal and colleagues (2014) 
who found that HF feeding of 3x Tg mice (hAPPswe, PS1M146V, tauP301L) was marked by 
worsened glucose tolerance. In addition, they found that the transgenic model 
accumulated amyloid in their pancreatic islets whilst HF feeding of these mice caused 
pancreatic islet degeneration and further exacerbated the cognitive impairment seen 
under basal conditions. Finally, Vandal et al. were able to show an increase in AD-like 
pathologies following HF feeding which were improved following acute insulin 
treatment in conjunction with improved cognitive performance. Similarly, another study 
using the same 3x Tg model demonstrated an increased presence of pathological 
hallmarks of AD following consumption of a western-style diet supporting the findings 
of Vandal and colleagues (Julien et al., 2010). In addition, Julien et al. suggested a role 
for the depletion of polyunsaturated fatty acids (PUFA) in the aggravation of AD 
pathology, with detrimental effects seen when mice were fed a diet low in n-3:n-6 fatty 
acids either alone or in combination with high levels of fat. Low levels of PUFAs has 
previously been suggested to be linked with increased risk of developing AD (Morris et 
al., 2003; Schaefer et al., 2006). This implicates a role for dysfunctional insulin 
signalling in AD.  
Work performed in our lab using the BACE
-/-
 mouse may act in support of these 
findings. We have previously published data showing that BACE1
-/-
 mice fail to gain 
weight following HF feeding and show improved response to both IPGTTs and ITTs. 
This further supports a potential role for the amyloidogenic pathway in alterations in 
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insulin signalling. Furthermore, these findings have been replicated using 
pharmacological inhibitors of BACE1 with similar results. However, contrasting with 
the findings described by Vandal et al., work performed by Catherine Lawrence’s lab 
showed HF diet induced cognitive impairments in the same 3x Tg model of AD but 
failed to find significant alterations in pathological markers such as amyloid in the 
brains of these mice (Knight et al., 2014). Finally, studies on a single mutant model of 
AD carrying the hAPPswe gene inclusion driven by the hamster prion protein promoter 
showed increased weight gain alongside the alterations in insulin and glucose signalling 
(Ho et al., 2004). Moreover, in addition to alterations in amyloid production, Ho et al. 
suggested a role for increased γ-secretase activity following HF feeding. However, it is 
worth noting that under the prion promoter, expression of the hAPPswe mutation has 
been shown to be over five-fold that of normal mouse APP making this a more 
aggressive model than that used in our studies (Elder et al., 2010). From this it is clear 
that the animal model used, in addition to the diet administered and the duration of the 
dietary intervention and age of testing may all play an important role in the outcomes 
described by the individual studies. In addition, these factors, in particular the 
prevalence of more aggressive models of AD in many of these studies, may explain why 
our findings have failed to replicate their work in instances such as the increased 
presence of pathological markers. What does seem clear is that the interaction between 
insulin signalling and the APP pathway is intricate and further investigation is required 
to tease out the actions of the pathways involved.  
Further to the alterations in both weight gain and insulin signalling, other key 
organs were assessed for both genotype and diet induced changes, namely heart, liver 
and spleen. Increased inflammation, OS and lipogenesis all have the ability to impact on 
organ morphology. Moreover, it has previously been reported that Nrf2
-/-
 mice on a HF 
diet have an increased risk of developing both steatohepatitis and cirrhosis (Chowdhry 
et al., 2010; Meakin et al., 2014), which highlights the impact of Nrf2 loss on liver 
health. Given the increased duration of this study in comparison to other similar studies 
performed to date, long term impacts of an obesogenic diet such as cardiac hypertrophy 
were also assessed in our mouse models. We found that the hearts taken from our Nrf2
-/-
 
and Nrf2
-/-
/hAPPswe mice had undergone tissue hypertrophy by 16 months of age 
irrespective of the diet being fed. This suggests a role for increased ROS production and 
OS, through the loss of Nrf2, in driving cardiac remodelling, a phenomenon that has 
been previously described in other models of obesity (Ceylan-Isik et al., 2013). This is 
further supported by research published by Li and colleagues indicating activation of 
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Nrf2 aids in counteracting hyperglycaemia-driven cardiac hypertrophy in an STZ-
induced diabetic rat model (Li et al., 2015). In addition, activation of Nrf2 has been 
suggested to protect the murine heart from cardiac hypertrophy and damage resulting 
from haemodynamic stress, contrasting with the aggravated response observed in Nrf2
-/-
 
mice (Li et al., 2009). Furthermore, chemical activation of Nrf2 with well-known Nrf2 
activating compounds has attenuated the detrimental cardiac alterations associated with 
diabetic cardiomyopathy, resulting in renewed interest in Nrf2 activators for the 
treatment of some cardiovascular complications (Bai et al., 2013; Wang et al., 2013c). 
As a result, it would be interesting to go back and investigate this further by examining 
whether the change in heart size is linked with any particular regional alterations of 
cardiac physiology and whether this is linked with increased ER stress or markers of 
oxidative damage. This may be of particular interest given the lack of prior information 
available regarding the effects of long-term HF feeding on the cardiac system of Nrf2
-/-
 
mice. 
Building on work previously published from ours and others labs, we also found 
significant decreases in liver size in both our mouse models lacking Nrf2 expression. 
This complements previous findings indicating increased fibrosis and liver damage in 
HF fed Nrf2
-/-
 mice both of which are known to negatively impact on liver size. This 
change in liver size was maintained after accounting for body weight indicating it is not 
solely as a result of attenuated body weight increase seen in Nrf2
-/-
 and Nrf2
-/-
/hAPPswe 
mice. In addition, no further significant impact was seen following the supplementation 
of hAPPswe despite the single transgenic hAPPswe mice displaying no alteration in liver 
size when fed a RC diet. Furthermore, there was an increase in splenic size in both Nrf2
-
/-
 and Nrf2
-/-
/hAPPswe mice. Whilst spleen size is relatively consistent when not 
challenged by immunoreactive or toxic factors, the change in spleen size seen in our 
study is likely a result of altered immune cell production. Ongoing research in 
collaboration with Prof. J. Hayes and his lab has shown that there is no alteration in the 
ratio of immune cell types produced by the spleen in HF fed Nrf2
-/-
 mice, rather there is 
an overall increase in immune cells. Furthermore, the majority of these cells appear to 
relocate towards the liver, with a distinct lack of immune cell infiltration seen in the 
WAT of these mice contrary to HF fed WT controls. 
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3.14.2 Mice Lacking Nrf2 Have Increased Locomotor Activity in Early 
Adulthood Following High Fat Feeding 
There has, to date, been very little published work examining the effects of Nrf2 
loss on behavioural phenotype and differences. A paper published by Muramatsu and 
colleagues (2013) reported no changes in social interaction, open-field and rotarod tests 
in young Nrf2
-/-
 mice. This in turn suggests a lack of impact of Nrf2 loss on anxiety 
levels, motor activity and muscle tone when compared to controls at the age tested. 
However, this does not assess any long-term effects the loss of Nrf2
-/-
 may have on 
cognitive ability. Finally, Muramatsu and colleagues also performed a forced swim test 
on young Nrf2
-/-
 mice that indicated a resistant phenotype of Nrf2
-/-
 towards the despair 
profile associated with acute forced swim stress. However, despite the recent interest in 
Nrf2
-/-
 mice little other cognitive phenotyping has been performed. Furnari performed a 
battery of behaviour and motor skill related tests on WT and Nrf2
-/-
 mice including tasks 
such as the Morris water maze and the open-arm elevated plus maze model of anxiety 
(Furnari, 2013; Furnari et al., 2014); however, the majority of the effects seen on 
cognition resulted from additional treatment alterations as opposed to effects of 
genotype alone. In addition, similar to the study undertaken by Muramatsu and 
colleagues, the mice used were all aged younger than six months at time of testing, 
preventing the assessment of ageing contributions on cognitive performance. 
As described, mice were tested at 4 distinct ages using a simple working 
memory model of a closed arm elevated plus maze where continuous spontaneous 
alternation was assessed in a non-cued environment. In the first instance we found no 
effect of genotype on locomotor activity as described by the number of arm entries 
performed by each group. Furthermore, whilst all groups showed age-dependent 
attenuation in both the number of arm entries performed as well as the number of 
alternations performed, these were not further affected by genotypic alterations. In 
contrast, upon calculation of SA values, which has been previously described by 
McNay and colleagues (2000), we found both time and genotype dependent effects on 
performance. A time dependent attrition in SA was seen in all groups, with Nrf2
-/-
/hAPPswe mice performing significantly worse than WT and Nrf2
-/-
 mice. A similar trend 
is seen in Nrf2
-/-
 mice over time, though this fails to reach significance in comparison to 
WT controls. However, loss of Nrf2 may act as a priming force, exacerbating the effects 
of any additional challenges administered such as the addition of hAPPswe. It would be 
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interesting to pursue this further looking at the effect of Nrf2 loss on cognition over 
time, especially in light of the negative correlation of Nrf2 with ageing.  
The measure of SA measured in a continuous format (in either a Y- or +- maze 
model) is often linked to a measurement of spatial working memory (Chu et al., 2012; 
Joshi et al., 2014). Changes in hippocampal glucose consumption and reversal of SA 
impairment following hippocampal interventions suggests that the continuous SA 
alternation task may rely at least in part on hippocampal involvement for task 
completion, even when this task is un-cued (McNay et al., 2000; Krebs & Parent, 2005; 
McNay et al., 2010). However, the specific regional requirements for successful SA 
may be heavily influenced by the design setup and as such depending on the availability 
of external cues, and the type of memory encoding believed to be in use during the task 
performance this may not be the case (Lennartz, 2008; Vorhees & Williams, 2014; 
Hargrave et al., 2015). At the very least, it is likely that the hippocampus is not solely 
responsible in enabling successful task completion, and care should be given in the 
design and setup of this outwardly simple task as well as the interpretation of the 
subsequent results. As such, and given the previously described results for our model, it 
is possible that with an egocentric task design our model reflects a non-hippocampal-
dependent task, instead relying more on other brain areas associated with egocentric 
task completion, such as the dorsal striatum (Vorhees & Williams, 2014). It should be 
noted, however, that there remains limited research on regional influences for 
egocentric tasks in comparison to allocentric tasks. Further testing using one of the 
more strongly correlated hippocampal dependent tasks, such as the MWM, would aid in 
confirming the presence or lack of hippocampal involvement within this model. 
Furthermore, in light of the predominantly hippocampal related inflammatory response 
recorded, tasks that are dependent on this function for successful completion may be of 
relevance for the characterisation of this model following an ageing intervention. 
Further to this, we also assessed the effect of long-term HF feeding on WT and 
Nrf2
-/-
 mice and their ability to SA. Given that obesity and the metabolic syndrome are 
associated with chronic low grade inflammation as well as alterations in substrate 
utilisation, it was proposed this might act to challenge the already primed environment 
of the Nrf2
-/-
 mouse. We found that HF feeding had a significant impact on locomotor 
activity in the Nrf2
-/-
 mice as described by increased arm entries performed and this 
occurred in conjunction with attenuated weight gain following consumption of a 45% 
HF diet. Moreover, as this increase in activity was matched by an increase in 
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alternations successfully performed, Nrf2
-/-
 mice demonstrated no significant attrition in 
SA following HF feeding. The increased activity seen in HF fed Nrf2
-/-
 mice is 
supported by activity measures performed during other HF feeding studies, and has also 
been shown to correlate with an increase in oxygen consumption (Meakin et al., 2014). 
And whilst the changes reported in behaviour remain relatively mild, this supports 
further research into the impact of HF feeding on Nrf2
-/-
 mice. This may also advocate 
for the development of a more selective KO model, allowing the roles driven by Nrf2 in 
the liver which are clearly important and complex to be separated from potential 
alterations in central energy regulation. 
3.14.3 High Fat Feeding and Inflammation Following Loss of Nrf2 and 
a Role for Contrasting Organ Specific Effects 
It is now well accepted that inflammation plays a role in many forms of 
neurodegenerative disorders. In addition, it is a well described presence in both obesity 
and TIID, whilst the efficacy of our immune responses is slowly impaired with ageing. 
It has been shown that consumption of a diet high in fat can affect both peripheral and 
central tissues, with inflammation previously being reported in brain regions such as the 
hypothalamus (Thaler et al., 2012). Given the already described significant alterations 
observed in the livers of Nrf2
-/-
 mice, it was originally hypothesised that HF feeding 
may induce a similar detrimental effect in the brain which would be amplified by HF 
feeding. We were able to show that, in contrast to the liver, long term HF feeding 
attenuates the basal inflammatory state present in the aged Nrf2
-/-
 mouse brain, with the 
expression of pro-inflammatory cytokines, such as IL-1β and TNF-α, significantly 
diminished by HF feeding. Furthermore, whilst Nrf2
-/-
/hAPPswe mice have a reduced 
inflammatory profile when compared to Nrf2
-/-
 mice, HF feeding is still able to further 
attenuate this inflammatory response.  
In contrast, mice carrying the hAPPswe gene fail to replicate the increased pro-
inflammatory profile seen in the Nrf2
-/-
 mice with many markers appearing at the same 
expression level or lower than those reported for WT mice. This is maybe surprising in 
light of other publications which have studied the effects of AD mouse models and 
mouse models of obesity as many of these report increases in markers related to 
inflammation (Pistell et al., 2010; Takeda et al., 2010; Ferretti et al., 2012). Still, the 
majority of the models in use in these studies describe more aggressive AD pathology 
than is seen in our model. It has been well described that addition of Aβ can act to 
induce inflammatory markers (Benito et al., 2012), but we were unable to visualise 
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plaque deposition in our mouse model. Furthermore, many high fat feeding studies in 
AD mouse models have failed to quantify changes in inflammatory cytokines, 
concentrating instead on markers of OS or markers of immune cell activation. And this 
we have been able to reiterate, with elevation of the microglial marker F4/80 following 
HF feeding in the hippocampus of our hAPPswe mice (Figure 3.12 A). What we can 
conclude, therefore, is that hAPPswe mice do not require overt pathology to demonstrate 
altered insulin sensitivity following ageing. However, it is possible that more substantial 
elevations in amyloid than is likely occurring in the model used here, may be essential 
in the potentiation of other inflammation related markers that have been shown by 
groups using alternative mouse models of AD. 
Studies performed using HF fed Nrf2
-/-
 mice have so far concentrated on the 
effects of Nrf2 loss on peripheral organs. However, we can corroborate the improved 
inflammatory profile seen in the brains of our HF fed Nrf2
-/-
 mice with similar 
apparently protective effects reported in other peripheral organs. It has been previously 
reported that Nrf2
-/-
 fail to gain the same amount weight as WT mice when placed on a 
HF diet (Meakin et al., 2014). This prompted further investigation into the effects of 
Nrf2 loss on lipogenesis, alterations in WAT including impaired adipogenesis and 
changes in hepatic function following HF feeding. Pi and colleagues (2010) described a 
role for impaired PPAR-γ activation in vitro through the manipulation of the adipogenic 
cell line 3T3-L1and mouse embryonic fibroblasts (MEFs) taken from WT and Nrf2
-/-
 
mice. Meher and colleagues (2012) took this one step further, combining the use of 
global Nrf2
-/-
 with a novel myeloid cell specific Nrf2
-/-
 model to assess the role Nrf2 loss 
may play on obesity induced inflammation. Contrary to what might have been expected 
given the literature available, which demonstrates an aggravated inflammatory response 
in livers deficient in Nrf2, Meher found that whole body Nrf2
-/-
 mice had improved 
WAT inflammatory profiles in addition to continued insulin sensitivity. Their myeloid-
specific Nrf2
-/-
 was not capable of reproducing these effects although it did show an 
improved inflammatory profile upon analysis of the stromal vascular fraction from 
WAT, which contains a high percentage of immune cells.  
This robust reduction in obesity associated inflammatory response is similar to 
that which we have described here in the brain. Moreover, a study performed using a 
Keap1 KD model, which is characterised by continued increased Nrf2 activity, 
demonstrated a potentiation of the standard responses to HF feeding seen in WT mice 
(More et al., 2013). Keap1 KD mice put on significantly more weight than their WT 
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counterparts on a HF diet. In addition, HF fed Keap1 KD mice were shown to have 
significantly increased lipid and triglyceride accumulation in the liver, significantly 
increased induction in both lipogenic and Nrf2 target genes in the liver and WAT, along 
with increased WAT inflammatory markers and further impairment in insulin signalling 
and glucose sensitivity. Furthermore, unpublished data produced by our collaborators in 
Prof. J.D. Hayes lab have shown, using fluorescence-activated cell sorting (FACS), that 
the immune cell profile in the liver and WAT of Nrf2
-/-
 mice are in exact opposition to 
each other. In addition, preliminary data from our lab looking at alterations in 
inflammation related gene expression suggest a distinct attenuation or prevention in the 
induction of these genes in the WAT of Nrf2
-/-
 mice following HF feeding. Further to 
this, loss of Nrf2 is associated with increased fatty acid production within the liver as 
well as altered triglyceride metabolism; in fact, the liver might almost be suggested to 
act as a sink for the pro-inflammatory immune responses induced by HF feeding. 
Therefore, this suggests an important apparently protective role of HF feeding in Nrf2
-/-
 
mice that comes at a detrimental cost to the liver. 
At this stage, it is worth remembering the different profiles of expression seen in 
the hippocampus and cortex, in particular with relation to the Nrf2
-/-
 mice. We have 
shown region specific alterations in inflammatory profile with the hippocampus 
reporting an increased presence of pro-inflammatory markers, whilst the cortex 
demonstrated a more dominant anti-inflammatory profile with increased induction of 
alternative immune pathways such as that of the complement cascade. This was 
complemented by a reduction in the formation of protein carbonyl adducts in the cortex 
of Nrf2
-/-
 mice. Furthermore, whilst the anti-inflammatory response is again 
predominantly induced in the brains of aged Nrf2
-/-
 mice, this is still attenuated by HF 
feeding in a similar manner to that seen for the pro-inflammatory markers. This may 
indicate the cortex is better able to support resolution of the pro-inflammatory and 
stress-inducing environment produced by the loss of Nrf2
-/-
 than the hippocampus. It 
would be of interest to assess this further, potentially by using a more aggressive 
intervention on the model to accelerate the time line. If over time the cortex also 
succumbs to the damaging effects of Nrf2 loss, a more complete analysis of important 
brain regions may be warranted. Further work looking at other brain regions such as the 
hypothalamus, which plays a crucial role in energy homeostasis, and separate cortical 
and subcortical regions such as the striatum, important in a variety of memory and 
reward pathways, may help clarify the regions of the brain most vulnerable to the loss 
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of Nrf2. Furthermore, if there is a distinct progression profile across the brain, this may 
help clarify the likely role of altered Nrf2 activity under different disease conditions.  
In conjunction with the changes in inflammatory markers described above, 
alterations in both F4/80, a marker found on many macrophage immune cells, and 
GFAP, a commonly used marker of astrocytic glial cells, were observed. Whilst F4/80 
alone cannot differentiate the type of immune cell being detected without additional tags 
such as cluster of differentiation molecule 11b, it is found at higher levels in mature 
macrophages, including brain microglia (van den Berg & Kraal, 2005). Furthermore, 
GFAP has previously been positively associated with astrocytic activation and is known 
to play a role in cellular processes important in regeneration and synaptic plasticity 
(Kamphuis et al., 2012). We found increased expression of F4/80 in the hippocampus 
and cortex of both Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice whilst a diet dependent increase in 
expression is seen in the hippocampus of hAPPswe mice. It is very difficult to 
differentiate macrophage phenotype by surface marker alone. However, when taken 
together with the other inflammatory markers analysed, it is possible to suggest the 
hippocampal increases in F4/80 are likely linked to an increase in M1 like macrophages. 
This is supported by attenuation of F4/80 expression in the hippocampus of HF fed 
mice lacking Nrf2
-/-
. In contrast, whilst the basal upregulation in F4/80 expression may 
be due to M1 factors, latterly this is likely linked instead with an increase in M2:M1 
ratio given the associated increased anti-inflammatory profile present in the cortex. This 
is further supported by the decreased expression of GFAP in all groups except in the 
cortex of RC fed Nrf2
-/-
 mice whilst no significant change in GFAP expression was seen 
in the hippocampus.  
The increased presence of macrophages within the Nrf2
-/-
 and Nrf2
-/-
/hAPPswe 
brain is further supported by increased expression of chemoattractant proteins such as 
MCP-1 and RANTES. Expression of these chemokines is predominantly present in 
those mice fed a RC diet and is higher in the hippocampus than the cortex. Chemokines 
such as MCP-1 and RANTES have been shown to be released from a multitude of cells 
including resident immune cells such as microglia as well as both astrocytes and 
endothelial cells (Deshmane et al., 2009). In addition, and in line with the majority of 
other chemokines identified to date, both MCP-1 and RANTES function in a 
predominantly immune driven manner. Chemokine receptors were shown to have 
altered expression in the hippocampus, with in particular CCR2 being elevated in Nrf2
-/-
 
mice. Microglia, as well as astrocytes, have been shown to express key chemokine 
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receptors in the brain with a small number of chemokine receptors also expressed by 
neurons (Liu et al., 2014). This enables the chemokine signalling pathways to conduct 
elaborate reorganisation of the cells required to resolve an insult in the CNS. 
Furthermore, chemokine receptors such as CCR2 and CCR5 are known to interact not 
only with those chemokines analysed here, but a multitude of other commonly found 
chemokines such as various MIP-1 isoforms, as well as further MCP variants including 
2 and 3, further complicating the chemokine signalling cascade. 
Using fluorescent confocal microscopy, we were able to show that Nrf2
-/-
/hAPPswe mice depicted increased astrocytic branching in both the CA3 and CA1 
regions of the hippocampus, which was increased following HF feeding. In addition, 
astrocytes within the CA1 region of the hippocampus were shown to have aggregated 
following HF feeding in Nrf2
-/-
/hAPPswe mice. Unfortunately, we were unable to 
visualise any amyloid staining within these sections and therefore it is unclear at this 
stage what might be causing this spatial relocation. The staining seen in the brain 
sections from Nrf2
-/-
/hAPPswe mice is in contrast to that observed in Nrf2
-/-
 mice which 
show minimal alteration in cell branching when compared to controls in the CA3 region 
and fail to display a similar aggregation of astrocytes within the CA1 region of HF fed 
mice. AD has previously been linked with increased gliosis and astrocytes have been 
shown to congregate around not only aberrant amyloid deposits but also other forms of 
tissue damage such as is seen following reperfusion injury (Sofroniew, 2009).  
Contrary to F4/80, Iba1, which is thought to be important in calcium 
homeostasis, is specifically expressed in macrophages including resident microglia, and 
is believed to be upregulated during activation of these immune cells (Ito et al., 2001). 
Increased Iba1 staining is seen in both RC and HF fed Nrf2
-/-
/hAPPswe mice along with 
HF fed Nrf2
-/-
 mice in both the CA3 and CA1 regions of the hippocampus. In addition, 
RC fed Nrf2
-/-
 mice show Iba1 staining which appears more dominant in the CA1 than 
CA3 region of the hippocampus. Although this profile largely matches the expression of 
F4/80 previously described it is likely that the F4/80 expression also encompasses 
additional non-macrophage immune cells there to supplement the immune response. 
Furthermore, whilst we might expect increased activation of glial cells in Nrf2
-/-
 mice 
fed a RC diet given the increase in pro-inflammatory markers described, the lack of 
inflammation described in the brains of HF fed Nrf2
-/-
 mice is perhaps more surprising. 
However, as Iba1 is not able to differentiate the different forms of macrophage 
activation (M1 vs M2) it is possible that following HF feeding the microglia in Nrf2
-/-
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brains are predominantly driven to a more protective M2 phenotype. Further work 
making use of techniques such as FACS analysis may allow us to clarify if this is the 
case in the brain following HF feeding.  
Furthermore, it would be very interesting to see if even short term HF feeding 
induces the same changes in microglia and astrocytes staining described here. To date, 
the only other group to have published work on an AD*Nrf2
-/-
 mouse model failed to 
show similar changes in astrocytic and microglial staining (Joshi et al., 2015). Their 
model consisting of a double AD mutation (hAPPswe/PSEN1ΔE9) crossed onto an Nrf2
-/-
 
background, whilst not challenged by additional stressors such as HF feeding as ours 
was, demonstrated increased protein expression of both GFAP and Iba1. However, they 
were unable to show any clear alteration in astrocytic branching in the triple transgenic 
mice, nor was there any alteration in the spatial localisation of astrocytes across the 
section presented. They also failed to see any changes in glial expression in their Nrf2
-/-
 
mice, albeit only measured at 7-8 months of age. In addition, whilst they reported 
numerous alterations in AD related proteins, which will be expanded on below, they 
failed to measure any additional markers assessing inflammation. This makes it hard to 
compare the effects seen in our less aggressive model with those reported in this novel 
triple transgenic model. 
Finally, whilst we have now shown that loss of Nrf2, both by itself and in 
combination with the addition of hAPPswe, is capable of inducing an inflammatory 
effect in addition to inducing activation of key immune cells; we have yet to look at the 
impact this may have had on the neuronal population. Blotting for the synaptic marker 
SYP, we showed that aged RC fed Nrf2
-/-
 mice showed depleted levels of SYP in the 
hippocampus, as might be expected given the increased inflammatory presence in this 
tissue. Contrary to other publications (Unno et al., 2009; Calvo-Ochoa et al., 2014), HF 
feeding induced an upregulation of hippocampal SYP protein in both WT and Nrf2
-/-
 
mice whilst mice carrying the hAPPswe gene displayed increased levels of SYP protein 
irrespective of the dietary grouping. Furthermore, these affects appear to be brain region 
specific with no alteration in SYP in WT, Nrf2
-/-
 and hAPPswe mice in the cortex and 
Nrf2
-/-
/hAPPswe reporting the opposite effect to that seen in the hippocampus with 
decreased SYP expression which is further attenuated by HF feeding. It is possible that 
in the Nrf2
-/-
 mice the increase in SYP protein observed following long term HF feeding 
may result from the improved inflammatory profile seen in these mice in addition to the 
altered metabolic profile observed. However, from blots alone it is not possible to 
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discern whether the change in SYP is due to changes in number of functional synapses 
or whether there is a build of damaged synapses inducing increased synaptic turnover. 
Further work is required to clarify what may be occurring in these models, although 
unfortunately the resolution on a standard confocal microscope is not high enough to 
allow clear visualisation at the synaptic level and therefore primary cultures may be of 
more use on this occasion. 
3.14.4 High Fat Feeding Increased AD Related Proteins in the Brains 
of Aged Mice 
There are now a small number of publications that describe the effects of HF 
feeding on mouse models of AD, in addition to the effects of HF feeding on AD related 
proteins in WT mice. Whilst we saw very limited effects of genotype and diet on gene 
expression levels of both mAPP and BACE, in the hippocampus both WT and Nrf2
-/-
 
mice reported a significant induction in BACE1 protein following HF feeding. This is in 
agreement with previous publications demonstrating that BACE1 can be induced by cell 
stressors including those associated with HF feeding (Meakin et al., 2012; Wang et al., 
2013b). It is worth noting that whilst both hAPPswe and Nrf2
-/-
/hAPPswe mice fail to 
demonstrate significant increases in hippocampal BACE1, they both sit at higher basal 
levels of induction than their WT and Nrf2
-/-
 compatriots.  
In contrast, total APP expression appears to be solely influenced by genotype, 
with no additional effects being driven by changes in diet. Both the hippocampus and 
the cortex of our models lacking Nrf2 show a small increase in hippocampal APP with a 
concomitant decrease seen in cortical protein, whilst the addition of hAPPswe produces 
elevated APP protein in both brain regions. Furthermore, alterations in Nrf2
-/-
/hAPPswe 
land in between their single transgenic counterparts with hippocampal APP expression 
remaining high whilst cortical expression is brought down to a similar level to those 
seen in WT mice. The cortical profile seen for APP protein levels is mimicked by 
BACE1 protein with both Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice describing decreased protein 
levels whilst WT and hAPPswe mice remain constant. In addition, an ELISA assay 
performed to assess changes in triton-X soluble murine Aβ1-42 in cortical lysates 
revealed no significant difference between WT and Nrf2
-/-
 mice irrespective of the diet 
administered. Whilst more aggressive models of AD have reported aggravated amyloid 
pathology following HF feeding, as previously described, the lack of a prominent 
change in amyloid pathology in our models may play a key role in explaining the milder 
phenotype described in other areas such as in cognitive ability. Finally, both HF diet 
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and loss of Nrf2 appear to influence mouse tau phosphorylation, with increased 
phosphorylation seen in both the hippocampus and cortex of mice. Prior publications 
have shown that along with amyloid pathology, obesity and TIID can also aggravate tau 
phosphorylation (Jung et al., 2013). This corroborates recent research published on Nrf2 
implicating its activation in the regulation of tau phosphorylation (Jo et al., 2014; Stack 
et al., 2014). 
3.14.5 HF Feeding and Other Stress Activated Proteins 
3.14.5.1 NF-κB and Glutathione Signalling 
In addition to the plethora of inflammatory cytokines and other signalling 
molecules previously described, there exist a variety of other stress induced pathways; 
many of which work in harmony with the signalling molecules mentioned. One of the 
most commonly named pathways in relation to the inflammatory response is that of NF-
κB. Like many stress activated kinases, NF-κB has the ability to be activated by and 
influence many different pathways and as such it is tightly regulated under basal 
conditions (Lawrence, 2009). When we analysed blots for the repressor protein IκBα, 
we found protein levels were significantly decreased in Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice 
in both the hippocampus and cortex, indicating targeting of IκBα for degradation and 
translocation of NF-κB to the nucleus. The role of NF-κB in inflammation is complex 
and multi-faceted. As such, it has been shown to act in both pro- and anti- inflammatory 
roles, distinguished by the activity of different subsets of proteins which form part of 
the NF-κB cascade (Lawrence et al., 2001). In the hippocampus, therefore, the 
activation of NF-κB likely coincides with the previously described increase in 
inflammation, whilst that present in the cortex may play a more complex part, balancing 
out the remaining anti-inflammatory signalling. In order to clarify the role of the NF-κB 
pathway with regards to Nrf2
-/-
 mice, further work is required to elucidate the function 
of other key proteins within this pathway. It has previously been shown that astrocytes 
lacking Nrf2 have an increased NF-κB response to scratch injury than WT cells (Pan et 
al., 2012), and activation of NF-κB is known to be induced under inflammatory 
conditions like those described above. 
One of the many antioxidant proteins whose transcription is driven by the Nrf2-
ARE complex, GSH plays an important role in the management and neutralisation of 
ROS. GCLC is one of two proteins involved in the first rate limiting step in GSH 
production. GCLC and other members of the antioxidant GSH pathway have previously 
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been suggested to be impaired by aging in their response to stress inputs (Chen et al., 
2010). In addition, along with downstream GSH, GCLC has previously been shown to 
be essential for neuronal survival which can be negatively affected by HF feeding 
(Diaz-Hernandez et al., 2005). When we analysed expression of GCLC, however, we 
found no significant change in either the hippocampus or cortex of WT, Nrf2
-/-
 and 
hAPPswe, with only a small reduction seen in the cortex of Nrf2
-/-
/hAPPswe mice. This 
would indicate that the production of GSH is not directly affected by HF feeding at the 
age tested. In order to pursue this further a GSH assay ought to be performed allowing 
for the measurement of the ratio oxidised to reduced GSH present in the tissue. 
However, the recommended tissue requirement for this assay is around 50-100 mg, 
which makes it prohibitive given the small amount of tissue available. Finally, whilst 
insulin has been suggested to have neuroprotective effects, we saw no change in Akt 
phosphorylation under either RC or HF fed conditions; indicating this is unlikely to be 
the cause of the improved inflammatory profile seen in HF fed Nrf2
-/-
 mice. It may, 
however, be of interest to pursue this further given that acute insulin treatment may 
provide a clearer description of the HF induced insulin signalling changes seen in Nrf2
-/-
 
mice than those seen here under non-stimulated conditions. 
3.14.5.2 MAPK Signalling: A Role for Its Dysregulation in Nrf2-/- Mice 
Stress activated kinases, as the name implies, are activated in response to a 
variety of different signalling molecules. One of the most well-known families is that of 
the MAPK proteins, whose best characterised members include isoforms of ERK, JNK 
and p38. Known to react to factors outside of the immune system such as insulin and 
osmotic stress, MAPKs have also been shown to interact with Aβ, with increased JNK 
expression shown to upregulate both BACE1 and γ-secretase activation (Tamagno et 
al., 2009; Mazzitelli et al., 2011). When analysed we found a significant increase in 
JNK phosphorylation compared to WT in both the Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice. This 
increase in protein phosphorylation was present in both the cortical and hippocampal 
tissue and contrary to many of the other inflammatory and stress markers described up 
till now, this increased phosphorylation ratio did not disappear following HF feeding 
indicating that an alternative pathway may be involved to that affecting other 
inflammatory markers. In contrast, despite showing a trend towards increased 
phosphorylation in the hippocampus, we saw no significant change in JNK 
phosphorylation in the hAPPswe mice irrespective of dietary group. These changes did 
appear comparable to the induction in BACE1 seen in the hippocampus of these mice, 
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which given the supposed activating effect of JNK phosphorylation on BACE1 may be 
important.  
Furthermore, when ERK phosphorylation was assessed we saw a trend towards 
increased basal phosphorylation of ERK in Nrf2
-/-
 and Nrf2
-/-
/hAPPswe which was 
greatly potentiated by HF feeding. Again, the presence of hAPPswe alone did not 
significantly affect ERK phosphorylation, whilst HF feeding of WT mice even induced 
a reduction in hippocampal ERK phosphorylation. The known sensitivity of ERK to 
insulin signalling may be of importance in the accentuated signalling described in Nrf2
-/-
 
mice. All of these facts point towards an Nrf2 dependent alteration in MAPK 
phosphorylation. In addition, the discrepancy in phosphorylation of JNK and ERK 
proteins seen in hAPPswe mice may be in relation to the different roles played by these 
two MAPK. Whilst JNK has previously been described to interact intimately with the 
pro-amyloidogenic pathway as described previously, activation of various ERK 
requiring pathways have been shown to attenuate amyloid related detrimental effects 
(Wang et al., 2012; Zhang et al., 2015).  
Upon further examination, and in collaboration with Prof. S. Keyse, we found 
that under basal conditions mice lacking Nrf2 have elevated MEK phosphorylation in 
the hippocampus. Given the amplifying nature of the MAPK cascade, even a small 
increase in phosphorylation can cause considerable activation of the pathway. However, 
no further induction of MEK phosphorylation was observed following HF feeding of 
Nrf2
-/-
 mice. This suggested additional means of mediation must be involved to induce 
the potentiation of MAPK phosphorylation. DUSP enzymes are the largest family of 
dephosphatases known to act specifically on MAPK proteins. Whilst numerous, these 
have been classified into different sub groups over the years depending on their cellular 
localisation (Caunt & Keyse, 2013). Some are constitutively active proteins found in the 
cytoplasm, whilst others are localised in the nucleus and are termed inducible. Further 
to this, characterisation work has enabled the identification of the various target MAPKs 
associated with different DUSPs. We concentrated on those known to interact with 
ERK, many of which do so specifically. Whilst we found some variance in RNA and 
protein levels, the predominant change observed was that of a HF diet induced loss of 
DUSP proteins.  
Relatively little work has been published looking at the role of DUSPs in obesity 
and animal models lacking DUSP expression are only available for a select number of 
DUSPs. In addition, the data published to date gives contradictory roles for DUSPs and 
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their involvement in obesity depending on the individual protein studied. DUSP1 (aka 
MKP1) is being touted as playing an important role in glucose homeostasis with 
increased liver expression linked with the development of hepatic steatosis (Lawan et 
al., 2015), whilst DUSP 6 (aka MKP3) has been suggested to play a role in the 
induction of hyperglycaemia following high fat feeding by increasing hepatic glucose 
output (Feng et al., 2014). Furthermore, Feng and colleagues found that DUSP6
-/-
 mice 
have attenuated weight gain and altered liver triglyceride content. In addition, 
overexpression of the nuclear DUSP9 (aka MKP4) has been suggested to be protective 
against DIO, improving the glucose tolerance and homeostasis in ob/ob mice 
(Emanuelli et al., 2008). Although complex, these findings do in part link in with the 
phenotype of our model. We saw an increase in DUSP1 in the hippocampus following 
long-term HF feeding of Nrf2
-/-
 mice which may be indicative of their altered insulin 
sensitivity, although it would be worth pursuing this further in the livers of Nrf2
-/-
 mice 
given their predisposition towards the development of NASH following HF feeding. 
Furthermore, we saw no change in the expression of DUSP6, which may be surprising 
given the similar body phenotype described by both DUSP6
-/-
 and Nrf2
-/-
. However, 
these models appear to have opposing actions on triglyceride content indicating they 
probably function through different mechanisms of action. Finally, we saw diet 
dependent decreases in DUSP9, which complements its proposed action under WT 
conditions as decreased DUSP9 may contribute towards impairments in glucose 
homeostasis. However, we might have expected an increase in expression in the Nrf2
-/-
 
mice fed a HF diet given their phenotype. This suggests that DUSP9 may not be 
causative in the improved insulin signalling seen in the Nrf2
-/-
 mice although further 
work will need to be undertaken on key peripheral tissues such as the liver to confirm 
this. To summarise, therefore, this indicates that Nrf2
-/-
 mice have constitutively 
increased activation of the MAPK pathway, as demonstrated by increased MEK 
phosphorylation, which when fed a HF diet is combined with a diet dependent decrease 
in DUSP expression. This contrasts with WT mice which undergo a diet dependent 
decrease in DUSPs but also have decreased MEK phosphorylation following HF 
feeding.  
3.14.6 Mitochondrial Impairment Following Loss of Nrf2 
Mitochondria are the powerhouses of the cell; however, as such they are also 
known to naturally release ROS making them more vulnerable to alterations in the 
antioxidant capacity of the cell. It has previously been shown that Nrf2 activation can 
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attenuate mitochondrial impairment in vitro (Miller et al., 2013), whilst there have been 
links suggested between Nrf2 loss, mitochondrial impairment and AD (Greco & 
Fiskum, 2010). When we assessed the effect of Nrf2 loss on mitochondrial health we 
found no basal alteration in either the channel protein VDAC1 or the COX IV protein 
from the electron transport chain. However, both of these were diminished following 
HF feeding, with Nrf2
-/-
 mice showing further impairment when compared to WT mice 
in the cortex but not the hippocampus where HF feeding has less impact than in the WT 
cohort. WAT from insulin resistant and HF fed rodents had previously been shown to 
contain decreased levels of mitochondrial proteins, such as COX IV (Valerio et al., 
2006; Sutherland et al., 2008). In contrast, AD has been linked with increasing levels of 
VDAC1 in the brain further to which it has been suggested that Aβ and tau may both 
interact with VDAC1, potentially blocking the mitochondrial pores and driving the rise 
in VDAC1 expression (Manczak & Reddy, 2012). Furthermore, through its regulation 
of calcium, VDAC1 is able to regulate the TCA cycle and subsequent ROS production. 
Given the lack of Aβ build-up in our model and a potentially attenuating effect from HF 
feeding, the additional impairment seen in Nrf2
-/-
 mice may be as a result of increased 
ROS production. A slew of recent research in the field of Nrf2 further supports an 
important interaction of the Nrf2 pathway with mitochondrial health and protection 
(Dinkova-Kostova & Abramov, 2015; Itoh et al., 2015). 
Further to these changes, when key fusion proteins mitofusin 1 and 2 were 
analysed diet dependent increases were seen in the hippocampus of both WT and Nrf2
-/-
 
mice. However in the cortex Nrf2
-/-
 mice have depleted mitofusin 2 expression, which is 
recovered following HF feeding. Decreased expression of mitofusin proteins has been 
associated with increased targeting of mitochondria for degradation via mitophagy 
(Pallanck, 2013). It will be important to pursue this further by assessing key fission 
proteins, as it is the disconnect between mitochondrial fission and fusion which can 
prove key in mitochondrial dysfunction. Furthermore, the surge in research supporting 
an important role for Nrf2 in mitochondria has also highlighted other organelles prone 
to targeting by ROS such as the ER. This is maybe even more important in the context 
of our research given the importance of the ER in lipid metabolism and its increased 
dysfunction in mice lacking Nrf2, but also its influential role in amyloid processing 
(Pinho et al., 2014). 
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3.14.7 Conclusions 
We have presented here a novel mouse model designed from the outset to try 
and model an early disease environment of AD. This was done by combining the loss of 
ROS regulating transcription factor Nrf2, which is known to decrease with ageing, with 
a mild model of FAD containing hAPPswe mutation under the mouse APP promoter. 
Although we found some small changes in cognition, the main effects observed through 
our research indicated a dominant role for the loss of Nrf2 in defining the responses 
observed through the double transgenic model. Of interest in the double transgenic 
model, clear changes in glial cell responses were observed and it would be interesting to 
pursue this further given the roles suggested for gliosis in AD. Indeed, as demonstrated 
by Joshi et al. (2015), use of a more aggressive AD mouse model may help to elucidate 
the mechanism occurring behind these changes and help in understanding the 
interaction occurring between Nrf2 and the amyloidogenic pathway. In addition, with 
the mild phenotype of the hAPPswe model used and the protective effect HF feeding was 
found to have in the brains of Nrf2
-/-
 mouse brains, our model failed to show the 
aggravated inflammatory profile that had initially been hypothesized. In light of this, 
challenging these mice along with the single transgenic Nrf2
-/-
 mice with a calorie 
deficient diet as opposed to a diet containing a calorie surplus may be of even greater 
interest. This may be even more relevant now, in view of the recent controversial Lancet 
publication by Quizilbash et al. (2015) suggesting that the lower a person’s BMI, the 
greater their risk of developing dementia. 
In an attempt to understand the effects of HF feeding on the mouse brain 
following loss of Nrf2, we followed up with further work on this single transgenic 
model. We were able to show that despite long-term HF feeding, Nrf2
-/-
 mice maintain a 
degree of insulin sensitivity and further we hypothesize this may play a role in the 
protective effects seen in mice fed a HF diet as demonstrated by dampening of 
inflammatory markers. Furthermore, these mice displayed altered activity when 
examined at a young age which slowly diminished over time, advocating further 
investigation into Nrf2 loss in an aged mouse model. With no increase in amyloid 
pathology but changes in tau phosphorylation, research may be better focussed on the 
role played by attenuated Nrf2 expression on the development of dysfunctional tau 
aggregates. The increased presence of ROS, and as we have shown here, altered 
mitochondrial function may play a role in the induction of disturbed tau processing. 
Whilst it will be important to also assess whether there are alterations in ER stress given 
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the links previously reported between amyloid, ER stress and mitochondrial 
dysfunction. 
Finally, we described important alterations in the regulation of MAPK pathways 
in Nrf2
-/-
 mice (see Figure 3.28 for simplified pictorial summary). These were further 
affected by HF feeding, and given the ability of insulin as well as ROS to interact with 
the MAPK cascade it would be interesting to pursue this further. MAPK proteins have 
previously been reported to have both pro- and anti- inflammatory effects. Given the 
context in which the changes described here are occurring it is possible that maintained 
MAPK, and more specifically ERK activation, is playing a role in inflammatory 
resolution and tissue protection. It has previously been shown that proteins such as 
Ghrelin, the so-called ‘hunger hormone’, activate the ERK signalling pathway resulting 
in protection of cells such as oligodendrocytes within the CNS (Lee et al., 2011). 
Furthermore, ERK has also been reported to promote hippocampal neuron survival in a 
model of excitotoxicity, which itself has been linked with AD and other 
neurodegenerative diseases such as PD (Ortuño-Sahagún et al., 2014). The attenuated 
weight gain in Nrf2
-/-
 mice would also support a role for this type of signalling pathway. 
A key step in clarifying what may be occurring in the brain would be to assess the 
MAPK pathways within the liver, which is known to be highly affected by HF feeding. 
If the changes presented here are limited to tissues that appear protected by HF feeding 
in Nrf2
-/-
 mice it may advocate a role for this pathway in the differential treatment of 
tissues lacking Nrf2 following HF feeding. 
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Figure 3.28 Simplified pictorial summary of some of the main long-term HF diet-
driven alterations described in the brains of WT (A) and Nrf2
-/-
 (B) mice 
Where FA = fatty acids, oxLDL = oxidised low-density lipoprotein, Mt = mitochondria and Pi = 
phosphate. 
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4 THE ROLE OF NRF2 IN 
INFECTION-INDUCED 
INFLAMMATION 
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4.1 INTRODUCTION 
AD, like many neurodegenerative disorders, is a complex combination of 
elements, only a small percentage of which are currently known to be linked directly 
with genetic risk factors. A role for neuroinflammation, not only in AD but also in other 
neurodegenerative diseases, such as PD and ALS to name but a few, has grown in 
popularity over the last decade (Miklossy et al., 2006; DeLegge & Smoke, 2008; Dibaj 
et al., 2011; Ferretti et al., 2012). The origins of this inflammation, however, are 
unclear; as is its place in the disease development timeline. It has been suggested that it 
may form part of the earlier stages of neurodegenerative development, but no 
conclusive results have yet been able to tie down its role as being causative or 
consequential. Inflammation is a key component of the pathological lesions associated 
with AD and these lesions are often associated with conglomerations of reactive 
astrocyte and microglial cells. Acutely, activation of the immune system and the 
initiation of an inflammatory related response in early AD are likely to be of a 
beneficial nature.  
The role of immunological activation is two-fold; to remove cellular debris and 
necrotised tissue, and to tackle the causative elements behind the damage. This is 
supported by the ability of protective cells activated by an immune response, such as 
microglia and astrocytes, to degrade and clear proteins whose dysregulation is 
associated with AD pathology, such as amyloid (Weldon et al., 1998; Wyss-Coray et 
al., 2003; Shimizu et al., 2008; Nielsen et al., 2010; Farfara et al., 2011; Pihlaja et al., 
2011). However, long-term chronic inflammation is thought to be the dark side of the 
inflammatory response. Development of chronic inflammation, such as occurs in 
obesity, as a result of increased markers of infection (e.g. LPS) or as a natural 
development of ageing, is believed to provide a priming environment for AD 
development and exacerbate disease progression (Blasko et al., 2000; Mehlhorn et al., 
2000; Blasko et al., 2004; Sokolova et al., 2009; Fuller et al., 2010). Scientists have 
also postulated that the chronic neuroinflammation found associated with 
neurodegeneration may be factorial in the development of synaptic dysfunction and 
subsequent cell degeneration (Hauss-Wegrzyniak et al., 2002). Certainly, synaptic 
dysfunction or loss has shown a high degree of correlation, accurately matching 
symptomatological disease progression (Shankar & Walsh, 2009). In addition, targeting 
of immune markers has shown improvement in other associated pathologies of AD such 
as Aβ build up and tau phosphorylation (Kitazawa et al., 2011). 
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Greater understanding of the functions undertaken by cells such as astrocytes 
and microglia, and how this is altered in relation to ageing, has raised their profile with 
regards to a potential role for their dysfunction in disease. It has been suggested that 
microglia, in their role as brain resident macrophages, may undergo a so called 
‘priming’ process. A degree of cell priming is believed to occur as a direct result of 
ageing. This is supported by age related alterations in response to cellular insults, but it 
may be further enhanced by other stimuli such as chronic inflammation described 
previously (Tateda et al., 1996; Kohman et al., 2007; Cunningham et al., 2009; Murray 
et al., 2012). Largely considered to be pro-inflammatory in basis, priming is not thought 
to have a significant impact on the basal release of signalling molecules from cells. 
Cells would therefore appear indistinguishable from non-primed cells under basal 
conditions. However, upon reaction to insult the response initiated by primed microglia 
is in acute excess of their non-primed counterparts, inducing an exponential increase in 
inflammatory response (Cunningham et al., 2005; Cunningham et al., 2009; Henry et 
al., 2009; Wynne et al., 2009). This could make even minor central challenges into 
largescale inflammatory events, which long-term could contribute to the accumulation 
of toxic species and malformed proteins, as well as negatively impacting the clearance 
mechanisms normally put in place to deal with these events. 
LPS, normally found on the outer membrane of gram-negative bacteria, has 
previously been used acutely in the exploration of sepsis, but also in the manipulation of 
macrophage responses, including microglia. LPS is frequently used in vitro in the 
induction of macrophage maturation from a basal M0 state to an M1 pro-inflammatory 
phenotype and an increased LPS presence has been associated with increased obesity 
and development of metabolic disorders as was alluded to previously (Cani et al., 2007; 
de La Serre et al., 2010). The role of systemic infection, and in particular LPS, with 
regards to obesity has evolved over recent years beyond a simple correlation between 
levels of LPS and weight gain. Indeed, some recent research has suggested a role for 
LPS in altering insulin signalling and more specifically the development and 
maintenance of insulin resistance. Animal studies performed by Fei and Zhao (2013) 
have demonstrated that treatment of germfree mice with bacteria from obese individuals 
can lead to the development of obesity and insulin resistance. Whilst low grade 
endotoxemia has been associated with the development of obesity and insulin resistance 
along with alterations in gut permeability, in particular to lipid soluble molecules such 
as LPS (Cani et al., 2007; de La Serre et al., 2010). Furthermore, exercise has been 
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shown to reduce both circulating LPS and activation of its immune receptor TLR4 in 
DIO rats, whilst concomitantly improving insulin signalling (Oliveira et al., 2011). 
Diseases such as obesity, TIID and metabolic syndrome have long been 
associated with an increased risk of AD development in old age. Taken alongside the 
described link between increased systemic infection and development of these disorders 
including recent studies on clinical cohorts (Lassenius et al., 2011; Pussinen et al., 
2011); a logical progression was to investigate the potential role of infection in age-
related alterations and neurodegenerative conditions. Indeed, it has been previously 
described that an increased prevalence of systemic infection is found in the elderly, 
which is further compounded in patients presenting with neurodegenerative conditions 
(Holmes et al., 2003; Roubaud-Baudron et al., 2012). Research performed using animal 
models has implicated chronic inflammation and systemic infection as potentially 
important players in the development of AD (Sly et al., 2001; Sy et al., 2011; Krstic et 
al., 2012). Systemic infections, even under short-term conditions, have been shown to 
exacerbate AD related symptoms including negatively impacting cognition (Erickson et 
al., 2012; Zhang et al., 2013).Furthermore, the apparent protective effect of long term 
treatment of other inflammatory diseases such as rheumatoid arthritis have prompted 
investigations into the use of anti-inflammatory agents for the treatment of AD (McGeer 
et al., 1996). 
Nrf2 is known to play an important role in clearing ROS and preventing a build-
up of related cellular damage through activation of the ARE. Subsequent to this role, 
Nrf2 can also be induced following activation of the immune system and induction of 
its plethora of signalling molecules. Research has demonstrated a protective role for 
Nrf2 in vitro in the suppression of inflammation-related damage such as is induced 
through infectious agents like LPS (Wang et al., 2010; Khodagholi & Tusi, 2011; Koh 
et al., 2011). Furthermore, studies using a rodent model of uveitis have shown that 
activation of the Nrf2 pathway can reduce the inflammatory response with an altered 
immune response profile observed in Nrf2
-/-
 transgenic mice (Nagai et al., 2009). 
Finally, Innamorato and colleagues (2008) demonstrated a role for Nrf2 as a potential 
therapeutic target against brain inflammation. Using an LPS driven acute inflammatory 
model and Nrf2
-/-
 transgenic mice, they showed that Nrf2
-/-
 mice had an increased 
susceptibility to LPS-driven inflammation. Activation of Nrf2 with sulforaphane, which 
has been shown to cross the BBB, was able to effectively counteract the ROS changes 
induced by LPS. 
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In light of the links suggested between AD and systemic infection, such as 
through LPS, it was decided to further investigate the impact of short-term chronic 
infection on an antioxidant compromised background. This study was put in place to try 
and tease out links that may be present between a pro-oxidant environment and systemic 
inflammation with regards to changes within the brain. However, LPS itself when 
injected peripherally does not cross the BBB unless impairment of said barrier has 
occurred. Instead, researchers have suggested that it may exert central immune effects 
via alternative indirect mechanisms (Banks & Robinson, 2010; Mallard, 2012). In light 
of this, the decision was made to administer LPS through IP injection to maintain a 
more physiological mechanistic response than would occur through direct ICV 
injection. Following on from repeated IP LPS injections, behavioural tasks were 
performed to assess any alterations in cognitive ability. Key factors related to the 
immune response and AD were also assessed through gene and protein expression in the 
brain regions most commonly associated with AD, namely the hippocampus and the 
cortex. 
In an attempt to model some of the many facets of AD, a variety of different 
behavioural tasks have been designed over the decades. Each task attempts to replicate a 
cognitive facet of AD, which can include examples such as recognition, working and 
episodic memory. Commonly used behavioural tasks in the study of AD include those 
such as the Morris water maze (MWM), Barnes maze, T-maze/Y-Maze alternation, 
NOR and fear conditioning tasks (Puzzo et al., 2014; Webster et al., 2014). The type of 
learning and memory being assessed will also dictate the brain region required for 
correct encoding of the task in use. Models, such as NOR in its most basic form, rely on 
recognition memory which is now believed to require correct functioning of the 
perirhinal cortex and dentate gyrus with less importance placed on a role for the 
hippocampus (Langston et al., 2010; Aggleton et al., 2012; Olarte-Sanchez et al., 2014). 
In contrast, tasks such as the frequently reported Morris water maze and radial arm 
maze, both of which are more complex in nature, rely on a combination of working and 
reference memory. Moreover, episodic memory, which is one of the first forms of 
memory to be affected in AD, is one of the less explored in the context of rodent models 
of AD. Episodic memory is also one of the more challenging types of memory to model 
due to its complexity. However, variations on the NOR task, often referred to as the 
what-where-which model, use the integration of contextual and spatial location 
information alongside recognition memory (Eacott & Easton, 2010).  
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The main aim of this study was to assess the effects of a short-term repeated 
systemic low dose LPS exposure on the brains of mice with an inflammatory and OS 
primed brain environment in the presence or absence of a pro-amyloidogenic human 
mutation. The main hypotheses based on the information available at the 
commencement of this study were as follows: 
1) Repeated peripheral administration of LPS to mice will result in an 
aggravated inflammatory state within the central tissue, similar to that seen 
in previous studies. This will be further aggravated by the loss of Nrf2 and 
the use of aged adult animals which will impact on the ability of the immune 
system to respond, mimicking the increased vulnerability of AD patients to 
infection. 
2) Loss of Nrf2 when targeted with a commonly used marker and inducer of 
infection leading to systemic inflammation will negatively impact on 
cognition. 
3) Loss of Nrf2 when combined with a pro-amyloidogenic APP mutation 
(hAPPswe) and under the increased inflammatory conditions induced by 
repeated peripheral LPS will accelerate the development of amyloid related 
pathology such as has previously been described in other models of AD. 
In order to try and confirm or disprove these hypotheses, mice from the 
previously described genotypes (WT, Nrf2
-/-
, Nrf2
-/-
/hAPPswe) were used. The main 
output measures for this study were an assessment of cognitive competence through the 
use of three different cognitive tasks, namely the entorhinal cortex-dependent OL task, 
the perirhinal cortex-dependent NOR task, and the continuous non-cued elevated plus 
maze model of SA. This was combined with an evaluation of AD related pathology 
advancement through protein and RNA assessment of specific AD-related proteins, and 
an evaluation of the central inflammatory and OS levels through the measurement of 
commonly associated cytokines, proteins and support cells at either an RNA or protein 
level. 
In order to achieve this, adult mice (± 1 year) fed a RC diet were handled daily 
for a minimum of two weeks prior to being randomly allocated to either the vehicle or 
LPS group (see Chapter 2.3.2 for full group numbers and gender breakdown). Mice 
were weighed daily in the week prior to and the week of the study, with animals given 
access to softened food once the course of injections were started. Mice were injected 
daily starting on day 0 between the hours of 9 and 10 in the morning, for seven days 
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(see Chapter 2.3.2.1). On days 0-2 no additional activities were done with the mice, and 
these were left to recover. On day 3, mice were habituated to the box environment 
required for both the OL and NOR tasks, first in their cage groups then individually (see 
Chapter 2.3.2.2.1). On day 4, mice were again habituated to the box environment 
individually, with day 5 allocated for the behavioural assessment of OL (see Chapter 
2.3.2.2.2). On day 6 mice underwent NOR assessment (see Chapter 0), with assessment 
of SA happening on the morning of day 7 (see Chapter 2.3.2.2.4) followed by 
termination and tissue harvest and processing for biochemistry (see Chapters 2.4.1.1, 
2.4.2-2.4.6). For a pictorial representation of the study plan please refer to Figure 2.4, 
chapter 2.3.2. It is important to note that as a result of the genotyping problems that 
occurred (see Chapter 2.2.5.2), a limited number of mice within the required age bracket 
were available from the Nrf2
-/-
/hAPPswe genotype. As a result, these were deemed too 
small to include in the behaviour analysis as the small number available may not 
accurately represent the phenotype, whilst also preventing an even gender allocation. 
The limited number of animals within the two Nrf2
-/-
/hAPPswe groups means any 
biochemical output should also be interpreted with a degree of caution especially where 
there is a high degree of variance between animals. 
4.2 REPEATED IP LPS INDUCES WEIGHT LOSS IN AGED ADULT MICE  
Prior publications have shown that administration of LPS in rodents can have an 
age dependent effect with older animals proving more susceptible to infection (Tateda et 
al., 1996; Kohman et al., 2007; Tarr et al., 2011). Aged adult mice (1 year) were used 
for the purposes of this study in order to better mimic the effects of inflammatory 
interferences, such as LPS, on an ageing environment. Mice were administered a daily 
set dose and volume of LPS (2.5 μg in saline) or an equivalent volume of saline vehicle. 
Research has previously shown an effect of LPS on weight maintenance and mobility, 
with animals displaying sickness behaviour following acute injection (Bluthé et al., 
1999; O'Connor et al., 2008; Bay-Richter et al., 2011). Given the often acute nature of 
these symptoms, mice were injected daily for seven days and behavioural testing was 
not performed until day five to bypass the acute sickness and weight loss response. In 
order to assess the severity of the effect of LPS on the different transgenic mouse lines, 
weight was recorded daily. 
No significant difference was seen in overall weight at the commencement of the 
study, either between genotypes (p > 0.05; Figure 4.1 A) or between treatment groups (p 
> 0.05; Figure 4.1 B). However, when measuring weight change over the duration of the 
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study, a main overall effect of LPS treatment was observed for all groups, with LPS 
inducing weight loss (WT saline vs WT LPS p < 0.001, Nrf2
-/-
 saline vs Nrf2
-/-
 LPS p < 
0.001, Nrf2
-/-
/hAPPswe saline vs Nrf2
-/-
/hAPPswe LPS p < 0.05; n = 3-14; Figure 4.1 C, D 
and E respectively). This effect was observed as early as 24h post initial IP LPS 
injection. In contrast, there was no main effect of genotype on the rate of weight loss 
over time in response to LPS injection. By day three, all LPS-treated mice were 
showing indications of weight gain and/or weight stabilisation, demonstrating the 
presence of an initial acute phase response to IP LPS at the dosage used. As a result, all 
behavioural testing was performed in the later phase of the study to minimise the effect 
of this acute response on the ability of mice to complete the tasks required.  
4.3 KNOCKING OUT NRF2 IMPAIRS SHORT TERM SPATIAL LOCATION 
MEMORY IN MICE AS SHOWN BY OBJECT LOCATION 
Total time spent exploring during the sampling phase was measured for three 
main reasons: 1) to exclude animals that spent insufficient time exploring the objects as 
these animals may therefore still consider the ‘known object’ as novel in the test phase, 
2) to investigate whether there was a genotype-dependent effect on exploration, and 3) 
to assess whether LPS treatment was negatively impacting overall mobility and 
therefore biasing the cognitive outputs garnered from the behavioural tests. In addition, 
any preferences in box location (i.e. left or right) could also be assessed, although box 
side preferences are controlled for by alternating the placement of the novel object 
during the test phase as detailed previously (see Chapter 2.3.2.2.2). 
No significant effect of genotype or treatment was observed on total exploration 
time during the sample phase (p > 0.05; Figure 4.2 A). Ensuring mice are exploring 
objects to a similar degree lends confidence to the results obtained during the test phase 
as differential sample exploration could skew the novelty appreciation of the mouse 
undergoing the test. In order to investigate any effect of object bias, preference indices 
(PI1 and PI2) were calculated using the equation described in Figure 4.2 B. There was 
no significant change in exploration between objects (p > 0.05; Figure 4.2 C and D (PI1 
and PI2 respectively)). Nevertheless, the localisation and choice of the novel object 
during the subsequent test phase was routinely alternated to further reduce the potential 
for any introduced bias in the test phase of the task. Finally, there was no significant 
difference in total body weight between groups on the day of behavioural testing (p > 
0.05; Figure 4.2 E).  
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Figure 4.1 Repeated IP LPS induces acute weight loss in aged adult mice 
irrespective of genotype. 
Age matched adult mice from WT, Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice were handled for 2 weeks 
prior to commencing the study. Mice were given 2.5 μg of LPS IP daily for 7 days or a saline 
vehicle equivalent. Mice were weighed daily from 5 days prior to the initial injection. Net body 
weight displayed by genotype (A) or treatment (B) is described for day -5. Subsequent graphs 
depict weight change after treatment for each of the three genotype groups, namely WT (C), 
Nrf2
-/-
 (D) and Nrf2
-/-
/hAPPswe (E). All results depicted as means ± s.e.m. Data analysed by 
ANOVA, Student’s t-test or repeated measures ANOVA as appropriate with * p < 0.05, *** p < 
0.001. WT n = 11-14; Nrf2
-/-
 n = 12-13; Nrf2
-/-
/hAPPswe n = 3-4.  
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Total exploration time was measured during the test phase to ascertain whether 
the introduction of novelty to the paradigm affected each cohort’s tendency for 
exploration. Exploration of objects during the test phase was comparable to that seen 
during the sample phase, with no significant differences seen between groups in object 
exploration (p > 0.05; Figure 4.3 A).  
Two of the main measurements reported for the analysis of both the OL and 
NOR task are the discrimination (D3) and recognition indices (RI). The D3 allows for 
discrimination between the novel and familiar objects in use (see Figure 4.3 C for 
equation). Values for the D3 are expressed between 1 and -1; values closer to one 
indicate increased exploration of novelty whereas values closer to -1 indicate an 
increased exploration of the familiar. The RI is thought to be the main index of retention 
(Antunes & Biala, 2012) and is usually reported as a percentage; the higher the 
percentage the greater the exploration of the novel object (see Figure 4.3 E for 
equation). As these indices can provide slightly different interpretations of the data, 
both were reported for the purposes of these studies. 
After 10 min, a main effect of treatment is observed on D3 (F1, 43 = 18.298, p < 
0.0001, n = 11-12; Figure 4.3 B) and RI (F1, 43 = 18.314, p < 0.0001, n = 11-12; Figure 
4.3 D) scores, with LPS impairing the ability of mice to perform the task. A main effect 
of genotype is also observed that borders on significant for both the D3 (F1, 43 = 4.074, p 
= 0.05, n = 11-12) and RI (F1, 43 = 4.085, p = 0.05, n = 11-12) results. However, both of 
these main effects are superseded by the significant interaction observed between 
genotype*treatment for both D3 (F1, 43 = 5.162, p < 0.05, n = 11-12) and RI (F1, 43 = 
5.181, p < 0.05, n = 11-12) indices. Further analysis, using simple main effects, shows 
that loss of Nrf2 alone significantly impairs the ability of mice to perform the task when 
compared to saline-injected WT mice as measured by both D3 (WT saline: 0.214 A.U. 
± 0.03; Nrf2
-/-
 saline: 0.050 A.U. ± 0.04; WT saline vs Nrf2
-/-
 Saline p < 0.01, n = 11-
12) and RI  (WT saline: 60.70 % ± 1.4; Nrf2
-/-
 saline: 52.52 % ± 1.7; WT saline vs Nrf2
-
/-
 saline p < 0.01, n = 11-12) indices. No significant further decrease in competency is 
seen in Nrf2
-/-
 mice following repeated LPS administration. 
  
175 
 
 
Figure 4.2 Neither genotype nor treatment affect exploration or object preference 
during the sample phase of the OL task. 
Age-matched adult mice were handled for two weeks prior to the starting the study. Mice were 
given daily IP injections of either 2.5 μg LPS or equivalent volume of saline for seven days. On 
day 5 post initial injection, mice were put through a short term OL task. Measures taken during 
the sample phase included total exploration time (A), preference indices for objects (C + D) 
calculated using the equation described in (B) and body weight on day of behaviour (E). All 
data is presented as means ± s.e.m. and analysed by ANOVA or MANOVA as appropriate. 
(WT: n = 8-12; Nrf2
-/-
: n = 9-12, Nrf2
-/-
/hAPPswe: n = 3). Due to low mouse numbers Nrf2
-/-
/hAPPswe mice were not included in behaviour statistical analysis. 
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Figure 4.3 Both repeated LPS administration and loss of Nrf2 inhibit the ability of 
mice to perform a short term OL task. 
Adult mice previously habituated to the behaviour environment were given daily IP injections 
of either 2.5 μg LPS or equivalent volume of saline for seven days. On day 5 post initial 
injection, mice were put through a short term OL task (10 min holding time). Measures taken 
during the test phase included total object exploration time (A), Discrimination indices (B) 
calculated using the equation described in (C) and Recognition indices (D) calculated using the 
equation described in (E). All data is presented as means ± s.e.m. and analysed by ANOVA or 
MANOVA as appropriate. When positive interaction effects were reported, these replaced main 
effects on graphical representations of data, and were followed up through analysis of simple 
main effects with post-hoc Bonferroni. # denotes a treatment*genotype interaction effect, # p < 
0.05. (WT: n = 11-12; Nrf2
-/-
: n = 12, Nrf2
-/-
/hAPPswe: n = 3). Due to low mouse numbers Nrf2
-/-
/hAPPswe mice were not included in behaviour statistical analysis.  
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4.4 LOW DOSE IP LPS SIGNIFICANTLY IMPAIRS THE ABILITY OF MICE 
TO PERFORM SHORT TERM NOVEL OBJECT RECOGNITION 
No significant effect of genotype or treatment was observed on total exploration 
time during the sample phase (p > 0.05; Figure 4.4 A). In order to investigate any effect 
of object localisation, bias preference indices (PI1 and PI2) were calculated. A small but 
significant main effect of treatment was observed on PI (F1, 41 = 4.225; p < 0.05, n = 11-
12). A mild preference for objects placed in the top right corner of the box following 
LPS treatment was observed as shown by the left (Figure 4.4 B) and right (Figure 4.4 C) 
PI results. To counteract this localisation effect, routine alternation of the localisation of 
the novel object during the subsequent test phase was performed across groups. As for 
the OL task, mice were weighed on the day of behaviour. No significant change in body 
weight was observed between groups (p > 0.05; Figure 4.4 D). 
During the test phase, total exploration time was again measured with no 
significant change in exploration observed between groups (p > 0.05; Figure 4.5 A). 
NOR evaluation is commonly assessed using the same tools as for the previously 
described OL task. As a result, both D3 and RI indices were calculated for the short-
term NOR task. When analysed, a main effect of treatment is seen for both the D3 (F1, 44 
= 8.672, p < 0.01, n = 11-13; Figure 4.5 B) and RI (F1, 44 = 8.697, p < 0.01, n = 11-13; 
Figure 4.5 C) indices. Following LPS treatment, the ability of WT and Nrf2
-/-
 mice to 
perform the NOR task is inhibited in a treatment-dependent manner. There was no main 
effect of genotype observed on either measurement index (p > 0.05), nor was there a 
significant interaction between genotype*treatment as was seen in the OL task. This 
indicates that contrary to the OL task, loss of Nrf2 does not have an impact on adult 
rodents’ ability to recognise the presence of novel objects. LPS treatment, however, 
significantly impairs the ability of all mice to perform the proposed task. This 
impairment is not derived from a reduced mobility due to treatment-related sickness, 
corroborated by the lack of difference in time spent exploring. 
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Figure 4.4 Neither genotype nor treatment affect exploration or object location 
preference during the sample phase of the NOR task. 
Age-matched adult mice were handled for two weeks prior to the starting the study, where they 
were administered daily IP injections of either 2.5 μg LPS or equivalent volume of saline for 
seven days. On day 6 post initial injection, mice were put through a short term NOR task. 
Measures taken during the sample phase included total exploration time (A), preference indices 
for object location (B + C) and body weight on day of behaviour (D). All data are presented as 
means ± s.e.m. and analysed by ANOVA or MANOVA as appropriate. (WT: n = 11-12; Nrf2
-/-
: 
n = 11, Nrf2
-/-
/hAPPswe: n = 3). Due to low mouse numbers Nrf2
-/-
/hAPPswe mice were not 
included in behaviour statistical analysis.  
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Figure 4.5 Repeated IP LPS in adult mice impedes their ability to perform a short 
term NOR task. 
Adult mice previously habituated to the behaviour environment, were given daily IP injections 
of either 2.5 μg LPS or saline for seven days. On day 6 post first injection, mice were put 
through a short term NOR task (10 min holding time). Measures taken during the test phase 
included total object exploration time (A), Discrimination indices (B) and Recognition indices 
(C). All data are presented as means ± s.e.m. and analysed by ANOVA or MANOVA as 
appropriate. * denotes a significant main effect, ** p < 0.01. (WT: n = 11-13; Nrf2
-/-
: n = 11-13, 
Nrf2
-/-
/hAPPswe: n = 3). Due to low mouse numbers Nrf2
-/-
/hAPPswe mice were not included in 
behaviour analysis.  
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4.5 LOW DOSE IP LPS DOES NOT AFFECT THE ABILITY OF MICE TO 
SPONTANEOUSLY ALTERNATE 
Finally, to further assess the effect of LPS-induced inflammation on spatial 
working memory, mice were placed in a closed arm elevated plus maze for a period of 
10 min. Measurements were recorded for total number of arm entries and alternations 
performed, where an alternation is described as entry into all four arms within any 
rotation of five consecutive arm entries (McNay et al., 2000). The total number of 
possible alternations is therefore the total number of arm entries minus four. The data 
acquired from these measures was used to calculate the percentage SA (Figure 4.6 D). 
There was no significant difference in the number of arm entries performed between 
WT and Nrf2
-/-
 mice, nor was there a difference between treatment groups (Figure 4.6 
A). From this, it is also possible to show that there is no change in locomotor ability as 
assessed by the number of arm entries performed. In line with these results, no 
significant effect of either genotype or treatment was observed on the total number of 
alternations performed (Figure 4.6 B). Furthermore, once analysed, the %SA obtained 
did not vary significantly between groups (Figure 4.6 E) indicating that neither loss of 
Nrf2
-/-
 nor repeated peripheral LPS treatment inhibit the ability of mice to spontaneously 
alternate at the age tested. 
4.6 LOW DOSE REPEATED IP LPS INDUCES A PERIPHERAL 
INFLAMMATORY STATE 
In order to confirm that peripheral inflammation was induced at the dosage of 
LPS used (2.5 μg/mouse), terminal tissue weights were recorded. More specifically the 
weights for key organs related to both the metabolism of toxins (liver) and 
inflammatory status (spleen) as well as the heart; which is thought to be affected by 
both oxidative stress and shifts in metabolism, were recorded (Purushothaman et al., 
2011). Values were analysed both as raw tissue weight and as a percentage of total 
bodyweight to ensure the effects seen were not solely due to the drop in body weight as 
a result of LPS treatment. Data obtained from the tissue harvest showed no significant 
changes in heart weight (p > 0.05; Figure 4.7 A) or heart weight as a percentage of total 
body mass (p > 0.05; Figure 4.7 D).  
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Figure 4.6 Neither repeated LPS administration nor loss of Nrf2 prevent mice 
spontaneously alternating in a closed arm elevated plus maze. 
Adult mice previously habituated to the behaviour environment were given daily IP injections 
of either 2.5 μg LPS or equivalent volume of saline for seven days. On day 7 post initial 
injection, mice were placed in a closed arm elevated plus maze. The number of arm entries (A) 
and alternations (B) performed were recorded and used to calculate the percentage spontaneous 
alternation for each mouse (C) using the calculation delineated in (D). Finally, total body 
weight was also measured (E). All data is presented as means ± s.e.m. and analysed by ANOVA 
or MANOVA as appropriate. (WT: n = 11-14; Nrf2
-/-
: n = 11-12, Nrf2
-/-
/hAPPswe: n = 3). Due to 
low numbers Nrf2
-/-
/hAPPswe mice were not included in behaviour analysis. 
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A significant main effect of LPS was seen on total liver weight (F1, 49 = 8.870, p 
< 0.01, n = 3-13), with administration of repeated LPS IP increasing raw liver tissue 
weight across genotypes. When total body weight was accounted for, a main effect of 
treatment remained for the measurement of liver as % total weight (F1, 49 = 16.39, p < 
0.001, n = 3-13; Figure 4.7 E). However, a main effect of genotype is also reported with 
saline-treated Nrf2
-/-
/hAPPswe having significantly smaller livers in comparison to the 
WT control group (F2, 49 = 4.510, p < 0.05, n = 3-13).  
A clear change of total spleen weight is observed as a result of LPS treatment 
(F1, 50 = 98.46, p < 0.0001, n = 3-14; Figure 4.7 C), all the more notable due to the lack 
of variation observed under control conditions. It is generally understood that there is 
little variation in the ratio of splenic to body weight regardless of age, making changes 
in this ratio a robust measure of the induction of peripheral inflammation (Cesta, 2006). 
No main effect of genotype on spleen weight is observed (p > 0.05). When expressed as 
a percentage of total body weight, spleens display a similar profile to that seen for the 
raw weight, with no effect of genotype but a significant main effect of treatment 
recorded (F1, 50 = 62.93, p < 0.0001, n = 3-14; Figure 4.7 F).  
Finally, confirming the weight changes seen over time reported in Figure 4.1, a 
significant main effect of treatment is seen on the weight change recorded on the final 
day of the study (F1, 51 = 28.89, p < 0.0001, n = 3-14; Figure 4.7 G). Repeated IP LPS at 
the dosage used causes a significant drop in body weight when compared to the 
commencement of the study. No effect of genotype is noted when comparing weight 
change (p > 0.05), nor is there an interaction effect between treatment and genotype. 
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Figure 4.7 Repeated administrations of IP LPS induce changes in both liver and 
spleen tissues irrespective of genotype. 
Tissue was harvested from adult (± 11 months) saline or LPS treated WT, Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice. Organ weights were obtained for hearts (A) after clearing of any remaining 
blood, livers (B) and spleens (C) to investigate genotype-related effects on peripheral tissue 
health. Organ weight was assessed in relation to total body weight on day of harvest in order to 
clarify any treatment-related changes resulting from changes in body weight. These are reported 
as percentage body weight for the heart (D), liver (E) and spleen (F). To assess the effect of 
repeated LPS on total body weight, the weight change on the final day of the study is also 
reported (G; WT n = 11-14, Nrf2
-/-
 n = 12-13, Nrf2
-/-
/hAPPswe n = 3-4). Data is presented as 
means ± s.e.m. and analysed using two-way ANOVA with genotype and treatment as 
designated factors, post-hoc Bonferroni performed as necessary. * indicates significant main 
effect of individual factor (*, p < 0.05; ***, p < 0.001).  
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4.7 PERIPHERAL IP LPS DRIVES A MILD INCREASE IN INFLAMMATORY 
STATE IN THE BRAINS OF ADULT MICE 
To assess any central inflammation occurring following repeated peripheral LPS 
insult, a panel of commonly assessed cytokines and related markers were evaluated by 
RT-qPCR for gene expression. Snap frozen tissue from both the hippocampus and the 
cortex of saline and LPS-treated mice was assessed following seven days of IP 
injections. A significant effect of treatment is seen in WT mice with LPS increasing IL-
1β in the hippocampus (WT saline: 1.00; WT LPS: 2.15 ± 0.31; WT saline vs WT LPS 
p < 0.01, n = 8-9; Figure 4.8 A). Nrf2
-/-
 mice show an effect of genotype with increased 
basal levels of IL-1β in the hippocampus compared to WT controls, with a further 
increase observed following LPS treatment (Nrf2
-/-
 saline: 2.13 ± 0.46; Nrf2
-/-
 LPS: 4.55 
± 1.0; WT saline vs Nrf2
-/-
 saline p < 0.05; WT saline vs Nrf2
-/-
 LPS p < 0.01, Nrf2
-/-
 
saline vs Nrf2
-/-
 LPS p < 0.05, WT LPS vs Nrf2
-/- 
LPS p = 0.06, n = 8-10). 
A genotype effect is seen in the cortex of Nrf2
-/-
 mice with increased basal 
expression of IL-1β, whilst a non-significant trend to the same effect is seen in Nrf2-/-
/hAPPswe mice (WT: 1.00; Nrf2
-/-
 saline: 1.23 ± 0.10; Nrf2
-/-
/hAPPswe saline: 1.27 ± 0.09; 
WT saline vs Nrf2
-/-
 saline p < 0.05, WT saline vs Nrf2
-/-
/hAPPswe saline p = 0.06, n = 3-
9; Figure 4.8 E). Expression of IL-1β is also significantly affected by treatment across 
all groups, with induction of expression observed following LPS treatment (WT LPS: 
1.68 ± 0.26; Nrf2
-/-
 LPS: 1.85 ± 0.22; Nrf2
-/-
/hAPPswe LPS: 1.71 ± 0.15; WT saline vs 
Nrf2
-/-
 LPS p < 0.01, WT saline vs Nrf2
-/-
/hAPPswe LPS p < 0.05, Nrf2
-/-
 saline vs Nrf2
-/-
 
LPS p < 0.05, Nrf2
-/-
/hAPPswe saline vs Nrf2
-/-
/hAPPswe LPS p < 0.05, n = 3-10). 
No effect of genotype or treatment is seen in the expression of either IL-6 or 
iNOS in the hippocampus (IL-6: p > 0.05; Figure 4.8 B. iNOS: p > 0.05; Figure 4.1 C). 
A modest effect of genotype is seen in the cortex of Nrf2
-/-
/hAPPswe mice with an 
increase in IL-6 expression (WT saline: 1.00; Nrf2
-/-
/ hAPPswe saline: 1.21 ± 0.07; WT 
saline vs Nrf2
-/-
/hAPPswe saline p < 0.05, n = 4-9; Figure 4.8 F). However, due to the 
ability of IL-6 to perform in both a pro- and anti- inflammatory capacity it is unclear 
what action it is having on this occasion. There is also no significant change in the 
expression of cortical iNOS (p > 0.05; Figure 4.8 G).  
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Figure 4.8 Peripheral LPS administration induces a predominantly IL1β driven 
pro-inflammatory environment in the brains of adult mice. 
Brains harvested from adult saline or LPS treated WT, Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice were 
dissected and the hippocampus and cortex were processed for gene expression analysis. A panel 
of commonly associated pro-inflammatory markers were investigated in all groups in both 
tissues; namely IL-1β (A + E), IL-6 (B + F), iNOS (C + G) and TNF-α (D + H) (WT n = 8-9, 
Nrf2
-/-
 n = 9-10, Nrf2
-/-
/hAPPswe n = 3-4). Results are reported as means ± s.e.m., and analysed 
by one-way and unpaired t-tests where * p < 0.05. 
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Finally, expression of the pro-inflammatory cytokine TNF-α was examined. A 
trend for a treatment-induced increase in TNF-α expression was seen in the 
hippocampus of all genotypes; however, this failed to reach significance (p > 0.05; 
Figure 4.8 D). A significant genotype*treatment effect is seen for cortical TNF-α with 
LPS treated WT mice reporting a significant increase when compared to saline-treated 
controls that is not seen in either Nrf2
-/-
 or Nrf2
-/-
/hAPPswe mice (WT saline: 1.00; WT 
LPS: 1.50 ± 0.21; WT saline vs WT LPS p < 0.05, n = 9; Figure 4.8 H). This suggests 
that repeated peripheral injections of low dose LPS induce a predominantly IL1-β driven 
inflammatory response in the brains of WT, Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice. 
As inflammatory cytokines are just one of the outputs available to assess stress-
related damage, oxyblots were run on protein lysates from hippocampal and cortical 
samples of brain tissue. Oxyblots, as described previously make use of the site-specific 
introduction of carbonyl groups following oxidative modification to assess the amount 
of protein carbonylation occurring. This is used as a marker for oxidative-related protein 
damage. Derivatisation of the protein carbonyl groups with DNP-hydrazone allows 
them to be visualised using DNP specific antibodies. To better assess the changes in 
total protein carbonylation, four areas on each positive sample lane were chosen at 
random and densitometry calculated for each box region. Exemplar blots are depicted 
with the regions analysed delineated on the control lane for both the hippocampus 
(Figure 4.9 A) and the cortex (Figure 4.9 B) in saline and LPS-treated mice.  
A total change in carbonylation was assessed using cumulative scores from all 
of the boxed regions analysed. Tables depicting the means ± s.e.m. values for the 
individual box regions for each mouse group are depicted in Figure 4.10 A for the 
hippocampus and Figure 4.10 B for the cortex. Values obtained for total carbonylation 
were taken forward and assessed for significant effects of genotype from either the loss 
of Nrf2
 
or presence of hAPPswe, or an LPS treatment induced effect following repeated 
peripheral administration. A significant increase in total carbonylated protein was seen 
in the hippocampus of saline-treated Nrf2
-/-
 mice (WT: 1.00; Nrf2
-/-
 saline: 1.63 ± 0.47; 
WT saline vs Nrf2
-/-
 saline p < 0.05, n = 5; Figure 4.10 C). No significant additional 
effect was observed following peripheral LPS despite a trend towards increased protein 
carbonylation in LPS treated WT mice (p > 0.05). No significant change was seen in 
Nrf2
-/-
/hAPPswe mice which may indicate the addition of hAPPswe provides a putative 
protective effect on protein carbonylation in an environment lacking Nrf2.   
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Figure 4.9 Pictorial representations of oxyblot assays performed in the 
hippocampus and cortex of adult saline or LPS treated animals.  
Adult mice given either saline or 2.5 μg LPS IP for seven days were harvested for tissue. Brains 
were excised and dissected from WT, Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice, and half each of the 
hippocampus and cortex were lysed for protein. Equal amounts of protein were calculated and 
samples were run through the oxyblot assay to assess changes in protein carbonylation. 
Exemplar blots depicting the hippocampus (A) and cortex (B) are labelled with regions used for 
later analysis on the left of the blot.  
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Figure 4.10 Loss of Nrf2 drives increases in protein carbonylation in both the 
hippocampus and cortex of adult mice. 
Adult mice from WT, Nrf2
-/-
 and Nrf2
-/-
/hAPPswe backgrounds administered either saline or LPS 
IP for seven days were harvested for tissue. Brains were dissected and hippocampal and cortical 
tissue were lysed for protein and processed for an oxyblot assay as per manufacturer’s 
instructions. Blots were analysed at pre-selected points and means ± s.e.m. displayed for the 
individual regions and the averaged total for both the hippocampus (A) and the cortex (B). 
Analysis of averaged total values is indicated in (C) for the hippocampus and (D) for the cortex. 
Data is reported as means ± s.e.m., and analysis was performed using one-sample and unpaired 
t-test where * = p < 0.05. (WT: n = 5; Nrf2
-/-
: n = 4-5; Nrf2
-/-
/hAPPswe: n = 3-4)  
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When cortical tissue was examined, a significant increase in protein 
carbonylation of Nrf2
-/-
 mice treated with LPS was observed when compared to saline-
treated WT controls (WT saline: 1.00; Nrf2
-/-
 LPS: 1.38 ± 0.21; WT saline vs Nrf2
-/-
 
LPS p < 0.05, n = 4-5; Figure 4.10 D). As for the hippocampus, a trend for increased 
carbonylation following LPS treatment was seen in WT mice but this failed to reach 
significance (p > 0.05). There were also no significant changes seen in protein 
carbonylation in Nrf2
-/-
/hAPPswe mice. This suggests the loss of Nrf2
-/-
 is sufficient to 
induce increased protein carbonylation, even in tightly regulated tissue such as the 
brain. 
Due to the relatively mild pro-inflammatory response recorded, a selection of 
anti-inflammatory markers was evaluated to assess the inflammatory resolution capacity 
of the brain following peripheral LPS dosing. Markers such as Arg1 and YM1, 
commonly assessed outputs from the alternative microglial activation pathway, were 
evaluated alongside MRC1, which causes the endocytosis of glycoproteins acting in part 
as a phagocytic receptor for bacteria and other pathogens.  
No induction of Arg1 was seen in the hippocampus of mice irrespective of 
genotype or treatment group (p > 0.05; Figure 4.11 A). Mice lacking expression of Nrf2 
demonstrated a non-significant increase in cortical expression of Arg1 (p > 0.05; Figure 
4.11 D), which was enhanced following LPS treatment but failed to reach significance 
(p > 0.05). In addition, no genotype or treatment induced alteration of Arg1 was seen in 
either the WT or Nrf2
-/-
/hAPPswe mice (p > 0.05). In contrast to Arg1, expression of 
MRC1 shows an LPS treatment driven effect in both WT and Nrf2
-/-
 mice in both the 
hippocampus (WT saline: 1.00; WT LPS: 1.42 ± 0.14; Nrf2
-/-
 saline: 1.16 ± 0.16; Nrf2
-/-
 
LPS: 1.81 ± 0.25; WT saline vs WT LPS p < 0.05, WT saline vs Nrf2
-/-
 saline p < 0.05, 
Nrf2
-/-
 saline vs Nrf2
-/-
 LPS p < 0.05, n = 9-10; Figure 4.11 B) and cortex (WT saline: 
1.00; WT LPS: 1.64 ± 0.22; Nrf2
-/-
 saline: 1.19 ± 0.19; Nrf2
-/-
 LPS: 1.74 ± 0.17; WT 
saline vs Nrf2
-/-
 LPS p < 0.01, Nrf2
-/-
 saline vs Nrf2
-/-
 LPS p < 0.05, n = 9-10; Figure 
4.11 E) of adult mice. As for Arg1, no significant changes in the MRC1 expression were 
seen in the hippocampus or cortex of Nrf2
-/-
/hAPPswe mice. 
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Figure 4.11 Repeated peripheral LPS treatment prompts a predominantly cortical 
induction of anti-inflammatory markers with mild escalation following loss of 
Nrf2. 
Brains harvested from adult saline and LPS treated WT, Nrf2
-/-
, and Nrf2
-/-
/hAPPswe mice were 
dissected and the hippocampus and cortex were processed for gene expression analysis. 
Commonly referenced anti-inflammatory markers Arg1 (A + D), MRC 1 (B + E) and YM1 (C + 
F) (WT n = 5-6, Nrf2
-/-
 n = 4-7, Nrf2
-/-
/hAPPswe n = 3-4). Results are reported as means ± s.e.m., 
and analysed by unpaired t-test where * indicates a significant change from saline treated WT 
and † indicates a change from LPS treated WT mice. *, p < 0.05, ** p < 0.01, *** p < 0.001; † p 
< 0.05. 
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Lastly, induction of YM1 expression appears most tightly associated with a 
treatment driven effect. Increased expression is observed following LPS administration 
irrespective of genotype or tissue analysed, with both the hippocampus (Figure 4.11 C) 
and cortex (Figure 4.11 F) exhibiting changes. Although not always achieving statistical 
significance due to a higher degree of variation, a trend towards increased expression in 
comparison to saline treatment is observed in the hippocampus of both WT and Nrf2
-/-
/hAPPswe mice (WT saline: 1.00; WT LPS: 5.28 ± 2.2; Nrf2
-/-
/hAPPswe saline: 0.821 ± 
0.33; Nrf2
-/-
/hAPPswe LPS: 5.60 ± 2.1; WT saline vs WT LPS p = 0.09, Nrf2
-/-
/hAPPswe 
saline vs Nrf2
-/-
/hAPPswe LPS p = 0.09, n = 3-9), whilst a significant induction is 
observed in LPS-treated Nrf2
-/-
 mice (Nrf2
-/-
 saline: 1.84 ± 3.4; Nrf2
-/-
 LPS: 6.87 ± 2.0; 
WT saline vs Nrf2
-/-
 LPS p < 0.05, Nrf2
-/-
 saline vs Nrf2
-/-
 LPS p < 0.05, n = 8-10).  
Cortical expression outlines a similar profile to that discerned in the 
hippocampus, with increased expression in YM1 following repeated peripheral LPS 
treatment. WT mice demonstrate an almost fourfold induction in gene expression, 
whilst both Nrf2
-/-
 and Nrf2
-/-
/hAPPswe are closer to a sevenfold induction following LPS 
treatment with mildly elevated basal levels (WT saline: 1.00; WT LPS: 3.59 ± 0.85; 
Nrf2
-/-
 saline: 1.72 ± 0.44; Nrf2
-/-
 LPS: 7.48 ± 0.93; Nrf2
-/-
/hAPPswe saline: 2.10 ± 0.40; 
6.97 ± 3.7; WT saline vs WT LPS p < 0.05, WT saline vs Nrf2
-/-
 LPS p < 0.0001, Nrf2
-/-
 
saline vs Nrf2
-/-
 LPS p < 0.0001, WT saline vs Nrf2
-/-
/hAPPswe saline p = 0.07, WT 
saline vs Nrf2
-/-
/hAPPswe LPS p > 0.05, n = 3-10; Figure 4.11 F). As with the previous 
study examining the effects of long term HF feeding, the anti-inflammatory response in 
the brain appears greater in the cortex than the hippocampus of mice, irrespective of 
genotype analysed. 
In contrast, activation of the complement immune system occurs across both 
brain regions assessed. A trend towards increased hippocampal expression of the C3 
complement cascade protein is observed following loss of Nrf2
-/-
 (WT saline: 1.00; WT 
LPS: 1.01 ±0.15; Nrf2
-/-
 saline: 2.22 ± 0.89; Nrf2
-/-
 LPS: 2.47 ± 0.79; WT saline vs Nrf2
-
/-
 saline and LPS p > 0.05, WT LPS vs Nrf2
-/-
 LPS p > 0.05, n = 8-10; Figure 4.12 A). 
No induction is seen following LPS treatment of Nrf2
-/-
/hAPPswe mice (p > 0.05) with 
non-significant increase in basal levels similar to that observed in the Nrf2
-/-
 mice (p > 
0.05).   
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Figure 4.12 Loss of Nrf2 and LPS both impact on the activation of the complement 
immune pathway. 
The dissected hippocampus and cortex harvested from adult WT, Nrf2
-/-
, and Nrf2
-/-
/hAPPswe 
mice were processed for gene expression analysis. A marker for the alternative complement 
immune pathway, C3 (A + C), and the transcription factor controlling the expression of a 
multitude of antioxidant genes, Nrf2 (B + D) were analysed for changes in expression following 
repeated peripheral LPS treatment. (WT n = 5-6, Nrf2
-/-
 n = 6-7, Nrf2
-/-
/hAPPswe n = 3-4). 
Results are reported as means ± s.e.m., and analysed by one-way and unpaired t-tests where * 
indicates a significant change from saline treated WT. 
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In comparison, cortical expression of C3 is induced by LPS in WT mice (WT 
saline: 1.00; WT LPS: 3.61 ± 1.2; WT saline vs WT LPS p = 0.06, n = 8-9; Figure 4.12 
C). A trend towards an inducing effect of genotype is seen in both Nrf2
-/-
 and Nrf2
-/-
/hAPPswe  with no additive effect of treatment observed (Nrf2
-/-
 saline: 1.89 ± 0.91; Nrf2
-
/-
 LPS: 1.80 ± 0.52; Nrf2
-/-
/hAPPswe saline: 2.13 ± 0.45; Nrf2
-/-
/hAPPswe LPS: 2.64 ± 
0.59; WT saline vs Nrf2
-/-
 saline and LPS p > 0.05, WT saline vs Nrf2
-/-
/hAPPswe saline 
p = 0.09, WT saline vs Nrf2
-/-
/hAPPswe LPS p > 0.05, n = 3-10). Contrary to C3 
expression, LPS does not appear to induce an increased expression of Nrf2, a major 
regulator of the production of antioxidant molecules, in WT mice in either the 
hippocampus (Figure 4.12 B) or the cortex (Figure 4.12 D). 
4.8 NRF2 PLAYS AN IMPORTANT ROLE IN THE MODULATION OF GLIAL 
CELL RESPONSES TO PERCEIVED CELLULAR INSULTS 
As changes in inflammatory response were observed following repeated 
peripheral LPS administration, markers of activation were analysed for two of the major 
glial cell populations found in the brain, namely microglia and astrocytes. As previously 
mentioned, both of these cell populations play an important role in maintaining neuronal 
cell health. Microglia represent the resident macrophage population of the CNS 
demonstrating an ability to be polarised into an M1 or M2 state. Astrocytes also play a 
role in response to trauma and oxidative or inflammatory damage. Furthermore, they are 
important in nutrient management and neurotransmitter regulation. 
F4/80, a marker for microglia, peripheral macrophages and a selection of other 
immune cells, demonstrated a trend towards a genotype-dependent increase in basal 
expression driven by the loss of Nrf2 in the hippocampus (WT saline: 1.00; Nrf2
-/-
 
saline: 1.28 ± 0.10; Nrf2
-/-
/hAPPswe saline: 1.43 ± 0.28; WT saline vs Nrf2
-/-
 saline p < 
0.05, WT saline vs Nrf2
-/-
/hAPPswe saline p > 0.05, n = 4-6; Figure 4.13 A). All LPS-
treated animals showed significant increases in hippocampal F4/80 expression, with 
Nrf2
-/-
 mice recording a further increase over and above that seen basally (WT LPS: 
1.49 ± 0.13; Nrf2
-/-
 LPS: 1.83 ± 0.16; Nrf2
-/-
/hAPPswe LPS: 1.41 ± 0.053; WT saline vs 
WT LPS p < 0.01, WT saline vs Nrf2
-/-
 LPS p < 0.001, WT saline vs Nrf2
-/-
/hAPPswe 
LPS p < 0.05, Nrf2
-/-
 saline vs Nrf2
-/-
 LPS p < 0.05, n = 3-10).   
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Figure 4.13 Loss of Nrf2 and LPS both modulate markers of glial cell activation 
and recruitment. 
Brains from adult mice were harvested, dissected and processed for gene and protein 
expression. Markers for macrophage activation (F4/80; A + E), astrocyte activation (GFAP; B + 
F) and the chemokine MCP-1 (D and G) were analysed by RT-qPCR or Western blot for 
changes in expression in the hippocampus and cortex regions of the brain. Exemplar blots of 
GFAP expression are portrayed for both the cortex and hippocampus where β-actin was used as 
the protein loading control (C). The non-specific band seen at 48 kDa has been previously 
reported as a GFAP derived band, thought to be a degradation product of GFAP. Data portrayed 
as means ± s.e.m. and analysed by unpaired t-test where * indicates significantly different from 
WT control; *, p < 0.05; **, p < 0.01, *** p < 0.001. Genes: WT n = 8-9, Nrf2
-/-
 n = 9-10, Nrf2
-/-
/hAPPswe = 3-4; and protein: WT n = 6, Nrf2
-/-
 n = 6, Nrf2
-/-
/hAPPswe = 3-4.  
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In the cortex, a treatment driven increase in expression of F4/80 was observed 
with no cross-genotype changes (WT saline: 1.00; WT LPS: 1.44 ± 0.11; Nrf2
-/-
 saline: 
1.14 ± 0.086; Nrf2
-/-
 LPS: 1.72 ± 0.15; Nrf2
-/-
/hAPPswe saline: 1.05 ± 0.067; Nrf2
-/-
/hAPPswe LPS: 1.43 ± 0.037; WT saline vs WT LPS p < 0.01, WT saline vs Nrf2
-/-
 LPS 
p < 0.01, Nrf2
-/-
 saline vs Nrf2
-/-
 LPS p < 0.01, WT saline vs Nrf2
-/-
/hAPPswe LPS p < 
0.01, Nrf2
-/-
/hAPPswe saline vs Nrf2
-/-
/hAPPswe LPS p < 0.01, n = 3-10; Figure 4.13 E). 
Activation of astrocytes, glial cells that perform a multitude of roles including 
nutrient transport and neurotransmitter modulation, was assessed using protein changes 
in GFAP. Hippocampal expression of GFAP was not significantly altered in either WT 
mice or Nrf2
-/-
/hAPPswe mice despite a trend towards lower expression in the LPS-
treated WT mice and a genotype-dependent trend towards decreased levels in the double 
transgenic model (WT saline: 1.00; WT LPS: 0.789 ± 0.13; Nrf2
-/-
/hAPPswe saline: 
0.729 ± 0.13; WT saline vs WT LPS and Nrf2
-/-
/hAPPswe saline p > 0.05, n = 4-6; Figure 
4.13 B). Loss of Nrf2 alone appears to decrease hippocampal GFAP expression; this 
loss is not significantly affected by additional treatment with LPS (Nrf2
-/-
 saline: 0.678 
± 0.098; WT saline vs Nrf2
-/-
 saline p < 0.05, n = 6). In contrast to the changes observed 
in hippocampal GFAP, no effect of genotype or treatment is seen on cortical expression 
in adult mice (p > 0.05; Figure 4.13 F). 
Increases in expression of glial related markers may indicate an increase in the 
recruitment of macrophage cells, whether they are residential cells such as the microglia 
or peripheral macrophages. Chemokines can both be released from and target the 
different forms of immune cell in order to accrue the selection of cells necessary to 
resolve the relevant damage. As a result, they are a key mode of communication in the 
initiation and evolution of the immune cascade response. MCP-1, released from a range 
of cell types including neurons, targets the recruitment of monocytes and macrophages 
to the site of injury and has been reported to be involved in the progression of 
inflammation in AD (Sokolova et al., 2009; McLarnon, 2012; Zhang et al., 2013). A 
significant increase in MCP-1 was seen in the hippocampus of LPS-treated WT mice 
(WT saline: 1.00; WT LPS: 2.15 ± 0.48; WT saline vs WT LPS p < 0.05, n = 8-9; 
Figure 4.13 D). Whilst Nrf2
-/-
 mice show a non-significant increase in basal levels of 
MCP-1 expression with little further induction following LPS-treatment (Nrf2
-/-
 saline: 
3.61 ± 1.48; Nrf2
-/-
 LPS: 4.89 ± 2.3; WT saline vs Nrf2
-/-
 saline and LPS p > 0.05, n = 9-
10). Nrf2
-/-
/hAPPswe mice mimic the increased basal levels of MCP-1 in the KO model 
but show a return to WT saline treated levels of MCP-1 following LPS treatment (Nrf2
-/-
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/hAPPswe saline: 3.46 ± 1.7; WT saline vs Nrf2
-/-
/hAPPswe saline and LPS p > 0.05, n = 
3-6). This altered response in the double transgenic model to LPS may be due to the 
additional presence of hAPPswe. 
No effect of genotype is seen on the cortical expression of MCP-1, contrary to 
that seen in the hippocampus (Figure 4.13 G). Peripheral LPS, however, continues to 
induce expression of MCP-1 in the cortex of both WT and Nrf2
-/-
 mice (WT saline: 
1.00; WT LPS: 1.56 ± 0.21; Nrf2
-/-
 saline: 1.07 ± 0.12; Nrf2
-/-
 LPS: 1.72 ± 0.18; WT 
saline vs WT LPS p < 0.05, WT saline vs Nrf2
-/-
 LPS p < 0.01, Nrf2
-/-
 saline vs Nrf2
-/-
 
LPS p < 0.01, n = 9-10). No significant changes in expression of MCP-1 are observed in 
the cortex of Nrf2
-/-
/hAPPswe mice (p > 0.05). These observations indicate a primarily 
hippocampus localised pro-inflammatory response following LPS treatment, with 
increased expression of markers such as IL-1β, F4/80, MCP-1 and protein carbonylation 
combining with a loss of GFAP. In contrast, a much stronger anti-inflammatory 
presence is seen in the cortical tissue of the mouse brain with an attenuated pro-
inflammatory response in markers such as IL1-β and MCP-1, when compared to the 
hippocampus, and an amplified response in anti-inflammatory markers such as YM1, 
Arg1 and C3. It also implicates Nrf2 in the management and amplitude of the response 
to peripheral LPS administration in the murine brain with an increased basal 
inflammatory state potentiating the response to peripheral LPS challenge. 
4.9 SHORT-TERM REPEATED IP LPS AFFECTS SYNAPTIC HEALTH IN 
THE CORTEX OF THE MURINE BRAIN 
As previously described, SYP is a commonly used marker for the measurement 
of synaptic density and health. Its exact function is still unclear although putative roles 
include regulation of synaptic vesicle endocytosis (Kwon & Chapman, 2011). In 
addition, it has previously been reported that changes in dietary composition can alter 
SYP expression with increased expression of SYP following a diet with a higher ratio of 
n-3:n-6 PUFAs (Hajjar et al., 2013). Due to its ubiquitous presence in the synapse, SYP 
is commonly used to monitor synapse number. Hippocampal lysates obtained from mice 
given repeated LPS or saline injections IP showed an increase in SYP in Nrf2
-/-
 mice 
under basal conditions with LPS negatively impacting protein levels (WT saline: 1.00; 
Nrf2
-/-
 saline: 1.32 ± 0.14; Nrf2
-/-
 LPS: 1.01 ± 0.14; WT saline vs Nrf2
-/-
 saline p = 0.05, 
Nrf2
-/-
 saline vs Nrf2
-/-
 LPS p > 0.05, n = 9; Figure 4.14 A). No hippocampal changes in 
SYP were seen in either WT or Nrf2
-/-
/hAPPswe mice irrespective of treatment.   
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Figure 4.14 Repeated peripheral LPS administration induces a small loss of 
cortical synapses in Nrf2
-/-
 mice. 
Dissected brain tissue from adult saline and LPS treated mice was processed for protein 
expression and probed for the synapse marker SYP in the hippocampus (A) and cortex (B), with 
(C) showing images of exemplar blots for both the hippocampus and cortex. Data portrayed as 
means ± s.e.m. and analysed by one-way and unpaired t-test where * indicates significantly 
different from RC fed WT control, where *, p < 0.05, ***, p < 0.001. WT n = 9, Nrf2
-/-
 n = 9, 
Nrf2
-/-
/hAPPswe n = 3-4. 
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When lysates from the cortical region were compared, a significant attenuating 
effect of treatment was observed in WT mice, with expression levels of SYP decreasing 
with LPS treatment (WT saline: 1.00; WT LPS: 0.781 ± 0.082; WT saline vs WT LPS p 
< 0.05, n = 9; Figure 4.14 B). A similar treatment effect is seen in mice lacking Nrf2, 
with a non-significant drop in SYP under basal levels amplified following treatment 
(Nrf2
-/-
 saline: 0.882 ± 0.10; Nrf2
-/-
 LPS: 0.689 ± 0.052; WT saline vs Nrf2
-/-
 saline p > 
0.05, WT saline vs Nrf2
-/-
 LPS p < 0.001, n = 9). A trend for decreased SYP is also seen 
in the Nrf2
-/-
/hAPPswe saline treated mice (Nrf2
-/-
/hAPPswe saline: 0.721 ± 0.11; WT 
saline vs Nrf2
-/-
/hAPPswe saline p = 0.09) with no further effect of treatment. This is 
visualised by representative blots controlled against loading error by the housekeeping 
protein β-actin (Figure 4.14 C). 
4.10 REPEATED PERIPHERAL LPS ADMINISTRATION SELECTIVELY 
AFFECTS KEY AD RELATED PROTEINS 
Expression of proteins associated with the hallmark pathologies described in AD 
were analysed for changes in both gene and protein expression in the brains of mice 
exposed to repeated IP LPS. Environmental stresses, such as those seen from the 
consumption of diets high in fat content, have been shown to impact on expression 
levels of AD related proteins such as BACE1 and Tau phosphorylation (Carroll et al., 
2011; Meakin et al., 2012). In addition, it has been well established that both APP and 
BACE1 are strongly expressed in the murine brain (Cole & Vassar, 2007). 
Basal levels of mAPP were reduced in the hippocampus of Nrf2
-/-
/hAPPswe mice 
(WT saline: 1.00; Nrf2
-/-
/hAPPswe saline: 0.880 ± 0.022; WT saline vs Nrf2
-/-
/hAPPswe 
saline p < 0.01, n = 4-6; Figure 4.15 A). Whilst LPS treatment caused a small drop in 
expression of mAPP in WT mice, in Nrf2
-/-
/hAPPswe mice an increase in expression was 
seen bringing levels up to those of saline-treated WT mice (WT LPS: 0.926 ± 0.016; 
Nrf2
-/-
/hAPPswe LPS: 0.989 ± 0.038; WT saline vs WT LPS p < 0.05, Nrf2
-/-
/hAPPswe 
saline vs Nrf2
-/-
/hAPPswe LPS p < 0.05, n = 3-6). Changes in basal expression of mAPP 
were not observed in Nrf2
-/-
 mice nor were any changes seen following treatment.   
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Figure 4.15 Administration of repeated IP LPS reduces BACE1 protein expression 
in the cortex of adult mice with no effect on APP expression.  
Brain tissue collected from adult mice was processed for gene and protein expression. Measures 
were taken for murine APP (A + F) and BACE1 (B + G) gene expression as well as total APP 
(human + mouse; D + I) and BACE1 (E + J) protein expression, with C and H showing 
exemplar blots for the hippocampus and cortex respectively. Data portrayed as means ± s.e.m. 
and analysed by one-way and unpaired t-test where * indicates significantly different from 
saline treated WT control and † indicates significantly different from HF fed WT. *, p < 0.05; 
**, p < 0.01; †, p < 0.05. WT n = 6, Nrf2-/- n = 6-7, Nrf2-/-/hAPPswe n = 3-4.  
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The treatment-induced modest decrease in mAPP by LPS is maintained in the 
cortex of WT mice (WT saline: 1.00; WT LPS: 0.914 ± 0.026; WT saline vs WT LPS p 
< 0.05, n = 6; Figure 4.15 F). As a result, Nrf2
-/-
 mice given LPS have a significantly 
higher level of mAPP expression than WT mice given the same treatment with no 
alteration in basal expression of mAPP in Nrf2
-/-
 mice (Nrf2
-/-
 LPS: 1.08 ± 0.050; WT 
LPS vs Nrf2
-/-
 LPS p < 0.05, n = 6-7). Furthermore, no alteration in expression of 
cortical mAPP was detected in Nrf2
-/-
/hAPPswe mice in either treatment group (p > 0.05). 
With regards to BACE1, basal levels of gene expression in Nrf2
-/-
 mice are 
significantly lower than saline treated WT mice (WT saline: 1.00; Nrf2
-/-
 saline: 0.843 ± 
0.045; WT saline vs Nrf2
-/-
 saline p < 0.05, n = 6; Figure 4.15 B). A similar reduction in 
BACE1 is observed in WT mice following treatment with LPS (WT LPS: 0.881 ± 0.029; 
WT saline vs WT LPS p < 0.01, n = 6). In the cortex, however, no reduction is seen in 
BACE1. Instead, LPS treated Nrf2
-/-
/hAPPswe mice show increased expression of BACE1 
in comparison to saline treated mice (Nrf2
-/-
/hAPPswe saline: 0.914 ± 0.052; Nrf2
-/-
/hAPPswe LPS: 1.09 ± 0.030; p < 0.05, n = 3-4; Figure 4.15 G). 
When protein expression was evaluated by densitometry from Western blots, as 
depicted in Figure 4.15 C and H for the hippocampus and cortex respectively; a main 
effect of genotype was seen in Nrf2
-/-
 mice with no additional protein induction 
following treatment with LPS and no change observed in WT mice (WT saline: 1.00; 
Nrf2
-/-
 saline: 1.25 ± 0.067; Nrf2
-/-
 LPS: 1.26 ± 0.085; WT saline vs Nrf2
-/-
 saline p < 
0.05, WT saline vs Nrf2
-/-
 LPS p < 0.05, n = 6; Figure 4.15 D). Nrf2
-/-
/hAPPswe mice had 
increased levels of total APP in both the hippocampus and the cortex, which is not 
unexpected and corresponds to the additional expression of the hAPPswe protein 
(hippocampus: Nrf2
-/-
/hAPPswe saline: 1.68 ± 0.094; Nrf2
-/-
/hAPPswe LPS: 1.53 ± 0.085; 
WT saline vs Nrf2
-/-
/hAPPswe saline p < 0.01, WT saline vs Nrf2
-/-
/hAPPswe LPS p < 
0.05, n = 3-6. Cortex: WT saline: 1.00; Nrf2
-/-
/hAPPswe saline: 1.87 ± 0.26; Nrf2
-/-
/hAPPswe LPS: 1.72 ± 0.28; WT saline vs Nrf2
-/-
/hAPPswe p < 0.05, WT saline vs Nrf2
-/-
/hAPPswe LPS p > 0.05, n = 3-6; Figure 4.15 I). Loss of Nrf2 and treatment with LPS 
failed to impact on the expression of total APP in the cortex of WT and Nrf2
-/-
 mice. 
Neither genotype nor treatment altered the levels of BACE1 protein in the 
hippocampus of adult mice (p > 0.05; Figure 4.15). An interesting main effect of 
treatment was seen in the cortex of LPS treated mice, with treatment significantly 
attenuating BACE1 protein in both WT and Nrf2
-/-
 mice compared to controls (WT 
saline: 1.00; WT LPS: 0.655 ± 0.12; Nrf2
-/-
 saline: 0.946 ± 0.15; Nrf2
-/-
 LPS: 0.536 ± 
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0.099; WT saline vs WT LPS p < 0.05, WT saline vs Nrf2
-/-
 LPS p < 0.01, Nrf2
-/-
 saline 
vs Nrf2
-/-
 LPS p < 0.05, n = 6; Figure 4.15 J). A similar pattern is seen in Nrf2
-/-
/hAPPswe 
mice with a decrease in BACE1 protein, however, this falls short of being statistically 
significant (p > 0.05). 
Despite being labelled as the second hallmark pathology for AD and 
predominantly associated therewith, tauopathies are found in a variety of other 
dementias and neurodegenerative disorders. A multitude of mutations have been 
reported for tau; however, even non-mutated tau can be affected by changes in the 
amyloidogenic pathway. This makes it a worthwhile target to investigate, even when 
not using a mutant tau transgenic mouse model. Total tau along with a marker for one of 
its phosphorylation sites were investigated in the hippocampus and cortex of saline and 
LPS treated mice.  
A significant drop in phosphorylation at location Ser396 of tau was seen in Nrf2
-
/-
 mice under basal conditions, with LPS treatment increasing fold phosphorylation to 
that of saline-treated controls (WT saline: 1.00; Nrf2
-/-
 saline: 0.801 ± 0.068; Nrf2
-/-
 
LPS: 1.03 ± 0.15; WT saline vs Nrf2
-/-
 saline p < 0.05, Nrf2
-/-
 saline vs Nrf2
-/-
 LPS p > 
0.05, n = 9; Figure 4.16 A). A similar profile was seen for the Nrf2
-/-
/hAPPswe mice with 
lower basal levels of phosphorylation at Ser396 that were increased, albeit non-
significantly, following treatment with LPS (WT saline: 1.00; Nrf2
-/-
/hAPPswe saline: 
0.743 ± 0.063; Nrf2
-/-
/hAPPswe LPS: 0.885 ± 0.087; WT saline vs Nrf2
-/-
/hAPPswe saline 
p < 0.05, Nrf2
-/-
/hAPPswe saline vs Nrf2
-/-
 LPS p > 0.05, n = 3-9).
  
However, no significant change is seen in phosphorylation of Tau at Ser396 in 
the cortex of vehicle or LPS treated mice WT or Nrf2
-/-
 mice (p > 0.05; Figure 4.16 C). 
A small drop in tau phosphorylation is still detected in Nrf2
-/-
/hAPPswe mice under basal 
conditions (WT saline: 1.00; Nrf2
-/-
/hAPPswe saline: 0.823 ± 0.043; WT saline vs Nrf2
-/-
/hAPPswe saline p < 0.05, n = 4-9). 
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Figure 4.16 Modest changes in phosphorylated and total tau can be seen following 
LPS treatment of Nrf2
-/-
 mice. 
Brain tissue collected from adult mice was processed for protein expression. Measures were 
taken for two tau phosphorylation sites, Ser396 (A and C) and total tau expression (B and D) in 
both the hippocampus and cortex. E displays exemplar blots for both tissues, where β-actin was 
used as the protein loading control. Data portrayed as means ± s.e.m. and analysed by one-way 
and unpaired t-test where * indicates significantly different from saline treated WT controls. *, p 
< 0.05; **, p < 0.01. WT n = 5-6, Nrf2
-/-
 n = 6-7, Nrf2
-/-
/hAPPswe n = 3-4.  
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A significant effect of treatment is seen for total tau protein in the hippocampus 
of WT mice treated with LPS (WT saline: 1.00; WT LPS: 1.46 ± 0.17; WT saline vs 
WT LPS p < 0.05, n = 9; Figure 4.16 B). Loss of Nrf2 appears to drive an increase in 
production of total tau under basal conditions in hippocampal tissue, with little further 
treatment induced effect from LPS (Nrf2
-/-
 saline: 1.57 ± 0.19; Nrf2
-/-
 LPS: 1.37 ± 0.10; 
WT saline vs Nrf2
-/-
 saline p < 0.05, WT saline vs Nrf2
-/-
 LPS p < 0.01, n = 9). No 
significant change in hippocampal total tau protein is seen in Nrf2
-/-
/hAPPswe mice, 
likely hampered by low n-numbers. In contrast, no significant changes are seen in total 
cortical tau proteins irrespective of genotype and treatment (p > 0.05; Figure 4.16 D). 
This is reflected in the exemplar blots displayed in Figure 4.16 E. 
4.11 REPEATED IP INJECTIONS OF LPS DOES NOT IMPACT ON THE PI-
3K-DEPENDENT PATHWAY IN THE MOUSE BRAIN 
A flurry of recent publications has proposed a role for LPS in the development 
of obesity and insulin resistance (Cani et al., 2007; Fei & Zhao, 2013), with other work 
implicating a role for the insulin pathway in AD development and progression (Sly et 
al., 2001; Sy et al., 2011). We have previously described a link between loss of Nrf2 
and prevention of peripheral diet-induced insulin resistance and dysregulation of 
glucose management (Meakin et al., 2014). Therefore it was decided to investigate the 
impact LPS might have on the insulin sensitive PI3-K pathway in hippocampal and 
cortical brain homogenates. Changes in Akt phosphorylation at the two principle 
phosphorylation sites were assessed along with the downstream activation of the stress 
activated NF-κB pathway. LPS induced no change in phosphorylated protein level at the 
Ser473 site of Akt in the hippocampus of adult mice in the presence or absence of Nrf2, 
with Nrf2
-/-
/hAPPswe mice demonstrating a small but significant drop in phosphorylation 
of the Ser473 site following LPS treatment (WT saline: 1.00; Nrf2
-/-
/hAPPswe LPS: 
0.792 ± 0.025; WT saline vs Nrf2
-/-
/hAPPswe LPS p < 0.05, n = 3-6; Figure 4.17 A). No 
significant changes in the level of Ser473 phosphorylated were seen in the cortex, 
irrespective of genotype and treatment group analysed (p > 0.05; Figure 4.17 E). 
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Figure 4.17 Repeated IP LPS has little effect on PI3-K driven Akt phosphorylation 
or IκBα degradation in the hippocampus and cortex of adult Nrf2-/- and mice. 
Brain tissue collected from adult mice was processed for gene and protein expression. Measures 
were taken for relative expression of Akt phosphorylation (Ser473, A + E; Thr308, B + F), and 
IκBα (C + G) protein expression, with D and H showing exemplar blots for the hippocampus 
and cortex respectively. Data portrayed as means ± s.e.m. and analysed by one-way and 
unpaired t-test where * indicates significantly different from saline treated WT controls and † 
significantly different from LPS treated WT mice. *, p < 0.05, and †, p < 0.05. WT n = 6, Nrf2-/- 
n = 4-6, Nrf2
-/-
/hAPPswe n = 3-4. 
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Phosphorylation at the Thr308 site of Akt was assessed, as it can provide an 
alternative activation pathway. LPS treatment induced a non-significant increase in WT 
mice when compared to the vehicle group (WT saline: 1.00; WT LPS: 1.12 ± 0.064; 
WT saline vs WT LPS p > 0.05, n = 6; Figure 4.17 B). A genotype*treatment effect was 
seen in Nrf2
-/-
 mice, with LPS decreasing Akt phosphorylation (Thr308; Nrf2
-/-
 LPS: 
0.895 ± 0.054; WT LPS vs Nrf2
-/-
 LPS p < 0.05, n = 6). A similar phosphorylation 
decrease was seen in the cortex of LPS-treated Nrf2
-/-
 mice (WT saline: 1.00; Nrf2
-/-
 
LPS: 0.823 ± 0.066; WT saline vs Nrf2
-/-
 LPS p < 0.05, n = 6; Figure 4.17 F). 
Furthermore, in the cortex neither WT nor Nrf2
-/-
/hAPPswe mice displayed a significant 
alteration in the level of phosphorylated Akt (Thr308), irrespective of treatment.  
Finally, changes in IκBα were used as a representation of NF-κB activation. A 
small but significant effect of genotype was seen in hippocampal IκBα in Nrf2-/- (WT 
saline: 1.00; Nrf2
-/-
 saline: 1.14 ± 0.052; Nrf2
-/-
 LPS: 1.21 ± 0.068; WT saline vs Nrf2
-/-
 
saline p < 0.05, WT saline vs Nrf2
-/-
 LPS p < 0.05, n = 6; Figure 4.17 C). No further 
changes were seen in the hippocampus, nor were any significant changes in IκBα seen 
in the cortex of saline and LPS treated mice irrespective of genotype (p > 0.05; Figure 
4.17 G). These changes are depicted in the exemplar blots for both the hippocampus and 
cortex shown in Figure 4.17 D and H respectively. 
4.12 REPEATED IP LPS FAILS TO IMPACT THE GLUTATHIONE PATHWAY 
IN THE BRAINS OF ADULT MICE 
GCLC, a rate-limiting enzyme in the synthesis of GSH, was measured as a 
means of assessing changes in glutathione production following LPS insult. No change 
in expression of GCLC was observed in the hippocampus following LPS treatment of 
WT control mice (p > 0.05; Figure 4.18 A). A trend towards decreased production of 
GCLC was observed in hippocampal lysates from Nrf2
-/-
 mice with no significant 
further effect following injections of LPS (WT saline: 1.00; Nrf2
-/-
 saline: 0.756 ± 0.11; 
WT saline vs Nrf2
-/-
 saline p = 0.07, n = 6). Addition of hAPPswe demonstrated no 
further change on GCLC expression upon analysis of Nrf2
-/-
/hAPPswe hippocampal 
lysates (p > 0.05). Cortical expression of GCLC showed no alterations in expression in 
WT or Nrf2
-/-
 mice (p > 0.05; Figure 4.18 B and C for exemplar blots). Only Nrf2
-/-
/hAPPswe mice suggested any change in cortical GCLC expression with a tendency 
towards lowered GCLC levels following LPS administration (WT saline: 1.00; Nrf2
-/-
/hAPPswe LPS: 0.740 ± 0.077; WT saline vs Nrf2
-/-
/hAPPswe LPS p = 0.08, n = 3-6).  
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Figure 4.18 Repeated IP LPS does not significantly affect expression of the rate 
limiting glutathione pathway GCLC enzyme in brain tissue. 
Brain tissue collected from adult mice was processed for protein expression and Western blots 
were probed for the glutathione pathway enzyme GCLC (A + B). C portrays exemplar blots for 
the hippocampus and cortex respectively. Data portrayed as means ± s.e.m. and analysed by 
unpaired t-test. WT n = 6, Nrf2
-/-
 n = 6, Nrf2
-/-
/hAPPswe n = 3-4. 
 
  
207 
4.13 REPEATED IP LPS INDUCES BRAIN REGION SPECIFIC INDUCTION OF 
KEY MAPK MEMBERS 
JNK, along with ERK, is one of the most well studied members of the MAPK 
pathway. It is often induced following activation of common stressor responses, 
including cytokines. Although there are no known functional difference between the 
two primary isoforms, JNK46 and JNK54, these were still analysed individually in 
order to assess whether any isoform specific changes were occurring. A very small but 
significant decrease in phosphorylation of the JNK54 isoform is seen following 
treatment of Nrf2
-/-
 mice with LPS in the hippocampus with no significant changes seen 
in the hippocampus of WT or Nrf2
-/-
/hAPPswe mice (WT saline: 1.00; Nrf2
-/-
 LPS: 0.95 ± 
0.020; WT saline vs Nrf2
-/-
 LPS p < 0.05, n = 6; Figure 4.19 A). Furthermore, there was 
no change from basal phosphorylation of the JNK46 isoform in the hippocampus of any 
of the cohort groups (p > 0.05; Figure 4.19 B). This led to no significant difference in 
total JNK phosphorylation in the hippocampus in any group (p > 0.05; Figure 4.19 C, 
and G for exemplar blots).  
Following analysis of cortical expression, there is a treatment-dependent trend 
towards increased JNK phosphorylation at the JNK54 isoform in WT and Nrf2
-/-
 mice 
(WT saline: 1.00; WT LPS: 1.49 ± 0.34; Nrf2
-/-
 LPS: 1.65 ± 0.36; WT saline vs WT and 
Nrf2
-/-
 LPS p > 0.05, n = 9; Figure 4.19 D). A non-significant increase in 
phosphorylation is also seen in Nrf2
-/-
/hAPPswe mice given repeated saline injections 
(Nrf2
-/-
/hAPPswe saline: 1.48 ± 0.20; WT saline vs Nrf2
-/-
/hAPPswe saline p = 0.09, n = 4-
6). This profile is repeated for the JNK46 isoform in cortical tissue lysates with a trend 
towards increased p-JNK46 in LPS-treated WT and Nrf2
-/-
 mice and increased basal 
phosphorylation in Nrf2
-/-
/hAPPswe mice (Nrf2
-/-
/hAPPswe saline: 1.44 ± 0.14; WT saline 
vs WT and Nrf2
-/-
 LPS p > 0.05, WT saline vs Nrf2
-/-
/hAPPswe saline p = 0.05, n = 4-9; 
Figure 4.19 E). LPS treated Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice treated with vehicle were 
both shown to have a trend towards increased levels of total JNK phosphorylation (WT 
saline: 1.00; Nrf2
-/-
 LPS: 1.53 ± 0.30; Nrf2
-/-
/hAPPswe saline: 1.44 ± 0.14; WT saline vs 
Nrf2
-/-
 LPS p > 0.05, WT saline vs Nrf2
-/-
/hAPPswe saline p = 0.05, n = 4-9; Figure 4.19 
F, and G for exemplar blots).  
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Figure 4.19 Nrf2
-/-
 and WT mice show a mild induction of SAPK/JNK in the cortex 
following repeated IP LPS injections 
Brain tissue collected from adult mice was processed for protein expression and run on Western 
blots. Membranes were probed for phosphorylated (Thr183/Tyr185) and total JNK. A ratio of 
phosphorylated to total protein was calculated for p54 JNK (A and D), p46 JNK (B and E) and 
total JNK (C and F) in the hippocampal and cortical protein homogenates. G portrays exemplar 
blots for both the hippocampus and cortex. Data portrayed as means ± s.e.m. and analysed by 
one-way and unpaired t-test. WT n = 6-9, Nrf2
-/-
 n = 6-9, Nrf2
-/-
/hAPPswe n = 3-4.  
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Having previously described HF dependent changes in the dual-phosphorylation 
of the MAPK ERK, we were keen to assess the impact of an alternative stress pathway 
on MAPK phosphorylation via administration of LPS. In the hippocampus, a trend 
towards a treatment-dependent increase in ERK 1 and ERK 2 phosphorylation was seen 
in WT mice treated with LPS (ERK 1: WT saline: 1.00; WT LPS: 1.28 ± 0.13; WT 
saline vs WT LPS p = 0.06, n = 9; Figure 4.20 A. ERK 2: WT saline: 1.00; WT LPS: 
1.58 ± 0.27; WT saline vs WT LPS p = 0.06, n = 9; Figure 4.20 B). In addition, Nrf2
-/-
 
mice revealed significantly increased basal phosphorylation of ERK 1 (Nrf2
-/-
 saline: 
1.48 ± 0.18; WT saline vs Nrf2
-/-
 saline p < 0.05, n = 8-9) which fell just short of 
significant for ERK 2 (Nrf2
-/-
 saline: 1.80 ± 0.36; WT saline vs Nrf2
-/-
 saline p = 0.06, n 
= 8-9).  
And finally whilst Nrf2
-/-
/hAPPswe mice described what appeared to be a 
treatment-induced increase in both ERK 1 and ERK 2 phosphorylation, this failed to 
become significant (ERK 1: Nrf2
-/-
/hAPPswe saline: 1.60 ± 0.31; Nrf2
-/-
/hAPPswe LPS: 
1.92 ± 0.44; WT saline vs Nrf2
-/-
/hAPPswe saline and LPS p > 0.05, n = 3-9. ERK 2: 
Nrf2
-/-
/hAPPswe saline: 2.16 ± 0.80; Nrf2
-/-
/hAPPswe LPS: 2.90 ± 0.84; WT saline vs 
Nrf2
-/-
/hAPPswe saline and LPS p > 0.05, n = 3-9). These findings were recapitulated 
when total ERK 1/2 phosphorylation was assessed with a treatment-dependent increase 
seen in WT mice and genotype-dependent increases seen in both Nrf2
-/-
 and Nrf2
-/-
/hAPPswe mice (WT saline: 1.00; WT LPS: 1.48 ± 0.22; Nrf2
-/-
 saline: 1.72 ± 0.30; Nrf2
-
/-
/hAPPswe saline: 1.99 ± 0.62; Nrf2
-/-
/hAPPswe LPS: 2.60 ± 0.69; WT saline vs WT LPS 
p = 0.06, WT saline vs Nrf2
-/-
 saline p < 0.05, WT vs Nrf2
-/-
/hAPPswe saline and LPS p > 
0.05, n = 3-9; Figure 4.20 C and see G for blot exemplars). 
Cortical ERK 1 shows a treatment-dependent increase in phosphorylation in 
Nrf2
-/-
 mice administered LPS (WT saline: 1.00; Nrf2
-/-
 LPS: 1.88 ± 0.38; WT saline vs 
Nrf2
-/-
 LPS p < 0.05, n = 9; Figure 4.20 D), with a similar trend seen in WT mice (p > 
0.05). No significant change is seen in phosphorylation levels of either ERK 1 or ERK 2 
in Nrf2
-/-
/hAPPswe mice, although there is a trend for increased basal phosphorylation of 
both (ERK 1: Nrf2
-/-
/hAPPswe saline: 1.85 ± 0.35; WT vs Nrf2
-/-
/hAPPswe saline p = 0.09, 
n = 4-9; Figure 4.20 D. ERK 2: Nrf2
-/-
/hAPPswe saline: 1.73 ± 0.37; WT vs Nrf2
-/-
/hAPPswe saline p > 0.05, n = 4-9; Figure 4.20 E). 
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Figure 4.20 Transgenic mouse models lacking Nrf2 show a trend towards increased 
ERK 1 and 2 MAPK phosphorylation with brain region dependent responses to 
peripheral LPS treatment. 
Brain tissue was harvested from mice and processed for protein expression by Western blot. 
Measures were taken for relative expression of phosphorylated (Thr202/Tyr204) and total 
ERK1 (A + D), ERK2 (B + E) and combined ERK1/2 MAPK expression (C + F) in the 
hippocampus and cortex of mice, with G showing exemplar blots for the hippocampus and 
cortex respectively. Data portrayed as means ± s.e.m. and analysed by one-way and unpaired t-
test. WT n = 9, Nrf2
-/-
 n = 9, Nrf2
-/-
/hAPPswe n = 3-4.  
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This phosphorylation profile is largely matched by that of ERK 2, with a 
treatment-dependent induction seen in WT and Nrf2
-/-
 mice which falls just short of 
significance (WT saline: 1.00; WT LPS: 1.53 ± 0.29; Nrf2
-/-
 LPS: 1.63 ± 0.29; WT 
saline vs WT LPS p > 0.05, WT saline vs Nrf2
-/-
 saline p = 0.06, n = 9; Figure 4.20 E). 
With no noteworthy differences in the phosphorylation of ERK 1 and ERK 2, total ERK 
phosphorylation maintains the same features as those shown for the individual isoforms 
with a treatment driven effect in WT and Nrf2
-/-
 mice and a basal genotype driven 
increase in Nrf2
-/-
/hAPPswe mice (WT saline: 1.00; WT LPS: 1.64 ± 0.38; Nrf2
-/-
 LPS: 
1.78 ± 0.34;  WT saline vs WT LPS p > 0.05, WT saline vs Nrf2
-/-
 saline p = 0.06, n = 9; 
Nrf2
-/-
/hAPPswe saline: 1.82 ± 0.33; WT saline vs WT LPS p > 0.05, WT saline vs Nrf2
-/-
 
LPS p < 0.05, WT saline vs Nrf2
-/-
/hAPPswe saline p = 0.09, n = 4-9; Figure 4.20 F and 
see G for exemplar blots). 
4.14 LPS AND NRF2-/- SIGNIFICANTLY IMPACT ON BRAIN DERIVED 
MITOCHONDRIAL HEALTH IN ADULT MICE 
Previous work has described links between LPS-induced inflammatory 
responses and increased mitochondrial dysfunction (Nakanishi et al., 2011; Nicholas et 
al., 2011). In addition, work done by Piantadosi and colleagues (2011) suggests a link 
between Nrf2 and both mitochondrial biogenesis and mitochondrial response to 
inflammatory insult in the liver; whilst induction of Nrf2 is protective following 
induction of mitochondrial stress (Shih et al., 2005). To assess whether peripherally 
administered LPS could impact mitochondria located within the brain regions of the 
hippocampus and cortex, commonly utilised markers for mitochondrial health and 
mitophagy were assessed in WT and Nrf2
-/-
 mice repeatedly treated peripherally with 
LPS or saline.  
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Figure 4.21 Loss of Nrf2 and repeated LPS injections both impact on 
mitochondrial health and mitophagy markers. 
Brain tissue was harvested from mice and processed for protein expression by Western blot as 
previously described using whole lysates, with exemplars shown in A where β-actin was used as 
the protein loading control. Measures were taken for relative expression of COX IV (B + C), 
VDAC 1 (D + E), mitofusin 1 (F + H) and mitofusin 2 (G + I) in the hippocampus and cortex 
of RC and HF fed WT and Nrf2
-/-
 mice. Data portrayed as means ± s.e.m. and analysed by one-
way and unpaired t-test where * indicates significance between groups. *, p < 0.05; **, p < 0.01, 
***, p < 0.001. WT n = 6, Nrf2
-/-
 n = 6.  
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In the hippocampus, neither of the outer mitochondrial membrane markers, 
COX IV and VDAC 1, are affected by administration of peripheral LPS (p > 0.05; 
Figure 4.21 B and C respectively and A for exemplar blots). However, Nrf2
-/-
 mice 
demonstrate a trend towards an effect of genotype with increased expression of COX IV 
in both treatment groups (WT saline: 1.00; Nrf2
-/-
 saline: 1.21 ± 0.15; Nrf2
-/-
 LPS: 1.21 
± 0.18; WT saline vs Nrf2
-/-
 saline and LPS p > 0.05, n = 9). An effect of genotype is 
seen following loss of Nrf2 in the cortex, with a significant decrease in COX IV (WT 
saline: 1.00; Nrf2
-/-
 saline: 0.730 ± 0.071; WT saline vs Nrf2
-/-
 saline p < 0.05, n = 9; 
Figure 4.21 D). Furthermore, a genotype*treatment effect is observed following 
repeated peripheral injections with LPS, depicted by a decrease in COX IV levels in 
WT mice but an increase in those of Nrf2
-/-
 mice (WT LPS: 0.781 ± 0.10; Nrf2
-/-
 LPS: 
0.952 ± 0.19; WT saline vs WT LPS p = 0.06, Nrf2
-/-
 saline vs Nrf2
-/-
 LPS p > 0.05, n = 
9). Neither genotype nor treatment significantly affects levels of the mitochondrial 
channel marker VDAC1 (p > 0.05; Figure 4.21 E). 
Mitofusin proteins are essential in the correct progression of mitochondrial 
fusion. Increases in mitochondrial fusion can lead to elongation of the mitochondria, 
whilst decreases can lead to mitochondrial fragmentation through mitochondrial fission. 
Mitochondrial fission and fusion are key in balancing the dynamic changes in 
mitochondrial state essential for their proper function (Westermann, 2012). Imbalance 
in either of these processes can cause cell death, increased ROS production and 
impaired mitochondrial function. Neither mitofusin 1 nor mitofusin 2, when measured 
in the hippocampus of WT and Nrf2
-/-
 mice, show a significant change in protein levels 
irrespective of treatment (mitofusin 1: p > 0.05, n = 9; Figure 4.21 F. Mitofusin 2: p > 
0.05, n = 9; Figure 4.21 G.). Finally, cortical mitofusin 1 is significantly lowered in the 
lysates of Nrf2
-/-
 mice treated with LPS, whilst no change is seen in WT mice even after 
LPS treatment (WT saline: 1.00; Nrf2
-/-
 saline: 1.10 ± 0.12; Nrf2
-/-
 LPS: 0.790 ± 0.070; 
WT saline vs Nrf2
-/-
 LPS p < 0.05, Nrf2
-/-
 saline vs Nrf2
-/-
 LPS p < 0.05, n = 9; Figure 
4.21 H). In contrast, a main effect of treatment is seen for Mitofusin 2, with both WT 
and Nrf2
-/-
 mice treated with LPS displaying a decrease in protein (WT saline: 1.00; WT 
LPS: 0.730 ± 0.054; Nrf2
-/-
 saline: 1.00 ± 0.11; Nrf2
-/-
 LPS: 0.757 ± 0.055; WT saline vs 
WT LPS p < 0.05, WT saline vs Nrf2
-/-
 LPS p < 0.05, Nrf2
-/-
 saline vs Nrf2
-/-
 LPS p = 
0.06, n = 9; Figure 4.21 I). Previous work has shown Mitofusin 1 and, in particular, 
Mitofusin 2 to be of importance in the targeting of mitochondria for degradation 
(Leboucher et al., 2012). As a result, peripheral LPS may be targeting mitochondria for 
degradation, potentially impacting on brain bioenergetics. 
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4.15 DISCUSSION 
4.15.1 The Effects of Nrf2-/- and LPS-Induced Inflammation on 
Behaviour May Highlight a Hippocampal-Dependent Memory 
Impairment 
LPS is frequently used in research to investigate the effects of inflammation and 
infection on disease pathways. Given the important role played by the spleen in the 
production of blood born immune cells in response to an immune challenge, the 
significant increase in spleen size following LPS treatment is a positive marker of an 
induction of peripheral inflammation in our mice. In addition treatment-dependent 
increases in liver size may also be attributable to activation of a peripheral inflammatory 
state due to the livers key role in detoxification. Previous work has reported an effect of 
LPS on weight, with animals administered LPS demonstrating treatment-dependent 
weight loss (Henry et al., 2008). Examination of weight change in our mouse cohort 
support this finding, with LPS treated mice showing acute weight loss in response to 
LPS injections. There was, however, no significant effect of genotype on the degree of 
weight-loss seen. This would indicate that the effects of LPS on weight loss are not 
directly related to the altered inflammatory response seen in mice lacking Nrf2, but 
rather on the well documented sickness behaviour often associated with LPS treatment. 
In addition, a stabilisation in body weight was observed which may be indicative of LPS 
tolerance. Previous studies have indicated an exacerbated response to LPS with ageing 
in mouse models (Godbout et al., 2007). The inability of our LPS-treated mice to make 
a return to baseline weight, as demonstrated by the maintained weight-loss on the final 
day of the study, may result from this aggravated stimulus response. However, due to 
the amount of weight-loss recorded, the short duration of the study is likely to have 
been insufficient to expect those mice treated with LPS to make up the weight deficit.
 
Memory impairments, sometimes in combination with changes from normal 
behaviour, are the predominant symptoms that prompt the diagnosis of dementia, with 
the majority of dementia cases subsequently attributed to AD. As a result of this, tasks 
assessing learning and memory have played an important role not only in the clinic, 
where they are used to assess disease progression and the effectiveness of novel 
therapeutics, but also in the assessment of animal models of dementia and AD. Many 
rodent behavioural tasks have been designed with the idea of modelling different 
aspects of cognition known to be affected in AD (see chapter 4.1 for some examples). 
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These tasks can be subdivided into categories based on the type of memory and 
behaviour tested and the resultant primary linked brain region. 
Much of the AD-related cognition work performed to date has made use of 
transgenic mice carrying either one or more of the mutations associated with FAD. 
From these models it has been possible to show that many demonstrate impaired 
cognitive behaviour over time in a variety of commonly assessed tasks. The case for 
inflammation-induced cognitive impairment is already well defined with several groups 
showing alterations in learning following a variety of inflammatory challenges. Some of 
which, such as LPS, have been shown to worsen cognitive performance with ageing 
(Kohman et al., 2007). However, despite the recent interest in Nrf2 with regards not 
only to AD but also to PD and other neurodegenerative disorders and the availability of 
transgenic knockout mouse models, there is very little published work investigating the 
impact of Nrf2 loss on cognition. As our interest in the Nrf2
-/-
 model is based on the 
potential role of Nrf2 in AD, we made use of a small selection of tasks to assess any 
impact on cognition that global loss of Nrf2 may have caused. In addition, we assessed 
a small number of the novel double transgenic model which incorporated both a loss of 
Nrf2 and the addition of hAPPswe; unfortunately genotyping issues (see Chapter 2.2.5.2) 
resulted in insufficient mice in each group to allow for them to be incorporated into the 
behavioural analysis. 
As described previously, NOR is classed as a recognition memory task and is 
one of the more commonly used tasks. We found that repeated peripheral LPS treatment 
impaired the ability of mice to successfully differentiate novelty in the NOR test, whilst 
saline-treated animals performed to a similar capacity irrespective of genotype. This 
response profile was altered when short-term OL recognition tasks were performed 
instead of NOR. Here, mice deficient in Nrf2 appeared completely incapable of 
performing the task under basal conditions in contrast to their saline-treated WT 
counterparts. This impaired response in the Nrf2
-/-
 was similar to that seen in WT mice 
following peripheral treatment with LPS. This suggests loss of Nrf2 alone is sufficient 
to negatively impact on important AD related brain regions. 
NOR, when lacking additional factors such as place and context, is no longer 
believed to require a fully functional hippocampus for task completion (Langston et al., 
2010) as demonstrated by studies using specific lesion models (Lee et al., 2005). 
Instead, the recognition memory required for successful participation in the NOR task is 
believed to be centred in the perirhinal cortex region of the MTL where short-term 
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memory retention is thought to be seated (Reger et al., 2009). Studies using lesion 
models of the perirhinal-postrhinal cortex and/or the hippocampus in behavioural 
paradigms for both spatial memory (Morris water maze, Radial maze, etc.) and 
spontaneous object recognition (NOR task variants) strongly suggest a distinctive task-
related regional involvement. Animals with hippocampal lesions present with intact 
basic object recognition but severely impaired spatial memory whilst the inverse is 
observed in those that have undergone perirhinal-postrhinal cortical lesions (Bussey et 
al., 1999; Winters et al., 2004). Whilst these findings have not been unanimous in 
nature, it has been suggested that studies implicating the hippocampus in spontaneous 
object recognition should be evaluated with care. Replication of certain lesion models 
previously implicating the hippocampus have been reported to occur alongside 
decreased exploration, which may act as a confounding factor on the evaluation of task 
completion and falsely implicate the lesioned area as necessary for the successful 
completion of basic object recognition (Ainge et al., 2006). It is also worth noting there 
remains some debate regarding long-term NOR, where there is a requirement for 
recollection that may involve additional brain regions. Studies performed using 
hippocampal lesion models have both supported and opposed a role for the 
hippocampus in memory retention (Hammond et al., 2004; Forwood et al., 2005), with 
some recent research advocating a role for the hippocampus in object recency memory 
instead (Albasser et al., 2012).  
In contrast, OL tasks, which rely on the integration of both recognition memory 
and spatial orientation, may more heavily involve the hippocampus in their encoding 
and retention (Barker & Warburton, 2011). However, the variation on OL task 
described here, sometimes referred to as an object-place task, is currently thought to be 
centred within the entorhinal cortex (Wilson et al., 2013), further supported by the lack 
of hippocampal involvement shown by Langston & Wood (2010). As such it may be of 
particular relevance for the further study of AD models, given that many of the initial 
pathological changes associated with AD are believed to occur within the entorhinal 
cortex. In addition, the behavioural pattern recorded here in Nrf2
-/-
 mice reflects that 
seen by Wilson et al. in their entorhinal cortex lesion model further supporting a role for 
entorhinal cortex impairment in these mice. This subtle difference in the brain region 
believed to play the dominant role in these tasks may help to explain the inability of 
Nrf2
-/-
 mice to fulfil the OL task (entorhinal cortex) whilst maintaining a similar 
cognitive ability to WT in the NOR task (perirhinal cortex). Furthermore, future 
research may benefit from specifically dissecting out the entorhinal region of the cortex 
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instead of the mixed cortical subdivision region overlaying the hippocampus that was 
dissected here, which will not incorporate the full entorhinal region. 
Finally, SA was performed in a closed arm elevated plus maze. This task can 
provide a different insight into the cognitive capacity of the model under consideration. 
The SA task, as described previously, has been reported to rely on any of spatial 
working memory, dead reckoning, self-movement cues and/or response strategies rather 
than the recognition memory needed for the NOR and OL tasks (McNay et al., 2000; 
Lennartz, 2008; Hargrave et al., 2015). In addition, it can provide a measure of 
locomotor ability by quantifying the number of arm entries performed within a finite 
time period. We saw no significant difference in SA, extrapolated from the continuous 
spontaneous alternation task, in any of the groups analysed at the time of testing. 
Furthermore, when tested no significant difference in locomotion was seen as measured 
by the number of arm entries performed, even following repeated LPS treatment. Joshi 
et al. (2014) also failed to find a difference in SA in a 3x Tg model of AD treated with 
LPS twice a week for six weeks suggesting this type of task may not be affected 
following treatment with LPS. Taken together this indicates that aged Nrf2
-/-
 mice may 
have an entorhinal cortex-dependent cognitive impairment demonstrated by their 
inability to perform the OL task, with no impairment to the perirhinal cortex. 
4.15.2 Inflammation and Cytokine Expression May Suggest a Role for 
Immune Cell Priming and Inflammasome Activation 
As predicted, examination of Nrf2
-/-
 mice showed an increased central 
inflammatory response to peripheral LPS treatment in keeping with previous in vitro 
and in vivo work using acute LPS stimulation (Thimmulappa et al., 2006). Increased 
basal expression of pro-inflammatory IL-1β in the hippocampus occurred in conjunction 
with increased protein carbonylation and increased F4/80 expression in mice lacking 
Nrf2
-/-
 when compared to the hippocampus of age-matched WT mice. In contrast, the 
cortex of Nrf2
-/-
 mice undergoes less basal inflammatory priming with only a small 
increase in IL-1β documented. Peripheral activation of the immune system by repeated 
LPS is able to induce a central inflammatory state in line with other published research 
(Henry et al., 2009; Bian et al., 2013; Biesmans et al., 2013; Thomson et al., 2014). In 
the hippocampus this is depicted by increased pro-inflammatory IL-1β as well as anti-
inflammatory MRC1 expression combined with increases in F4/80 expression as well as 
the chemokine MCP-1 in WT mice. Loss of Nrf2 in the hippocampus results in an 
aggravated response to a peripheral LPS-induced inflammatory challenge with further 
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induction of IL-1β and F4/80 above that displayed basally, combined with an increased 
presence of anti-inflammatory markers such as MRC1 and YM1. And whilst a small 
increase in pro-inflammatory markers such as IL-1β and protein carbonylation is seen in 
the cortex of Nrf2
-/-
 mice, this goes hand in hand with an increased anti-inflammatory 
profile (Arg1, MRC-1) with YM1 being increased over and above that seen in WT mice.  
It has been previously reported that there can be age-dependent changes in the 
sensitivity and susceptibility of mice to LPS (Tateda et al., 1996; Kohman et al., 2007; 
Chen et al., 2008; Henry et al., 2009). Research has indicated this holds true for mouse 
models of AD, with mice carrying the hAPPswe gene driven by the hamster prion protein 
(PrP) promoter showing increased basal inflammation with ageing combined with an 
aggravated response to acute LPS (Sly et al., 2001). Work done by Ifuku and colleagues 
(2012) has since shown a prolonged induction of IL-1β in combination with TNF-α in 
both the hippocampus and cortex of C57/Bl6J mice of a similar age to those used in the 
above cohort which differs from what we have reported here. However, although LPS 
was administered daily in a similar manner to that described here, the dose of LPS used 
was more than double that used for our cohort. This alone may account for the altered 
cytokine profile described. 
Limited research has been published to date looking at the changes in 
inflammation in the brains of mice lacking functional Nrf2. Of this, even less has 
investigated the effect of an inflammatory stimulus such as LPS on this transgenic 
background. However, activation of Nrf2 has been suggested as being protective in 
fighting against LPS-induced damage and inflammation in the brain and purified 
microglial cells (Lee et al., 2014; Qin et al., 2015). Loss of Nrf2 is implicated in an 
aggravated immune response to acute LPS treatment both in vivo and in vitro in isolated 
immune cells (Innamorato et al., 2008; Kong et al., 2010). It is possible that the lack of 
significant change in some of the markers commonly associated with inflammation, 
such as TNF-α, may be in part due to the development of a so-called adaptive response 
or tolerance which has previously been described in chronic models of LPS infection 
(Morris & Li, 2012). Furthermore, whilst acute activation of astrocytes has been 
reported in response to LPS administration, repeated LPS treatments have been 
demonstrated to result in reduced levels of GFAP expression further promoting the 
potential for a tolerance response (Biesmans et al., 2015). In addition, the duration of 
time between LPS administration and tissue harvest has been shown to influence the 
fluctuations in cytokine levels reported, with both acute and variations on repeated 
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injection models demonstrating time dependent alterations in cytokine profile (Erickson 
& Banks, 2011). However, it is worth noting that this tolerance effect is not necessarily 
indicative of an improved state of health as it can be linked with immunosuppressive 
pathology. With a decrease in synaptophysin in the cortex of LPS-treated mice, it would 
be foolish to assume that the improved inflammatory profile was indicative of cellular 
health. Nevertheless, it is clear from the data presented that not all immune signalling 
has been curbed following chronic administration of LPS as there is clearly a 
maintained upregulation in IL-1β signalling in addition to glial cell activation.  
IL-1β signalling, as previously described (see chapter 1.5.3.1), is an important 
modulator of the body’s pro-inflammatory response. It has been shown to activate and 
be released from a variety of immune cells, including macrophages, in addition to 
resident brain cells such as astrocytes and microglia under conditions of gliosis (Goshen 
& Yirmiya, 2009). IL-1β is capable of activating a multitude of immune-related 
pathways including the stress-related NF-κB pathway and members of the MAPK 
family, such as JNK. Activation of the PRR TLRs by PAMP (e.g. LPS) and DAMP 
(e.g. Aβ) compounds is known to induce IL-1β release through priming of 
inflammasomes, as is initiation of the complement cascade. Instigation of many of these 
pathways causes positive feedback enabling further production and transcription of IL-
1β, producing a self-perpetuating state unless interrupted. There are a variety of points 
at which this signalling can be affected and these can include sequestration of PAMP 
receptors such as TLR4, activation of ‘signal transducer and activator of transcription 3’ 
signalling as well as increased specific DUSP activity downregulating the MAPK stress 
response. One of the most important mediating factors, however, is the inhibition of 
inflammasome production as this has recently been shown to promote the propagation 
of inflammation from cell to cell (Franklin et al., 2014). The presence of 
inflammasomes has also been corroborated in both in vitro and in vivo models of AD, 
whilst post-mortem tissue from AD patients showed elevate cleaved caspase-1 in both 
the frontal cortex and hippocampus (Heneka et al., 2013; Sheedy et al., 2013). In light 
of the results described above, it would be of particular interest to see if the exacerbated 
IL-1β signalling seen in Nrf2-/- mice is down to increased inflammasome production and 
whether this occurs in an age dependent manner. In support of a role for inflammasome 
activation, recent work into treatment of rheumatoid arthritis has put forward a role for 
Nrf2 activation and the subsequent antioxidant gene activation in the suppression of 
both NLRP3 and NLRC4 inflammasomes in bone marrow derived macrophages 
(BMDM; Rzepecka et al., 2015). However, decreased expression of NLRP3 and NLRC4 
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were also seen under basal conditions in the BMDMs derived from Nrf2
-/-
 mice, 
indicating the involvement of a more complex mechanism than may have initially been 
hypothesised. 
4.15.3 Seven Day LPS Exposure Induced Little Change in AD-Related 
Proteins 
A role for inflammation has already been suggested in the development and 
progression of neurodegenerative disease and a variety of studies have suggested an 
effect of LPS on amyloid production in vitro (Spitzer et al., 2010). We failed to see an 
increase in BACE1 protein following LPS treatment, with cortical lysates even 
reporting a drop in BACE1 levels following treatment with LPS. In addition, despite a 
small reduction in the gene expression of both mAPP and BACE1 in the hippocampus of 
WT mice treated with LPS, this did not translate to any treatment dependent alteration 
in protein levels. Activation of BACE1 following the application of common stressors 
has been established using a variety of different models (Cole & Vassar, 2007). It is 
possible that the increased anti-inflammatory profile combined with the decrease in 
protein levels are in accordance with the development of LPS tolerance and an 
associated move towards resolution of the inflammatory state. This may then be present 
at a more advanced stage in the cortex than in the hippocampus. In addition, despite a 
small induction in APP protein levels in the hippocampus of Nrf2
-/-
 mice, no effect of 
treatment was observed in either tissue. Furthermore, although an increase in APP 
expression is seen in the Nrf2
-/-
/hAPPswe this corresponds with the added insertion of 
hAPP and there is no indication of further amplification following LPS treatment. 
Indeed, a similar BACE1 profile is seen to that of the other groups with a decrease in 
BACE1 in the cortex following treatment.  
In keeping with what we found, a study published by Kitazawa and colleagues 
(2005) showed no effect of LPS on amyloid-related markers in a 3x Tg AD mouse 
model but instead reported increased tau phosphorylation, which has since been 
supported by additional studies (Sy et al., 2011). This is in contrast to work done by 
Sheng et al. (2003), who reported increased APP expression as well as an increase in 
Aβ accumulation in twelve month old PrP driven hAPPswe transgenic mice. However, 
with a protocol that consisted of weekly LPS injections for a period of twelve weeks, 
the increased study duration may be of importance in detecting the changes observed by 
Sheng et al.. Moreover, despite LPS treatment causing a significant increase in total tau 
protein in WT mice, alterations in Nrf2
-/-
 mice appear to be driven by genotype with no 
221 
further induction following treatment. And although only one of the known tau 
phosphorylation sites was blotted for, no overt treatment-induced changes were seen. 
More in depth tau pathology analysis from Frank LaFerla’s lab has suggested an effect 
of LPS on tau pathology in a 3x Tg model of AD (Kitazawa et al., 2005; Sy et al., 
2011). This is compounded by a recent publication describing a potential link between 
Nrf2 loss and aggravated tau pathology, with Nrf2 reportedly aiding in the clearance of 
phosphorylated tau through the autophagy adaptor protein NDP52 (Jo et al., 2014). 
Because of this, it may be worth pursuing this avenue further by making use of the 
markers highlighted in their research to clarify whether our cohort mimics any of these 
changes. As it stands, the results presented here suggest that the concentration of LPS 
used for the duration indicated impacted minimally on these AD pathologies. 
4.15.4 Loss of Nrf2 Causes Dysregulation of Members of the MAPK 
Family 
We have previously described important impacts of Nrf2 loss on insulin 
signalling pathway in the liver made more apparent following HF feeding (Meakin et 
al., 2014). It has been previously established that the insulin pathway can exert 
protective effects on cell survival, and in vitro work has implicated PI3-K in the 
mediation of key Nrf2 activated antioxidant genes such as HMOX1 (Nakaso et al., 
2003). We therefore wanted to assess whether the addition of a well-established 
alternative stress, LPS, would impact on known insulin activated pathways. However, 
when we analysed the PI3-K dependent phosphorylation of Akt at Ser473 we saw no 
change in the levels of phosphorylation in WT and Nrf2
-/-
 mice, and only a small drop in 
Thr308 phosphorylation in the cortex of Nrf2
-/-
 mice. This contrasts with recent research 
that has proposed insulin can attenuate LPS-induced alterations in iNOS and NF-κB 
signalling in astrocytes in vitro, supported by alterations in Akt phosphorylation (Li et 
al., 2013). In addition, NF-κB, which is known to be affected by a variety of different 
signalling pathways in response to stress, showed minimal genotype or treatment 
dependent effects as measured by the levels of the inhibitory IκBα molecule. This may 
run contrary to initial expectations, with previous studies demonstrating that LPS can 
induce activation of the NF-κB pathway (Gorina et al., 2011). Moreover, several 
compounds shown to attenuate LPS-induced inflammation have been suggested to act 
through manipulation of the NF-κB pathway (Lee et al., 2012b). Furthermore, GCLC 
which is rate limiting in the synthesis of glutathione also failed to show any significant 
alteration following either genotypic or treatment manipulation. Although, Nagai and 
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colleagues (2009) reported an LPS dependent drop in glutamate cysteine ligase modifier 
subunit (GCLM) gene expression, the other half of the GCL heterodimer, in the retinas 
of WT mice with Nrf2
-/-
 mice recording constitutively lower expression. However, with 
no measurement of protein these results are not directly comparable to those reported 
here. 
MAPK proteins are activated by a variety of different pathways including 
various stress related factors such as inflammatory cytokines. Furthermore, LPS has 
been shown to activate MAPK signalling, and increased MAPK signalling is known to 
occur in both activated astrocytes and microglia (Kaminska et al., 2009). Able to govern 
a variety of outputs, MAPK cover a wide range of tasks from cytokine production, to 
regulation of apoptosis to cell migration and proliferation. We have already shown that 
high-fat feeding causes a dysregulated MAPK response in Nrf2
-/-
 mice, whilst both LPS 
treatment and Nrf2 induction have been linked with MAPK signalling (Kim et al., 
2010). We were therefore interested to see whether the altered MAPK signalling 
reported in HF-fed mice was replicated under an alternate stressor model. No change in 
the levels of hippocampal JNK phosphorylation were seen, contrary to the effects 
reported from long-term HF-feeding; and whilst a trend towards increased cortical 
phosphorylation was observed in LPS-treated WT mice, Nrf2
-/-
 mice and Nrf2
-/-
/hAPPswe 
mice this failed to reach significance. Given that JNK phosphorylation has been linked 
with LPS treatment as well as being implicated in amyloid processing, a lack of JNK 
activation may support a state of LPS tolerance. In contrast, ERK MAPK 
phosphorylation was seen in both the hippocampus and cortex of LPS treated WT mice, 
with both genotype and treatment driven increases in phosphorylation seen in Nrf2
-/-
 
mice. Unlike HF feeding, LPS treatment only produced a moderate increase in 
phosphorylation of both ERK isoforms. However, a recent publication by Bellaver et al. 
(2015) indicated that phosphorylation of MAPK proteins such as p38 and ERK may be 
detrimental to the resolution of LPS-related inflammation. Therefore whilst 
phosphorylation of ERK is important for many cellular functions, following LPS 
treatment it is able to help perpetuate the inflammatory response and therefore may be 
detrimental in action. 
4.15.5 Loss of Nrf2 Impacts on Mitochondrial Function Following LPS-
Induced Inflammation 
In addition to their important role in energy homeostasis and their susceptibility 
to ROS, dysfunction of mitochondria is known to increase with ageing and has 
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previously been linked with neurodegenerative disorders such as PD (Hunter et al., 
2007). In conjunction with the alterations in MAPK mentioned above, Emre et al. 
(2007) described a link between altered mitochondrial ROS production and MAPK 
activity in macrophages following LPS treatment. Uncoupling protein 2, a carrier 
protein able to negatively regulate mitochondrial ROS production was shown to be 
downregulated following LPS treatment. Moreover, THP-1 human leukaemia 
monocytic macrophage cells exposed to mitochondrial extracts underwent a similar 
response to that seen following LPS administration, with further work supporting the 
presence of the LPS receptor TLR4 within mitochondria (Nicholas et al., 2011). We 
found no changes in hippocampal mitochondrial proteins assessed in any of the groups 
analysed. Furthermore, there was no change in the mitochondrial channel protein 
VDAC1 in the cortical lysates of any of the mice investigated. However, cortical 
expression of COX IV was diminished in both LPS-treated WT mice and saline treated 
Nrf2
-/-
 mice. This may implicate changes in the electron chain management of 
mitochondria following challenge with LPS. It also suggests the loss of Nrf2 may be 
influential in maintaining mitochondrial health. Moreover, whilst LPS decreased the 
level of mitofusin 2 in the cortex of WT mice, mitofusin 1 and 2 were significantly 
decreased in the LPS-treated Nrf2
-/-
 mice. This suggests an increase in mitochondrial 
fission and at the very least would support a drop in mitochondrial fusion.  
Changes in mitofusin proteins have been associated with increased 
mitochondrial dysfunction. Indeed, a reduction in mitofusin proteins is associated with 
increased targeting of mitochondria for degradation. This is corroborated by recent 
research demonstrating that low-dose LPS causes a reduction in mitofusin 1 whilst 
concomitantly promoting mitochondrial fusion through the de-phosphorylation of 
dynamin-related protein 1 in BMDMs  (Baker et al., 2014). These findings are of 
particular interest in light of recent studies using cybrid cell models which link 
increased ERK phosphorylation in AD patients with perturbation of mitochondrial 
fission and fusion markers leading to defects in mitochondrial function (Gan et al., 
2014). This supports prior research where analysis of frontal cortex samples from AD 
patients, with diagnoses ranging from mild to severe, showed a similar disconnect in 
mitochondrial protein levels (Manczak et al., 2011). Furthermore, whilst not fully 
replicative, data from a double transgenic APP/PSEN1 mouse model supported a role 
for dysregulation of mitochondrial fission/fusion in AD (Wu et al., 2014). Finally, 
inflammasome activation has been shown to occur as a result of translocation to the 
mitochondria and through release of mitochondrial ROS (Zhou et al., 2011), both of 
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which are likely to be increased following impairment in the ability of mitochondria to 
undergo fission/fusion. When combined, these facts support the importance of further 
investigation of the mitochondrial-related alterations observed. In particular, this 
advocates the importance of quantifying crucial fission-related proteins as this will 
enable us to fully assess the impact of the factors involved in our models on 
mitochondrial dynamics and may also suggest further mechanisms to pursue. 
4.15.6 Conclusions 
In addition to LPS-induced cognitive deficits, loss of Nrf2 appears to negatively 
impact on cognition in entorhinal cortex dependent tasks such as OL. There is limited 
other published research looking at the behavioural impact of Nrf2 loss to date, with the 
little available concentrating on mobility driven tasks. Given the changes reported here, 
in combination with both the detrimental effect of inflammation and the beneficial 
effect of Nrf2 activation on cognition, this is an avenue worthy of further investigation. 
Loss of Nrf2 aggravated the inflammatory response to LPS in line with previous 
research published. However, little alteration was seen in the stress activated pathways 
of NF-κB and glutathione, nor was there any change in the insulin sensitive Akt 
pathway. This may result from the timeframe used for this study as it has been 
previously established that LPS-activation of the immune system can be prompted into 
a state of tolerance after repeated exposures. An intriguing avenue of further research 
would be to investigate the potential alteration in inflammasome production and 
signalling in light of the increased IL-1β expression seen in the Nrf2-/- mice. A link 
between these factors may provide important information on the development of 
inflammation given the age associated decline seen in Nrf2 expression in humans. 
We were unable to show any effect of LPS on APP protein levels, whilst 
BACE1 levels were decreased in the cortex of treated mice in contrast to previous 
publications which have reported increased processing of APP through the β-secretase 
pathway. In contrast, both lack of Nrf2 and LPS treatment affect the relative 
phosphorylation of MAPK proteins JNK and ERK with brain region specific changes 
observed. This is of interest as MAPK activation has previously been suggested to 
influence amyloid metabolism. Moreover, ERK MAPK is known to be affected by 
insulin signalling, which we have previously shown to be altered in Nrf2
-/-
 mice. 
Finally, alterations in MAPK signalling combine with changes in electron transport 
chain and mitochondrial fusion markers, indicating a potentially important role of 
mitochondrial dysfunction following LPS-induced inflammation. This dysfunction 
225 
appears aggravated by the loss of Nrf2, making the phenotyping of Nrf2
-/-
 mitochondria 
an avenue worth clarifying further. Mitochondrial dysfunction is often associated with 
increased ROS production, altered energy homeostasis, activation of inflammasomes 
and increased ER stress; all of which have been linked with AD pathology and 
progression making it an important target in future AD research.
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5 FINAL CONCLUSIONS AND 
FURTHER WORK 
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5.1 MOUSE MODELS IN AD: BREAKTHROUGHS, SHORTFALLS AND THE 
AMYLOID CASCADE 
Rodent models have always played an important role in the progression of 
research; allowing the evolution from biochemistry orientated mechanistic research 
utilising a vast array of in vitro models to more heavily physiologically driven studies 
incorporating effects of cellular and organ crosstalk. AD is no exception to this rule, 
indeed given that the greatest predictor of AD is age, the use of rodent models, with 
their shorter lifespan, is of particular importance. Furthermore, the lack of firm disease 
aetiology and the failure of rodents to present key disease-associated pathologies, make 
the modelling of AD both more complex but also crucial to the better understanding of 
its pathology, progression and treatment. The discovery of the first gene mutation 
(hAPPswe) associated with FAD by Mullan and colleagues (1992) was a major 
breakthrough in the furthering of understanding of the mechanisms likely to be involved 
in the development of sporadic AD. 
The first transgenic mouse models carrying FAD related mutations were 
developed by Games et al. (APPV717F; 1995) and Hsiao et al. (APPK670N/M671L;1996). The 
incorporation of FAD mutations allowing the development of models that demonstrated 
comparative AD pathology drove an explosion in the development of new animal 
disease models of AD. By the mid 1990’s, the first mouse model carrying mutations on 
two separate AD related genes had been developed (PSEN1A246E/APPswe; Borchelt et al., 
1996), whilst the turn of the century saw the development of the first mouse model 
carrying a double mutation on the APP protein (APPV717F/APPK670N/M671L; Mucke, 2000). 
Animal models presenting tau inclusions have also been developed, furthering 
understanding of the likely involvement and progression of tau dysregulation in AD. 
However, the genetic mutations that have so far been found in tau protein are not ones 
that have been associated with AD, being largely related to tauopathies from a subset of 
other diseases including FTD. Furthermore, the discovery of mutations within the tau 
protein has enabled the development of the highly popular triple transgenic mouse 
model (hAPPK670N/M671L, PSEN1M146V and htauP301L) of AD or 3x Tg model (Oddo et al., 
2003). This model was one of the first models able to replicate both amyloid plaque and 
tau tangle pathology in the same animal, and has also been shown to develop age-
dependent cognitive decline and synapse loss (Oddo et al., 2003; Filali et al., 2012). 
However, it is worth noting that the models described above all require a considerable 
amplification in the expression of the inserted proteins in order to observe the 
228 
pathological changes recorded. Therefore, the physiological relevance of some of these 
results may be skewed due to the excessive protein production. 
In recent years, research interests have spread to incorporate other factors as 
they have grown in importance and relevance to AD. Our model, combining the 
depleted antioxidant response with a mild model of FAD was designed in an attempt to 
model the environment which might be present in the very early stages of AD. It was 
hypothesised that the loss of Nrf2 might act in a priming manner on key immune cells, 
such as the microglia and astrocytes in the brain. In addition, increased ROS production 
and basal inflammation from the imbalance in resolution capacity induced by Nrf2 loss 
would lead to a state of chronic low-grade inflammation. Combined with the presence 
of hAPPswe which is more susceptible to cleavage by β-secretase and therefore has 
increased Aβ production, low grade inflammation was hypothesised to potentiate the 
pro-amyloidogenic processing of APP, promoting the cascade of events culminating in 
AD related pathology. However, the AD model chosen, whilst deliberately picked as 
one of the more physiologically relevant models available, we now believe may have 
been too mild to provide sufficient impetus to initiate the cascade of events, especially 
when maintained on a heterozygotic background. In comparison, the novel model 
produced by Joshi et al. (2015) incorporating a more aggressive APPswe/PSEN1 AD 
mouse model, demonstrated clear alterations in amyloid pathology, indicating that this 
is an avenue that is still worth pursuing. 
5.2 LOSS OF NRF2 AND THE ALTERED RESPONSE TO DIO AND PATHOGEN 
ASSOCIATED INFLAMMATION 
Since the development of these early models, many more have been developed, 
in part, as a result of the increasing number of FAD related mutations that have been 
discovered. Moreover, models incorporating other risk factors associated with AD have 
also been created such as those crossing known FAD mutations with human APO-ε 
isoforms, or more recently, models targeting parts of the immune system such as those 
lacking the fractalkine receptor CX3CR1, which is located predominantly within the 
CNS. Following the recent increased interest in inflammation in AD, CX3CR1
-/-
 mice 
have been crossed with both tau and Aβ transgenic mouse models with opposite results, 
indicating the key and complex role played by the immune system in the regulation of 
pathological factors within AD. Furthermore, and given the importance of age related 
changes in AD, the development of the senescence-accelerated prone mouse (SAMP) 
models and their control strains (senescence-accelerated resistant mouse (SAMR) 
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models) may play a crucial role in incorporating natural ageing factors into the equation. 
Something that has, to date, been lacking in many models of AD given their accelerated 
profile of pathology. The complexity of AD development and the growing number of 
factors believed to be implicated in its progression mean that modelling basic AD 
pathology is unlikely to be sufficient to recapitulate sufficient disease related factors in 
order to mimic the environment likely involved in disease initiation. With this in mind 
we decided to add additional environmental challenges to our models using factors that 
have previously been linked with AD in human patients.  
Two different challenges of HF feeding and pathogen-driven inflammation were 
used to provide a trigger for the primed environment created by the loss of Nrf2. 
Publications using HF-feeding on mouse models of amyloid pathology have previously 
indicated a role for altered APP processing in insulin regulation, weight-gain and in 
some cases increased disease pathology. Even with our mild model we were able to 
replicate the dysregulation of insulin signalling and the increased weight-gain in our 
hAPPswe model following long-term HF feeding. However, we were unable to record 
any changes in amyloid production, indicating that the significant build-up of amyloid 
plaque deposition seen in many of the more aggressive models of AD in use is less 
likely to be causative in the altered insulin regulation observed. In addition, the lack of 
detectable plaque deposition in these mice may account for the lack of inflammatory 
response observed. Further investigation, particularly of the DAMP/PAMP driven 
inflammasome pathway, which is known to be activated by Aβ may be crucial in further 
understanding the responses, or lack thereof, observed in these mice. It is possible that 
the lack of substantial inflammatory response observed in our mouse model of AD 
(hAPPswe) may correlate with a lack of inflammasome activation, in light of the much 
lower levels of Aβ previously reported in this model compared to others currently in 
use. Furthermore, whilst loss of Nrf2 has the opposite effect on both insulin signalling 
and weight-gain, the more surprising outcome was the apparent protective effect exerted 
by long term HF feeding, which contrasts with that reported for the liver work done on 
these mice (Sugimoto et al., 2010; Okada et al., 2013; Meakin et al., 2014). This 
indicates a crucial role for Nrf2 in the regulation of tissue health in relation to changes 
in glucose and insulin homeostasis. Crucially this may indicate that a more relevant and 
important model to test would replace the HF feeding reported here with a calorie 
restriction model. The steady decrease in Nrf2 previously recorded in humans following 
ageing and the link between ageing and declining body weight may suggest this is a 
more physiologically relevant model in neurodegeneration. In addition, whilst obesity in 
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midlife has previously associated with increased with the development of AD, a recent 
study published by Qizilbash et al. (2015) has suggested the opposite may actually be 
true as they reported decreasing risk of AD with every increase in BMI grouping 
assessed. 
Development of obesity has long been linked with the development of a chronic 
low grade inflammatory response, whilst the ability of our immune system to respond to 
challenges correlates negatively with ageing, hence the impaired response to infection in 
aged populations. We have been able to show that following ageing, mice lacking Nrf2 
have basally elevated markers of inflammation within the brain which can be further 
potentiated by administration of an infection related marker such as LPS. With little 
information available regarding the effects of Nrf2 in the brain it is impossible at this 
stage to say whether this inflammation is present from a young age or slowly 
accumulates with ageing. However, the two studies described here suggest that there 
may be a strong role for ageing in the aggravation of the inflammatory state with basal 
levels of commonly assessed inflammatory markers increased in mice at 16 months (HF 
study) when compared to those recorded at 11 months (LPS study). This further 
enforces the importance of looking at mouse models that incorporate ageing related 
factors, such as the SAMP models, as key changes may be lacking in mouse models 
assessed at a younger age even if those models demonstrate relevant pathological 
alterations associated with AD. In addition, a recent publication using the SAMP8 and 
SAMR8 mouse lines was able to demonstrate age related decreases in Nrf2 expression 
in the liver of the SAMP8 but not SAMR8 mice further supporting the potentially 
important role of Nrf2 loss in ageing related impairments (Tomobe et al., 2012). 
5.3 LOSS OF NRF2 AND THE IMPACT THIS MAY HAVE ON AGE RELATED 
COGNITIVE DECLINE 
Following on from the links described above between inflammation and ageing 
in the Nrf2
-/-
 mice, this facet may also be of importance when assessing the impact of 
different interventions on cognition. It has already been described in various reviews 
that the design of the AD mouse model chosen can have major implications on the 
degree of cognitive impairment observed and the behavioural tasks that report the most 
significant impairments (Webster et al., 2014).Models such as the 3x Tg model may 
show cognitive deficits as early as 3-5 months of age, whilst the Tg2576 mouse model 
has shown less consistent behavioural changes with some groups reporting changes as 
early 5 months and others only seeing changes in more aged mice (King & Arendash, 
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2002; Westerman et al., 2002). In addition to the inherent differences reported between 
mouse models, the choice of behavioural task assessed can also have a significant role 
in whether cognitive impairment is reported or not. Tasks such as the MWM, often 
referred to as the gold standard for assessment of spatial memory in rodent models, 
appear to demonstrate consistent impairment in the majority of AD models assessed. 
Other tasks, such as NOR, have been less consistent in both the age of onset of 
impairment and even whether any impairment has been recorded. However, it is worth 
noting that there is often increased variability in the exact set-up and measurements 
done in the NOR task, and these may impact heavily on the degree of variability 
reported across publications (Antunes & Biala, 2012).  
There are some publications available using the same hAPPswe model as what we 
have described in our results (Subaiea et al., 2013); although these are not as numerous 
as those for other models with accelerated pathology. However, very little has been 
published on the effects of Nrf2 loss on cognition, particularly in relation to ageing. 
What little has been published has suggested there may be a role for depletion of Nrf2 in 
protection against the forced swim task, and further hypothesises a role for altered 
neuronal signalling in Nrf2
-/-
 mice (Muramatsu et al., 2013). Further to this, Furnari et 
al. (2014) reported a mild impairment in Nrf2
-/-
 mice in the MWM, where they had 
increased latency in locating the visible platform during the test when compared to WT 
mice. Our novel work in aged Nrf2
-/-
 mice suggests that these may develop entorhinal 
cortex dependent cognitive impairment with ageing, whilst maintaining their ability to 
partake in tasks that rely more on the perirhinal cortex for successful completion. This 
further supports the need for more detailed characterisation of the Nrf2
-/-
 model with 
regards to ageing and its potential involvement in neurodegenerative disorders.  
It is unlikely that the drop in Nrf2
 
expression alone would be sufficient to induce 
the effects seen in the early stages of AD, else it might be expected the number of AD 
cases reported would be exponentially larger than what is currently observed. Instead, it 
is more probable that other factors act to tip the scales towards a favourable 
environment for AD development. This promotes the importance of assessing other 
environmental factors on the progression of AD like pathology, particularly in more 
physiologically relevant models. Factors such as obesity and TIID are obvious targets of 
environmental stress in the study of AD and there is a growing amount of work being 
devoted to modelling these changes, including the work reported here. However, other 
effects may prove to be equally important such as the incorporation of factors including 
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environmental enrichment (Maesako et al., 2012a; Williamson et al., 2012; Barak et al., 
2013; Verret et al., 2013), environmental impoverishment and stress (Jeong et al., 2006; 
Diniz et al., 2010; Perez Nievas et al., 2011), and the potential interaction of long term 
medications such as statins and non-steroidal anti-inflammatory drugs (Daneschvar et 
al., 2015); many of which have been suggested to impact on disease development. 
5.4 A ROLE FOR NRF2 IN THE REGULATION OF MAPK SIGNALLING AND 
ITS IMPACT IN AD 
The results obtained from our Nrf2
-/-
 mouse models also provided novel 
information regarding the role of MAPK proteins in the brain. We found significant 
activation of the ERK specific MEK protein in the brains of mice lacking Nrf2, which 
long-term treatment with HF feeding failed to reduce as was seen in the HF fed WT 
mice. It has previously been suggested that MAPK enzymes lie upstream of Nrf2 
activation in a variety of in vitro cell culture models (Correa et al., 2011; Ernst et al., 
2011), whilst dendritic cells lacking Nrf2 have been reported to demonstrate a mild 
increase in ERK and p38 phosphorylation following challenge with LPS (Yeang et al., 
2012). Although there is limited research on the role of ERK in Nrf2
-/-
 mice, ERK has 
previously been suggested to have neuroprotective effects. Furthermore, the Nrf2 
activator tBHQ has been suggested to act in a protective manner via alternative 
pathways when Nrf2 expression is silenced. Recent work by Li et al. (2014) using 
primary hepatocyte cultures has reported that after silencing of Nrf2, addition of tBHQ 
is still able to produce a protective effect against lipotoxicity. The mechanisms utilised 
to produce this effect have been suggested to include increased autophagy, increased 
AMPK phosphorylation and increased phosphorylation of ERK MAPK. Furthermore, a 
study investigating the protective effects of argon has suggested a protective role for 
ERK phosphorylation following retinal ischaemia and reperfusion injury (Ulbrich et al., 
2015). This was suggested to occur by decreasing both Nrf2 dependent HMOX1 
expression and pro-apoptotic caspase-3. Finally, the anti-epileptic drug valproic acid has 
been hypothesised to exert protective effects over traumatic brain injury via Akt and 
ERK activating pathways (Zhang et al., 2014). 
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Figure 5.1 Simplified pictorial summary of some of the principle biochemical 
alterations observed in completion of this project. 
The overall effects of long-term HF diet or repeated peripheral LPS driven alterations in the 
brains of WT (A) and Nrf2
-/-
 (B) mice. Where FA = fatty acids, oxLDL = oxidised low-density 
lipoprotein, Mt = mitochondria and Pi = phosphate. The red rings depict potential areas of 
damage or activation that necessitate further investigation in order to achieve a clearer 
understanding. 
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Other members of the MAPK enzyme family, such as p38 and JNK, have been 
suggested to interact with Aβ, implicating a role for MAPK activity in the propagation 
of Aβ pathology (Tamagno et al., 2005; Quiroz-Baez et al., 2009; Tamagno et al., 2009; 
Mazzitelli et al., 2011). This suggests MAPK enzymes interact in a key manner across 
multiple pathways and may be important in the switch from neuroprotective effects to 
amyloidogenic effects. However, further work is required to gain understanding of the 
mechanisms responsible for these regulations both in the absence of Nrf2, but also in 
AD models. 
5.5 MITOCHONDRIA, ER STRESS AND THEIR IMPORTANCE IN FURTHER 
AD RESEARCH 
Previously associated solely with the turnover of ATP within the cell, 
mitochondria are being studied increasingly with regard to their ability to interact in a 
sophisticated manner to their cellular environment. Mitochondria are the primary source 
of ROS production. In addition, oxidative damage to mitochondrial components has 
been suggested to occur prior to that of other areas within the cell in the development of 
neurodegenerative disorders such as AD (Selfridge et al., 2013). Increasingly, research 
is indicating an important role in altered mitochondrial status in the progression of AD 
with changes in mitochondrial fusion/fission and membrane potential already having 
been reported in both mouse models of AD and tissue samples from post-mortem AD 
brains (Manczak et al., 2011). In addition, it has previously been shown that 
mitochondria are able to uptake Aβ, with mitochondria from AD models showing 
accumulation of Aβ within the organelle (Pinho et al., 2014). Furthermore, altered 
mitochondrial functionality can directly impact on energy homeostasis known to be 
progressively affected in AD and related research models (Yao et al., 2009). This is 
particularly important in light of the design of our model described here and that 
described by Joshi et al. (2015) given the recent findings that Nrf2 is able to directly 
regulate mitochondrial bioenergetics by regulating substrate availability (Holmström et 
al., 2013). 
Whilst mitochondrial impairment has been suggested to be involved in AD from 
as early as the mid 1980’s (Selfridge et al., 2013), interest in the interaction between 
Nrf2 and mitochondria has grown exponentially, particularly in the last few years. The 
suggested direct interaction between Nrf2 and mitochondrial bioenergetics described by 
Holmström et al. (2013), in combination with the crucial role of Nrf2 in regulating 
mitochondrial ROS levels (Kovac et al., 2015), and the close link between ER stress 
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and mitochondrial dysfunction (Marchi et al., 2014; Rainbolt et al., 2014), all combine 
to implicate an important role for Nrf2 in the regulation and dysregulation of 
mitochondria during ageing. This supports the early findings we have described in our 
mouse models. In addition, the strong links now indicated between APP, amyloid, the 
ER and mitochondria suggest a co-localisation of both the toxic pathology associated 
with AD alongside regions now believed to be strongly reliant on Nrf2 for maintained 
functioning. The growing research surrounding the role of mitochondria-associated ER 
membranes (MAMs) in the development of AD, serves to highlight the importance of 
further understanding the role of both the ER and mitochondria within AD development 
(Area‐Gomez et al., 2012; Hedskog et al., 2013). This is supported by animal studies 
that indicate mitochondrial dysfunction has been shown to occur prior to the 
development of plaque pathology (Wu et al., 2014). Taken together this further supports 
the need to investigate markers of ER stress in our model detailed here, but also 
highlights the need for better understanding of the intricate crosstalk occurring between 
mitochondria, Nrf2, the ER and amyloid pathology; where MAMs may play a crucial 
linking role between these different components. On a final note, as has been previously 
suggested here these alterations may also further support a role for the inflammasome 
pathway, especially given its strong ties not only with mitochondrial dysfunction but 
also dysregulated APP cleavage and Aβ production (Salminen et al., 2008; Kapetanovic 
et al.). 
5.6 STUDY LIMITATIONS 
The main aim of this study was to provide a novel model describing some of the 
key factors involved in early AD pathology. Although the phenotype was very mild 
with apparent limited effects, the studies themselves have illuminated some key 
limitations as to why this may have occurred. One of the key limitations for these 
studies has been linked to the genotyping issues that occurred (see Chapter 2.2.5.2), 
resulting in a loss of statistical power as well as reducing the number of mice available 
carrying either the hAPPswe mutation alone or in combination with the disrupted Nrf2 
gene. However, the publishing of a paper by Joshi and colleagues (2015) describing a 
novel triple transgenic model (APP/PSEN/Nrf2
-/-
) suggests that this avenue may still be 
worth pursuing further albeit from a slightly different angle.  
The second major study limitation was unknown at the time of study 
commencement given the literature available, and revolves around the role of Nrf2 loss 
in tissues outside of the liver and WAT. Our attempts to elucidate the importance of the 
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transcription factor Nrf2 centrally, has subsequently raised some questions about the 
limitations of using a global Nrf2
-/-
 model and the role for alternative compensatory 
mechanisms. The apparently blunted effects reported here in the brain, in comparison to 
those previously reported in the liver, have been supported recently by studies in other 
Nrf2
-/-
 tissues. Recent research looking at the effect of ultraviolet radiation on skin in 
mice either lacking (Nrf2
-/-
) or overexpressing (Keap1 KD) Nrf2, failed to see the same 
degree of attenuation of downstream molecules in mice lacking Nrf2 (Knatko et al., 
2015). This was also characterized by a much milder phenotype than that previously 
observed in hepatic studies. Overall, this indicates a potential for markedly differential 
tissue related effects for this model, which should be used as a marker of caution when 
designing future experiments. 
Finally, some technical limitations were also inherent to our studies, as is the 
case in most research. Additional behavioural testing would have been very interesting 
to pursue, in particular some of the commonly used hippocampal dependent tasks 
(MWM, radial arm maze). In addition, the small size of the mouse limits the volume of 
dissected cerebral tissue available, which in turn can impact in the number of assays that 
can be performed using the tissue from any single animal. Some of these problems 
could soon be addressed by switching to one of the newly developed Nrf2
-/-
 rat models, 
such as that described by Priestley et al. (2015), for future experiments. This may also 
be a beneficial move from a behavioural standpoint, given the increased complexity of 
tasks that are commonly used when studying rats over mice. 
5.7 PHYSIOLOGICAL RELEVANCE  
The importance placed on the role of inflammation in the brain of many 
neurodegenerative disorders has grown in recent years and has led to various clinical 
trials being put in place. Unfortunately the evidence from these trials is mixed and 
therefore harder to interpret. Clinical trials in addition to retrospective studies 
investigating the effects of long-term prescription of drugs such as non-steroidal anti-
inflammatory drugs and statins have so far provided evidence both for and against their 
relevance in the treatment of AD (de Jong et al., 2008; Daneschvar et al., 2015). 
However, recent research published by researchers from the Gladstone Institute in 
California suggests that there may yet be potential in this field (Min et al., 2015). Min 
and colleagues demonstrated a protective effect of the arthritis NSAID drug Salsalate on 
the propagation of detrimental tau inclusions. In contrast, the mitochondria targeted 
antioxidant compound, MitoQ, failed to show any amelioration in disease progression 
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of PD, although improvements were observed in a trial of MitoQ on liver damage 
resulting from chronic hepatitis C virus (Smith & Murphy, 2010). It should be noted 
that inflammation remains a hot topic within AD research. This is exemplified by the 
media coverage surrounding the publication by Olmos-Alonso et al. (2016). Their 
recent research describes the novel attenuating effects of the anti-inflammatory 
microglial proliferation and differentiation targeting compound GW2580 on the 
propagation of AD-driven central inflammation, cognitive decline and relevant 
pathology in a mouse model of AD. 
The increasing information surrounding the role of inflammation and ROS in the 
development of AD suggest an important involvement of these factors in future disease 
management. Clarification of the chronological relevance of the different immune 
factors is likely to prove pivotal in the furthering of these factors as clinical targets in 
disease management (Heneka et al., 2015). Furthermore, combination with other novel 
targets such as the inhibition of the β-secretase enzyme (Menting & Claassen, 2014) 
may be required to provide targeting of multiple disease related factors. This in turn 
may allow for a decrease in the active drug load administered, lessening the risk of drug 
side effects and promoting the likelihood of disease-fighting effects. 
238 
6 REFERENCES 
 
239 
Abdullah, A., Kitteringham, N. R., Jenkins, R. E., Goldring, C., Higgins, L., 
Yamamoto, M., Hayes, J. & Park, B. K. (2012). Analysis of the role of Nrf2 in 
the expression of liver proteins in mice using two-dimensional gel-based 
proteomics. Pharmacological Reports 64(3): 680-697. 
Aggleton, J. P., Brown, M. W. & Albasser, M. M. (2012). Contrasting brain activity 
patterns for item recognition memory and associative recognition memory: 
insights from immediate-early gene functional imaging. Neuropsychologia 
50(13): 3141-3155. 
Aguirre, E., Woods, R. T., Spector, A. & Orrell, M. (2013). Cognitive stimulation for 
dementia: A systematic review of the evidence of effectiveness from randomised 
controlled trials. Ageing Research Reviews 12(1): 253-262. 
Agyare, E. K., Leonard, S. R., Curran, G. L., Yu, C. C., Lowe, V. J., Paravastu, A. K., 
Poduslo, J. F. & Kandimalla, K. K. (2013). Traffic Jam at the Blood–Brain 
Barrier Promotes Greater Accumulation of Alzheimer’s Disease Amyloid-β 
Proteins in the Cerebral Vasculature. Molecular Pharmaceutics 10(5): 1557-
1565. 
Ainge, J. A., Heron-Maxwell, C., Theofilas, P., Wright, P., de Hoz, L. & Wood, E. R. 
(2006). The role of the hippocampus in object recognition in rats: Examination 
of the influence of task parameters and lesion size. Behavioural Brain Research 
167(1): 183-195. 
Akhter, H., Katre, A., Li, L., Liu, X. & Liu, R.-M. (2011). Therapeutic Potential and 
Anti-Amyloidosis Mechanisms of Tert-Butylhydroquinone for Alzheimer’s 
Disease. Journal of Alzheimer's disease : JAD 26(4): 767-778. 
Albasser, M. M., Amin, E., Lin, T.-C. E., Iordanova, M. D. & Aggleton, J. P. (2012). 
Evidence That the Rat Hippocampus Has Contrasting Roles in Object 
Recognition Memory and Object Recency Memory. Behavioral Neuroscience 
126(5): 659-669. 
Allaman, I., Gavillet, M., Bélanger, M., Laroche, T., Viertl, D., Lashuel, H. A. & 
Magistretti, P. J. (2010). Amyloid-beta aggregates cause alterations of astrocytic 
metabolic phenotype: impact on neuronal viability. J Neurosci 30(9): 3326-
3338. 
Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N. & Murtagh, F. R. (1995). An 
English translation of Alzheimer's 1907 paper, "Uber eine eigenartige 
Erkankung der Hirnrinde". Clin Anat 8(6): 429-431. 
Amour, A., Knight, C. G., Webster, A., Slocombe, P. M., Stephens, P. E., Knäuper, V., 
Docherty, A. J. P. & Murphy, G. (2000). The in vitro activity of ADAM-10 is 
inhibited by TIMP-1 and TIMP-3. FEBS Letters 473(3): 275-279. 
Antunes, M. & Biala, G. (2012). The novel object recognition memory: neurobiology, 
test procedure, and its modifications. Cogn Process 13(2): 93-110. 
Area‐Gomez, E., del Carmen Lara Castillo, M., Tambini, M. D., Guardia‐Laguarta, C., 
de Groof, A. J. C., Madra, M., Ikenouchi, J., Umeda, M., Bird, T. D., Sturley, S. 
L. & Schon, E. A. (2012). Upregulated function of mitochondria‐associated ER 
membranes in Alzheimer disease. The EMBO Journal 31(21): 4106-4123. 
Arnold, S. E., Lucki, I., Brookshire, B. R., Carlson, G. C., Browne, C. A., Kazi, H., 
Bang, S., Choi, B.-R., Chen, Y., McMullen, M. F. & Kim, S. F. (2014). High fat 
diet produces brain insulin resistance, synaptodendritic abnormalities and altered 
behavior in mice. Neurobiology of Disease 67: 79-87. 
ARUK (2015). About Dementia: Facts and Stats. 
http://www.alzheimersresearchuk.org/about-dementia/facts-stats/. 
Ashrafian, H., Czibik, G., Bellahcene, M., Aksentijevic, D., Smith, A. C., Mitchell, S. 
J., Dodd, M. S., Kirwan, J., Byrne, J. J., Ludwig, C., Isackson, H., Yavari, A., 
Stottrup, N. B., Contractor, H., Cahill, T. J., Sahgal, N., Ball, D. R., Birkler, R. 
240 
I., Hargreaves, I., Tennant, D. A., Land, J., Lygate, C. A., Johannsen, M., 
Kharbanda, R. K., Neubauer, S., Redwood, C., de Cabo, R., Ahmet, I., Talan, 
M., Gunther, U. L., Robinson, A. J., Viant, M. R., Pollard, P. J., Tyler, D. J. & 
Watkins, H. (2012). Fumarate is cardioprotective via activation of the Nrf2 
antioxidant pathway. Cell Metab 15(3): 361-371. 
Avila, J., Lucas, J. J., Pérez, M. & Hernandéz, F. (2004). Role of Tau Protein in Both 
Physiological and Pathological Conditions. edn, vol. 84. 
Avrahami, L., Farfara, D., Shaham-Kol, M., Vassar, R., Frenkel, D. & Eldar-Finkelman, 
H. (2013). Inhibition of Glycogen Synthase Kinase-3 Ameliorates β-Amyloid 
Pathology and Restores Lysosomal Acidification and Mammalian Target of 
Rapamycin Activity in the Alzheimer Disease Mouse Model: IN VIVO AND IN 
VITRO STUDIES. Journal of Biological Chemistry 288(2): 1295-1306. 
Azizi, G., Khannazer, N. & Mirshafiey, A. (2014). The Potential Role of Chemokines in 
Alzheimer's Disease Pathogenesis. Am J Alzheimers Dis Other Demen. 
Bai, Y., Cui, W., Xin, Y., Miao, X., Barati, M. T., Zhang, C., Chen, Q., Tan, Y., Cui, T., 
Zheng, Y. & Cai, L. (2013). Prevention by sulforaphane of diabetic 
cardiomyopathy is associated with up-regulation of Nrf2 expression and 
transcription activation. Journal of Molecular and Cellular Cardiology 57: 82-
95. 
Baik, S. H., Cha, M.-Y., Hyun, Y.-M., Cho, H., Hamza, B., Kim, D. K., Han, S.-H., 
Choi, H., Kim, K. H., Moon, M., Lee, J., Kim, M., Irimia, D. & Mook-Jung, I. 
(2014). Migration of neutrophils targeting amyloid plaques in Alzheimer's 
disease mouse model. Neurobiology of Aging 35(6): 1286-1292. 
Baird, L., Lleres, D., Swift, S. & Dinkova-Kostova, A. T. (2013). Regulatory flexibility 
in the Nrf2-mediated stress response is conferred by conformational cycling of 
the Keap1-Nrf2 protein complex. Proc Natl Acad Sci U S A 110(38): 15259-
15264. 
Baker, B., Maitra, U., Geng, S. & Li, L. (2014). Molecular and Cellular Mechanisms 
Responsible for Cellular Stress and Low-grade Inflammation Induced by a 
Super-low Dose of Endotoxin. Journal of Biological Chemistry 289(23): 16262-
16269. 
Balistreri, C. R., Caruso, C. & Candore, G. (2010). The role of adipose tissue and 
adipokines in obesity-related inflammatory diseases. Mediators Inflamm 2010: 
802078. 
Banks, W. A. & Robinson, S. M. (2010). Minimal penetration of lipopolysaccharide 
across the murine blood–brain barrier. Brain, Behavior, and Immunity 24(1): 
102-109. 
Barak, B., Shvarts-Serebro, I., Modai, S., Gilam, A., Okun, E., Michaelson, D. M., 
Mattson, M. P., Shomron, N. & Ashery, U. (2013). Opposing actions of 
environmental enrichment and Alzheimer's disease on the expression of 
hippocampal microRNAs in mouse models. Transl Psychiatry 3: e304. 
Barker, G. R. I. & Warburton, E. C. (2011). When Is the Hippocampus Involved in 
Recognition Memory? The Journal of Neuroscience 31(29): 10721-10731. 
Barreto, G. E., Gonzalez, J., Torres, Y. & Morales, L. (2011). Astrocytic-neuronal 
crosstalk: Implications for neuroprotection from brain injury. Neuroscience 
Research 71(2): 107-113. 
Baumkötter, F., Wagner, K., Eggert, S., Wild, K. & Kins, S. (2012). Structural aspects 
and physiological consequences of APP/APLP trans-dimerization. Exp Brain 
Res 217(3-4): 389-395. 
Bay-Richter, C., Janelidze, S., Hallberg, L. & Brundin, L. (2011). Changes in behaviour 
and cytokine expression upon a peripheral immune challenge. Behavioural 
Brain Research 222(1): 193-199. 
241 
Bélanger, M., Allaman, I. & Magistretti, P. J. (2011). Differential effects of pro- and 
anti-inflammatory cytokines alone or in combinations on the metabolic profile of 
astrocytes. Journal of Neurochemistry 116(4): 564-576. 
Bellaver, B., Souza, D., Bobermin, L., Souza, D., Gonçalves, C.-A. & Quincozes-
Santos, A. (2015). Resveratrol Protects Hippocampal Astrocytes Against LPS-
Induced Neurotoxicity Through HO-1, p38 and ERK Pathways. Neurochemical 
Research 40(8): 1600-1608. 
Ben Khalifa, N., Tyteca, D., Marinangeli, C., Depuydt, M., Collet, J.-F., Courtoy, P. J., 
Renauld, J.-C., Constantinescu, S., Octave, J.-N. & Kienlen-Campard, P. (2012). 
Structural features of the KPI domain control APP dimerization, trafficking, and 
processing. The FASEB Journal 26(2): 855-867. 
Benedict, C., Hallschmid, M., Schmitz, K., Schultes, B., Ratter, F., Fehm, H. L., Born, 
J. & Kern, W. (2007). Intranasal insulin improves memory in humans: 
Superiority of insulin aspart. Neuropsychopharmacology 32(1): 239-243. 
Benito, C., Tolón, R. M., Castillo, A. I., Ruiz-Valdepeñas, L., Martínez-Orgado, J. A., 
Fernández-Sánchez, F. J., Vázquez, C., Cravatt, B. F. & Romero, J. (2012). β-
Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide 
hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but 
not CB 1 or CB 2 receptors. British Journal of Pharmacology 166(4): 1474-
1489. 
Beyer, T. A., Xu, W., Teupser, D., Auf Dem Keller, U., Bugnon, P., Hildt, E., Thiery, 
J., Kan, Y. W. & Werner, S. (2008). Impaired liver regeneration in Nrf2 
knockout mice: Role of ROS-mediated insulin/IGF-1 resistance. EMBO Journal 
27(1): 212-223. 
Bian, Y., Zhao, X., Li, M., Zeng, S. & Zhao, B. (2013). Various roles of astrocytes 
during recovery from repeated exposure to different doses of lipopolysaccharide. 
Behavioural Brain Research 253: 253-261. 
Biesmans, S., Acton, P. D., Cotto, C., Langlois, X., Ver Donck, L., Bouwknecht, J. A., 
Aelvoet, S.-A., Hellings, N., Meert, T. F. & Nuydens, R. (2015). Effect of stress 
and peripheral immune activation on astrocyte activation in transgenic 
bioluminescent Gfap-luc mice. Glia 63(7): 1126-1137. 
Biesmans, S., Meert, T. F., Bouwknecht, J. A., Acton, P. D., Davoodi, N., De Haes, P., 
Kuijlaars, J., Langlois, X., Matthews, L. J., Ver Donck, L., Hellings, N. & 
Nuydens, R. (2013). Systemic immune activation leads to neuroinflammation 
and sickness behavior in mice. Mediators Inflamm 2013: 271359. 
Blasko, I., Stampfer-Kountchev, M., Robatscher, P., Veerhuis, R., Eikelenboom, P. & 
Grubeck-Loebenstein, B. (2004). How chronic inflammation can affect the brain 
and support the development of Alzheimer's disease in old age: the role of 
microglia and astrocytes. Aging Cell 3(4): 169-176. 
Blasko, I., Veerhuis, R., Stampfer-Kountchev, M., Saurwein-Teissl, M., Eikelenboom, 
P. & Grubeck-Loebenstein, B. (2000). Costimulatory effects of interferon-
gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of 
Abeta1-40 and Abeta1-42 by human astrocytes. Neurobiol Dis 7(6 Pt B): 682-
689. 
Blass, J. P., Sheu, R. K. F. & Gibson, G. E. (2000). Inherent abnormalities in energy 
metabolism in Alzheimer disease: Interaction with cerebrovascular compromise 
Vol. 903, pp 204-221. 
Bluthé, R.-M., Castanon, N., Pousset, F., Bristow, A., Ball, C., Lestage, J., Michaud, B., 
Kelley, K. W. & Dantzer, R. (1999). Central injection of IL-10 antagonizes the 
behavioural effects of lipopolysaccharide in rats. Psychoneuroendocrinology 
24(3): 301-311. 
242 
Bonda, D. J., Stone, J. G., Torres, S. L., Siedlak, S. L., Perry, G., Kryscio, R., Jicha, G., 
Casadesus, G., Smith, M. A., Zhu, X. & Lee, H.-g. (2014). Dysregulation of 
leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. 
Journal of Neurochemistry 128(1): 162-172. 
Bonda, D. J., Wang, X., Perry, G., Nunomura, A., Tabaton, M., Zhu, X. & Smith, M. A. 
(2010). Oxidative stress in Alzheimer disease: A possibility for prevention. 
Neuropharmacology 59(4-5): 290-294. 
Bonifati, D. M. & Kishore, U. (2007). Role of complement in neurodegeneration and 
neuroinflammation. Molecular Immunology 44(5): 999-1010. 
Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, 
T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., Slunt, H. H., Wang, R., 
Seeger, M., Levey, A. I., Gandy, S. E., Copeland, N. G., Jenkins, N. A., Price, 
D. L., Younkin, S. G. & Sisodia, S. S. (1996). Familial Alzheimer's Disease–
Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo. 
Neuron 17(5): 1005-1013. 
Borger, E., Aitken, L., Muirhead, Kirsty E. A., Allen, Zoe E., Ainge, James A., 
Conway, Stuart J. & Gunn‑Moore, Frank J. (2011). Mitochondrial β-amyloid in 
Alzheimer's disease. Biochemical Society Transactions 39(4): 868-873. 
Bose, S. & Cho, J. (2013). Role of chemokine CCL2 and its receptor CCR2 in 
neurodegenerative diseases. Arch. Pharm. Res. 36(9): 1039-1050. 
Boseman-Roberts, S., Ripellino, J. A., Ingalls, K. M., Robakis, N. K. & Felsenstein, K. 
M. (1994). Non-amyloidogenic Cleavage of the beta-Amyloid Precursor Protein 
by an Integral Membrane Metalloendopeptidase. Journal of Biological 
Chemistry 269(4): 3111-3116. 
Bourne, K. Z., Ferrari, D. C., Lange-Dohna, C., Roßner, S., Wood, T. G. & Perez-Polo, 
J. R. (2007). Differential regulation of BACE1 promoter activity by nuclear 
factor-κB in neurons and glia upon exposure to β-amyloid peptides. Journal of 
Neuroscience Research 85(6): 1194-1204. 
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Analytical 
biochemistry 72: 248-254. 
Brunnström, H. R. & Englund, E. M. (2009). Cause of death in patients with dementia 
disorders. European Journal of Neurology 16(4): 488-492. 
Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P. & Gibson, G. E. (2005). 
Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications. 
Annals of Neurology 57(5): 695-703. 
Bussey, T. J., Muir, J. L. & Aggleton, J. P. (1999). Functionally Dissociating Aspects of 
Event Memory: the Effects of Combined Perirhinal and Postrhinal Cortex 
Lesions on Object and Place Memory in the Rat. The Journal of Neuroscience 
19(1): 495-502. 
Butovsky, O., Talpalar, A. E., Ben-Yaakov, K. & Schwartz, M. (2005). Activation of 
microglia by aggregated -amyloid or lipopolysaccharide impairs MHC-II 
expression and renders them cytotoxic whereas IFN- and IL-4 render them 
protective. Mol Cell Neurosci 29(3): 381-393. 
Callewaere, C., Banisadr, G., Rostene, W. & Parsadaniantz, S. M. (2007). Chemokines 
and chemokine receptors in the brain: implication in neuroendocrine regulation. 
J Mol Endocrinol 38(3): 355-363. 
Calvo-Ochoa, E., Hernandez-Ortega, K., Ferrera, P., Morimoto, S. & Arias, C. (2014). 
Short-term high-fat-and-fructose feeding produces insulin signaling alterations 
accompanied by neurite and synaptic reduction and astroglial activation in the 
rat hippocampus. J Cereb Blood Flow Metab 34(6): 1001-1008. 
243 
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. 
M., Fava, F., Tuohy, K. M., Chabo, C., Waget, A., Delmée, E., Cousin, B., 
Sulpice, T., Chamontin, B., Ferrières, J., Tanti, J.-F., Gibson, G. R., Casteilla, 
L., Delzenne, N. M., Alessi, M. C. & Burcelin, R. (2007). Metabolic 
Endotoxemia Initiates Obesity and Insulin Resistance. Diabetes 56(7): 1761-
1772. 
Cao, D., Lu, H., Lewis, T. L. & Li, L. (2007). Intake of Sucrose-sweetened Water 
Induces Insulin Resistance and Exacerbates Memory Deficits and Amyloidosis 
in a Transgenic Mouse Model of Alzheimer Disease. Journal of Biological 
Chemistry 282(50): 36275-36282. 
Cardoso, S. M., Santana, I., Swerdlow, R. H. & Oliveira, C. R. (2004). Mitochondria 
dysfunction of Alzheimer's disease cybrids enhances Aβ toxicity. Journal of 
Neurochemistry 89(6): 1417-1426. 
Carroll, J. C., Iba, M., Bangasser, D. A., Valentino, R. J., James, M. J., Brunden, K. R., 
Lee, V. M. Y. & Trojanowski, J. Q. (2011). Chronic Stress Exacerbates Tau 
Pathology, Neurodegeneration, and Cognitive Performance through a 
Corticotropin-Releasing Factor Receptor-Dependent Mechanism in a Transgenic 
Mouse Model of Tauopathy. Journal of Neuroscience 31(40): 14436-14449. 
Casley, C. S., Canevari, L., Land, J. M., Clark, J. B. & Sharpe, M. A. (2002). Beta-
amyloid inhibits integrated mitochondrial respiration and key enzyme activities. 
J Neurochem 80(1): 91-100. 
Caspersen, C., Wang, N., Yao, J., Sosunov, A., Chen, X., Lustbader, J. W., Xu, H. W., 
Stern, D., McKhann, G. & Yan, S. D. (2005). Mitochondrial Aβ: a potential 
focal point for neuronal metabolic dysfunction in Alzheimer’s disease. The 
FASEB Journal 19(14): 2040-2041. 
Castellani, R. J., Harris, P. L. R., Sayre, L. M., Fujii, J., Taniguchi, N., Vitek, M. P., 
Founds, H., Atwood, C. S., Perry, G. & Smith, M. A. (2001). Active glycation in 
neurofibrillary pathology of Alzheimer disease: Nε-(Carboxymethyl) lysine and 
hexitol-lysine. Free Radical Biology and Medicine 31(2): 175-180. 
Castellani, R. J. & Smith, M. A. (2011). Compounding artefacts with uncertainty, and 
an amyloid cascade hypothesis that is ‘too big to fail’. The Journal of Pathology 
224(2): 147-152. 
Caunt, C. J. & Keyse, S. M. (2013). Dual-specificity MAP kinase phosphatases 
(MKPs). FEBS Journal 280(2): 489-504. 
Cesta, M. F. (2006). Normal Structure, Function, and Histology of the Spleen. 
Toxicologic Pathology 34(5): 455-465. 
Ceylan-Isik, A. F., Kandadi, M. R., Xu, X., Hua, Y., Chicco, A. J., Ren, J. & Nair, S. 
(2013). Apelin administration ameliorates high fat diet-induced cardiac 
hypertrophy and contractile dysfunction. Journal of Molecular and Cellular 
Cardiology 63: 4-13. 
Chakrabarty, P., Ceballos-Diaz, C., Beccard, A., Janus, C., Dickson, D., Golde, T. E. & 
Das, P. (2010). IFN-γ Promotes Complement Expression and Attenuates 
Amyloid Plaque Deposition in Amyloid β Precursor Protein Transgenic Mice. 
The Journal of Immunology 184(9): 5333-5343. 
Chami, L. & Checler, F. (2012). BACE1 is at the crossroad of a toxic vicious cycle 
involving cellular stress and beta-amyloid production in Alzheimer's disease. 
Molecular Neurodegeneration 7(1): 52. 
Chan, J. Y., Cheung, M. C., Moi, P., Chan, K. & Kan, Y. W. (1995). Chromosomal 
localization of the human NF-E2 family of bZIP transcription factors by 
fluorescence in situ hybridization. Human Genetics 95(3): 265-269. 
Chan, K., Lu, R., Chang, J. C. & Kan, Y. W. (1996). NRF2, a member of the NFE2 
family of transcription factors, is not essential for murine erythropoiesis, growth, 
244 
and development. Proceedings of the National Academy of Sciences of the 
United States of America 93(24): 13943-13948. 
Chanas, S. A., Jiang, Q., McMahon, M., McWalter, G. K., McLellan, L. I., Elcombe, C. 
R., Henderson, C. J., Wolf, C. R., Moffat, G. J., Itoh, K., Yamamoto, M. & 
Hayes, J. D. (2002). Loss of the Nrf2 transcription factor causes a marked 
reduction in constitutive and inducible expression of the glutathione S-
transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers 
of male and female mice. Biochem J 365(Pt 2): 405-416. 
Chartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., 
Goate, A., Rossor, M., Roques, P., Hardy, J. & Mullan, M. (1991). Early-onset 
Alzheimer's disease caused by mutations at codon 717 of the amyloid 
precursor protein gene. Nature 353(6347): 844-846. 
Chartoumpekis, D. V., Ziros, P. G., Psyrogiannis, A. I., Papavassiliou, A. G., 
Kyriazopoulou, V. E., Sykiotis, G. P. & Habeos, I. G. (2011). Nrf2 Represses 
FGF21 During Long-Term High-Fat Diet-Induced Obesity in Mice. Diabetes 
60(10): 2465-2473. 
Chartoumpekis, D. V., Ziros, P. G., Zaravinos, A., Iskrenova, R. P., Psyrogiannis, A. I., 
Kyriazopoulou, V. E., Sykiotis, G. P. & Habeos, I. G. (2013). Hepatic Gene 
Expression Profiling in Nrf2 Knockout Mice after Long-Term High-Fat Diet-
Induced Obesity. Oxidative Medicine and Cellular Longevity 2013: 17. 
Chen, C.-n., Brown-Borg, H. M., Rakoczy, S. G., Ferrington, D. A. & Thompson, L. V. 
(2010). Aging Impairs the Expression of the Catalytic Subunit of Glutamate 
Cysteine Ligase in Soleus Muscle Under Stress. The Journals of Gerontology 
Series A: Biological Sciences and Medical Sciences 65A(2): 129-137. 
Chen, J., Buchanan, J. B., Sparkman, N. L., Godbout, J. P., Freund, G. G. & Johnson, R. 
W. (2008). Neuroinflammation and disruption in working memory in aged mice 
after acute stimulation of the peripheral innate immune system. Brain Behav 
Immun 22(3): 301-311. 
Chen, K., Ayutyanont, N., Langbaum, J. B. S., Fleisher, A. S., Reschke, C., Lee, W., 
Liu, X., Bandy, D., Alexander, G. E., Thompson, P. M., Shaw, L., Trojanowski, 
J. Q., Jack, C. R., Landau, S. M., Foster, N. L., Harvey, D. J., Weiner, M. W., 
Koeppe, R. A., Jagust, W. J. & Reiman, E. M. (2011). Characterizing 
Alzheimer's disease using a hypometabolic convergence index. NeuroImage 
56(1): 52-60. 
Cholerton, B., Baker, L. D. & Craft, S. (2011). Insulin resistance and pathological brain 
ageing. Diabetic Medicine: no-no. 
Chou, J. L., Shenoy, D. V., Thomas, N., Choudhary, P. K., LaFerla, F. M., Goodman, S. 
R. & Breen, G. A. M. (2011). Early dysregulation of the mitochondrial proteome 
in a mouse model of Alzheimer's disease. Journal of Proteomics 74(4): 466-479. 
Choudhry, F., Howlett, D. R., Richardson, J. C., Francis, P. T. & Williams, R. J. (2012). 
Pro-oxidant diet enhances β/γ secretase-mediated APP processing in APP/PS1 
transgenic mice. Neurobiology of Aging 33(5): 960-968. 
Chowdhry, S., Nazmy, M. H., Meakin, P. J., Dinkova-Kostova, A. T., Walsh, S. V., 
Tsujita, T., Dillon, J. F., Ashford, M. L. & Hayes, J. D. (2010). Loss of Nrf2 
markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 48(2): 
357-371. 
Chowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A. & Hayes, J. D. 
(2013). Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its 
Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 
32(32): 3765-3781. 
245 
Chu, J., Giannopoulos, P., Ceballos-Diaz, C., Golde, T. & Pratico, D. (2012). Adeno-
associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-
like phenotype of APP mice. Molecular Neurodegeneration 7(1): 1. 
Clarke, J. R., Lyra e Silva, N. M., Figueiredo, C. P., Frozza, R. L., Ledo, J. H., 
Beckman, D., Katashima, C. K., Razolli, D., Carvalho, B. M., Frazão, R., 
Silveira, M. A., Ribeiro, F. C., Bomfim, T. R., Neves, F. S., Klein, W. L., 
Medeiros, R., LaFerla, F. M., Carvalheira, J. B., Saad, M. J., Munoz, D. P., 
Velloso, L. A., Ferreira, S. T. & De Felice, F. G. (2015). Alzheimer‐associated 
Aβ oligomers impact the central nervous system to induce peripheral metabolic 
deregulation. EMBO Molecular Medicine 7(2): 190-210. 
Cleveland, D. W., Hwo, S.-Y. & Kirschner, M. W. (1977a). Physical and chemical 
properties of purified tau factor and the role of tau in microtubule assembly. 
Journal of Molecular Biology 116(2): 227-247. 
Cleveland, D. W., Hwo, S.-Y. & Kirschner, M. W. (1977b). Purification of tau, a 
microtubule-associated protein that induces assembly of microtubules from 
purified tubulin. Journal of Molecular Biology 116(2): 207-225. 
Cole, S. L. & Vassar, R. (2007). The basic biology of BACE1: A key therapeutic target 
for Alzheimer's disease. Curr. Genomics 8(8): 509-530. 
Copanaki, E., Chang, S., Vlachos, A., Tschäpe, J.-A., Müller, U. C., Kögel, D. & 
Deller, T. (2010). sAPPα antagonizes dendritic degeneration and neuron death 
triggered by proteasomal stress. Molecular and Cellular Neuroscience 44(4): 
386-393. 
Correa, F., Ljunggren, E., Mallard, C., Nilsson, M., Weber, S. G. & Sandberg, M. 
(2011). The Nrf2-inducible antioxidant defense in astrocytes can be both up- and 
down-regulated by activated microglia:Involvement of p38 MAPK. GLIA 59(5): 
785-799. 
Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Candeias, E., Santos, M. S., 
Oliveira, C. R. & Moreira, P. I. (2012). Insulin signaling, glucose metabolism 
and mitochondria: Major players in Alzheimer's disease and diabetes 
interrelation. Brain Research 1441(0): 64-78. 
Craft, S., Baker, L. D., Montine, T. J., Minoshima, S., Watson, G. S., Claxton, A., 
Arbuckle, M., Callaghan, M., Tsai, E., Plymate, S. R., Green, P. S., Leverenz, J., 
Cross, D. & Gerton, B. (2012). Intranasal insulin therapy for Alzheimer disease 
and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 
69(1): 29-38. 
Cruts, M., Theuns, J. & Van Broeckhoven, C. (2012). Locus-specific mutation 
databases for neurodegenerative brain diseases. Human Mutation 33(9): 1340-
1344. 
Cruz-Sánchez, F. F., Gironès, X., Ortega, A., Alameda, F. & Lafuente, J. V. (2010). 
Oxidative stress in Alzheimer's disease hippocampus: A topographical study. 
Journal of the Neurological Sciences 299(1-2): 163-167. 
Cunnane, S., Nugent, S., Roy, M., Courchesne-Loyer, A., Croteau, E., Tremblay, S., 
Castellano, A., Pifferi, F., Bocti, C., Paquet, N., Begdouri, H., Bentourkia, M., 
Turcotte, E., Allard, M., Barberger-Gateau, P., Fulop, T. & Rapoport, S. I. 
(2011). Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 27(1): 
3-20. 
Cunningham, C., Campion, S., Lunnon, K., Murray, C. L., Woods, J. F., Deacon, R. M., 
Rawlins, J. N. & Perry, V. H. (2009). Systemic inflammation induces acute 
behavioral and cognitive changes and accelerates neurodegenerative disease. 
Biol Psychiatry 65(4): 304-312. 
Cunningham, C., Wilcockson, D. C., Campion, S., Lunnon, K. & Perry, V. H. (2005). 
Central and Systemic Endotoxin Challenges Exacerbate the Local Inflammatory 
246 
Response and Increase Neuronal Death during Chronic Neurodegeneration. The 
Journal of Neuroscience 25(40): 9275-9284. 
Dandona, P., Mohamed, I., Ghanim, H., Sia, C. L., Dhindsa, S., Dandona, S., Makdissi, 
A. & Chaudhuri, A. (2011). Insulin Suppresses the Expression of Amyloid 
Precursor Protein, Presenilins, and Glycogen Synthase Kinase-3β in Peripheral 
Blood Mononuclear Cells. The Journal of Clinical Endocrinology & Metabolism 
96(6): 1783-1788. 
Daneschvar, H. L., Aronson, M. D. & Smetana, G. W. (2015). Do statins prevent 
Alzheimer's disease? A narrative review. Eur J Intern Med. 
Dang, J., Brandenburg, L. O., Rosen, C., Fragoulis, A., Kipp, M., Pufe, T., Beyer, C. & 
Wruck, C. J. (2012). Nrf2 expression by neurons, astroglia, and microglia in the 
cerebral cortical penumbra of ischemic rats. J Mol Neurosci 46(3): 578-584. 
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., 
Dustin, M. L. & Gan, W.-B. (2005). ATP mediates rapid microglial response to 
local brain injury in vivo. Nat Neurosci 8(6): 752-758. 
Davies, L. C. & Taylor, P. R. (2015). Tissue-resident macrophages: then and now. 
Immunology 144(4): 541-548. 
Davis, C., Mudd, J. & Hawkins, M. (2014). Neuroprotective effects of leptin in the 
context of obesity and metabolic disorders. Neurobiology of Disease 72, Part A: 
61-71. 
de Ferranti, S. & Mozaffarian, D. (2008). The Perfect Storm: Obesity, Adipocyte 
Dysfunction, and Metabolic Consequences. Clinical Chemistry 54(6): 945-955. 
de Jong, D., Jansen, R., Hoefnagels, W., Jellesma-Eggenkamp, M., Verbeek, M., Borm, 
G. & Kremer, B. (2008). No Effect of One-Year Treatment with Indomethacin 
on Alzheimer's Disease Progression: A Randomized Controlled Trial. PLoS 
ONE 3(1): e1475. 
de la Monte, S. M. (2009). Insulin resistance and Alzheimer's disease. BMB Rep. 42(8): 
475-481. 
de la Monte, S. M. & Wands, J. R. (2008). Alzheimer's disease is type 3 diabetes-
evidence reviewed. Journal of diabetes science and technology 2(6): 1101-1113. 
de La Serre, C. B., Ellis, C. L., Lee, J., Hartman, A. L., Rutledge, J. C. & Raybould, H. 
E. (2010). Propensity to high-fat diet-induced obesity in rats is associated with 
changes in the gut microbiota and gut inflammation. edn, vol. 299. 
De Santi, S., de Leon, M. J., Rusinek, H., Convit, A., Tarshish, C. Y., Roche, A., Tsui, 
W. H., Kandil, E., Boppana, M., Daisley, K., Wang, G. J., Schlyer, D. & Fowler, 
J. (2001). Hippocampal formation glucose metabolism and volume losses in 
MCI and AD. Neurobiology of Aging 22(4): 529-539. 
de Vries, H. E., Witte, M., Hondius, D., Rozemuller, A. J. M., Drukarch, B., 
Hoozemans, J. & van Horssen, J. (2008). Nrf2-induced antioxidant protection: A 
promising target to counteract ROS-mediated damage in neurodegenerative 
disease? Free Radical Biology and Medicine 45(10): 1375-1383. 
DeLegge, M. H. & Smoke, A. (2008). Neurodegeneration and Inflammation. Nutrition 
in Clinical Practice 23(1): 35-41. 
Deshmane, S. L., Kremlev, S., Amini, S. & Sawaya, B. E. (2009). Monocyte 
Chemoattractant Protein-1 (MCP-1): An Overview. Journal of Interferon & 
Cytokine Research 29(6): 313-326. 
Devi, L., Alldred, M. J., Ginsberg, S. D. & Ohno, M. (2012). Mechanisms Underlying 
Insulin Deficiency-Induced Acceleration of β-Amyloidosis in a Mouse Model of 
Alzheimer's Disease. PLoS ONE 7(3): e32792. 
DiabetesUK (2015). Prediabetes and insulin resistance. 
http://www.diabetes.co.uk/insulin-resistance.html. 
247 
Diaz-Hernandez, J. I., Almeida, A., Delgado-Esteban, M., Fernandez, E. & Bolaños, J. 
P. (2005). Knockdown of Glutamate-Cysteine Ligase by Small Hairpin RNA 
Reveals That Both Catalytic and Modulatory Subunits Are Essential for the 
Survival of Primary Neurons. Journal of Biological Chemistry 280(47): 38992-
39001. 
Dibaj, P., Steffens, H., Zschüntzsch, J., Nadrigny, F., Schomburg, E. D., Kirchhoff, F. 
& Neusch, C. (2011). In Vivo Imaging Reveals Distinct Inflammatory Activity 
of CNS Microglia versus PNS Macrophages in a Mouse Model for ALS. PLoS 
ONE 6(3): e17910. 
Didic, M., Barbeau, E. J., Felician, O., Tramoni, E., Guedj, E., Poncet, M. & Ceccaldi, 
M. (2011). Which memory system is impaired first in alzheimer's disease? 
Journal of Alzheimer's Disease 27(1): 11-22. 
Dilger, R. N. & Johnson, R. W. (2008). Aging, microglial cell priming, and the 
discordant central inflammatory response to signals from the peripheral immune 
system. Journal of Leukocyte Biology 84(4): 932-939. 
Diniz, D. G., Foro, C. A., Rego, C. M., Gloria, D. A., de Oliveira, F. R., Paes, J. M., de 
Sousa, A. A., Tokuhashi, T. P., Trindade, L. S., Turiel, M. C., Vasconcelos, E. 
G., Torres, J. B., Cunnigham, C., Perry, V. H., Vasconcelos, P. F. & Diniz, C. 
W. (2010). Environmental impoverishment and aging alter object recognition, 
spatial learning, and dentate gyrus astrocytes. Eur J Neurosci 32(3): 509-519. 
Dinkova-Kostova, A. T. & Abramov, A. Y. (2015). The emerging role of Nrf2 in 
mitochondrial function. Free Radical Biology and Medicine. 
Du, H., Guo, L., Yan, S. Q., Sosunov, A. A., McKhann, G. M. & Yan, S. S. (2010). 
Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. 
Proceedings of the National Academy of Sciences of the United States of 
America 107(43): 18670-18675. 
Eacott, M. J. & Easton, A. (2010). Episodic memory in animals: Remembering which 
occasion. Neuropsychologia 48(8): 2273-2280. 
Edwards, D. R., Handsley, M. M. & Pennington, C. J. (2008). The ADAM 
metalloproteinases. Molecular Aspects of Medicine 29(5): 258-289. 
Eftekharzadeh, B., Maghsoudi, N. & Khodagholi, F. (2010). Stabilization of 
transcription factor Nrf2 by tBHQ prevents oxidative stress-induced amyloid β 
formation in NT2N neurons. Biochimie 92(3): 245-253. 
Eggert, S., Paliga, K., Soba, P., Evin, G., Masters, C. L., Weidemann, A. & Beyreuther, 
K. (2004). The Proteolytic Processing of the Amyloid Precursor Protein Gene 
Family Members APLP-1 and APLP-2 Involves α-, β-, γ-, and ϵ-Like Cleavages: 
MODULATION OF APLP-1 PROCESSING BY N-GLYCOSYLATION. 
Journal of Biological Chemistry 279(18): 18146-18156. 
Eggler, A. L., Liu, G., Pezzuto, J. M., van Breemen, R. B. & Mesecar, A. D. (2005). 
Modifying specific cysteines of the electrophile-sensing human Keap1 protein is 
insufficient to disrupt binding to the Nrf2 domain Neh2. Proc Natl Acad Sci U S 
A 102(29): 10070-10075. 
Elder, G. A., Gama Sosa, M. A. & De Gasperi, R. (2010). Transgenic Mouse Models of 
Alzheimer’s Disease. The Mount Sinai journal of medicine, New York 77(1): 69-
81. 
Emanuelli, B., Eberlé, D., Suzuki, R. & Kahn, C. R. (2008). Overexpression of the dual-
specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin 
resistance. Proceedings of the National Academy of Sciences 105(9): 3545-3550. 
Emerit, J., Edeas, M. & Bricaire, F. (2004). Neurodegenerative diseases and oxidative 
stress. Biomedicine &amp; Pharmacotherapy 58(1): 39-46. 
Emre, Y., Hurtaud, C., Nübel, T., Criscuolo, F., Ricquier, D. & Cassard-Doulcier, A.-
M. (2007). Mitochondria contribute to LPS-induced MAPK activation via 
248 
uncoupling protein UCP2 in macrophages. Biochemical Journal 402(2): 271-
278. 
Erickson, M. A. & Banks, W. A. (2011). Cytokine and chemokine responses in serum 
and brain after single and repeated injections of lipopolysaccharide: Multiplex 
quantification with path analysis. Brain, Behavior, and Immunity 25(8): 1637-
1648. 
Erickson, M. A., Hartvigson, P. E., Morofuji, Y., Owen, J. B., Butterfield, D. A. & 
Banks, W. A. (2012). Lipopolysaccharide impairs amyloid beta efflux from 
brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral 
clearance and transporter function at the blood-brain barrier. J 
Neuroinflammation 9: 150. 
Erlichman, J. S., Hewitt, A., Damon, T. L., Hart, M., Kurascz, J., Li, A. & Leiter, J. C. 
(2008). Inhibition of monocarboxylate transporter 2 in the retrotrapezoid nucleus 
in rats: A test of the astrocyte-neuron lactate-shuttle hypothesis. Journal of 
Neuroscience 28(19): 4888-4896. 
Ernst, I. M. A., Wagner, A. E., Schuemann, C., Storm, N., Höppner, W., Döring, F., 
Stocker, A. & Rimbach, G. (2011). Allyl-, butyl- and phenylethyl-isothiocyanate 
activate Nrf2 in cultured fibroblasts. Pharmacological Research 63(3): 233-240. 
Farfara, D., Trudler, D., Segev-Amzaleg, N., Galron, R., Stein, R. & Frenkel, D. (2011). 
γ-Secretase component presenilin is important for microglia β-amyloid 
clearance. Annals of Neurology 69(1): 170-180. 
Fei, N. & Zhao, L. (2013). An opportunistic pathogen isolated from the gut of an obese 
human causes obesity in germfree mice. ISME J 7(4): 880-884. 
Fellmann, L., Nascimento, A. R., Tibiriça, E. & Bousquet, P. (2013). Murine models for 
pharmacological studies of the metabolic syndrome. Pharmacology & 
Therapeutics 137(3): 331-340. 
Fellous, A., Francon, J., Lennon, A. M. & Nunez, J. (1977). Microtubule Assembly in 
vitro. European Journal of Biochemistry 78(1): 167-174. 
Felsenstein, K. M., Hunihan, L. W. & Roberts, S. B. (1994). Altered cleavage and 
secretion of a recombinant -APP bearing the Swedish familial Alzheimer's 
disease mutation. Nat Genet 6(3): 251-256. 
Feng, B., Jiao, P., Helou, Y., Li, Y., He, Q., Walters, M. S., Salomon, A. & Xu, H. 
(2014). Mitogen-Activated Protein Kinase Phosphatase 3 (MKP-3)–Deficient 
Mice Are Resistant to Diet-Induced Obesity. Diabetes 63(9): 2924-2934. 
Ferretti, M. T., Bruno, M. A., Ducatenzeiler, A., Klein, W. L. & Cuello, A. C. (2012). 
Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's 
disease. Neurobiology of Aging 33(7): 1329-1342. 
Filali, M., Lalonde, R., Theriault, P., Julien, C., Calon, F. & Planel, E. (2012). Cognitive 
and non-cognitive behaviors in the triple transgenic mouse model of Alzheimer's 
disease expressing mutated APP, PS1, and Mapt (3xTg-AD). Behavioural Brain 
Research 234(2): 334-342. 
Forwood, S. E., Winters, B. D. & Bussey, T. J. (2005). Hippocampal lesions that 
abolish spatial maze performance spare object recognition memory at delays of 
up to 48 hours. Hippocampus 15(3): 347-355. 
Fourquet, S., Guerois, R., Biard, D. & Toledano, M. B. (2010). Activation of NRF2 by 
Nitrosative Agents and H2O2 Involves KEAP1 Disulfide Formation. Journal of 
Biological Chemistry 285(11): 8463-8471. 
Franklin, B. S., Bossaller, L., De Nardo, D., Ratter, J. M., Stutz, A., Engels, G., 
Brenker, C., Nordhoff, M., Mirandola, S. R., Al-Amoudi, A., Mangan, M. S., 
Zimmer, S., Monks, B. G., Fricke, M., Schmidt, R. E., Espevik, T., Jones, B., 
Jarnicki, A. G., Hansbro, P. M., Busto, P., Marshak-Rothstein, A., Hornemann, 
S., Aguzzi, A., Kastenmuller, W. & Latz, E. (2014). The adaptor ASC has 
249 
extracellular and 'prionoid' activities that propagate inflammation. Nat Immunol 
15(8): 727-737. 
Freeman, L. R., Haley-Zitlin, V., Stevens, C. & Granholm, A. C. (2011). Diet-induced 
effects on neuronal and glial elements in the middle-aged rat hippocampus. Nutr 
Neurosci 14(1): 32-44. 
Freeman, L. R., Zhang, L., Dasuri, K., Fernandez-Kim, S.-O., Bruce-Keller, A. J. & 
Keller, J. N. (2012). Mutant Amyloid Precursor Protein Differentially Alters 
Adipose Biology under Obesogenic and Non-Obesogenic Conditions. PLoS 
ONE 7(8): e43193. 
Fujii, S., Sawa, T., Ihara, H., Tong, K. I., Ida, T., Okamoto, T., Ahtesham, A. K., 
Ishima, Y., Motohashi, H., Yamamoto, M. & Akaike, T. (2010). The Critical 
Role of Nitric Oxide Signaling, via Protein S-Guanylation and Nitrated Cyclic 
GMP, in the Antioxidant Adaptive Response. Journal of Biological Chemistry 
285(31): 23970-23984. 
Fukumoto, H., Rosene, D. L., Moss, M. B., Raju, S., Hyman, B. T. & Irizarry, M. C. 
(2004). β-Secretase Activity Increases with Aging in Human, Monkey, and 
Mouse Brain. The American Journal of Pathology 164(2): 719-725. 
Fuller, S., Steele, M. & Münch, G. (2010). Activated astroglia during chronic 
inflammation in Alzheimer's disease—Do they neglect their neurosupportive 
roles? Mutation Research/Fundamental and Molecular Mechanisms of 
Mutagenesis 690(1–2): 40-49. 
Furnari, M. A. (2013). Behavioral, neurochemical, and neuroimmune changes in Nrf2 
knockout mice following early postnatal exposure to valproic acid. 
Furnari, M. A., Saw, C. L.-L., Kong, A.-N. & Wagner, G. C. (2014). Altered behavioral 
development in Nrf2 knockout mice following early postnatal exposure to 
valproic acid. Brain Research Bulletin 109: 132-142. 
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., 
Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagopian, S., 
Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., 
Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, L., 
Penniman, E., Power, M., Schenk, D., Seubert, P., Snyder, B., Soriano, F., Tan, 
H., Vitale, J., Wadsworth, S., Wolozin, B. & Zhao, J. (1995). Alzheimer-type 
neuropathology in transgenic mice overexpressing V717F [beta]-amyloid 
precursor protein. Nature 373(6514): 523-527. 
Gan, X., Huang, S., Wu, L., Wang, Y., Hu, G., Li, G., Zhang, H., Yu, H., Swerdlow, R. 
H., Chen, J. X. & Yan, S. S. (2014). Inhibition of ERK-DLP1 signaling and 
mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's 
disease cybrid cell. Biochimica et Biophysica Acta (BBA) - Molecular Basis of 
Disease 1842(2): 220-231. 
Ghanim, H., Monte, S. V., Sia, C. L., Abuaysheh, S., Green, K., Caruana, J. A. & 
Dandona, P. (2012). Reduction in Inflammation and the Expression of Amyloid 
Precursor Protein and Other Proteins Related to Alzheimer's Disease following 
Gastric Bypass Surgery. The Journal of Clinical Endocrinology & Metabolism 
97(7): E1197-E1201. 
Giulian, D. & Baker, T. J. (1986). Characterization of ameboid microglia isolated from 
developing mammalian brain. J Neurosci 6(8): 2163-2178. 
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., 
Giuffra, L., Haynes, A., Irving, N., James, L., Mant, R., Newton, P., Rooke, K., 
Roques, P., Talbot, C., Pericak-Vance, M., Roses, A., Williamson, R., Rossor, 
M., Owen, M. & Hardy, J. (1991). Segregation of a missense mutation in the 
amyloid precursor protein gene with familial Alzheimer's disease. Nature 
349(6311): 704-706. 
250 
Godbout, J. P., Moreau, M., Lestage, J., Chen, J., Sparkman, N. L., Connor, J. O., 
Castanon, N., Kelley, K. W., Dantzer, R. & Johnson, R. W. (2007). Aging 
Exacerbates Depressive-like Behavior in Mice in Response to Activation of the 
Peripheral Innate Immune System. Neuropsychopharmacology 33(10): 2341-
2351. 
Goedert, M. (2015). Alzheimer’s and Parkinson’s diseases: The prion concept in 
relation to assembled Aβ, tau, and α-synuclein. Science 349(6248). 
Gorina, R., Font-Nieves, M., Márquez-Kisinousky, L., Santalucia, T. & Planas, A. M. 
(2011). Astrocyte TLR4 activation induces a proinflammatory environment 
through the interplay between MyD88-dependent NFκB signaling, MAPK, and 
Jak1/Stat1 pathways. Glia 59(2): 242-255. 
Goshen, I. & Yirmiya, R. (2009). Interleukin-1 (IL-1): a central regulator of stress 
responses. Front Neuroendocrinol 30(1): 30-45. 
Granholm, A. C., Bimonte-Nelson, H. A., Moore, A. B., Nelson, M. E., Freeman, L. R. 
& Sambamurti, K. (2008). Effects of a saturated fat and high cholesterol diet on 
memory and hippocampal morphology in the middle-aged rat. J Alzheimers Dis 
14(2): 133-145. 
Greco, T. & Fiskum, G. (2010). Neuroprotection through stimulation of mitochondrial 
antioxidant protein expression. J Alzheimers Dis 20 Suppl 2: S427-437. 
Grinberg, L. T., Korczyn, A. D. & Heinsen, H. (2012). Cerebral amyloid angiopathy 
impact on endothelium. Experimental Gerontology 47(11): 838-842. 
Guo, H., Callaway, J. B. & Ting, J. P. Y. (2015). Inflammasomes: mechanism of action, 
role in disease, and therapeutics. Nat Med 21(7): 677-687. 
Haass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., Lannfelt, L. & 
Selkoe, D. J. (1995). The Swedish mutation causes early-onset Alzheimer's 
disease by -secretase cleavage within the secretory pathway. Nat Med 1(12): 
1291-1296. 
Haj-ali, V., Mohaddes, G. & Babri, S. H. (2009). Intracerebroventricular insulin 
improves spatial learning and memory in male Wistar rats. Behav Neurosci 
123(6): 1309-1314. 
Hajjar, T., Goh, Y. M., Rajion, M. A., Vidyadaran, S., Li, T. A. & Ebrahimi, M. (2013). 
Alterations in neuronal morphology and synaptophysin expression in the rat 
brain as a result of changes in dietary n-6: n-3 fatty acid ratios. Lipids Health Dis 
12: 113. 
Hall, A. M. & Roberson, E. D. (2012). Mouse models of Alzheimer's disease. Brain 
Research Bulletin 88(1): 3-12. 
Hamby, M. E., Hewett, J. A. & Hewett, S. J. (2006). TGF-β1 potentiates astrocytic 
nitric oxide production by expanding the population of astrocytes that express 
NOS-2. Glia 54(6): 566-577. 
Hammond, R. S., Tull, L. E. & Stackman, R. W. (2004). On the delay-dependent 
involvement of the hippocampus in object recognition memory. Neurobiology of 
Learning and Memory 82(1): 26-34. 
Hargrave, S. L., Davidson, T. L., Lee, T.-J. & Kinzig, K. P. (2015). Brain and 
behavioral perturbations in rats following Western diet access. Appetite 93: 35-
43. 
Hauss-Wegrzyniak, B., Lynch, M. A., Vraniak, P. D. & Wenk, G. L. (2002). Chronic 
Brain Inflammation Results in Cell Loss in the Entorhinal Cortex and Impaired 
LTP in Perforant Path-Granule Cell Synapses. Experimental Neurology 176(2): 
336-341. 
Hayashi, T., Shishido, N., Nakayama, K., Nunomura, A., Smith, M. A., Perry, G. & 
Nakamura, M. (2007). Lipid peroxidation and 4-hydroxy-2-nonenal formation 
251 
by copper ion bound to amyloid-β peptide. Free Radical Biology and Medicine 
43(11): 1552-1559. 
Hayes, J. D. & McMahon, M. (2009). NRF2 and KEAP1 mutations: permanent 
activation of an adaptive response in cancer. Trends Biochem.Sci. 34(4): 176-
188. 
Hedskog, L., Pinho, C. M., Filadi, R., Rönnbäck, A., Hertwig, L., Wiehager, B., 
Larssen, P., Gellhaar, S., Sandebring, A., Westerlund, M., Graff, C., Winblad, 
B., Galter, D., Behbahani, H., Pizzo, P., Glaser, E. & Ankarcrona, M. (2013). 
Modulation of the endoplasmic reticulum–mitochondria interface in Alzheimer’s 
disease and related models. Proceedings of the National Academy of Sciences 
110(19): 7916-7921. 
Hellström-Lindahl, E., Viitanen, M. & Marutle, A. (2009). Comparison of Aβ levels in 
the brain of familial and sporadic Alzheimer's disease. Neurochemistry 
International 55(4): 243-252. 
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, 
D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., Herrup, K., 
Frautschy, S. A., Finsen, B., Brown, G. C., Verkhratsky, A., Yamanaka, K., 
Koistinaho, J., Latz, E., Halle, A., Petzold, G. C., Town, T., Morgan, D., 
Shinohara, M. L., Perry, V. H., Holmes, C., Bazan, N. G., Brooks, D. J., Hunot, 
S., Joseph, B., Deigendesch, N., Garaschuk, O., Boddeke, E., Dinarello, C. A., 
Breitner, J. C., Cole, G. M., Golenbock, D. T. & Kummer, M. P. (2015). 
Neuroinflammation in Alzheimer's disease. The Lancet Neurology 14(4): 388-
405. 
Heneka, M. T., Kummer, M. P. & Latz, E. (2014). Innate immune activation in 
neurodegenerative disease. Nat Rev Immunol 14(7): 463-477. 
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, 
A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., Gelpi, E., Halle, A., Korte, M., 
Latz, E. & Golenbock, D. T. (2013). NLRP3 is activated in Alzheimer/'s disease 
and contributes to pathology in APP/PS1 mice. Nature 493(7434): 674-678. 
Henry, C. J., Huang, Y., Wynne, A., Hanke, M., Himler, J., Bailey, M. T., Sheridan, J. 
F. & Godbout, J. P. (2008). Minocycline attenuates lipopolysaccharide (LPS)-
induced neuroinflammation, sickness behavior, and anhedonia. Journal of 
Neuroinflammation 5: 15-15. 
Henry, C. J., Huang, Y., Wynne, A. M. & Godbout, J. P. (2009). Peripheral 
lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged 
mice that is associated with exaggerated induction of both pro-inflammatory IL-
1 and anti-inflammatory IL-10 cytokines. Brain Behav Immun 23(3): 309-317. 
Hiltunen, M., Khandelwal, V. K. M., Yaluri, N., Tiilikainen, T., Tusa, M., Koivisto, H., 
Krzisch, M., Vepsäläinen, S., Mäkinen, P., Kemppainen, S., Miettinen, P., 
Haapasalo, A., Soininen, H., Laakso, M. & Tanila, H. (2012). Contribution of 
genetic and dietary insulin resistance to Alzheimer phenotype in APP/PS1 
transgenic mice. Journal of Cellular and Molecular Medicine 16(6): 1206-1222. 
Ho, L., Qin, W., Pompl, P. N., Xiang, Z., Wang, J., Zhao, Z., Peng, Y., Cambareri, G., 
Rocher, A., Mobbs, C. V., Hof, P. R. & Pasinetti, G. M. (2004). Diet-induced 
insulin resistance promotes amyloidosis in a transgenic mouse model of 
Alzheimer's disease. The FASEB Journal. 
Holmes, C., El-Okl, M., Williams, A. L., Cunningham, C., Wilcockson, D. & Perry, V. 
H. (2003). Systemic infection, interleukin 1β, and cognitive decline in 
Alzheimer’s disease. Journal of Neurology, Neurosurgery & Psychiatry 74(6): 
788-789. 
Holmström, K. M., Baird, L., Zhang, Y., Hargreaves, I., Chalasani, A., Land, J. M., 
Stanyer, L., Yamamoto, M., Dinkova-Kostova, A. T. & Abramov, A. Y. (2013). 
252 
Nrf2 impacts cellular bioenergetics by controlling substrate availability for 
mitochondrial respiration. Biology Open 2(8): 761-770. 
Hong, Y., Yan, W., Chen, S., Sun, C.-r. & Zhang, J.-m. (2010). The role of Nrf2 
signaling in the regulation of antioxidants and detoxifying enzymes after 
traumatic brain injury in rats and mice. Acta Pharmacol Sin 31(11): 1421-1430. 
Hook, V. Y. H., Kindy, M. & Hook, G. (2008). Inhibitors of Cathepsin B Improve 
Memory and Reduce β-Amyloid in Transgenic Alzheimer Disease Mice 
Expressing the Wild-type, but Not the Swedish Mutant, β-Secretase Site of the 
Amyloid Precursor Protein. Journal of Biological Chemistry 283(12): 7745-
7753. 
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F. & 
Cole, G. (1996). Correlative memory deficits, Abeta elevation, and amyloid 
plaques in transgenic mice. Science 274(5284): 99-102. 
Hughes, M. M., Field, R. H., Perry, V. H., Murray, C. L. & Cunningham, C. (2010). 
Microglia in the degenerating brain are capable of phagocytosis of beads and of 
apoptotic cells, but do not efficiently remove PrPSc, even upon LPS stimulation. 
GLIA 58(16): 2017-2030. 
Hunter, R. L., Dragicevic, N., Seifert, K., Choi, D. Y., Liu, M., Kim, H.-C., Cass, W. 
A., Sullivan, P. G. & Bing, G. (2007). Inflammation induces mitochondrial 
dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. 
Journal of Neurochemistry 100(5): 1375-1386. 
Ifuku, M., Katafuchi, T., Mawatari, S., Noda, M., Miake, K., Sugiyama, M. & Fujino, 
T. (2012). Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in 
lipopolysaccharide-induced neuroinflammation in adult mice. Journal of 
Neuroinflammation 9: 197-197. 
Innamorato, N. G., Rojo, A. I., García-Yagüe, Á. J., Yamamoto, M., de Ceballos, M. L. 
& Cuadrado, A. (2008). The Transcription Factor Nrf2 Is a Therapeutic Target 
against Brain Inflammation. The Journal of Immunology 181(1): 680-689. 
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., 
Khatoon, S., Li, B., Liu, F., Rahman, A., Tanimukai, H. & Grundke-Iqbal, I. 
(2005). Tau pathology in Alzheimer disease and other tauopathies. Biochimica et 
Biophysica Acta (BBA) - Molecular Basis of Disease 1739(2–3): 198-210. 
Ishii, M., Wang, G., Racchumi, G., Dyke, J. P. & Iadecola, C. (2014). Transgenic mice 
overexpressing amyloid precursor protein exhibit early metabolic deficits and a 
pathologically low leptin state associated with hypothalamic dysfunction in 
arcuate neuropeptide y neurons. J Neurosci 34(27): 9096-9106. 
Ito, D., Tanaka, K., Suzuki, S., Dembo, T. & Fukuuchi, Y. (2001). Enhanced 
Expression of Iba1, Ionized Calcium-Binding Adapter Molecule 1, After 
Transient Focal Cerebral Ischemia In Rat Brain. Stroke 32(5): 1208-1215. 
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, 
N., Satoh, K., Hatayama, I., Yamamoto, M. & Nabeshima, Y. I. (1997). An 
Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying 
enzyme genes through antioxidant response elements. Biochemical and 
Biophysical Research Communications 236(2): 313-322. 
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D. & Yamamoto, 
M. (1999). Keap1 represses nuclear activation of antioxidant responsive 
elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes 
and Development 13(1): 76-86. 
Itoh, K., Ye, P., Matsumiya, T., Tanji, K. & Ozaki, T. (2015). Emerging functional 
cross-talk between the Keap1-Nrf2 system and mitochondria. Journal of Clinical 
Biochemistry and Nutrition 56(2): 91-97. 
253 
JacksonLaboratories (2015). R1.40 mouse strain. 
http://jaxmice.jax.org/strain/005300.html. 
Jacobsen, K. T., Adlerz, L., Multhaup, G. & Iverfeldt, K. (2010). Insulin-like Growth 
Factor-1 (IGF-1)-induced Processing of Amyloid-β Precursor Protein (APP) and 
APP-like Protein 2 Is Mediated by Different Metalloproteinases. Journal of 
Biological Chemistry 285(14): 10223-10231. 
Jeong, Y. H., Park, C. H., Yoo, J., Shin, K. Y., Ahn, S.-M., Kim, H.-S., Lee, S. H., 
Emson, P. C. & Suh, Y.-H. (2006). Chronic stress accelerates learning and 
memory impairments and increases amyloid deposition in APPV717I-CT100 
transgenic mice, an Alzheimer's disease model. The FASEB Journal. 
Jiang, T., Huang, Z., Lin, Y., Zhang, Z., Fang, D. & Zhang, D. D. (2010). The 
Protective Role of Nrf2 in Streptozotocin-Induced Diabetic Nephropathy. 
Diabetes 59(4): 850-860. 
Jo, C., Gundemir, S., Pritchard, S., Jin, Y. N., Rahman, I. & Johnson, G. V. W. (2014). 
Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy 
adaptor protein NDP52. Nature communications 5. 
Johnson, J. A., Johnson, D. A., Kraft, A. D., Calkins, M. J., Jakel, R. J., Vargas, M. R. 
& Chen, P.-C. (2008). The Nrf2-ARE Pathway. Annals of the New York 
Academy of Sciences 1147(1): 61-69. 
Johnstone, M., Gearing, A. J. H. & Miller, K. M. (1999). A central role for astrocytes in 
the inflammatory response to β-amyloid; chemokines, cytokines and reactive 
oxygen species are produced. Journal of Neuroimmunology 93(1–2): 182-193. 
Jolivalt, C. G., Hurford, R., Lee, C. A., Dumaop, W., Rockenstein, E. & Masliah, E. 
(2010). Type 1 diabetes exaggerates features of Alzheimer's disease in APP 
transgenic mice. Experimental Neurology 223(2): 422-431. 
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., 
Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, 
A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, 
G., Andreassen, O. A., Jonsson, E. G., Palotie, A., Behrens, T. W., Magnusson, 
O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J. & Stefansson, K. (2012). A 
mutation in APP protects against Alzheimer/'s disease and age-related cognitive 
decline. Nature 488(7409): 96-99. 
Joshi, G., Gan, K. A., Johnson, D. A. & Johnson, J. A. (2015). Increased Alzheimer's 
disease–like pathology in the APP/ PS1ΔE9 mouse model lacking Nrf2 through 
modulation of autophagy. Neurobiology of Aging 36(2): 664-679. 
Joshi, Y. B., Giannopoulos, P. F., Chu, J. & Praticò, D. (2014). Modulation of 
lipopolysaccharide-induced memory insult, γ-secretase, and neuroinflammation 
in triple transgenic mice by 5-lipoxygenase. Neurobiology of Aging 35(5): 1024-
1031. 
Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Émond, V., Julien, P. & Calon, 
F. (2010). High-fat diet aggravates amyloid-beta and tau pathologies in the 
3xTg-AD mouse model. Neurobiology of Aging 31(9): 1516-1531. 
Jung, H.-J., Kim, Y.-J., Eggert, S., Chung, K. C., Choi, K. S. & Park, S. A. (2013). Age-
dependent increases in tau phosphorylation in the brains of type 2 diabetic rats 
correlate with a reduced expression of p62. Experimental Neurology 248: 441-
450. 
Jung, H. J., Park, S. S., Mok, J. O., Lee, T. K., Park, C. S. & Park, S. A. (2011). 
Increased expression of three-repeat isoforms of tau contributes to tau pathology 
in a rat model of chronic type 2 diabetes. Experimental Neurology 228(2): 232-
241. 
254 
Kaden, D., Munter, L. M., Reif, B. & Multhaup, G. (2012). The amyloid precursor 
protein and its homologues: Structural and functional aspects of native and 
pathogenic oligomerization. European Journal of Cell Biology 91(4): 234-239. 
Kalaria, R. N. (2010). Vascular basis for brain degeneration: faltering controls and risk 
factors for dementia. edn, vol. 68. 
Kaminska, B., Gozdz, A., Zawadzka, M., Ellert-Miklaszewska, A. & Lipko, M. (2009). 
MAPK Signal Transduction Underlying Brain Inflammation and Gliosis as 
Therapeutic Target. The Anatomical Record: Advances in Integrative Anatomy 
and Evolutionary Biology 292(12): 1902-1913. 
Kamphuis, W., Mamber, C., Moeton, M., Kooijman, L., Sluijs, J. A., Jansen, A. H. P., 
Verveer, M., de Groot, L. R., Smith, V. D., Rangarajan, S., Rodríguez, J. J., 
Orre, M. & Hol, E. M. (2012). GFAP Isoforms in Adult Mouse Brain with a 
Focus on Neurogenic Astrocytes and Reactive Astrogliosis in Mouse Models of 
Alzheimer Disease. PLoS ONE 7(8): e42823. 
Kanekiyo, T., Liu, C.-C., Shinohara, M., Li, J. & Bu, G. (2012). LRP1 in Brain 
Vascular Smooth Muscle Cells Mediates Local Clearance of Alzheimer's 
Amyloid-β. The Journal of Neuroscience 32(46): 16458-16465. 
Kanninen, K., Heikkinen, R., Malm, T., Rolova, T., Kuhmonen, S., Leinonen, H., Ylä-
Herttuala, S., Tanila, H., Levonen, A. L., Koistinaho, M. & Koistinaho, J. 
(2009). Intrahippocampal injection of a lentiviral vector expressing Nrf2 
improves spatial learning in a mouse model of Alzheimer's disease. Proceedings 
of the National Academy of Sciences of the United States of America 106(38): 
16505-16510. 
Kapetanovic, R., Bokil, N. J. & Sweet, M. J. (2015). Innate immune perturbations, 
accumulating DAMPs and inflammasome dysregulation: A ticking time bomb in 
ageing. Ageing Research Reviews. 
Karran, E., Mercken, M. & Strooper, B. D. (2011). The amyloid cascade hypothesis for 
Alzheimer's disease: an appraisal for the development of therapeutics. Nature 
Reviews Drug Discovery 10(9): 698-712. 
Karuppagounder, S. S., Xu, H., Shi, Q., Chen, L. H., Pedrini, S., Pechman, D., Baker, 
H., Beal, M. F., Gandy, S. E. & Gibson, G. E. (2009). Thiamine deficiency 
induces oxidative stress and exacerbates the plaque pathology in Alzheimer's 
mouse model. Neurobiol Aging 30(10): 1587-1600. 
Kasischke, K. A., Vishwasrao, H. D., Fisher, P. J., Zipfel, W. R. & Webb, W. W. 
(2004). Neural activity triggers neuronal oxidative metabolism followed by 
astrocytic glycolysis. Science 305(5680): 99-103. 
Katoh, Y., Iida, K., Kang, M. I., Kobayashi, A., Mizukami, M., Tong, K. I., McMahon, 
M., Hayes, J. D., Itoh, K. & Yamamoto, M. (2005). Evolutionary conserved N-
terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the 
protein by proteasome. Arch Biochem Biophys 433(2): 342-350. 
Kauwe, J. S. K., Cruchaga, C., Karch, C. M., Sadler, B., Lee, M., Mayo, K., Latu, W., 
Su'a, M., Fagan, A. M., Holtzman, D. M., Morris, J. C., Alzheimer's Disease 
Neuroimaging, I. & Goate, A. M. (2011). Fine Mapping of Genetic Variants in 
BIN1, CLU, CR1 and PICALM for Association with Cerebrospinal Fluid 
Biomarkers for Alzheimer's Disease. PLoS ONE 6(2): e15918. 
Kensler, T. W., Wakabayashi, N. & Biswal, S. (2007). Cell survival responses to 
environmental stresses via the Keap1-Nrf2-ARE pathway, Cho AK (ed) Vol. 47, 
pp 89-116. 
Kettenmann, H., Hanisch, U. K., Noda, M. & Verkhratsky, A. (2011). Physiology of 
microglia. Physiol Rev 91(2): 461-553. 
255 
Khodagholi, F. & Tusi, S. K. (2011). Stabilization of Nrf2 by tBHQ prevents LPS-
induced apoptosis in differentiated PC12 cells. Mol Cell Biochem 354(1-2): 97-
112. 
Kim, H.-S., Kim, E.-M., Lee, J.-P., Park, C. H., Kim, S., Seo, J.-H., Chang, K.-A., Yu, 
E., Jeong, S.-J., Chong, Y. H. & Suh, Y.-H. (2003). C-terminal fragments of 
amyloid precursor protein exert neurotoxicity by inducing glycogen synthase 
kinase-3β expression. The FASEB Journal. 
Kim, H., Jung, Y., Shin, B. S., Kim, H., Song, H., Bae, S. H., Rhee, S. G. & Jeong, W. 
(2010). Redox Regulation of Lipopolysaccharide-mediated Sulfiredoxin 
Induction, Which Depends on Both AP-1 and Nrf2. Journal of Biological 
Chemistry 285(45): 34419-34428. 
King, D. L. & Arendash, G. W. (2002). Behavioral characterization of the Tg2576 
transgenic model of Alzheimer's disease through 19 months. Physiology & 
Behavior 75(5): 627-642. 
Kitazawa, M., Cheng, D., Tsukamoto, M. R., Koike, M. A., Wes, P. D., Vasilevko, V., 
Cribbs, D. H. & LaFerla, F. M. (2011). Blocking IL-1 Signaling Rescues 
Cognition, Attenuates Tau Pathology, and Restores Neuronal β-Catenin Pathway 
Function in an Alzheimer’s Disease Model. The Journal of Immunology 
187(12): 6539-6549. 
Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N. & LaFerla, F. M. (2005). 
Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a 
Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of 
Alzheimer's Disease. The Journal of Neuroscience 25(39): 8843-8853. 
Knatko, E. V., Ibbotson, S. H., Zhang, Y., Higgins, M., Fahey, J. W., Talalay, P., Dawe, 
R. S., Ferguson, J., Huang, J. T.-J., Clarke, R., Zheng, S., Saito, A., Kalra, S., 
Benedict, A. L., Honda, T., Proby, C. M. & Dinkova-Kostova, A. T. (2015). 
Nrf2 Activation Protects against Solar-Simulated Ultraviolet Radiation in Mice 
and Humans. Cancer Prevention Research 8(6): 475-486. 
Knight, E. M., Martins, I. V., Gumusgoz, S., Allan, S. M. & Lawrence, C. B. (2014). 
High-fat diet-induced memory impairment in triple-transgenic Alzheimer's 
disease (3xTgAD) mice is independent of changes in amyloid and tau pathology. 
Neurobiol Aging 35(8): 1821-1832. 
Kobayashi, A., Kang, M. I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K. 
& Yamamoto, M. (2004). Oxidative stress sensor Keap1 functions as an adaptor 
for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell 
Biol 24(16): 7130-7139. 
Kobayashi, M., Itoh, K., Suzuki, T., Osanai, H., Nishikawa, K., Katoh, Y., Takagi, Y. & 
Yamamoto, M. (2002). Identification of the interactive interface and phylogenic 
conservation of the Nrf2-Keap1 system. Genes Cells 7(8): 807-820. 
Kobayashi, M. & Yamamoto, M. (2006). Nrf2-Keap1 regulation of cellular defense 
mechanisms against electrophiles and reactive oxygen species. Advances in 
Enzyme Regulation 46(1): 113-140. 
Koh, K., Kim, J., Jang, Y. J., Yoon, K., Cha, Y., Lee, H. J. & Kim, J. (2011). 
Transcription factor Nrf2 suppresses LPS-induced hyperactivation of BV-2 
microglial cells. Journal of Neuroimmunology 233(1‚Äì2): 160-167. 
Kohjima, M., Sun, Y. & Chan, L. (2010). Increased Food Intake Leads to Obesity and 
Insulin Resistance in the Tg2576 Alzheimer’s Disease Mouse Model. 
Endocrinology 151(4): 1532-1540. 
Kohman, R. A., Tarr, A. J., Byler, S. L. & Boehm, G. W. (2007). Age increases 
vulnerability to bacterial endotoxin-induced behavioral decrements. Physiology 
& Behavior 91(5): 561-565. 
256 
Kong, X., Thimmulappa, R., Kombairaju, P. & Biswal, S. (2010). NADPH Oxidase-
Dependent Reactive Oxygen Species Mediate Amplified TLR4 Signaling and 
Sepsis-Induced Mortality in Nrf2-Deficient Mice. The Journal of Immunology 
185(1): 569-577. 
Kovac, S., Angelova, P. R., Holmström, K. M., Zhang, Y., Dinkova-Kostova, A. T. & 
Abramov, A. Y. (2015). Nrf2 regulates ROS production by mitochondria and 
NADPH oxidase. Biochimica et Biophysica Acta (BBA) - General Subjects 
1850(4): 794-801. 
Krebs, D. L. & Parent, M. B. (2005). The enhancing effects of hippocampal infusions of 
glucose are not restricted to spatial working memory. Neurobiology of Learning 
and Memory 83(2): 168-172. 
Krstic, D., Madhusudan, A., Doehner, J., Vogel, P., Notter, T., Imhof, C., Manalastas, 
A., Hilfiker, M., Pfister, S., Schwerdel, C., Riether, C., Meyer, U. & Knuesel, I. 
(2012). Systemic immune challenges trigger and drive Alzheimer-like 
neuropathology in mice. Journal of Neuroinflammation 9. 
Kuhn, P. H., Koroniak, K., Hogl, S., Colombo, A., Zeitschel, U., Willem, M., 
Volbracht, C., Schepers, U., Imhof, A., Hoffmeister, A., Haass, C., Roßner, S., 
Bräse, S. & Lichtenthaler, S. F. (2012). Secretome protein enrichment identifies 
physiological BACE1 protease substrates in neurons. edn, vol. 31. 
Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., 
Vandersteen, A., Segers‐Nolten, I., Van Der Werf, K., Subramaniam, V., 
Braeken, D., Callewaert, G., Bartic, C., D'Hooge, R., Martins, I. C., Rousseau, 
F., Schymkowitz, J. & De Strooper, B. (2010). Neurotoxicity of Alzheimer's 
disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. edn, 
vol. 29. 
Kwon, S. E. & Chapman, E. R. (2011). Synaptophysin regulates the kinetics of synaptic 
vesicle endocytosis in central neurons. Neuron 70(5): 847-854. 
Lamb, B. A., Bardel, K. A., Kulnane, L. S., Anderson, J. J., Holtz, G., Wagner, S. L., 
Sisodia, S. S. & Hoeger, E. J. (1999). Amyloid production and deposition in 
mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome 
transgenic mice. Nat Neurosci 2(8): 695-697. 
Lamb, B. T., Call, L. M., Slunt, H. H., Bardel, K. A., Lawler, A. M., Eckman, C. B., 
Younkin, S. G., Holtz, G., Wagner, S. L., Price, D. L., Sisodia, S. S. & Gearhart, 
J. D. (1997). Altered Metabolism of Familial Alzheimer's Disease-Linked 
Amyloid Precursor Protein Variants in Yeast Artificial Chromosome Transgenic 
Mice. Human Molecular Genetics 6(9): 1535-1541. 
Langston, R. F., Stevenson, C. H., Wilson, C. L., Saunders, I. & Wood, E. R. (2010). 
The role of hippocampal subregions in memory for stimulus associations. 
Behavioural Brain Research 215(2): 275-291. 
Langston, R. F. & Wood, E. R. (2010). Associative recognition and the hippocampus: 
differential effects of hippocampal lesions on object-place, object-context and 
object-place-context memory. Hippocampus 20(10): 1139-1153. 
Lassenius, M. I., Pietiläinen, K. H., Kaartinen, K., Pussinen, P. J., Syrjänen, J., 
Forsblom, C., Pörsti, I., Rissanen, A., Kaprio, J., Mustonen, J., Groop, P.-H., 
Lehto, M. & Group, o. b. o. t. F. S. (2011). Bacterial Endotoxin Activity in 
Human Serum Is Associated With Dyslipidemia, Insulin Resistance, Obesity, 
and Chronic Inflammation. Diabetes Care 34(8): 1809-1815. 
Lawan, A., Zhang, L., Gatzke, F., Min, K., Jurczak, M. J., Al-Mutairi, M., Richter, P., 
Camporez, J. P. G., Couvillon, A., Pesta, D., Roth Flach, R. J., Shulman, G. I. & 
Bennett, A. M. (2015). Hepatic Mitogen-Activated Protein Kinase Phosphatase 
1 Selectively Regulates Glucose Metabolism and Energy Homeostasis. 
Molecular and Cellular Biology 35(1): 26-40. 
257 
Lawrence, T. (2009). The Nuclear Factor NF-κB Pathway in Inflammation. Cold Spring 
Harbor Perspectives in Biology 1(6). 
Lawrence, T., Gilroy, D. W., Colville-Nash, P. R. & Willoughby, D. A. (2001). Possible 
new role for NF-[kappa]B in the resolution of inflammation. Nat Med 7(12): 
1291-1297. 
Leboucher, Guillaume P., Tsai, Yien C., Yang, M., Shaw, Kristin C., Zhou, M., 
Veenstra, Timothy D., Glickman, Michael H. & Weissman, Allan M. (2012). 
Stress-Induced Phosphorylation and Proteasomal Degradation of Mitofusin 2 
Facilitates Mitochondrial Fragmentation and Apoptosis. Molecular Cell 47(4): 
547-557. 
Lee, D.-S., Ko, W., Yoon, C.-S., Kim, D.-C., Yun, J., Lee, J.-K., Jun, K.-Y., Son, I., 
Kim, D.-W., Song, B.-K., Choi, S., Jang, J.-H., Oh, H., Kim, S. & Kim, Y.-C. 
(2014). KCHO-1, a Novel Antineuroinflammatory Agent, Inhibits 
Lipopolysaccharide-Induced Neuroinflammatory Responses through Nrf2-
Mediated Heme Oxygenase-1 Expression in Mouse BV2 Microglia Cells. 
Evidence-Based Complementary and Alternative Medicine 2014: 11. 
Lee, E. B. (2011). Obesity, leptin, and Alzheimer's disease. Ann N Y Acad Sci 1243: 15-
29. 
Lee, I., Hunsaker, M. R. & Kesner, R. P. (2005). The role of hippocampal subregions in 
detecting spatial novelty. Behav Neurosci 119(1): 145-153. 
Lee, J.-M., Calkins, M. J., Chan, K., Kan, Y. W. & Johnson, J. A. (2003). Identification 
of the NF-E2-related Factor-2-dependent Genes Conferring Protection against 
Oxidative Stress in Primary Cortical Astrocytes Using Oligonucleotide 
Microarray Analysis. Journal of Biological Chemistry 278(14): 12029-12038. 
Lee, J. K., Schuchman, E. H., Jin, H. K. & Bae, J.-S. (2012a). Soluble CCL5 Derived 
from Bone Marrow-Derived Mesenchymal Stem Cells and Activated by 
Amyloid β Ameliorates Alzheimer's Disease in Mice by Recruiting Bone 
Marrow-Induced Microglia Immune Responses. STEM CELLS 30(7): 1544-
1555. 
Lee, J. W., Lee, Y. K., Yuk, D. Y., Choi, D. Y., Ban, S. B., Oh, K. W. & Hong, J. T. 
(2008). Neuro-inflammation induced by lipopolysaccharide causes cognitive 
impairment through enhancement of beta-amyloid generation. J 
Neuroinflammation 5: 37. 
Lee, J. Y., Oh, T. H. & Yune, T. Y. (2011). Ghrelin Inhibits Hydrogen Peroxide-
Induced Apoptotic Cell Death of Oligodendrocytes Via ERK and p38MAPK 
Signaling. Endocrinology 152(6): 2377-2386. 
Lee, Y. J., Choi, D. Y., Choi, I. S., Kim, K. H., Kim, Y. H., Kim, H. M., Lee, K., Cho, 
W. G., Jung, J. K., Han, S. B., Han, J. Y., Nam, S. Y., Yun, Y. W., Jeong, J. H., 
Oh, K. W. & Hong, J. T. (2012b). Inhibitory effect of 4-O-methylhonokiol on 
lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory 
impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. 
Journal of Neuroinflammation 9. 
Leger, M., Quiedeville, A., Bouet, V., Haelewyn, B., Boulouard, M., Schumann-Bard, 
P. & Freret, T. (2013). Object recognition test in mice. Nat. Protocols 8(12): 
2531-2537. 
Lei, P., Ayton, S., Finkelstein, D. I., Adlard, P. A., Masters, C. L. & Bush, A. I. (2010). 
Tau protein: Relevance to Parkinson's disease. The International Journal of 
Biochemistry & Cell Biology 42(11): 1775-1778. 
Lennartz, R. C. (2008). The role of extramaze cues in spontaneous alternation in a plus-
maze. Learning & behavior 36(2): 138-144. 
258 
Li, H., Liu, B., Huang, J., Chen, H., Guo, X. & Yuan, Z. (2013). Insulin inhibits 
lipopolysaccharide-induced nitric oxide synthase expression in rat primary 
astrocytes. Brain Research(0). 
Li, H., Yao, W., Irwin, M. G., Wang, T., Wang, S., Zhang, L. & Xia, Z. (2015). 
Adiponectin ameliorates hyperglycemia-induced cardiac hypertrophy and 
dysfunction by concomitantly activating Nrf2 and Brg1. Free Radical Biology 
and Medicine 84: 311-321. 
Li, J., Ichikawa, T., Villacorta, L., Janicki, J. S., Brower, G. L., Yamamoto, M. & Cui, 
T. (2009). Nrf2 Protects Against Maladaptive Cardiac Responses to 
Hemodynamic Stress. Arteriosclerosis, Thrombosis, and Vascular Biology 
29(11): 1843-1850. 
Li, M., Pisalyaput, K., Galvan, M. & Tenner, A. J. (2004). Macrophage colony 
stimulatory factor and interferon-γ trigger distinct mechanisms for augmentation 
of β-amyloid-induced microglia-mediated neurotoxicity. Journal of 
Neurochemistry 91(3): 623-633. 
Li, S., Li, J., Shen, C., Zhang, X., Sun, S., Cho, M., Sun, C. & Song, Z. (2014). tert-
Butylhydroquinone (tBHQ) protects hepatocytes against lipotoxicity via 
inducing autophagy independently of Nrf2 activation. Biochimica et Biophysica 
Acta (BBA) - Molecular and Cell Biology of Lipids 1841(1): 22-33. 
Li, Y., Du, X.-f., Liu, C.-s., Wen, Z.-l. & Du, J.-l. (2012). Reciprocal Regulation 
between Resting Microglial Dynamics and Neuronal Activity In Vivo. 
Developmental Cell 23(6): 1189-1202. 
Ling, Y., Morgan, K. & Kalsheker, N. (2003). Amyloid precursor protein (APP) and the 
biology of proteolytic processing: Relevance to Alzheimer's disease. 
International Journal of Biochemistry and Cell Biology 35(11): 1505-1535. 
Linker, R. A., Lee, D.-H., Ryan, S., van Dam, A. M., Conrad, R., Bista, P., Zeng, W., 
Hronowsky, X., Buko, A., Chollate, S., Ellrichmann, G., Brück, W., Dawson, 
K., Goelz, S., Wiese, S., Scannevin, R. H., Lukashev, M. & Gold, R. (2011). 
Fumaric acid esters exert neuroprotective effects in neuroinflammation via 
activation of the Nrf2 antioxidant pathway. Brain 134(3): 678-692. 
Liu, C., Cui, G., Zhu, M., Kang, X. & Guo, H. (2014). Neuroinflammation in 
Alzheimer’s disease: chemokines produced by astrocytes and chemokine 
receptors. Int. J. Clin. Exp. Pathol. 7(12): 8342-8355. 
Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W. & Gong, C.-X. (2004). O-
GlcNAcylation regulates phosphorylation of tau: A mechanism involved in 
Alzheimer's disease. Proceedings of the National Academy of Sciences of the 
United States of America 101(29): 10804-10809. 
Liu, F., Zaidi, T., Iqbal, K., Grundke-Iqbal, I. & Gong, C. X. (2002a). Aberrant 
glycosylation modulates phosphorylation of tau by protein kinase A and 
dephosphorylation of tau by protein phosphatase 2A and 5. Neuroscience 
115(3): 829-837. 
Liu, F., Zaidi, T., Iqbal, K., Grundke-Iqbal, I., Merkle, R. K. & Gong, C.-X. (2002b). 
Role of glycosylation in hyperphosphorylation of tau in Alzheimer’s disease. 
FEBS Letters 512(1–3): 101-106. 
Liu, Y., Liu, F., Iqbal, K., Grundke-Iqbal, I. & Gong, C.-X. (2008). Decreased glucose 
transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer 
disease. FEBS Letters 582(2): 359-364. 
Loaiza, A., Porras, O. H. & Barros, L. F. (2003). Glutamate triggers rapid glucose 
transport stimulation in astrocytes as evidenced by real-time confocal 
microscopy. Journal of Neuroscience 23(19): 7337-7342. 
Loh, K., Deng, H., Fukushima, A., Cai, X., Boivin, B., Galic, S., Bruce, C., Shields, B. 
J., Skiba, B., Ooms, L. M., Stepto, N., Wu, B., Mitchell, C. A., Tonks, N. K., 
259 
Watt, M. J., Febbraio, M. A., Crack, P. J., Andrikopoulos, S. & Tiganis, T. 
(2009). Reactive oxygen species enhance insulin sensitivity. Cell Metab 10(4): 
260-272. 
Luo, X. G., Ding, J. Q. & Chen, S. D. (2010). Microglia in the aging brain: relevance to 
neurodegeneration. Mol Neurodegener 5: 12. 
Luo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, 
H., Zhang, J., Gong, Y., Martin, L., Louis, J.-C., Yan, Q., Richards, W. G., 
Citron, M. & Vassar, R. (2001). Mice deficient in BACE1, the Alzheimer's -
secretase, have normal phenotype and abolished -amyloid generation. Nat 
Neurosci 4(3): 231-232. 
Maesako, M., Uemura, K., Kubota, M., Kuzuya, A., Sasaki, K., Asada, M., Watanabe, 
K., Hayashida, N., Ihara, M., Ito, H., Shimohama, S., Kihara, T. & Kinoshita, A. 
(2012a). Environmental enrichment ameliorated high-fat diet-induced Aβ 
deposition and memory deficit in APP transgenic mice. Neurobiology of Aging 
33(5): 1011.e1011-1011.e1023. 
Maesako, M., Uemura, K., Kubota, M., Kuzuya, A., Sasaki, K., Hayashida, N., Asada-
Utsugi, M., Watanabe, K., Uemura, M., Kihara, T., Takahashi, R., Shimohama, 
S. & Kinoshita, A. (2012b). Exercise Is More Effective than Diet Control in 
Preventing High Fat Diet-induced β-Amyloid Deposition and Memory Deficit in 
Amyloid Precursor Protein Transgenic Mice. Journal of Biological Chemistry 
287(27): 23024-23033. 
Magistretti, P. J. (2006). Neuron-glia metabolic coupling and plasticity. Journal of 
Experimental Biology 209(12): 2304-2311. 
Mallard, C. (2012). Innate Immune Regulation by Toll-Like Receptors in the Brain. 
ISRN Neurology 2012: 19. 
Mamelak, M. (2012). Sporadic Alzheimer's disease: the starving brain. J Alzheimers Dis 
31(3): 459-474. 
Manczak, M., Calkins, M. J. & Reddy, P. H. (2011). Impaired mitochondrial dynamics 
and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in 
neurons from patients with Alzheimer's disease: implications for neuronal 
damage. Human Molecular Genetics 20(13): 2495-2509. 
Manczak, M. & Reddy, P. H. (2012). Abnormal interaction of VDAC1 with amyloid 
beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's 
disease. Human Molecular Genetics 21(23): 5131-5146. 
Mandelkow, E.-M. & Mandelkow, E. (2012). Biochemistry and Cell Biology of Tau 
Protein in Neurofibrillary Degeneration. Cold Spring Harbor Perspectives in 
Medicine 2(7). 
Marchesi, V. T. (2011). Alzheimer's dementia begins as a disease of small blood 
vessels, damaged by oxidative-induced inflammation and dysregulated amyloid 
metabolism: Implications for early detection and therapy. FASEB Journal 25(1): 
5-13. 
Marchi, S., Patergnani, S. & Pinton, P. (2014). The endoplasmic reticulum–
mitochondria connection: One touch, multiple functions. Biochimica et 
Biophysica Acta (BBA) - Bioenergetics 1837(4): 461-469. 
Maretzky, T., Reiss, K., Ludwig, A., Buchholz, J., Scholz, F., Proksch, E., de Strooper, 
B., Hartmann, D. & Saftig, P. (2005). ADAM10 mediates E-cadherin shedding 
and regulates epithelial cell-cell adhesion, migration, and β-catenin 
translocation. Proceedings of the National Academy of Sciences of the United 
States of America 102(26): 9182-9187. 
Martinez, F. O. & Gordon, S. (2014). The M1 and M2 paradigm of macrophage 
activation: time for reassessment. F1000Prime Reports 6: 13. 
260 
Mazzitelli, S., Xu, P., Ferrer, I., Davis, R. J. & Tournier, C. (2011). The Loss of c-Jun 
N-Terminal Protein Kinase Activity Prevents the Amyloidogenic Cleavage of 
Amyloid Precursor Protein and the Formation of Amyloid Plaques In Vivo. 
Journal of Neuroscience 31(47): 16969-16976. 
McGeer, P. L., Schulzer, M. & McGeer, E. G. (1996). Arthritis and anti-inflammatory 
agents as possible protective factors for Alzheimer's disease: A review of 17 
epidemiologic studies. Neurology 47(2): 425-432. 
McLarnon, J. G. (2012). Microglial chemotactic signaling factors in Alzheimer’s 
disease. American Journal of Neurodegenerative Disease 1(3): 199-204. 
McMahon, M., Itoh, K., Yamamoto, M., Chanas, S. A., Henderson, C. J., McLellan, L. 
I., Wolf, C. R., Cavin, C. & Hayes, J. D. (2001). The Cap'n'Collar basic leucine 
zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both 
constitutive and inducible expression of intestinal detoxification and glutathione 
biosynthetic enzymes. Cancer Res 61(8): 3299-3307. 
McMahon, M., Itoh, K., Yamamoto, M. & Hayes, J. D. (2003). Keap1-dependent 
proteasomal degradation of transcription factor Nrf2 contributes to the negative 
regulation of antioxidant response element-driven gene expression. J Biol Chem 
278(24): 21592-21600. 
McMahon, M., Lamont, D. J., Beattie, K. A. & Hayes, J. D. (2010). Keap1 perceives 
stress via three sensors for the endogenous signaling molecules nitric oxide, 
zinc, and alkenals. Proceedings of the National Academy of Sciences 107(44): 
18838-18843. 
McMahon, M., Thomas, N., Itoh, K., Yamamoto, M. & Hayes, J. D. (2004). Redox-
regulated turnover of Nrf2 is determined by at least two separate protein 
domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 
degron. J Biol Chem 279(30): 31556-31567. 
McMahon, M., Thomas, N., Itoh, K., Yamamoto, M. & Hayes, J. D. (2006). 
Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation 
of proteins by a "tethering" mechanism: a two-site interaction model for the 
Nrf2-Keap1 complex. J Biol Chem 281(34): 24756-24768. 
McManus, M. J., Murphy, M. P. & Franklin, J. L. (2011). The Mitochondria-Targeted 
Antioxidant MitoQ Prevents Loss of Spatial Memory Retention and Early 
Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease. Journal 
of Neuroscience 31(44): 15703-15715. 
McNay, E. C., Fries, T. M. & Gold, P. E. (2000). Decreases in rat extracellular 
hippocampal glucose concentration associated with cognitive demand during a 
spatial task. Proceedings of the National Academy of Sciences 97(6): 2881-2885. 
McNay, E. C., Ong, C. T., McCrimmon, R. J., Cresswell, J., Bogan, J. S. & Sherwin, R. 
S. (2010). Hippocampal memory processes are modulated by insulin and high-
fat-induced insulin resistance. Neurobiol Learn Mem 93(4): 546-553. 
Meakin, P. J., Chowdhry, S., Sharma, R. S., Ashford, F. B., Walsh, S. V., McCrimmon, 
R. J., Dinkova-Kostova, A. T., Dillon, J. F., Hayes, J. D. & Ashford, M. L. 
(2014). Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon 
consumption of a high-fat diet is associated with oxidative stress, perturbation of 
the unfolded protein response, and disturbance in the expression of metabolic 
enzymes but not with insulin resistance. Mol Cell Biol 34(17): 3305-3320. 
Meakin, P. J., Harper, A. J., Hamilton, D. L., Gallagher, J., McNeilly, A. D., Burgess, 
L. A., Vaanholt, L. M., Bannon, K. A., Latcham, J., Hussain, I., Speakman, J. 
R., Howlett, D. R. & Ashford, M. L. J. (2012). Reduction in BACE1 decreases 
body weight, protects against diet-induced obesity and enhances insulin 
sensitivity in mice. Biochemical Journal 441(1): 285-295. 
261 
Meher, A. K., Sharma, P. R., Lira, V. A., Yamamoto, M., Kensler, T. W., Yan, Z. & 
Leitinger, N. (2012). Nrf2 deficiency in myeloid cells is not sufficient to protect 
mice from high-fat diet-induced adipose tissue inflammation and insulin 
resistance. Free Radical Biology and Medicine 52(9): 1708-1715. 
Mehlhorn, G., Hollborn, M. & Schliebs, R. (2000). Induction of cytokines in glial cells 
surrounding cortical β-amyloid plaques in transgenic Tg2576 mice with 
Alzheimer pathology. International Journal of Developmental Neuroscience 
18(4–5): 423-431. 
Menting, K. W. & Claassen, J. A. H. R. (2014). β-secretase inhibitor; a promising novel 
therapeutic drug in AD. Frontiers in Aging Neuroscience 6. 
Miklossy, J., Doudet, D. D., Schwab, C., Yu, S., McGeer, E. G. & McGeer, P. L. 
(2006). Role of ICAM-1 in persisting inflammation in Parkinson disease and 
MPTP monkeys. Experimental Neurology 197(2): 275-283. 
Milder, J. & Patel, M. (2012). Modulation of oxidative stress and mitochondrial 
function by the ketogenic diet. Epilepsy Research 100(3): 295-303. 
Millan Sanchez, M., Heyn, S. N., Das, D., Moghadam, S., Martin, K. J. & Salehi, A. 
(2012). Neurobiological Elements of Cognitive Dysfunction in Down 
Syndrome: Exploring the Role of APP. Biological Psychiatry 71(5): 403-409. 
Miller, D. M., Singh, I. N., Wang, J. A. & Hall, E. D. (2013). Administration of the 
Nrf2–ARE activators sulforaphane and carnosic acid attenuates 4-hydroxy-2-
nonenal-induced mitochondrial dysfunction ex vivo. Free Radical Biology and 
Medicine 57: 1-9. 
Min, S.-W., Chen, X., Tracy, T. E., Li, Y., Zhou, Y., Wang, C., Shirakawa, K., Minami, 
S. S., Defensor, E., Mok, S. A., Sohn, P. D., Schilling, B., Cong, X., Ellerby, L., 
Gibson, B. W., Johnson, J., Krogan, N., Shamloo, M., Gestwicki, J., Masliah, E., 
Verdin, E. & Gan, L. (2015). Critical role of acetylation in tau-mediated 
neurodegeneration and cognitive deficits. Nat Med 21(10): 1154-1162. 
Mody, N., Agouni, A., McIlroy, G. D., Platt, B. & Delibegovic, M. (2011). 
Susceptibility to diet-induced obesity and glucose intolerance in the APP 
SWE/PSEN1 A246E mouse model of Alzheimer’s disease is associated with 
increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-
binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein. 
Diabetologia 54(8): 2143-2151. 
Mohmmad Abdul, H., Sultana, R., Keller, J. N., St. Clair, D. K., Markesbery, W. R. & 
Butterfield, D. A. (2006). Mutations in amyloid precursor protein and presenilin-
1 genes increase the basal oxidative stress in murine neuronal cells and lead to 
increased sensitivity to oxidative stress mediated by amyloid β-peptide (1–42), 
H2O2 and kainic acid: implications for Alzheimer's disease. Journal of 
Neurochemistry 96(5): 1322-1335. 
Moi, P., Chan, K., Asunis, I., Cao, A. & Kan, Y. W. (1994). Isolation of NF-E2-related 
factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that 
binds to the tandem NF-E2/AP1 repeat of the β-globin locus control region. 
Proceedings of the National Academy of Sciences of the United States of 
America 91(21): 9926-9930. 
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R. & O’Neill, C. 
(2010). Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's 
disease indicate possible resistance to IGF-1 and insulin signalling. 
Neurobiology of Aging 31(2): 224-243. 
More, V. R., Xu, J., Shimpi, P. C., Belgrave, C., Luyendyk, J. P., Yamamoto, M. & 
Slitt, A. L. (2013). Keap1 knockdown increases markers of metabolic syndrome 
after long-term high fat diet feeding. Free Radic Biol Med 61: 85-94. 
262 
Morris, M., Evans, D. A., Bienias, J. L. & et al. (2003). Consumption of fish and n-3 
fatty acids and risk of incident alzheimer disease. Archives of Neurology 60(7): 
940-946. 
Morris, M. & Li, L. (2012). Molecular Mechanisms and Pathological Consequences of 
Endotoxin Tolerance and Priming. Arch. Immunol. Ther. Exp. 60(1): 13-18. 
Morrison, C. D., Pistell, P. J., Ingram, D. K., Johnson, W. D., Liu, Y., Fernandez-Kim, 
S. O., White, C. L., Purpera, M. N., Uranga, R. M., Bruce-Keller, A. J. & Keller, 
J. N. (2010). High fat diet increases hippocampal oxidative stress and cognitive 
impairment in aged mice: implications for decreased Nrf2 signaling. Journal of 
Neurochemistry 114(6): 1581-1589. 
Morroni, F., Tarozzi, A., Sita, G., Bolondi, C., Zolezzi Moraga, J. M., Cantelli-Forti, G. 
& Hrelia, P. (2013). Neuroprotective effect of sulforaphane in 6-
hydroxydopamine-lesioned mouse model of Parkinson's disease. 
NeuroToxicology 36: 63-71. 
Mosconi, L., De Santi, S., Li, J., Tsui, W. H., Li, Y., Boppana, M., Laska, E., Rusinek, 
H. & de Leon, M. J. (2008a). Hippocampal hypometabolism predicts cognitive 
decline from normal aging. Neurobiology of Aging 29(5): 676-692. 
Mosconi, L., Mistur, R., Switalski, R., Tsui, W. H., Glodzik, L., Li, Y., Pirraglia, E., 
Santi, S., Reisberg, B., Wisniewski, T. & Leon, M. J. (2009). FDG-PET changes 
in brain glucose metabolism from normal cognition to pathologically verified 
Alzheimer’s disease. European Journal of Nuclear Medicine and Molecular 
Imaging 36(5): 811-822. 
Mosconi, L., Pupi, A. & De Leon, M. J. (2008b). Brain Glucose Hypometabolism and 
Oxidative Stress in Preclinical Alzheimer's Disease. Annals of the New York 
Academy of Sciences 1147(1): 180-195. 
Mosser, D. M. & Edwards, J. P. (2008). Exploring the full spectrum of macrophage 
activation. Nature reviews. Immunology 8(12): 958-969. 
Mucke, L. (2000). High-level neuronal expression of a 1-42 in wild-type human 
amyloid protein precursor transgenic mice: synaptotoxicity without plaque 
formation. J. Neurosci. 20: 4050-4058. 
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B. & 
Lannfelt, L. (1992). A pathogenic mutation for probable Alzheimer's disease in 
the APP gene at the N-terminus of -amyloid. Nat Genet 1(5): 345-347. 
Müller, T., Meyer, H. E., Egensperger, R. & Marcus, K. (2008). The amyloid precursor 
protein intracellular domain (AICD) as modulator of gene expression, apoptosis, 
and cytoskeletal dynamics—Relevance for Alzheimer's disease. Progress in 
Neurobiology 85(4): 393-406. 
Müller, U. C. & Zheng, H. (2012). Physiological Functions of APP Family Proteins. 
Cold Spring Harbor Perspectives in Medicine 2(2). 
Muramatsu, H., Katsuoka, F., Toide, K., Shimizu, Y., Furusako, S. & Yamamoto, M. 
(2013). Nrf2 deficiency leads to behavioral, neurochemical and transcriptional 
changes in mice. Genes to Cells 18(10): 899-908. 
Murray, C., Sanderson, D. J., Barkus, C., Deacon, R. M. J., Rawlins, J. N. P., 
Bannerman, D. M. & Cunningham, C. (2012). Systemic inflammation induces 
acute working memory deficits in the primed brain: relevance for delirium. 
Neurobiology of Aging 33(3): 603-616.e603. 
Muthusamy, V. R., Kannan, S., Sadhaasivam, K., Gounder, S. S., Davidson, C. J., 
Boeheme, C., Hoidal, J. R., Wang, L. & Rajasekaran, N. S. (2012). Acute 
exercise stress activates Nrf2/ARE signaling and promotes antioxidant 
mechanisms in the myocardium. Free Radical Biology and Medicine 52(2): 366-
376. 
263 
Nagai, N., Thimmulappa, R. K., Cano, M., Fujihara, M., Izumi-Nagai, K., Kong, X., 
Sporn, M. B., Kensler, T. W., Biswal, S. & Handa, J. T. (2009). Nrf2 is a critical 
modulator of the innate immune response in a model of uveitis. Free Radical 
Biology and Medicine 47(3): 300-306. 
Nakamura, M., Shishido, N., Nunomura, A., Smith, M. A., Perry, G., Hayashi, Y., 
Nakayama, K. & Hayashi, T. (2007). Three Histidine Residues of Amyloid-β 
Peptide Control the Redox Activity of Copper and Iron. Biochemistry 46(44): 
12737-12743. 
Nakanishi, H., Hayashi, Y. & Wu, Z. (2011). The role of microglial mtDNA damage in 
age-dependent prolonged LPS-induced sickness behavior. Neuron Glia Biology 
7(Special Issue 01): 17-23. 
Nakarai, H., Yamashita, A., Nagayasu, S., Iwashita, M., Kumamoto, S., Ohyama, H., 
Hata, M., Soga, Y., Kushiyama, A., Asano, T., Abiko, Y. & Nishimura, F. 
(2012). Adipocyte-macrophage interaction may mediate LPS-induced low-grade 
inflammation: Potential link with metabolic complications. Innate Immunity 
18(1): 164-170. 
Nakaso, K., Yano, H., Fukuhara, Y., Takeshima, T., Wada-Isoe, K. & Nakashima, K. 
(2003). PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative 
proteins by hemin in human neuroblastoma cells. Febs Letters 546(2‚Äì3): 181-
184. 
Needham, B. E., Wlodek, M. E., Ciccotosto, G. D., Fam, B. C., Masters, C. L., Proietto, 
J., Andrikopoulos, S. & Cappai, R. (2008). Identification of the Alzheimer's 
disease amyloid precursor protein (APP) and its homologue APLP2 as essential 
modulators of glucose and insulin homeostasis and growth. The Journal of 
Pathology 215(2): 155-163. 
Newman, A. B., Fitzpatrick, A. L., Lopez, O., Jackson, S., Lyketsos, C., Jagust, W., 
Ives, D., DeKosky, S. T. & Kuller, L. H. (2005). Dementia and Alzheimer's 
Disease Incidence in Relationship to Cardiovascular Disease in the 
Cardiovascular Health Study Cohort. Journal of the American Geriatrics Society 
53(7): 1101-1107. 
Nicholas, S. A., Coughlan, K., Yasinska, I., Lall, G. S., Gibbs, B. F., Calzolai, L. & 
Sumbayev, V. V. (2011). Dysfunctional mitochondria contain endogenous high-
affinity human Toll-like receptor 4 (TLR4) ligands and induce TLR4-mediated 
inflammatory reactions. The International Journal of Biochemistry & Cell 
Biology 43(4): 674-681. 
Niedowicz, D., Reeves, V., Platt, T., Kohler, K., Beckett, T., Powell, D., Lee, T., 
Sexton, T., Song, E., Brewer, L., Latimer, C., Kraner, S., Larson, K., Ozcan, S., 
Norris, C., Hersh, L., Porter, N., Wilcock, D. & Murphy, M. (2014). Obesity and 
diabetes cause cognitive dysfunction in the absence of accelerated beta-amyloid 
deposition in a novel murine model of mixed or vascular dementia. Acta 
Neuropathologica Communications 2(1): 64. 
Nielsen, H. M., Mulder, S. D., Beliën, J. A. M., Musters, R. J. P., Eikelenboom, P. & 
Veerhuis, R. (2010). Astrocytic Aβ1-42 uptake is determined by Aβ-aggregation 
state and the presence of amyloid-associated proteins. Glia 58(10): 1235-1246. 
Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. (2005). Resting Microglial Cells Are 
Highly Dynamic Surveillants of Brain Parenchyma in Vivo. Science 308(5726): 
1314-1318. 
Nioi, P., Nguyen, T., Sherratt, P. J. & Pickett, C. B. (2005). The carboxy-terminal Neh3 
domain of Nrf2 is required for transcriptional activation. Mol Cell Biol 25(24): 
10895-10906. 
Noris, M. & Remuzzi, G. (2013). Overview of Complement Activation and Regulation. 
Seminars in Nephrology 33(6): 479-492. 
264 
Nunomura, A., Tamaoki, T., Tanaka, K., Motohashi, N., Nakamura, M., Hayashi, T., 
Yamaguchi, H., Shimohama, S., Lee, H.-g., Zhu, X., Smith, M. A. & Perry, G. 
(2010). Intraneuronal amyloid β accumulation and oxidative damage to nucleic 
acids in Alzheimer disease. Neurobiology of Disease 37(3): 731-737. 
O'Connor, J. C., Lawson, M. A., Andre, C., Moreau, M., Lestage, J., Castanon, N., 
Kelley, K. W. & Dantzer, R. (2008). Lipopolysaccharide-induced depressive-
like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. 
Mol Psychiatry 14(5): 511-522. 
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., 
Metherate, R., Mattson, M. P., Akbari, Y. & LaFerla, F. M. (2003). Triple-
Transgenic Model of Alzheimer's Disease with Plaques and Tangles: 
Intracellular Aβ and Synaptic Dysfunction. Neuron 39(3): 409-421. 
Okada, K., Warabi, E., Sugimoto, H., Horie, M., Gotoh, N., Tokushige, K., Hashimoto, 
E., Utsunomiya, H., Takahashi, H., Ishii, T., Yamamoto, M. & Shoda, J. (2013). 
Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed 
atherogenic plus high-fat diet. J Gastroenterol 48(5): 620-632. 
Olarte-Sanchez, C. M., Kinnavane, L., Amin, E. & Aggleton, J. P. (2014). Contrasting 
networks for recognition memory and recency memory revealed by immediate-
early gene imaging in the rat. Behav Neurosci 128(4): 504-522. 
Oliveira, A. G., Carvalho, B. M., Tobar, N., Ropelle, E. R., Pauli, J. R., Bagarolli, R. A., 
Guadagnini, D., Carvalheira, J. B. C. & Saad, M. J. A. (2011). Physical Exercise 
Reduces Circulating Lipopolysaccharide and TLR4 Activation and Improves 
Insulin Signaling in Tissues of DIO Rats. Diabetes 60(3): 784-796. 
Olmos-Alonso, A., Schetters, S. T. T., Sri, S., Askew, K., Mancuso, R., Vargas-
Caballero, M., Holscher, C., Perry, V. H. & Gomez-Nicola, D. (2016). 
Pharmacological targeting of CSF1R inhibits microglial proliferation and 
prevents the progression of Alzheimer’s-like pathology. Brain. 
Ortuño-Sahagún, D., González, R., Verdaguer, E., Huerta, V., Torres-Mendoza, B., 
Lemus, L., Rivera-Cervantes, M., Camins, A. & Zárate, C. B. (2014). Glutamate 
Excitotoxicity Activates the MAPK/ERK Signaling Pathway and Induces the 
Survival of Rat Hippocampal Neurons In Vivo. Journal of Molecular 
Neuroscience 52(3): 366-377. 
Pallanck, L. (2013). Mitophagy: Mitofusin Recruits a Mitochondrial Killer. Current 
Biology 23(13): R570-R572. 
Palomo, J., Dietrich, D., Martin, P., Palmer, G. & Gabay, C. (2015). The interleukin 
(IL)-1 cytokine family - Balance between agonists and antagonists in 
inflammatory diseases. Cytokine. 
Pan, H., Wang, H., Wang, X., Zhu, L. & Mao, L. (2012). The Absence of Nrf2 
Enhances NF-B-Dependent Inflammation following Scratch Injury in Mouse 
Primary Cultured Astrocytes. Mediators of Inflammation 2012: 9. 
Pardossi-Piquard, R., Petit, A., Kawarai, T., Sunyach, C., Alves da Costa, C., Vincent, 
B., Ring, S., D’Adamio, L., Shen, J., Müller, U., Hyslop, P. S. G. & Checler, F. 
(2005). Presenilin-Dependent Transcriptional Control of the Aβ-Degrading 
Enzyme Neprilysin by Intracellular Domains of βAPP and APLP. Neuron 46(4): 
541-554. 
Park, C. R., Seeley, R. J., Craft, S. & Woods, S. C. (2000). Intracerebroventricular 
insulin enhances memory in a passive-avoidance task. Physiology & Behavior 
68(4): 509-514. 
Park, L., Wang, G., Zhou, P., Zhou, J., Pitstick, R., Previti, M. L., Younkin, L., 
Younkin, S. G., Van Nostrand, W. E., Cho, S., Anrather, J., Carlson, G. A. & 
Iadecola, C. (2011). Scavenger receptor CD36 is essential for the 
cerebrovascular oxidative stress and neurovascular dysfunction induced by 
265 
amyloid-β. Proceedings of the National Academy of Sciences 108(12): 5063-
5068. 
Parkin, J. & Cohen, B. (2001). An overview of the immune system. The Lancet 
357(9270): 1777-1789. 
Patel, H. C., Boutin, H. & Allan, S. M. (2003). Interleukin-1 in the Brain. Annals of the 
New York Academy of Sciences 992(1): 39-47. 
Peake, B. F., Nicholson, C. K., Lambert, J. P., Hood, R. L., Amin, H., Amin, S. & 
Calvert, J. W. (2013). Hydrogen sulfide preconditions the db/db diabetic mouse 
heart against ischemia-reperfusion injury by activating Nrf2 signaling in an Erk-
dependent manner. American Journal of Physiology - Heart and Circulatory 
Physiology 304(9): H1215-H1224. 
Peng, B., Zhao, P., Lu, Y.-P., Chen, M.-M., Sun, H., Wu, X.-M. & Zhu, L. (2013). Z-
ligustilide activates the Nrf2/HO-1 pathway and protects against cerebral 
ischemia–reperfusion injury in vivo and in vitro. Brain Research 1520: 168-177. 
Perez-Gonzalez, R., Alvira-Botero, M. X., Robayo, O., Antequera, D., Garzon, M., 
Martin-Moreno, A. M., Brera, B., de Ceballos, M. L. & Carro, E. (2014). Leptin 
gene therapy attenuates neuronal damages evoked by amyloid-[beta] and rescues 
memory deficits in APP/PS1 mice. Gene Ther 21(3): 298-308. 
Pérez-González, R., Antequera, D., Vargas, T., Spuch, C., Bolós, M. & Carro, E. 
(2011). Leptin induces proliferation of neuronal progenitors and neuroprotection 
in a mouse model of alzheimer's disease. Journal of Alzheimer's Disease 
24(SUPPL. 2): 17-25. 
Perez Nievas, B. G., Hammerschmidt, T., Kummer, M. P., Terwel, D., Leza, J. C. & 
Heneka, M. T. (2011). Restraint stress increases neuroinflammation 
independently of amyloid β levels in amyloid precursor protein/PS1 transgenic 
mice. Journal of Neurochemistry 116(1): 43-52. 
Pi, J., Leung, L., Xue, P., Wang, W., Hou, Y., Liu, D., Yehuda-Shnaidman, E., Lee, C., 
Lau, J., Kurtz, T. W. & Chan, J. Y. (2010). Deficiency in the nuclear factor E2-
related factor-2 transcription factor results in impaired adipogenesis and protects 
against diet-induced obesity. J Biol Chem 285(12): 9292-9300. 
Piantadosi, C. A., Withers, C. M., Bartz, R. R., MacGarvey, N. C., Fu, P., Sweeney, T. 
E., Welty-Wolf, K. E. & Suliman, H. B. (2011). Heme Oxygenase-1 Couples 
Activation of Mitochondrial Biogenesis to Anti-inflammatory Cytokine 
Expression. Journal of Biological Chemistry 286(18): 16374-16385. 
Pihlaja, R., Koistinaho, J., Kauppinen, R., Sandholm, J., Tanila, H. & Koistinaho, M. 
(2011). Multiple cellular and molecular mechanisms Are involved in human Aβ 
clearance by transplanted adult astrocytes. Glia 59(11): 1643-1657. 
Pinho, C. M., Teixeira, P. F. & Glaser, E. (2014). Mitochondrial import and degradation 
of amyloid-β peptide. Biochimica et Biophysica Acta (BBA) - Bioenergetics 
1837(7): 1069-1074. 
Pistell, P. J., Morrison, C. D., Gupta, S., Knight, A. G., Keller, J. N., Ingram, D. K. & 
Bruce-Keller, A. J. (2010). Cognitive impairment following high fat diet 
consumption is associated with brain inflammation. J Neuroimmunol 219(1-2): 
25-32. 
Postina, R., Schroeder, A., Dewachter, I., Bohl, J., Schmitt, U., Kojro, E., Prinzen, C., 
Endres, K., Hiemke, C., Blessing, M., Flamez, P., Dequenne, A., Godaux, E., 
van Leuven, F. & Fahrenholz, F. (2004). A disintegrin-metalloproteinase 
prevents amyloid plaque formation and hippocampal defects in an Alzheimer 
disease mouse model. The Journal of Clinical Investigation 113(10): 1456-1464. 
Prasher, V. P., Farrer, M. J., Kessling, A. M., Fisher, E. M. C., West, R. J., Barber, P. C. 
& Butler, A. C. (1998). Molecular mapping of alzheimer-type dementia in 
Down's syndrome. Annals of Neurology 43(3): 380-383. 
266 
Priestley, J. R. C., Kautenburg, K. E., Casati, M. C., Endres, B. T., Geurts, A. M. & 
Lombard, J. H. (2015). THE NRF2 KNOCKOUT RAT: A NEW ANIMAL 
MODEL TO STUDY ENDOTHELIAL DYSFUNCTION, OXIDANT STRESS, 
AND MICROVASCULAR RAREFACTION. American Journal of Physiology - 
Heart and Circulatory Physiology. 
Puig, K. L., Floden, A. M., Adhikari, R., Golovko, M. Y. & Combs, C. K. (2012). 
Amyloid Precursor Protein and Proinflammatory Changes Are Regulated in 
Brain and Adipose Tissue in a Murine Model of High Fat Diet-Induced Obesity. 
PLoS ONE 7(1): e30378. 
Purisai, M. G., McCormack, A. L., Cumine, S., Li, J., Isla, M. Z. & Di Monte, D. A. 
(2007). Microglial activation as a priming event leading to paraquat-induced 
dopaminergic cell degeneration. Neurobiology of Disease 25(2): 392-400. 
Purushothaman, S., Renuka Nair, R., Harikrishnan, V. S. & Fernandez, A. C. (2011). 
Temporal relation of cardiac hypertrophy, oxidative stress, and fatty acid 
metabolism in spontaneously hypertensive rat. Mol Cell Biochem 351(1-2): 59-
64. 
Pussinen, P. J., Havulinna, A. S., Lehto, M., Sundvall, J. & Salomaa, V. (2011). 
Endotoxemia Is Associated With an Increased Risk of Incident Diabetes. 
Diabetes Care 34(2): 392-397. 
Puzzo, D., Lee, L., Palmeri, A., Calabrese, G. & Arancio, O. (2014). Behavioral assays 
with mouse models of Alzheimer's disease: Practical considerations and 
guidelines. Biochemical Pharmacology 88(4): 450-467. 
Qiao, X., Cummins, D. J. & Paul, S. M. (2001). Neuroinflammation-induced 
acceleration of amyloid deposition in the APPV717F transgenic mouse. 
European Journal of Neuroscience 14(3): 474-482. 
Qin, S., Du, R., Yin, S., Liu, X., Xu, G. & Cao, W. (2015). Nrf2 is essential for the anti-
inflammatory effect of carbon monoxide in LPS-induced inflammation. 
Inflamm. Res. 64(7): 537-548. 
Qiu, C., Kivipelto, M. & von Strauss, E. (2009). Epidemiology of Alzheimer's disease: 
occurrence, determinants, and strategies toward intervention. Dialogues Clin 
Neurosci 11(2): 111-128. 
Qizilbash, N., Gregson, J., Johnson, M. E., Pearce, N., Douglas, I., Wing, K., Evans, S. 
J. W. & Pocock, S. J. (2015). BMI and risk of dementia in two million people 
over two decades: a retrospective cohort study. The Lancet Diabetes & 
Endocrinology 3(6): 431-436. 
Quiroz-Baez, R., Rojas, E. & Arias, C. (2009). Oxidative stress promotes JNK-
dependent amyloidogenic processing of normally expressed human APP by 
differential modification of α-, β- and γ-secretase expression. Neurochemistry 
International 55(7): 662-670. 
Rada, P., Rojo, A. I., Chowdhry, S., McMahon, M., Hayes, J. D. & Cuadrado, A. 
(2011). SCF/-TrCP promotes glycogen synthase kinase 3-dependent 
degradation of the Nrf2 transcription factor in a Keap1-independent manner. 
Mol Cell Biol 31(6): 1121-1133. 
Rada, P., Rojo, A. I., Evrard-Todeschi, N., Innamorato, N. G., Cotte, A., Jaworski, T., 
Tobon-Velasco, J. C., Devijver, H., Garcia-Mayoral, M. F., Van Leuven, F., 
Hayes, J. D., Bertho, G. & Cuadrado, A. (2012). Structural and functional 
characterization of Nrf2 degradation by the glycogen synthase kinase 3/-TrCP 
axis. Mol Cell Biol 32(17): 3486-3499. 
Rainbolt, T. K., Saunders, J. M. & Wiseman, R. L. (2014). Stress-responsive regulation 
of mitochondria through the ER unfolded protein response. Trends in 
Endocrinology & Metabolism 25(10): 528-537. 
267 
Ramaglia, V., Hughes, T. R., Donev, R. M., Ruseva, M. M., Wu, X., Huitinga, I., Baas, 
F., Neal, J. W. & Morgan, B. P. (2012). C3-dependent mechanism of microglial 
priming relevant to multiple sclerosis. Proceedings of the National Academy of 
Sciences 109(3): 965-970. 
Ransohoff, R. M. (2009). Chemokines and Chemokine Receptors: Standing at the 
Crossroads of Immunobiology and Neurobiology. Immunity 31(5): 711-721. 
Reaume, A. G., Howland, D. S., Trusko, S. P., Savage, M. J., Lang, D. M., Greenberg, 
B. D., Siman, R. & Scott, R. W. (1996). Enhanced Amyloidogenic Processing of 
the β-Amyloid Precursor Protein in Gene-targeted Mice Bearing the Swedish 
Familial Alzheimer's Disease Mutations and a “Humanized” Aβ Sequence. 
Journal of Biological Chemistry 271(38): 23380-23388. 
Refolo, L. M., Pappolla, M. A., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, 
R., Tint, G. S., Sambamurti, K. & Duff, K. (2000). Hypercholesterolemia 
Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model. 
Neurobiology of Disease 7(4): 321-331. 
Reger, M. L., Hovda, D. A. & Giza, C. C. (2009). Ontogeny of Rat Recognition 
Memory measured by the novel object recognition task. Developmental 
Psychobiology 51(8): 672-678. 
Reichwald, J., Danner, S., Wiederhold, K. H. & Staufenbiel, M. (2009). Expression of 
complement system components during aging and amyloid deposition in APP 
transgenic mice. J Neuroinflammation 6: 35. 
Roses, A. D. (1996). Apolipoprotein E alleles as risk factors in Alzheimer's disease. 
Annu Rev Med 47: 387-400. 
Roßner, S., Lange-Dohna, C., Zeitschel, U. & Perez-Polo, J. R. (2005). Alzheimer's 
disease β-secretase BACE1 is not a neuron-specific enzyme. Journal of 
Neurochemistry 92(2): 226-234. 
Rostène, W., Dansereau, M.-A., Godefroy, D., Van Steenwinckel, J., Goazigo, A. R.-L., 
Mélik-Parsadaniantz, S., Apartis, E., Hunot, S., Beaudet, N. & Sarret, P. (2011). 
Neurochemokines: a menage a trois providing new insights on the functions of 
chemokines in the central nervous system. Journal of Neurochemistry 118(5): 
680-694. 
Roubaud-Baudron, C., Krolak-Salmon, P., Quadrio, I., Mégraud, F. & Salles, N. (2012). 
Impact of chronic Helicobacter pylori infection on Alzheimer's disease: 
preliminary results. Neurobiology of Aging 33(5): 1009.e1011-1009.e1019. 
Rzepecka, J., Pineda, M. A., Al-Riyami, L., Rodgers, D. T., Huggan, J. K., Lumb, F. E., 
Khalaf, A. I., Meakin, P. J., Corbet, M., Ashford, M. L., Suckling, C. J., Harnett, 
M. M. & Harnett, W. (2015). Prophylactic and therapeutic treatment with a 
synthetic analogue of a parasitic worm product prevents experimental arthritis 
and inhibits IL-1β production via NRF2-mediated counter-regulation of the 
inflammasome. Journal of Autoimmunity 60: 59-73. 
Salminen, A., Ojala, J., Suuronen, T., Kaarniranta, K. & Kauppinen, A. (2008). 
Amyloid-β oligomers set fire to inflammasomes and induce Alzheimer's 
pathology. Journal of Cellular and Molecular Medicine 12(6a): 2255-2262. 
Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J. & Drago, F. (2011). New 
pharmacological strategies for treatment of Alzheimer's disease: focus on 
disease-modifying drugs. British Journal of Clinical Pharmacology: no-no. 
Saraiva, M. & O'Garra, A. (2010). The regulation of IL-10 production by immune cells. 
Nat Rev Immunol 10(3): 170-181. 
Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., 
Evert, B. O., Dumitrescu-Ozimek, L., Thal, D. R., Landreth, G., Walter, J., 
Klockgether, T., van Leuven, F. & Heneka, M. T. (2006). Nonsteroidal anti-
inflammatory drugs repress β-secretase gene promoter activity by the activation 
268 
of PPARγ. Proceedings of the National Academy of Sciences of the United 
States of America 103(2): 443-448. 
Schaefer, E. J., Bongard, V., Beiser, A. S. & et al. (2006). Plasma phosphatidylcholine 
docosahexaenoic acid content and risk of dementia and alzheimer disease: The 
framingham heart study. Archives of Neurology 63(11): 1545-1550. 
Schilling, T. & Eder, C. (2011). Amyloid-beta-induced reactive oxygen species 
production and priming are differentially regulated by ion channels in microglia. 
J Cell Physiol 226(12): 3295-3302. 
Schuessel, K., Schäfer, S., Bayer, T. A., Czech, C., Pradier, L., Müller-Spahn, F., 
Müller, W. E. & Eckert, A. (2005). Impaired Cu/Zn-SOD activity contributes to 
increased oxidative damage in APP transgenic mice. Neurobiology of Disease 
18(1): 89-99. 
Seijkens, T., Kusters, P., Chatzigeorgiou, A., Chavakis, T. & Lutgens, E. (2014). 
Immune Cell Crosstalk in Obesity: A Key Role for Costimulation? Diabetes 
63(12): 3982-3991. 
Selfridge, J. E., E, L., Lu, J. & Swerdlow, R. H. (2013). Role of mitochondrial 
homeostasis and dynamics in Alzheimer's disease. Neurobiology of Disease 
51(0): 3-12. 
Seo, H.-A. & Lee, I.-K. (2013). The Role of Nrf2: Adipocyte Differentiation, Obesity, 
and Insulin Resistance. Oxidative Medicine and Cellular Longevity 2013: 7. 
Serres, S., Bezancon, E., Franconi, J. M. & Merle, M. (2004). Ex vivo analysis of 
lactate and glucose metabolism in the rat brain under different states of 
depressed activity. Journal of Biological Chemistry 279(46): 47881-47889. 
Shankar, G. M. & Walsh, D. M. (2009). Alzheimer's disease: synaptic dysfunction and 
Abeta. Mol Neurodegener 4: 48. 
Shariati, S. A. M. & De Strooper, B. (2013). Redundancy and divergence in the amyloid 
precursor protein family. FEBS Letters 587(13): 2036-2045. 
Sheedy, F. J., Grebe, A., Rayner, K. J., Kalantari, P., Ramkhelawon, B., Carpenter, S. 
B., Becker, C. E., Ediriweera, H. N., Mullick, A. E., Golenbock, D. T., Stuart, L. 
M., Latz, E., Fitzgerald, K. A. & Moore, K. J. (2013). CD36 coordinates NLRP3 
inflammasome activation by facilitating intracellular nucleation of soluble 
ligands into particulate ligands in sterile inflammation. Nat Immunol 14(8): 812-
820. 
Shen, C., Chen, Y., Liu, H., Zhang, K., Zhang, T., Lin, A. & Jing, N. (2008). Hydrogen 
peroxide promotes Aβ production through JNK-dependent activation of γ-
secretase. Journal of Biological Chemistry 283(25): 17721-17730. 
Sheng, J. G., Bora, S. H., Xu, G., Borchelt, D. R., Price, D. L. & Koliatsos, V. E. 
(2003). Lipopolysaccharide-induced-neuroinflammation increases intracellular 
accumulation of amyloid precursor protein and amyloid β peptide in APPswe 
transgenic mice. Neurobiology of Disease 14(1): 133-145. 
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, 
H., Lin, C., Li, G., Holman, K., Tsuda, T., Mar, L., Foncin, J. F., Bruni, A. C., 
Montesi, M. P., Sorbi, S., Rainero, I., Pinessi, L., Nee, L., Chumakov, I., Pollen, 
D., Brookes, A., Sanseau, P., Polinsky, R. J., Wasco, W., Da Silva, H. A. R., 
Haines, J. L., Pericak-Vance, M. A., Tanzi, R. E., Roses, A. D., Fraser, P. E., 
Rommens, J. M. & St  George-Hyslop, P. H. (1995). Cloning of a gene 
bearing missense mutations in early-onset familial Alzheimer's disease. Nature 
375(6534): 754-760. 
Shih, A. Y., Imbeault, S., Barakauskas, V., Erb, H., Jiang, L., Li, P. & Murphy, T. H. 
(2005). Induction of the Nrf2-driven antioxidant response confers 
neuroprotection during mitochondrial stress in vivo. Journal of Biological 
Chemistry 280(24): 22925-22936. 
269 
Shih, A. Y., Johnson, D. A., Wong, G., Kraft, A. D., Jiang, L., Erb, H., Johnson, J. A. & 
Murphy, T. H. (2003). Coordinate Regulation of Glutathione Biosynthesis and 
Release by Nrf2-Expressing Glia Potently Protects Neurons from Oxidative 
Stress. The Journal of Neuroscience 23(8): 3394-3406. 
Shimizu, E., Kawahara, K., Kajizono, M., Sawada, M. & Nakayama, H. (2008). IL-4-
Induced Selective Clearance of Oligomeric β-Amyloid Peptide1–42 by Rat 
Primary Type 2 Microglia. The Journal of Immunology 181(9): 6503-6513. 
Shin, S., Wakabayashi, J., Yates, M. S., Wakabayashi, N., Dolan, P. M., Aja, S., Liby, 
K. T., Sporn, M. B., Yamamoto, M. & Kensler, T. W. (2009). Role of Nrf2 in 
prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-
imidazolide. Eur J Pharmacol 620(1-3): 138-144. 
Six, E., Ndiaye, D., Laâbi, Y., Brou, C., Gupta-Rossi, N., Israël, A. & Logeat, F. (2003). 
The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and γ-
secretase. Proceedings of the National Academy of Sciences 100(13): 7638-
7643. 
Sly, L. M., Krzesicki, R. F., Brashler, J. R., Buhl, A. E., McKinley, D. D., Carter, D. B. 
& Chin, J. E. (2001). Endogenous brain cytokine mRNA and inflammatory 
responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse 
model of Alzheimer’s disease. Brain Research Bulletin 56(6): 581-588. 
Smith, E., Hay, P., Campbell, L. & Trollor, J. N. (2011). A review of the association 
between obesity and cognitive function across the lifespan: implications for 
novel approaches to prevention and treatment. Obesity Reviews 12(9): 740-755. 
Smith, E. E. & Greenberg, S. M. (2009). β-Amyloid, Blood Vessels, and Brain 
Function. Stroke 40(7): 2601-2606. 
Smith, M. A., Casadesus, G., Joseph, J. A. & Perry, G. (2002). Amyloid-β and τ serve 
antioxidant functions in the aging and Alzheimer brain. Free Radical Biology 
and Medicine 33(9): 1194-1199. 
Smith, R. A. J. & Murphy, M. P. (2010). Animal and human studies with the 
mitochondria-targeted antioxidant MitoQ. Annals of the New York Academy of 
Sciences 1201(1): 96-103. 
Sofroniew, M. V. (2009). Molecular dissection of reactive astrogliosis and glial scar 
formation. Trends Neurosci 32(12): 638-647. 
Sokolova, A., Hill, M. D., Rahimi, F., Warden, L. A., Halliday, G. M. & Shepherd, C. 
E. (2009). Monocyte Chemoattractant Protein-1 Plays a Dominant Role in the 
Chronic Inflammation Observed in Alzheimer's Disease. Brain Pathology 19(3): 
392-398. 
Song, M., Jin, J., Lim, J. E., Kou, J., Pattanayak, A., Rehman, J. A., Kim, H. D., Tahara, 
K., Lalonde, R. & Fukuchi, K. (2011). TLR4 mutation reduces microglial 
activation, increases A deposits and exacerbates cognitive deficits in a mouse 
model of Alzheimer's disease. J Neuroinflammation 8: 92. 
Sosa-Ortiz, A. L., Acosta-Castillo, I. & Prince, M. J. (2012). Epidemiology of 
Dementias and Alzheimer’s Disease. Archives of Medical Research 43(8): 600-
608. 
Spires-Jones, T. L., Stoothoff, W. H., de Calignon, A., Jones, P. B. & Hyman, B. T. 
(2009). Tau pathophysiology in neurodegeneration: a tangled issue. Trends in 
Neurosciences 32(3): 150-159. 
Spitzer, P., Herrmann, M., Klafki, H. W., Smirnov, A., Lewczuk, P., Kornhuber, J., 
Wiltfang, J. & Maler, J. M. (2010). Phagocytosis and LPS alter the maturation 
state of beta-amyloid precursor protein and induce different Abeta peptide 
release signatures in human mononuclear phagocytes. J Neuroinflammation 7: 
59. 
270 
Stack, C., Jainuddin, S., Elipenahli, C., Gerges, M., Starkova, N., Starkov, A. A., Jové, 
M., Portero-Otin, M., Launay, N., Pujol, A., Kaidery, N. A., Thomas, B., 
Tampellini, D., Beal, M. F. & Dumont, M. (2014). Methylene blue upregulates 
Nrf2/ARE genes and prevents tau-related neurotoxicity. Human Molecular 
Genetics 23(14): 3716-3732. 
Stienstra, R., van Diepen, J. A., Tack, C. J., Zaki, M. H., van de Veerdonk, F. L., Perera, 
D., Neale, G. A., Hooiveld, G. J., Hijmans, A., Vroegrijk, I., van den Berg, S., 
Romijn, J., Rensen, P. C. N., Joosten, L. A. B., Netea, M. G. & Kanneganti, T.-
D. (2011). Inflammasome is a central player in the induction of obesity and 
insulin resistance. Proceedings of the National Academy of Sciences 108(37): 
15324-15329. 
Strohmeyer, R., Shen, Y. & Rogers, J. (2000). Detection of complement alternative 
pathway mRNA and proteins in the Alzheimer’s disease brain. Molecular Brain 
Research 81(1–2): 7-18. 
Subaiea, G. M., Adwan, L. I., Ahmed, A. H., Stevens, K. E. & Zawia, N. H. (2013). 
Short-term treatment with tolfenamic acid improves cognitive functions in 
Alzheimer's disease mice. Neurobiology of Aging 34(10): 2421-2430. 
Sugimoto, H., Okada, K., Shoda, J., Warabi, E., Ishige, K., Ueda, T., Taguchi, K., 
Yanagawa, T., Nakahara, A., Hyodo, I., Ishii, T. & Yamamoto, M. (2010). 
Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and 
progression of nutritional steatohepatitis in mice. Am J Physiol Gastrointest 
Liver Physiol 298(2): G283-294. 
Sutherland, L. N., Capozzi, L. C., Turchinsky, N. J., Bell, R. C. & Wright, D. C. (2008). 
Time course of high-fat diet-induced reductions in adipose tissue mitochondrial 
proteins: potential mechanisms and the relationship to glucose intolerance. 
American Journal of Physiology - Endocrinology and Metabolism 295(5): 
E1076-E1083. 
Swerdlow, R. H. (2011). Brain aging, Alzheimer's disease, and mitochondria. 
Biochimica et Biophysica Acta - Molecular Basis of Disease 1812(12): 1630-
1639. 
Sy, M., Kitazawa, M., Medeiros, R., Whitman, L., Cheng, D., Lane, T. E. & Laferla, F. 
M. (2011). Inflammation induced by infection potentiates tau pathological 
features in transgenic mice. Am J Pathol 178(6): 2811-2822. 
Takeda, S., Sato, N., Uchio-Yamada, K., Sawada, K., Kunieda, T., Takeuchi, D., 
Kurinami, H., Shinohara, M., Rakugi, H. & Morishita, R. (2010). Diabetes-
accelerated memory dysfunction via cerebrovascular inflammation and Aβ 
deposition in an Alzheimer mouse model with diabetes. Proceedings of the 
National Academy of Sciences 107(15): 7036-7041. 
Takeuchi, O. & Akira, S. (2010). Pattern Recognition Receptors and Inflammation. Cell 
140(6): 805-820. 
Tamagno, E., Guglielmotto, M., Giliberto, L., Vitali, A., Borghi, R., Autelli, R., Danni, 
O. & Tabaton, M. (2009). JNK and ERK1/2 pathways have a dual opposite 
effect on the expression of BACE1. Neurobiology of Aging 30(10): 1563-1573. 
Tamagno, E., Parola, M., Bardini, P., Piccini, A., Borghi, R., Guglielmotto, M., Santoro, 
G., Davit, A., Danni, O., Smith, M. A., Perry, G. & Tabaton, M. (2005). β-site 
APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated 
by stress-activated protein kinases pathways. Journal of Neurochemistry 92(3): 
628-636. 
Tanaka, N., Ikeda, Y., Ohta, Y., Deguchi, K., Tian, F., Shang, J., Matsuura, T. & Abe, 
K. (2011). Expression of Keap1–Nrf2 system and antioxidative proteins in 
mouse brain after transient middle cerebral artery occlusion. Brain Research 
1370: 246-253. 
271 
Tanaka, Y., Aleksunes, L. M., Yeager, R. L., Gyamfi, M. A., Esterly, N., Guo, G. L. & 
Klaassen, C. D. (2008). NF-E2-Related Factor 2 Inhibits Lipid Accumulation 
and Oxidative Stress in Mice Fed a High-Fat Diet. Journal of Pharmacology and 
Experimental Therapeutics 325(2): 655-664. 
Tarr, A. J., McLinden, K. A., Kranjac, D., Kohman, R. A., Amaral, W. & Boehm, G. W. 
(2011). The effects of age on lipopolysaccharide-induced cognitive deficits and 
interleukin-1beta expression. Behav Brain Res 217(2): 481-485. 
Tateda, K., Matsumoto, T., Miyazaki, S. & Yamaguchi, K. (1996). Lipopolysaccharide-
induced lethality and cytokine production in aged mice. Infect Immun 64(3): 
769-774. 
Tebay, L. E., Robertson, H., Durant, S. T., Vitale, S. R., Penning, T. M., Dinkova-
Kostova, A. T. & Hayes, J. D. (2015). Mechanisms of activation of the 
transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and 
the pathways through which it attenuates degenerative disease. Free Radical 
Biology and Medicine 88, Part B: 108-146. 
Thal, D. R., Griffin, W. S. T. & Braak, H. (2008). Parenchymal and vascular Aβ-
deposition and its effects on the degeneration of neurons and cognition in 
Alzheimer's disease. Journal of Cellular and Molecular Medicine 12(5b): 1848-
1862. 
Thaler, J. P., Yi, C.-X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., 
Zhao, X., Sarruf, D. A., Izgur, V., Maravilla, K. R., Nguyen, H. T., Fischer, J. 
D., Matsen, M. E., Wisse, B. E., Morton, G. J., Horvath, T. L., Baskin, D. G., 
Tsch, xF, p, M. H. & Schwartz, M. W. (2012). Obesity is associated with 
hypothalamic injury in rodents and humans. The Journal of Clinical 
Investigation 122(1): 153-162. 
Thimmulappa, R. K., Mai, K. H., Srisuma, S., Kensler, T. W., Yamamoto, M. & 
Biswal, S. (2002). Identification of Nrf2-regulated genes induced by the 
chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 
62(18): 5196-5203. 
Thimmulappa, R. K., Scollick, C., Traore, K., Yates, M., Trush, M. A., Liby, K. T., 
Sporn, M. B., Yamamoto, M., Kensler, T. W. & Biswal, S. (2006). Nrf2-
dependent protection from LPS induced inflammatory response and mortality by 
CDDO-Imidazolide. Biochemical and Biophysical Research Communications 
351(4): 883-889. 
Thinakaran, G. & Koo, E. H. (2008). Amyloid precursor protein trafficking, processing, 
and function. Journal of Biological Chemistry 283(44): 29615-29619. 
Thirumangalakudi, L., Prakasam, A., Zhang, R., Bimonte-Nelson, H., Sambamurti, K., 
Kindy, M. S. & Bhat, N. R. (2008). High cholesterol-induced 
neuroinflammation and amyloid precursor protein processing correlate with loss 
of working memory in mice. Journal of Neurochemistry 106(1): 475-485. 
Thomson, C. A., McColl, A., Cavanagh, J. & Graham, G. J. (2014). Peripheral 
inflammation is associated with remote global gene expression changes in the 
brain. J Neuroinflammation 11: 73. 
Togo, T., Akiyama, H., Iseki, E., Kondo, H., Ikeda, K., Kato, M., Oda, T., Tsuchiya, K. 
& Kosaka, K. (2002). Occurrence of T cells in the brain of Alzheimer's disease 
and other neurological diseases. Journal of Neuroimmunology 124(1–2): 83-92. 
Tomobe, K., Shinozuka, T., Kuroiwa, M. & Nomura, Y. (2012). Age-related changes of 
Nrf2 and phosphorylated GSK-3Œ≤ in a mouse model of accelerated aging 
(SAMP8). Archives of Gerontology and Geriatrics 54(2): e1-e7. 
Tremblay, M.-È., Lowery, R. L. & Majewska, A. K. (2010). Microglial Interactions 
with Synapses Are Modulated by Visual Experience. PLoS Biol 8(11): 
e1000527. 
272 
Tremblay, M. E., Stevens, B., Sierra, A., Wake, H., Bessis, A. & Nimmerjahn, A. 
(2011). The Role of Microglia in the Healthy Brain. Journal of Neuroscience 
31(45): 16064-16069. 
Trimmer, P. A., Keeney, P. M., Borland, M. K., Simon, F. A., Almeida, J., Swerdlow, 
R. H., Parks, J. P., Parker Jr, W. D. & Bennett Jr, J. P. (2004). Mitochondrial 
abnormalities in cybrid cell models of sporadic Alzheimer's disease worsen with 
passage in culture. Neurobiology of Disease 15(1): 29-39. 
Tucsek, Z., Toth, P., Tarantini, S., Sosnowska, D., Gautam, T., Warrington, J. P., Giles, 
C. B., Wren, J. D., Koller, A., Ballabh, P., Sonntag, W. E., Ungvari, Z. & 
Csiszar, A. (2014). Aging Exacerbates Obesity-induced Cerebromicrovascular 
Rarefaction, Neurovascular Uncoupling, and Cognitive Decline in Mice. The 
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 
69(11): 1339-1352. 
Turner, P. R., O’Connor, K., Tate, W. P. & Abraham, W. C. (2003). Roles of amyloid 
precursor protein and its fragments in regulating neural activity, plasticity and 
memory. Progress in Neurobiology 70(1): 1-32. 
Ulbrich, F., Kaufmann, K. B., Coburn, M., Lagrèze, W. A., Roesslein, M., Biermann, J., 
Buerkle, H., Loop, T. & Goebel, U. (2015). Neuroprotective effects of Argon are 
mediated via an ERK-1/2 dependent regulation of heme-oxygenase-1 in retinal 
ganglion cells. Journal of Neurochemistry 134(4): 717-727. 
Unno, K., Yamamoto, H., Maeda, K.-i., Takabayashi, F., Yoshida, H., Kikunaga, N., 
Takamori, N., Asahina, S., Iguchi, K., Sayama, K. & Hoshino, M. (2009). 
Protection of brain and pancreas from high-fat diet: Effects of catechin and 
caffeine. Physiology & Behavior 96(2): 262-269. 
Valerio, A., Cardile, A., Cozzi, V., Bracale, R., Tedesco, L., Pisconti, A., Palomba, L., 
Cantoni, O., Clementi, E., Moncada, S., Carruba, M. O. & Nisoli, E. (2006). 
TNF-α downregulates eNOS expression and mitochondrial biogenesis in fat and 
muscle of obese rodents. The Journal of Clinical Investigation 116(10): 2791-
2798. 
Valladolid-Acebes, I., Stucchi, P., Cano, V., Fernández-Alfonso, M. S., Merino, B., Gil-
Ortega, M., Fole, A., Morales, L., Ruiz-Gayo, M. & Olmo, N. D. (2011). High-
fat diets impair spatial learning in the radial-arm maze in mice. Neurobiology of 
Learning and Memory 95(1): 80-85. 
van den Berg, T. K. & Kraal, G. (2005). A function for the macrophage F4/80 molecule 
in tolerance induction. Trends in Immunology 26(10): 506-509. 
van der Heide, L. P., Ramakers, G. M. J. & Smidt, M. P. (2006). Insulin signaling in the 
central nervous system: Learning to survive. Progress in Neurobiology 79(4): 
205-221. 
Van Leuven, F. (2013). Alzheimer's Disease. 
https://gbiomed.kuleuven.be/english/research/50000622/50525540/alzheimers-
disease. 
Vandal, M., White, P. J., Tremblay, C., St-Amour, I., Chevrier, G., Emond, V., 
Lefrançois, D., Virgili, J., Planel, E., Giguere, Y., Marette, A. & Calon, F. 
(2014). Insulin Reverses the High-Fat Diet–Induced Increase in Brain Aβ and 
Improves Memory in an Animal Model of Alzheimer Disease. Diabetes 63(12): 
4291-4301. 
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. 
L., Ravussin, E., Stephens, J. M. & Dixit, V. D. (2011). The NLRP3 
inflammasome instigates obesity-induced inflammation and insulin resistance. 
Nat Med 17(2): 179-188. 
Vassar, R. (2001). The β-secretase, BACE. Journal of Molecular Neuroscience 17(2): 
157-170. 
273 
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, 
D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., 
Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., 
Louis, J.-C., Collins, F., Treanor, J., Rogers, G. & Citron, M. (1999). β-
Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the 
Transmembrane Aspartic Protease BACE. Science 286(5440): 735-741. 
Vázquez-Vela, M. E. F., Torres, N. & Tovar, A. R. (2008). White Adipose Tissue as 
Endocrine Organ and Its Role in Obesity. Archives of Medical Research 39(8): 
715-728. 
Veerhuis, R., Nielsen, H. M. & Tenner, A. J. (2011). Complement in the brain. 
Molecular Immunology 48(14): 1592-1603. 
Velliquette, R. A., O'Connor, T. & Vassar, R. (2005). Energy inhibition elevates β-
secretase levels and activity and is potentially amyloidogenic in APP transgenic 
mice: Possible early events in Alzheimer's disease pathogenesis. Journal of 
Neuroscience 25(47): 10874-10883. 
Velmurugan, G. V., Sundaresan, N. R., Gupta, M. P. & White, C. (2013). Defective 
Nrf2-dependent redox signalling contributes to microvascular dysfunction in 
type 2 diabetes. Cardiovascular Research 100(1): 143-150. 
Venci, J. V. & Gandhi, M. A. (2013). Dimethyl Fumarate (Tecfidera): A New Oral 
Agent for Multiple Sclerosis. Annals of Pharmacotherapy 47(12): 1697-1702. 
Venugopal, R. & Jaiswal, A. K. (1996). Nrf1 and Nrf2 positively and c-Fos and Fra1 
negatively regulate the human antioxidant response element-mediated 
expression of NAD(P)H:quinone oxidoreductase1 gene. Proceedings of the 
National Academy of Sciences of the United States of America 93(25): 14960-
14965. 
Verkhratsky, A., Olabarria, M., Noristani, H. N., Yeh, C. Y. & Rodriguez, J. J. (2010). 
Astrocytes in Alzheimer's Disease. Neurotherapeutics 7(4): 399-412. 
Verret, L., Krezymon, A., Halley, H., Trouche, S., Zerwas, M., Lazouret, M., Lassalle, 
J.-M. & Rampon, C. (2013). Transient enriched housing before amyloidosis 
onset sustains cognitive improvement in Tg2576 mice. Neurobiology of Aging 
34(1): 211-225. 
Vingtdeux, V. & Marambaud, P. (2012). Identification and biology of α-secretase. 
Journal of Neurochemistry 120: 34-45. 
Viswanathan, A. & Greenberg, S. M. (2011). Cerebral amyloid angiopathy in the 
elderly. Annals of Neurology 70(6): 871-880. 
Vorhees, C. V. & Williams, M. T. (2014). Assessing Spatial Learning and Memory in 
Rodents. ILAR Journal 55(2): 310-332. 
Wang, H.-Q., Xu, Y.-X. & Zhu, C.-Q. (2012). Upregulation of Heme Oxygenase-1 by 
Acteoside Through ERK and PI3 K/Akt Pathway Confer Neuroprotection 
Against Beta-Amyloid-Induced Neurotoxicity. Neurotoxicity Research 21(4): 
368-378. 
Wang, H., Khor, T. O., Saw, C. L., Lin, W., Wu, T., Huang, Y. & Kong, A. N. (2010). 
Role of Nrf2 in suppressing LPS-induced inflammation in mouse peritoneal 
macrophages by polyunsaturated fatty acids docosahexaenoic acid and 
eicosapentaenoic acid. Mol Pharm 7(6): 2185-2193. 
Wang, H., Liu, K., Geng, M., Gao, P., Wu, X., Hai, Y., Li, Y., Li, Y., Luo, L., Hayes, J. 
D., Wang, X. J. & Tang, X. (2013a). RXRα Inhibits the NRF2-ARE Signaling 
Pathway through a Direct Interaction with the Neh7 Domain of NRF2. Cancer 
Research 73(10): 3097-3108. 
Wang, J., Ho, L., Qin, W., Rocher, A. B., Seror, I., Humala, N., Maniar, K., Dolios, G., 
Wang, R., Hof, P. R. & Pasinetti, G. M. (2005). Caloric restriction attenuates β-
274 
amyloid neuropathology in a mouse model of Alzheimer's disease. The FASEB 
Journal. 
Wang, L., Colodner, K. J. & Feany, M. B. (2011). Protein misfolding and oxidative 
stress promote glial-mediated neurodegeneration in an Alexander disease model. 
Journal of Neuroscience 31(8): 2868-2877. 
Wang, R., Li, Jing J., Diao, S., Kwak, Y.-D., Liu, L., Zhi, L., Büeler, H., Bhat, 
Narayan R., Williams, Robert W., Park, Edwards A. & Liao, F.-F. (2013b). 
Metabolic Stress Modulates Alzheimer’s β-Secretase Gene Transcription via 
SIRT1-PPARγ-PGC-1 in Neurons. Cell Metabolism 17(5): 685-694. 
Wang, X. J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., 
Zheng, W., Wondrak, G. T., Wong, P. K. & Zhang, D. D. (2008). Nrf2 enhances 
resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. 
Carcinogenesis 29(6): 1235-1243. 
Wang, Y., Sun, W., Du, B., Miao, X., Bai, Y., Xin, Y., Tan, Y., Cui, W., Liu, B., Cui, 
T., Epstein, P. N., Fu, Y. & Cai, L. (2013c). Therapeutic effect of MG-132 on 
diabetic cardiomyopathy is associated with its suppression of proteasomal 
activities: roles of Nrf2 and NF-κB. American Journal of Physiology - Heart and 
Circulatory Physiology 304(4): H567-H578. 
Wang, Z., Wu, D. & Vinters, H. V. (2002). Hypoxia and reoxygenation of brain 
microvascular smooth muscle cells in vitro: cellular responses and expression of 
cerebral amyloid angiopathy-associated proteins. APMIS 110(5): 423-434. 
Webster, S. J., Bachstetter, A. D., Nelson, P. T., Schmitt, F. A. & Van Eldik, L. J. 
(2014). Using mice to model Alzheimer's dementia: an overview of the clinical 
disease and the preclinical behavioral changes in 10 mouse models. Frontiers in 
Genetics 5: 88. 
Weggen, S. & Beher, D. (2012). Molecular consequences of amyloid precursor protein 
and presenilin mutations causing autosomal-dominant Alzheimer's disease. 
Alzheimers Res Ther 4(2): 9. 
Weldon, D. T., Rogers, S. D., Ghilardi, J. R., Finke, M. P., Cleary, J. P., O'Hare, E., 
Esler, W. P., Maggio, J. E. & Mantyh, P. W. (1998). Fibrillar beta-amyloid 
induces microglial phagocytosis, expression of inducible nitric oxide synthase, 
and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 
18(6): 2161-2173. 
Westerman, M. A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, 
T., Younkin, L. H., Carlson, G. A., Younkin, S. G. & Ashe, K. H. (2002). The 
Relationship between Aβ and Memory in the Tg2576 Mouse Model of 
Alzheimer's Disease. The Journal of Neuroscience 22(5): 1858-1867. 
Westermann, B. (2012). Bioenergetic role of mitochondrial fusion and fission. 
Biochimica et Biophysica Acta (BBA) - Bioenergetics 1817(10): 1833-1838. 
White, C. L., Pistell, P. J., Purpera, M. N., Gupta, S., Fernandez-Kim, S. O., Hise, T. L., 
Keller, J. N., Ingram, D. K., Morrison, C. D. & Bruce-Keller, A. J. (2009). 
Effects of high fat diet on Morris maze performance, oxidative stress, and 
inflammation in rats: contributions of maternal diet. Neurobiol Dis 35(1): 3-13. 
WHO (2015a). Dementia (Fact Sheet N°362). 
http://www.who.int/mediacentre/factsheets/fs362/en/. 
WHO (2015b). Obesity and overweight (Fact Sheet N°311). 
http://www.who.int/mediacentre/factsheets/fs311/en/. 
Williamson, L. L., Chao, A. & Bilbo, S. D. (2012). Environmental enrichment alters 
glial antigen expression and neuroimmune function in the adult rat 
hippocampus. Brain, Behavior, and Immunity 26(3): 500-510. 
275 
Wilson, D. I. G., Watanabe, S., Milner, H. & Ainge, J. A. (2013). Lateral entorhinal 
cortex is necessary for associative but not nonassociative recognition memory. 
Hippocampus 23(12): 1280-1290. 
Winters, B. D., Forwood, S. E., Cowell, R. A., Saksida, L. M. & Bussey, T. J. (2004). 
Double Dissociation between the Effects of Peri-Postrhinal Cortex and 
Hippocampal Lesions on Tests of Object Recognition and Spatial Memory: 
Heterogeneity of Function within the Temporal Lobe. The Journal of 
Neuroscience 24(26): 5901-5908. 
Winzell, M. S. & Ahrén, B. (2004). The High-Fat Diet–Fed Mouse: A Model for 
Studying Mechanisms and Treatment of Impaired Glucose Tolerance and Type 2 
Diabetes. Diabetes 53(suppl 3): S215-S219. 
Wu, G., Xu, G., Schulman, B. A., Jeffrey, P. D., Harper, J. W. & Pavletich, N. P. 
(2003). Structure of a -TrCP1-Skp1--catenin complex: destruction motif 
binding and lysine specificity of the SCF(-TrCP1) ubiquitin ligase. Mol Cell 
11(6): 1445-1456. 
Wu, Z., Zhu, Y., Cao, X., Sun, S. & Zhao, B. (2014). Mitochondrial Toxic Effects of 
Aβ Through Mitofusins in the Early Pathogenesis of Alzheimer’s Disease. Mol 
Neurobiol 50(3): 986-996. 
Wurtman, R. (2015). Biomarkers in the diagnosis and management of Alzheimer’s 
disease. Metabolism 64(3, Supplement 1): S47-S50. 
Wynne, A. M., Henry, C. J. & Godbout, J. P. (2009). Immune and behavioral 
consequences of microglial reactivity in the aged brain. Integrative and 
Comparative Biology 49(3): 254-266. 
Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., Silverstein, 
S. C. & Husemann, J. (2003). Adult mouse astrocytes degrade amyloid-β in vitro 
and in situ. Nature Medicine 9(4): 453-457. 
Wyss, M. T., Jolivet, R., Buck, A., Magistretti, P. J. & Weber, B. (2011). In Vivo 
Evidence for Lactate as a Neuronal Energy Source. Journal of Neuroscience 
31(20): 7477-7485. 
Xia, M. Q., Bacskai, B. J., Knowles, R. B., Qin, S. X. & Hyman, B. T. (2000). 
Expression of the chemokine receptor CXCR3 on neurons and the elevated 
expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation 
and role in Alzheimer’s disease. Journal of Neuroimmunology 108(1–2): 227-
235. 
Xie, L., Helmerhorst, E., Taddei, K., Plewright, B., Van Bronswijk, W. & Martins, R. 
(2002). Alzheimer's beta-amyloid peptides compete for insulin binding to the 
insulin receptor. J Neurosci 22(10): RC221. 
Yamamoto, T., Suzuki, T., Kobayashi, A., Wakabayashi, J., Maher, J., Motohashi, H. & 
Yamamoto, M. (2008). Physiological Significance of Reactive Cysteine 
Residues of Keap1 in Determining Nrf2 Activity. Molecular and Cellular 
Biology 28(8): 2758-2770. 
Yan, Y., Jiang, W., Liu, L., Wang, X., Ding, C., Tian, Z. & Zhou, R. (2015). Dopamine 
Controls Systemic Inflammation through Inhibition of NLRP3 Inflammasome. 
Cell 160(1–2): 62-73. 
Yao, J., Irwin, R. W., Zhao, L., Nilsen, J., Hamilton, R. T. & Brinton, R. D. (2009). 
Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female 
mouse model of Alzheimer's disease. Proceedings of the National Academy of 
Sciences 106(34): 14670-14675. 
Yasojima, K., Schwab, C., McGeer, E. G. & McGeer, P. L. (1999). Up-Regulated 
Production and Activation of the Complement System in Alzheimer's Disease 
Brain. The American Journal of Pathology 154(3): 927-936. 
276 
Yeang, H. X. A., Hamdam, J. M., Al-Huseini, L. M. A., Sethu, S., Djouhri, L., Walsh, 
J., Kitteringham, N., Park, B. K., Goldring, C. E. & Sathish, J. G. (2012). Loss 
of Transcription Factor Nuclear Factor-Erythroid 2 (NF-E2) p45-related Factor-
2 (Nrf2) Leads to Dysregulation of Immune Functions, Redox Homeostasis, and 
Intracellular Signaling in Dendritic Cells. The Journal of Biological Chemistry 
287(13): 10556-10564. 
Yoshida, T. & Nakagawa, M. (2012). Clinical aspects and pathology of Alexander 
disease, and morphological and functional alteration of astrocytes induced by 
GFAP mutation. Neuropathology 32(4): 440-446. 
Yoshiike, Y., Chui, D.-H., Akagi, T., Tanaka, N. & Takashima, A. (2003). Specific 
Compositions of Amyloid-β Peptides as the Determinant of Toxic β-
Aggregation. Journal of Biological Chemistry 278(26): 23648-23655. 
Yuzwa, S. A., Shan, X., Macauley, M. S., Clark, T., Skorobogatko, Y., Vosseller, K. & 
Vocadlo, D. J. (2012). Increasing O-GlcNAc slows neurodegeneration and 
stabilizes tau against aggregation. Nat Chem Biol 8(4): 393-399. 
Zenaro, E., Pietronigro, E., Bianca, V. D., Piacentino, G., Marongiu, L., Budui, S., 
Turano, E., Rossi, B., Angiari, S., Dusi, S., Montresor, A., Carlucci, T., Nani, S., 
Tosadori, G., Calciano, L., Catalucci, D., Berton, G., Bonetti, B. & Constantin, 
G. (2015). Neutrophils promote Alzheimer's disease-like pathology and 
cognitive decline via LFA-1 integrin. Nat Med 21(8): 880-886. 
Zhang, C., Zhu, J., Zhang, J., Li, H., Zhao, Z., Liao, Y., Wang, X., Su, J., Sang, S., 
Yuan, X. & Liu, Q. (2014). Neuroprotective and anti-apoptotic effects of 
valproic acid on adult rat cerebral cortex through ERK and Akt signaling 
pathway at acute phase of traumatic brain injury. Brain Research 1555: 1-9. 
Zhang, D. D., Lo, S. C., Cross, J. V., Templeton, D. J. & Hannink, M. (2004). Keap1 is 
a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase 
complex. Mol Cell Biol 24(24): 10941-10953. 
Zhang, L., Fang, Y., Xu, Y., Lian, Y., Xie, N., Wu, T., Zhang, H., Sun, L., Zhang, R. & 
Wang, Z. (2015). Curcumin Improves Amyloid β-Peptide (1-42) Induced Spatial 
Memory Deficits through BDNF-ERK Signaling Pathway. PLoS ONE 10(6): 
e0131525. 
Zhang, R., Miller, R. G., Gascon, R., Champion, S., Katz, J., Lancero, M., Narvaez, A., 
Honrada, R., Ruvalcaba, D. & McGrath, M. S. (2009). Circulating endotoxin 
and systemic immune activation in sporadic Amyotrophic Lateral Sclerosis 
(sALS). Journal of neuroimmunology 206(1-2): 121-124. 
Zhang, R., Miller, R. G., Madison, C., Jin, X., Honrada, R., Harris, W., Katz, J., 
Forshew, D. A. & McGrath, M. S. (2013). Systemic immune system alterations 
in early stages of Alzheimer's disease. Journal of Neuroimmunology 256(1–2): 
38-42. 
Zhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S. A., Liao, F.-F., Xu, H. & Zhang, Y.-
w. (2007). Hypoxia-inducible Factor 1α (HIF-1α)-mediated Hypoxia Increases 
BACE1 Expression and β-Amyloid Generation. Journal of Biological Chemistry 
282(15): 10873-10880. 
Zhang, Y.-K. J., Yeager, R. L., Tanaka, Y. & Klaassen, C. D. (2010). Enhanced 
expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- 
and choline-deficient diet. Toxicology and Applied Pharmacology 245(3): 326-
334. 
Zhang, Y. W., Thompson, R., Zhang, H. & Xu, H. (2011). APP processing in 
Alzheimer's disease. Mol Brain 4: 3. 
Zhao, W.-Q. & Townsend, M. (2009). Insulin resistance and amyloidogenesis as 
common molecular foundation for type 2 diabetes and Alzheimer's disease. 
277 
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1792(5): 
482-496. 
Zhao, W. Q., Chen, H., Quon, M. J. & Alkon, D. L. (2004). Insulin and the insulin 
receptor in experimental models of learning and memory. Eur J Pharmacol 
490(1-3): 71-81. 
Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. (2011). A role for mitochondria in 
NLRP3 inflammasome activation. Nature 469(7329): 221-225. 
Zipper, L. M. & Timothy Mulcahy, R. (2002). The Keap1 BTB/POZ dimerization 
function is required to sequester Nrf2 in cytoplasm. Journal of Biological 
Chemistry 277(39): 36544-36552. 
Zlokovic, B. V. (2005). Neurovascular mechanisms of Alzheimer's neurodegeneration. 
Trends in Neurosciences 28(4): 202-208. 
 
278 
7 APPENDICES 
 
279 
7.1 APPENDIX I - SOLUTIONS 
Protein Analysis 
Solution Ingredients 
OxyBlock 
PBS-T 0.05% 
BSA 
100 ml 
1 g 
PBS-T 0.05% 
(Oxyblot
TM
) 
PBS 
Tween 20 
500 ml 
0.05% (v/v) 
SDS-containing tris-
glycine sample buffer 
0.5 M Tris HCl 
100% Glycerol 
20% SDS 
β-mercaptoethanol 
Bromophenol blue 
4 ml 
3.2 ml 
3.2 ml 
1.6 ml 
pinch 
TAE buffer (1x) 
dH2O 
10x TAE buffer  
450 ml 
50 ml 
TBS-T (Western blot) 
4 M NaCl 
1 M Tris/HCl (pH 7.4) 
Tween-20 
dH2O 
40 ml 
74 ml 
1 ml 
to 2 L 
Transfer Buffer 
Glycine 
Tris Base 
Methanol 
dH2O 
2.93 g 
5.81 g 
200 ml 
800 ml 
Tris/glycine running 
buffer (1x) 
dH2O 
10x Running Buffer (National Diagnostics; 25 
mM Tris, 192 mM Glycine, 0.1% SDS) 
900 ml 
100 ml 
Triton X-100 Lysis 
buffer stock solution 
1 M Tris/HCl 
750 mM NaF 
5 M NaCl 
0.5 M EDTA 
0.2 M EGTA 
0.5 M NaPPi 
Triton X-100 
dH2O 
12.5 ml 
33.5 ml 
10.0 ml 
10.0 ml 
12.5 ml 
10.0 ml 
5% (v/v) 
To 500 ml 
Working Triton X-100 
Lysis buffer solution 
1 mM Na3VO4* 
1 mM Benzamidine 
0.1 mM PMSF 
β-mercaptoethanol 
Sucrose 
 
/ml of Triton X-100 Lysis buffer stock solution 
2 µl 
1 µl 
1 µl 
0.1% (v/v)  
92 mg 
 
Table 7.1 Table of content of common solutions used for protein elucidation 
* Denotes heated to 95°C and left to cool to room temperature prior to addition 
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SDS-PAGE tris-glycine gel composition (2 gels) 
Ingredient 
Resolution 
Gel (10%) 
Resolution 
Gel (15%) 
Stacking 
Gel (4%) 
d.H2O 4.15 ml 2.3 ml 2.8 ml 
0.5 M Tris, pH 6.8 3.15 ml 3.15 ml 1.25 ml 
Bis-Acrylamide 3.75 ml 5.5 ml 0.85 ml 
10% SDS 110 µl 110 µl 50 µl 
TEMED 11 µl 11 µl 5.4 µl 
20% APS 55.4 µl 55.4 µl 50 µl 
Table 7.2 Constituents of self-poured Acrylamide gels 
 
Immunohistochemistry Solutions 
Solutions Ingredients 
10 mM Citric Acid, 
pH 6.0 
Citric Acid 
dH2O 
0.96 g 
To 500 ml 
Blocking Solution PBST 
donkey serum 
As required 
10% (v/v) 
Cryoprotectant 
Solution 
Sucrose 
Polyvinyl-pyrrolidone (PVP-40) 
Ethylene Glycol 
0.1 M PB 
75 g 
2.5 g 
75 ml 
To 250 ml 
Permeabilisation 
Solution (PBST) 
PBS 
Triton-X 100 
500ml 
0.1% (v/v) 
0.1 M Phosphate 
buffer (PB) 
Na2HPO4 (anhydrous) 
NaH2PO4 (anhydrous) 
dH2O 
10.9 g 
3.2 g 
To 1 L 
Table 7.3 Table of content of common solutions used for immunohistochemistry 
 
PCR Solutions 
Solutions Ingredients 
TAE buffer (1x) 
dH2O 
10x TAE buffer  
450 ml 
50 ml 
Agarose gel (1%) Agarose 
1x TAE buffer 
Ethidium bromide 
1.125 g 
112.5 ml 
5.6 µl 
Agarose gel (2%) Agarose 
1x TAE buffer 
Ethidium bromide 
2.5 g 
112.5 ml 
5.6 µl 
Table.7.4 Table of content of other frequently used solutions. 
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7.2 APPENDIX II – BEHAVIOURAL TASK OBJECTS 
 
 
Figure 7.1 Pictorial representation and pairing of objectsused in behavioural tasks. 
Where A + B were used for OL tasks and C + D were used for NOR tasks. Pictures are provided 
against the backdrop of a ruler to provide a scaling factor for the objects. 
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7.3 APPENDIX III – TAQMAN PROBES 
NAME REACTIVITY CODE 
β-Actin Mouse 4352933E 
APP Mouse Mm01344172_m1 
APP Human Hs00169098_m1 
Arg1 Mouse Mm00475988_m1 
BACE1 Mouse Mm00478664_m1 
C3 Mouse Mm00437838_m1 
CCL2 (MCP-1) Mouse Mm00421242_m1 
CCL5 (RANTES) Mouse Mm01302427_m1 
CCR2 Mouse Mm00438270_m1 
CCR5 Mouse Mm01963251_s1 
EMR1 (F4/80) Mouse Mm00802529_m1 
IL-1β Mouse Mm00434228_m1 
IL-6 Mouse Mm00446190_m1 
MRC1 Mouse Mm00485148_m1 
NOS2 (iNOS) Mouse Mm00440488_m1 
Nrf2 Mouse Mm00477786_m1 
TNF-α Mouse Mm00443260_g1 
YM1 Mouse Mm00657889_mH 
Table 7.5 List of RT-PCR TaqMan probes – Prof. M.L.J. Ashford lab 
 
NAME REACTIVITY CODE 
β-Actin Mouse Mm00607939_s1 
DUSP1 Mouse Mm00457274_g1 
DUSP2 Mouse Mm00839675_g1 
DUSP4 Mouse Mm00723761_m1 
DUSP5 Mouse Mm01266104_m1 
DUSP6 Mouse Mm00518185_m1 
DUSP7 Mouse Mm01232570_m1 
Table 7.6 List of RT-PCR TaqMan probes – Prof. S.M. Keyse lab 
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7.4 APPENDIX IV – WESTERN BLOTTING ANTIBODIES 
Antibody 
Supplier 
Product ID 
Host MW Dilution 
Blocking 
Agent 
Actin 
Sigma Aldrich 
A2066 
Rabbit 42 1:10000 4% BSA 
APP (Ab54) 
GSK* 
N/A 
Rabbit ~110 1:4000 4% BSA 
Akt 
Cell Signalling 
9272 
Rabbit 60 1:1000 4% BSA 
BACE1 
Sigma Aldrich 
B0681 
Rabbit 
60-
75 
1:1000 4% BSA 
COX IV (G-20) 
Santa Cruz 
Biotechnology 
sc-69360 
Rabbit 17 1:1000 4% BSA 
GCLC 
Prof. John D. Hayes* 
N/A 
Sheep 73 1:2000 5%milk 
GFAP 
Millipore 
AB5541 
Chicken 55 1:1000 4% BSA 
IκBα (C21) 
Santa Cruz 
Biotechnology 
Sc-371 
Rabbit 
35-
41 
1:1000 4 % BSA 
Mitofusin 1 
AbCam 
ab57602 
Mouse 84 1:200 4% BSA 
Mitofusin 2 
AbCam 
ab56889 
Mouse 86 1:100 4% BSA 
ERK1/2 MAPK 
Cell Signalling 
9102 
Rabbit 
44, 
42 
1:2000 4% BSA 
p-Akt (Ser473) 
Cell Signalling 
9271 
Rabbit 60 1:1000 4% BSA 
p-Akt (Thr308) 
Cell Signalling 
9275 
Rabbit 60 1:1000 4% BSA 
p-ERK1/2 
MAPK 
(Thr202/Tyr204) 
Cell Signalling 
9101 
Rabbit 
44, 
42 
1:2000 4% BSA 
p-JNK 
(Thr183/Tyr185) 
Cell Signalling 
9102 
Rabbit 
46, 
54 
1:1000 4% BSA 
p-TAU (s396) 
Cell Signalling 
9632 
Mouse 
~50-
60 
1:1000 4% BSA 
JNK 
Cell Signalling 
9258 
Rabbit 
46, 
54 
1:1000 4% BSA 
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Antibody 
Supplier 
Product ID 
Host MW Dilution 
Blocking 
Agent 
SYP (D-4) 
Santa Cruz 
Biotechnology 
Sc-17750 
Mouse 
38-
48 
1:2000 4% BSA 
TAU-5 
Millipore 
MAB361 
Mouse 
~50-
60 
1:1000 4% BSA 
VDAC1 
AbCam 
ab15895 
Rabbit 31 1:1000 4% BSA 
Table.7.7 List of primary antibodies used for protein elucidation by Western 
blotting – Prof. M.L.J. Ashford Lab (*denotes gifts) 
 
Antibody 
Supplier 
Product ID 
Host MW Dilution 
Blocking 
Agent 
DUSP4 (S18) 
Santa Cruz 
Sc-1200 
Rabbit 43 1:100 5% Milk 
DUSP5 
In house 
N/A 
Sheep 42 1:2,000 5% BSA 
DUSP6 
AbCam 
Ab76310 
Rabbit 42/44 1:1,000 5% Milk 
DUSP9 
In house 
N/A 
Sheep 42 1:2,000 5% Milk 
p-MEK 
(Ser217/221) 
Cell Signalling 
9154 
Rabbit 45 1 ; 1,000 5% BSA 
MEK 
Cell Signalling 
9122 
Rabbit 45 1 ; 1,000 5% BSA 
β-Tubulin 
Sigma 
T8328 
Mouse 51 1:10,000 
5% Milk 
or 5% 
BSA 
Table 7.8 List of primary antibodies used for protein elucidation by Western 
blotting – Keyse Lab 
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7.5 APPENDIX V – PRELIMINARY DATA 
Preliminary work has been completed with regards to obtaining quantifiable data 
from the confocal microscopy work performed. Detailed below are the astrocyte cell 
counts for two regions of the hippocampus as reported by IF with GFAP. 
 
Figure 7.2 Portrayal of changes in astrocyte number resulting from genotype or 
dietary intervention as depicted by GFAP staining in the hippocampus 
All counts were performed on images taken ~0.6 mm from the mid-line of sagittally cut mouse 
brains with 2-3 animals in each grouping and cell counting was blinded and performed by a 
summer student (B.M. Pais). The number of cell bodies present within the image stack taken 
from a 30 µm brain section was quantified using non-compressed reference files. If branches 
were seen but the cell body was not included in the slice then the cell was not counted to 
prevent miscounting of cells from branches that may not have come from the same cell. At this 
time there are too few numbers to analyse the individual brain regions. Example images from 
WT mice are provided for the CA1 (A) and CA3/DG (C), with cell counts beneath (B and D 
respectively). All counts were then combined in (E) to provide a larger overview of astrocyte 
cell number within the hippocampus and analysed by two-way ANOVA with post hoc 
Bonferroni. Section numbers CA1: WT = 2-5, Nrf2
-/-
 = 2-3, Nrf2
-/-
/hAPPswe = 3; CA3/DG: WT = 
2-6, Nrf2
-/-
 = 2-3, Nrf2
-/-
/hAPPswe = 3; CA1 and CA3/DG: WT = 4-11, Nrf2
-/-
 = 4-6, Nrf2
-/-
/hAPPswe = 6. 
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